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Abstract 
 
Background: Decisions on which tests to use should be informed by evidence that they do 
more good than harm. Test-treatment RCTs are recommended as the ‘gold–standard’ 
approach, but have attracted criticism that question whether they are fit for purpose. 
Confronting this question, the thesis investigates four key challenges by finding and 
analysing all identifiable test-treatment RCTs (2004–2007). 
Methods: Capture–recapture analysis estimated the total population of trials; descriptive 
analysis characterised the diagnostic questions evaluated by RCT; reviews of reporting 
and methodological quality investigated how informative and valid trials are; analytic 
induction was used to develop a theoretical framework linking tests to health outcomes, 
from which a tool was designed. 
Results: Published trials were poor quality, and found to be highly complex studies that will 
be challenging to evaluate reliably: interventions are difficult to capture and translate into 
protocols; several methods traditionally used to eliminate bias are more difficult to 
implement; test-treatment strategies impact on patient health in numerous and highly 
complicated ways. 
Conclusion: Test-treatment trials have the potential to be very useful instruments, and 
though highly challenging they could be both reliable and informative. However, it must be 
acknowledged that trials will not be suited to all comparisons. 
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Chapter 1: Evidence–based diagnosis 
Will introducing a new diagnostic test benefit patients? In the era of evidence–based 
medicine, decisions on which tests to use should be informed by rigorous evidence that 
the selected interventions do patients more good than harm1. In contrast to the wealth of 
rigorous research into treatment effectiveness produced during the last three decades, 
comparatively little progress has been made toward ensuring that decisions on which 
diagnostic tests to use is similarly based on evidence of clinical effectiveness.  
This is perhaps surprising given that diagnoses, informed by the results of diagnostic tests, 
determine which patients receive treatment. In a world where an increasing number of 
tests are becoming available, and financial constraints on healthcare budgets are unlikely 
to ease, the ability to consult high–quality evidence that demonstrates which tests will be 
most beneficial to the health of patients offers a key resource to both clinicians and policy 
makers. This is particularly critical when one considers the accumulating evidence that 
diagnostic test use is increasing at a very fast rate, across all quarters of the clinical 
spectrum2–5. And yet for many of these tests there is no evidence that their use leads to 
any improvement in the health of patients, or in cost–effectiveness6–9. Without this 
information we risk using tests that are „inferior‟ to others, with grave consequences for 
both patients and resource–use. In the short–term fewer patients may receive prompt and 
appropriate treatment, with implications for longer–term differentials in patient health, 
including early death and severe morbidity. Inappropriate testing can also promulgate 
unnecessary further testing, increasing both the direct harms and costs of healthcare for 
no appreciable gain in patient health5,10–11.  
Recognising the importance of these issues, evidence–based diagnosis has experienced a 
significant investment in research activity over the last 25 years, albeit focussed on 
developing and promoting methods for evaluating diagnostic accuracy12–13. However better 
accuracy may not benefit patients unless it leads to changes in diagnoses and patient 
management14. In order to fully evaluate the consequences of testing, it is necessary to 
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measure the impact that competing tests have on both intermediate processes and 
downstream patient health.  
The test-treatment randomised controlled trial (RCT) is widely heralded as the „gold–
standard‟ study design for achieving this14–18. These designs randomise patients between 
testing strategies, follow participants up through their subsequent management, and 
measure outcomes only after treatment has been received19. Yet the complexity of 
performing these evaluations has roused concerns amongst the methodological 
community that these RCTs invite unique methodological challenges that may threaten 
how useful they really are6,8,20–22. However for now these concerns remain hypothetical 
since to date very little research has been conducted to verify their presence or extent in 
published test-treatment trials. 
RCTs have been widely used to assess the effectiveness of screening programmes23, 
however their application to diagnostic settings does not yet appear to be so common24. 
There are indications, however, that calls for these studies appear to be increasing: in 
2010 the UK‟s National Institute of Health and Clinical Excellence (NICE) launched the 
Diagnostics Assessment Programme, which aims to provide evidence–based guidelines 
on diagnostic tests and to date has published 3 guidelines with a further nine in 
development25; only one year earlier the National Institute for Health Research Health 
Technology Assessment programme (NIHR HTA) released a commissioned call for 
research evaluating the impact of diagnostic tests on patient health and clinical 
management. Over the last 10 years numerous test-treatment RCTs have been funded by 
UK grant–awarding bodies, including the RATPAC trial of point–of–care testing for 
suspected acute myocardial infarction patients26, the MRC–CUBE trial of h.pylori testing in 
dyspeptic patients27 and trials evaluating the benefits of X–ray in lower back pain 
sufferers28–29. As the focus of diagnostic research broadens and the requirements for 
evidence of clinical effectiveness increase, it becomes ever more essential to investigate
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whether the RCT can in fact be relied upon as the gold–standard method to produce this 
evidence–base. 
This thesis aims to investigate how useful the RCT is for assessing the patient health 
impact of diagnostic tests. The rest of this chapter provides a background to the area of 
diagnostic test research, defines the scope of this thesis, and sets out its aims and 
objectives. The first part positions the thesis within the analytic infrastructure of diagnostic 
research, introducing the reader to the phases of test evaluation and the specifics of test-
treatment RCT designs. The second part reviews what is currently known regarding the 
methodological and reporting quality of RCTs in general. The third part looks at four of the 
key challenges that have been levelled at the test-treatment RCT, and summarises the 
findings of existing research into these issues. The final section sets out the aims of the 
thesis in detail, providing an orientation of how subsequent chapters evaluate each of 
these goals. 
1.1 Evidence–based diagnosis 
 
1.1.1 Defining diagnostic tests 
Medical testing forms the basis of decision-making for clinical intervention. It describes the 
process of information-gathering to determine the presence, nature and future course of 
disease in patients, from which the most appropriate course of management is planned. 
This definition is necessarily expansive, since tests are used for a wide variety of 
purposes. 
Screening tests are used for the early detection of disease in individuals who have yet to 
manifest any symptoms or signs of illness, and so are often performed in large cohorts of 
the asymptomatic population as blanket screening programmes23. In the UK examples 
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include mammography screening for breast cancer in females30 and blood spot screening 
for a range of potentially serious congenital conditions in newborns31.  
Unlike screening tests that are initiated by the healthcare provider, diagnostic tests are 
used in patients presenting with suspicious signs and symptoms to determine the likely 
cause of their problem. For example, individuals who arrive at their GP with complaints of 
dysuria and urinary urgency may be given a „dipstick test‟ to test for the presence of micro-
organisms in their urine, and so determine whether a bacterial infection of the urinary tract 
is the cause of their discomfort32. In secondary care, patients referred to orthopaedic 
consultants because of knee pain may be given an imaging scan, such as magnetic 
resonance imaging (MRI), to establish whether their symptoms are caused by any internal 
derangement of the knee33. Any process that is used to formulate a diagnostic decision in 
symptomatic patients may be considered a „diagnostic test‟. This definition encompasses 
the directly identifiable „diagnostic technologies‟ (as defined by the NICE technology 
appraisal process), such as radiography, serology or electrocardiography, but more 
broadly also defines any sort of information used to confirm or rule out the presence of 
disease, including physical examination and patient history. 
Tests are also used to classify the severity (or stage) of known disease, for example 
tertiary care patients with an existing diagnosis of non–small–cell lung carcinoma may be 
given computed tomography (CT) scans, MRI scans, and positron emission tomography 
(PET) scans to determine the location and size of tumours34. Diagnostic staging is closely 
related to prognostic testing, where the purpose of testing is to predict the course of 
disease or the risk of adverse events in the future35, or even the likely response to 
treatment36. Indeed in many situations tests may be used for both diagnostic and 
prognostic purposes, as with the cancer staging example above.  
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Lastly, tests can be used to monitor disease states, such as the serial testing used in 
surveillance for recurrence of bladder cancer37, or to titrate treatment, as in the daily 
measurement of blood glucose levels to adjust insulin doses in diabetic individuals38. 
1.1.2 Scope of the thesis 
This thesis will examine the use of RCTs to evaluate the impacts of testing on patient 
health, with a focus on diagnostic tests. Trials of monitoring or prognostic tests present the 
investigator with a different range of study design issues. Monitoring situations require 
study designs to take repeated testing into account, and may often not need to evaluate 
subsequent treatment39. Evaluations of prognostic tests aim to compare the accuracy of 
predictions for the risk of future events, and may also not need to evaluate subsequent 
treatment40.  
Trials of screening tests also fall outside the scope of this thesis, since the role of the RCT 
is already established to be well–suited to evaluating the health consequences of 
screening23. RCTs are the only design that can evaluate the health risks of overdetection 
(treating individuals whose preclinical disease would not have progressed), the most 
important measure of patient harm resulting from a screening programme41. Indeed many 
screening policies are based on RCT evidence and the initiation of new programmes must 
show that the benefits of screening “outweigh the physical and psychological harm 
(caused by the test, diagnostic procedures and treatment)” 42. Arguably, screening trials 
must also consider several design issues that are unlikely to affect diagnostic RCTs, such 
as overdetection bias and lead–time bias (individuals in whom disease is detected through 
screening appear to survive longer when in fact there is no difference)43. 
Conversely, the use of RCTs to evaluate the effectiveness of diagnostic tests has received 
little attention and is not yet supported by a rigorous methodological understanding. The 
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following section places test-treatment RCTs within the broader context of diagnostic test 
evaluation, and describes the theoretical design of these studies. 
1.1.3 Phases of test evaluation 
Over the last three decades methodologists have proposed that the ideal evaluation of 
diagnostic tests requires several phases of assessment in order to arrive at decisive 
conclusions regarding their clinical effectiveness. These research frameworks were 
developed as a diagnostic alternative to the now commonly accepted phased evaluation of 
pharmaceuticals. They therefore sought to develop a standardised approach for assessing 
diagnostic tests from their technological conception through to evaluating their clinical 
effectiveness in routine medical practice14,44–56.  
Thirty–one research frameworks were published between 1978 and 2007, proposing 19 
different evaluative pathways that should guide the assessment of new tests. These 
models are comprehensively reviewed by Lijmer and colleagues57, however what is of 
consequence here is that these frameworks identified between four and seven necessary 
phases of assessment. Those with four stages tend to draw a direct parallel with the 
pharmaceutical evaluative pathway55–56. However the most commonly recognised 
framework is that published in the seminal paper by Dennis Fryback and John 
Thornbury14. They set out six phases of diagnostic efficacy, each aiming to evaluate a 
different aspect of a test‟s performance, which are arranged hierarchically (Figure 1.1). 
This structure reflects the principle, common to most permutations of the framework, that 
in order to be effective at any given level of assessment, a test must have demonstrated 
its efficacy during the preceding phase of evaluation.  
Fryback and Thornbury argued that the process of evaluation should commence by 
assessing a test‟s „technical efficacy‟, namely the properties of a test that reflect its ability 
to produce classificatory information reproducibly (precision). Once proven to be a precise 
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instrument, the test‟s ability to correctly identify or exclude disease could be determined in 
studies that evaluate its „diagnostic accuracy efficacy‟, now commonly referred to as 
diagnostic test accuracy studies14,44–46. Further up the hierarchy is the evaluation of 
diagnostic yield or „diagnostic thinking efficacy‟, defined by Fryback and Thornbury14 as 
measuring the extent to which diagnostic information succeeds in changing the diagnostic 
decisions that clinicians make. Since these changes will not necessarily lead to differences 
in treatment planning, tests should subsequently be evaluated with regard to the impact 
they have on „therapeutic efficacy‟14,44–46. At the summit of most of these frameworks lays 
the evaluation of patient outcomes, variously referred to as „clinical outcome efficacy‟ or 
„patient outcome efficacy‟, whereby the benefits and harms to patients‟ health as a result of 
testing are determined.  
1.1.4 Diagnostic accuracy  
Accuracy is defined as a test‟s ability to differentiate between diseased and non–diseased 
individuals58. Evaluating the accuracy of diagnostic tests is argued as key to determining 
Figure 1.1: Phases of diagnostic test evaluation. Hierarchy of study designs needed to demonstrate the 
full effectiveness of introducing tests into clinical practice
14
. Evaluations of test accuracy are 
located toward the beginning of this hierarchical framework. Clinical effectiveness studies 
that measure health impact and cost-effectiveness comprise the final two stages of 
assessment. 
Stage 6: Societal impact Is the test resource-efficient?  
Stage 5: Patient health impact Does the test improve patient health?  
Stage 4: Therapeutic impact Does the test contribute to treatment planning? 
Stage 3: Diagnostic impact Does the test change diagnostic decisions?  
Stage 2: Diagnostic performance Does the test accurately differentiate  
  diseased from non-diseased patients?  
Stage 1: Technical performance Is the test reliable and reproducible?  
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whether they are likely to be clinically effective, since tests that are less accurate cannot 
hope to lead to better diagnoses, which would enable more appropriate treatments to be 
selected, and so improve patient health14,59.  
Three concepts are central to these studies. First, the test‟s performance must be 
measured in the detection of a single disease, referred to as the „target condition‟60. 
Second, for the purposes of subsequent analysis the target condition must be able to be 
dichotomised into present or absent61. And third, individuals classified into these two 
groups by the new test, or „index test‟, must be compared against the „true‟ situation; that 
is the investigator must establish, independently of the index test, which individuals are 
really diseased and those that are free from disease. This third requirement is 
approximated by using the best available diagnostic information, or „reference standard‟ 
(generally a composite of tests), to determine the true presence or absence of disease62.   
Since several diagnostic tests already exist to detect many target conditions, the ideal 
approach is to evaluate the comparative accuracy of the index test. Paired designs involve 
giving study patients the index test, the existing comparator test, and the reference 
standard test63; an alternative is to randomise patients to receive the index or the 
comparator test, after which all patients also receive the reference standard61. The 
performance of each test relative to the reference standard can then be measured by 
cross–correlating the diagnoses produced by these tests. The most common statistics are 
the test‟s sensitivity, calculated as the proportion of truly diseased patients whom the index 
test identifies correctly, and the test‟s specificity, calculated as the proportion of truly 
disease–free individuals whom the index test identifies correctly64.  
During the last 25 years, methods for assessing and interpreting test accuracy studies 
have dominated research into diagnostic test evaluation65. This has led to significant 
advances in our understanding of methodological issues. For example, research has 
highlighted the decisive role that variability in the clinical context plays in test performance. 
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Estimates of test performance are shown to be affected by the demographic composition 
of patient groups, disease prevalence and severity, how the test is carried out and how its 
results are interpreted66. Target conditions may be detected more reliably in populations 
with higher disease prevalence or more severe presentations of disease, for example67. 
Variations in how the presence of disease is defined can alter the performance 
characteristics of tests, such as the selection of different threshold values for interpreting 
biochemical results or different operational criteria in the interpretation of images68. 
Numerous other factors, including the care setting, role of the new test in the existing 
pathway, prior investigations and practitioner experience are also known to influence 
diagnostic accuracy60,63. 
Methodological research has also defined the extent to which inadequate study design can 
bias the results of accuracy studies69–70. These reviews analyse large groups of published 
test accuracy meta–analyses by comparing studies with inadequate methods to those 
without the same shortcomings to determine whether effect sizes differ according to 
methodological quality. Results have revealed that inadequate methods and reporting are 
often associated with larger estimates of diagnostic accuracy, an indication of bias. For 
example Lijmer and colleagues found indications of bias in studies using different 
reference standards according to the patient‟s index test result (differential verification 
bias), performing the reference standard with knowledge of the index test result (review 
bias), and in studies that failed to report either the criteria used to arrive at a diagnosis or 
the population under study70.  
Other notable advances have been made in the field of evidence synthesis, including the 
development of a widely–used quality appraisal tool to assess the applicability and risk of 
bias in primary studies71, the publication of a checklist to improve reporting standards72, 
the design of search filters to ascertain primary studies73, and the development of methods 
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in the meta–analysis of data to manage the considerable heterogeneity of study 
populations74. 
Despite these considerable advances, there is a growing recognition that evidence of a 
test‟s diagnostic accuracy, no matter how rigorously obtained, is not in itself sufficient to 
recommend that the test is disseminated into clinical practice6,44,46. Rather, the discipline‟s 
approach to evaluating tests must broaden to also consider the impact these technologies 
have on downstream patient health12,16,44,75–78.  
1.1.5 Patient outcome effectiveness 
Studies that assess the relative benefits of testing in patients occupy their own phase of 
assessment, since the hierarchical frameworks recognise that tests which appear to be 
efficacious in terms of their accuracy and their impact on diagnostic and therapeutic 
thinking may still fail to improve downstream patient health14,17,44–46. Two main methods 
have been proposed to achieve this: RCTs and decision models. 
T e s t - t r e a t m e n t  R C T s  
The randomised controlled trial is widely proposed as the gold–standard study design for 
evaluating the patient health impact of diagnostic tests15–17,19,21,44,49,51,53,79. This position is 
based on the findings of extensive methodological research into treatment trials and non–
randomised evaluations of treatments, which demonstrate that when conducted rigorously 
the RCT provides us with the most reliable tool to evaluate the comparable effectiveness 
of healthcare interventions80.  
When treatments are evaluated, the trial participants are randomised to receive either the 
new treatment or the existing treatment (or placebo), and their health response is 
measured after an appropriate period of follow–up. Thus not only are these designs 
prospective, but they ensure a direct relationship between cause (the treatment) and effect 
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(health response). Their experimental design also enables investigators to distribute 
patients at random81 and to implement other controls that limit bias. In sum, the RCT is 
therefore the most powerful epidemiological design for concluding that observed 
differences in outcome are due to differences in the intervention under study, since all 
other things can be kept equal. 
When the goal is to measure the impact a test has on patient health, the RCT must 
evaluate a different intervention. Patients are randomised to undergo either the new test or 
the existing test, however the downstream health response is measured after the 
implementation of subsequent treatment. Therefore when we seek to evaluate tests we 
must compare entire management pathways, called „test-treatment‟ strategies, rather than 
single interventions (Figure 1.2). A recent example is provided by the MRC–CUBE trial 
which evaluated whether testing dyspeptic patients for the bacterium Helicobacter pylori, 
Patient study 
population 
R 
Figure 1.2: Schematic illustration of a typical single intervention RCT (left) by comparison to 
the multiple intervention test-treatment RCT (right). 
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would effectively reduce their symptoms when compared to the standard approach of 
giving acid suppression to all such patients27 (Figure 1.3).  
Test-treatment comparisons can take three general formats, depending on the role the 
new test will take within the existing strategy22. The MRC–CUBE trial describes a 
replacement comparison where the new test completely replaces the existing technique (in 
this case no testing), however RCTs can also measure the value of adding a new test to 
the existing strategy, as was compared recently in the RATPAC trial (Randomised 
Assessment of Treatment using Panel Assay of Cardiac markers)26 (Figure 1.4). This 
NIHR HTA funded trial contrasted two strategies for diagnosing acute myocardial infarction 
in patients who had presented to emergency departments with acute chest pain that was 
suspected to have been caused by acute myocardial infarction. It evaluated whether the 
Primary care patients with 
dyspepsia 
R 
Figure 1.3: Example of a replacement test-treatment RCT.  
 Patients randomised to the experimental arm receive a test for the presence of 
Helicobacter pylori, which is eradicated if found, while patients without bacterial 
infection are given proton pump inhibitors (acid suppression).  Patients randomised 
to the control arm receive no test and are all given proton pump inhibitors (acid 
suppression), reflecting standard care
27
. 
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+ - 
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addition of a new point–of–care marker panel to routinely used tests could reduce the 
proportion of patients suffering adverse events as a consequence of missed diagnoses, 
when compared to the standard measurement of cardiac biomarkers for AMI. 
Alternatively the new test can be inserted earlier in the management pathway, and used to 
select which patients will go on to receive the existing technology. This triage comparison 
was performed in the RELAPSE trial, which evaluated the benefit of triaging patients with a 
clinically suspected recurrence of throat cancer82. Since the standard strategy is to 
proceed directly to invasive inspection by laryngoscopy, the new strategy sought to spare 
patients unlikely to have a recurrence by first investigating with a contrast–enhanced 
imaging modality (fluorodeoxyglucose enhanced positron emission scanning) (Figure 1.5).  
ED patients with chest pain  
(suspected but not proven AMI) 
R 
Figure 1.4: Example of an add–on test-treatment trial
26
. 
 AMI – acute myocardial infarction; CK–MB – Creatine kinase muscle type; ED – 
emergency department; POC – point–of–care;  
 * Primary outcome defined as: discharge decision made within 4 hours of 
presentation AND suffered no major adverse event during the following 3 months.
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In all types of test-treatment RCT the final measure of effectiveness is made after all tests 
and treatments have been administered, thus these downstream outcomes measure the 
impact of all these processes. However test-treatment interventions are more than the sum 
of multiple interventions: tests and treatments are connected by several phases of clinical 
decision–making in which test results must be used to formulate diagnostic decisions, 
which in turn inform the treatments that must be administered to each resulting diagnostic 
group. For the MRC–CUBE trial, the chosen measure of downstream patient health 
(recovery of symptoms) was assessed at 1–year follow–up, thus it evaluated the 
Patients with clinical suspicion of 
recurrent laryngeal carcinoma 
after radiotherapy 
R 
Figure 1.5: Example of a triage test-treatment RCT.  
 Patients with symptoms of recurrent cancer currently undergo laryngoscopy to 
investigate, followed by partial or total removal of the larynx if confirmed. In this 
trial patients randomised to the experimental arm receive a fluorodeoxyglucose 
enhanced positron emission (FDG–PET) scan, only proceeding to laryngoscopy if the 
results are positive or indeterminate
82
. 
* defined as negative laryngoscopies with no recurrence was diagnosed within 6 
months follow–up.  
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effectiveness of the tests (13C Urea breath test for study arm and no test for controls), the 
treatments (acid suppression and bacterial eradication regime) but also of the clinical 
decisions that occurred between them (does the patient have a bacterial infection? should 
they be prescribed empirical acid suppression or the eradication regime?). 
Test-treatment strategies are therefore far more complicated interventions to evaluate by 
comparison to pharmaceutical interventions. Not only do test-treatment strategies 
comprise multiple healthcare components, but also multiple episodes of decision-making. 
Indeed, test-treatment strategies can be described as “interventions with several 
interacting components”, and so appear to satisfy the criteria for „complex interventions‟ as 
defined by the MRC in their guidance document for developing and evaluating complex 
interventions83.  
D e c i s i o n –m o d e l s  
The impact that testing strategies have on downstream patient outcomes can also be 
estimated indirectly using decision analysis. These models are constructed using existing 
clinical data and extrapolate the link between a test‟s accuracy and downstream health 
outcomes84. This is accomplished by setting out each test-treatment strategy along a 
decision tree which expresses the sequence of decisions and events that occur as a result 
of testing85. Decisions include the diagnoses that may be given, while events describe 
potential differences in the health status of patients such as whether or not they have the 
target condition. To illustrate, Howard and colleagues used modeling to compare two 
diagnostic strategies for managing patients with suspected common bile duct stones86. 
Diagnostic endoscopic retrograde cholangiopancreatography (ERCP) is the current gold–
standard for detecting stones in the bile duct, however it is also a highly invasive 
procedure risking serious morbidity. This is followed by therapeutic ERCP in patients found 
to have stones. By comparison, the new strategy would initially examine patients using 
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magnetic resonance cholangiopancreatography (MRCP), a non–invasive imaging 
technique, after which patients in whom stones were still suspected („test–positives‟) would 
undergo the standard management strategy. 
Figure 1.6 illustrates a simplified decision–tree that was used to compare ERCP–led and 
MRCP–led management. For every test-treatment strategy that is compared, each 
possible alternative sequence of decisions and events occupies a different „branch‟ of the 
tree. Namely, each branch describes a variation in the management patients receive as a 
result of being allocated a particular diagnosis, and undergoing a treatment dictated by 
that diagnosis. The difference in ultimate patient outcomes is estimated by comparing the 
proportion of simulated patients in each tree who experience the desired health outcome 
after having progressed along a particular branch. The lower branch describes patients 
undergoing ERCP who could receive either a positive or negative diagnosis. Those who 
test positive and truly have stones (true–positives) will proceed to treatment, removal 
during therapeutic ERCP, as will false–positive patients. Patients who initially test negative 
and are truly free of stones (true–negatives) will ultimately receive different diagnoses and 
so won‟t proceed to therapeutic ERCP, while false–negative patients will be erroneously 
discharged and re–present, after which the test–treat process is repeated through to 
completion. In the upper branch, patients who undergo MRCP and receive a positive 
indication for the presence of stones will proceed to diagnostic ERCP, regardless of 
whether this diagnosis is correct, after which all further management is the same as the 
standard care branch.  
These models must therefore estimate how many patients in each strategy will travel along 
each possible branch and experience the downstream effects of doing so. These 
parameters are quantified by probabilities that must be retrieved from several existing 
primary studies6,87–88. For example, Howard and colleagues obtained probability estimates 
of a patient having bile duct stones from a database listing epidemiological studies of
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 disease prevalence (the Australian Bureau of Statistics); the probability of receiving a 
positive or negative test result was gained from their systematic review of diagnostic test 
accuracy comparing MRCP with ERCP86; and the probability of experiencing adverse 
outcomes, including complications and death, were extracted from various sources 
including previous models that used mortality registers and extensive observational 
surveys89–90. The probability of responding to treatment can also be secured from trials 
evaluating treatment effectiveness87.  
The issue of what evidence is needed to perform an appropriate decision–analysis has 
been addressed by several groups of researchers21,84,91–92. Attention is drawn in particular 
to the meticulous and thought–provoking research published by Lord and colleagues19,21,93, 
who delineate what evidence of treatment efficacy should be sought and how it should be 
linked to evidence of a test‟s performance. They note that model design should be 
informed by appraising the trade–offs that occur within a given comparison of two tests; 
these trade–offs occur as a result of the various ways in which a new test is expected to 
improve patient health, most commonly as a consequence of superior diagnostic accuracy 
or through the direct harms and benefits of undergoing the test21. A common example is 
the trade–off that occurs with triage tests. CT–pulmonary angiography, for instance, can 
accurately diagnose suspected pulmonary embolism (PE), however a disadvantage is that 
it exposes the patient to radiation. D–dimer, a protein biomarker measured to detect 
clotting in blood samples, is highly sensitive and may be able to rule PE out safely in 
patients with a low clinical probability of disease, thus avoiding the more risky and costly 
CT94.  
The use of models to evaluate the clinical effectiveness of tests certainly offer several 
advantages over the RCT, as a result of which this approach is accepted by the major 
health technology assessment agencies, including NICE‟s Diagnostic Assessment 
Program here in the UK18, the Agency for Healthcare Research and Quality (AHRQ) in the
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USA16, and the Medical Services Advisory Committee (MSAC) in Australia95. Because 
models are constructed using existing data, they are relatively quick to perform and at 
lower cost than an RCT6,88. Various researchers note that models can be also used to 
indicate the need for an RCT8,84, to perform cost–effectiveness analyses88 or simply to 
contemplate what the health consequences of different diagnostic strategies might be87. 
Of course, the validity of decision models is limited by the availability and quality of existing 
evidence, by the need to rely on assumptions that all patients will be treated according to 
the protocol, but also by the need to extrapolate the results of several studies. This 
inevitably must assume that the estimates are transferable, however this may not always 
be a valid assumption; since diagnostic accuracy varies according to several factors, 
including the case–mix of study populations, the role of the test in the new pathway and 
how the test is carried out60, actual test performance may vary from that reported in the 
primary studies from which estimates are retrieved87.  
Perhaps the greatest limitation, however, is that models only provide indirect evidence of 
the effects that test-treatment strategies have on patient health. The only rigorous method 
for acquiring direct evidence is to perform RCT evaluations of test-treatment interventions. 
Yet because of their complexity, this approach has attracted some criticism regarding the 
feasibility with which rigorous test-treatment RCTs can be conducted. Before examining 
these criticisms, it is first appropriate to review existing knowledge regarding the 
methodological shortcomings of RCTs in general.   
1.2 Bias and poor reporting in RCTs 
 
The randomised controlled trial is argued to be the gold–standard design with which to 
evaluate the impact healthcare interventions exert on patient health17. This is due to the 
investigator‟s ability to implement several methodological techniques that can prevent any 
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distortions introducing bias, thus enabling the objective and reproducible empiricism that is 
required of scientific experiments. In practice, however, it may be difficult or undesirable to 
execute the necessary methods, resulting in estimates of effectiveness that may be biased 
and hence unreliable. The following section provides a review of the evidence regarding 
the biases that can occur as a result of implementing inadequate methodological 
safeguards in trials of treatment interventions. 
1.2.1 Bias in RCTs 
The goal of the RCT is to evaluate whether a new treatment succeeds in safely improving 
the health of patients by comparison to no treatment or existing treatment. In order to 
conclude that observed differences are caused only by the different treatments, trials must 
adhere to the fundamental principle that all other aspects of the comparison should be 
kept equal96. 
Biased RCTs are theorised to stem largely from four methodological misdemeanours that 
violate this principle: creating mismatched study groups (selection bias), treating study 
groups differently besides the interventions being compared (performance bias), 
measuring study groups differently (detection bias) or analysing mismatched study groups 
(attrition bias). Empirical analysis of trial design supports the role that methodological 
safeguards play in limiting these risks of bias by demonstrating that trials using inadequate 
methods tend to produce significantly different results to adequately–performed trials. The 
most rigorous evidence for these associations is produced by comparing the quality of 
trials included in subject–specific meta–analyses. Nine such „meta–epidemiological‟ 
reviews have been published97–105, five of which have been synthesised into two meta–
meta reviews106–107. A third meta–meta review, the largest of all, was published recently 
and combines seven meta–epidemiological studies108 (Table 1.1).  
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Study Included meta-analyses 
Quality components 
examined 
MAs  RCTs 
Schulz et al 
1995
97
 
Cochrane Pregnancy and Childbirth 
Group meta-analyses with ≥5 trials 
containing ≥25 events in the control 
group, and ≥1 trials with and ≥1 trials 
without adequate allocation 
concealment 
Random sequence generation, 
allocation concealment, blinding, 
reporting of exclusions. 
33 250 
Moher et al 
1998
98
 
Random sample from authors' 
database of meta-analyses, selected 
from 3 areas: digestive diseases, 
circulatory diseases, mental health. 
Random sample from the Cochrane 
Database of Systematic Reviews, one 
on stroke and two on pregnancy and 
childbirth. 
Random sequence generation, 
allocation concealment, blinding, 
reporting of exclusions. 
11 127 
Jüni et al 
2000
99
 
Handsearch of 8 journals 1993–1997 Allocation concealment, blinding. 133 NR 
Kjaergard et 
al 2001
100,110
 
Cochrane Library, Medline or PubMed 
with at least one trial 
with ≥1000 patients 
Random sequence generation, 
allocation concealment, blinding, 
description of dropouts  
and withdrawals. 
14 190 
Balk et al 
2002
101
 
Author selected cardiovascular 
medicine meta-analyses, and MEDLINE 
+ Cochrane Database of Systematic for 
infection, paediatrics, surgery 
including  ≥6 meta-analyses 
Random sequence generation, 
allocation concealment, blinding, 
reporting intent-to-treat analysis, 
reporting power calculation. 
26 276 
Egger et al 
2003
102
 
Cochrane Database of Systematic 
Reviews that had performed 
comprehensive literature searches. 
Allocation concealment, blinding. 122 1175 
Contopoulos–
Ioannidis et al 
2005
103
 
Cochrane Mental Health Library all 
meta–analyses with at least one 
“large” randomised trial (sample size 
>800) and at least one “smaller” trial. 
Random sequence generation, 
allocation concealment, blinding. 
16 133 
Siersma et al 
2007
104,111
 
Cochrane Library random selection, 
each with ≥5 trials with ≥1 inadequate 
and ≥1 adequate allocation 
concealment 
Random sequence generation, 
allocation concealment, blinding, 
reporting intent-to-treat analysis, 
reporting power calculation. 
48 523 
Nuesch et al 
2009
105
 
Cochrane Library, Medline, Embase, 
CINAHL, all trials comparing 
therapeutic interventions in hip or 
knee osteoarthritis 
Exclusions to primary analysis. 14 167 
Table 1.1: Overview of meta–epidemiological studies investigating the association between RCT 
methodological quality components and treatment effects (continued overleaf). 
 NR–Not Reported; MAs–Meta–analyses; RCT–Randomised controlled trial 
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These reviews begin by categorising all trials included in the original meta–analyses 
according to the adequacy with which each methodological safeguard has been 
performed. The effect estimates are then pooled for each category (generally „adequate‟ 
and „inadequate/unclear‟), and a ratio of these pooled estimates is calculated for each 
meta–analysis. The weighted averages of the resulting relative odds ratios (RORs) are 
subsequently examined using a random–effects meta–meta–analysis in order to examine 
the association between quality components and treatment effects109. The main findings of 
these reviews are summarised below. 
1.2.2 Randomisation, allocation concealment and selection bias 
Randomisation of eligible participants ensures that, on average, study groups are 
comparable in their composition of participants, specifically regarding particular prognostic 
subgroups of patients that may be predisposed to experience poorer or better downstream 
outcomes81. This is achieved using two methodological safeguards. First, an allocation 
sequence based on random number generation is designed to eliminate the predictability 
of the next participant‟s group assignment, as well as to ensure that prognostic factors are 
distributed at random between study groups. Second, this schedule is concealed from 
Study Included meta-analyses 
Quality components 
examined 
MAs  RCTs 
Jüni et al 
2001
106
 
Schulz 1995a, Moher 1998, Juni 2000, 
Kjaergard 2001 
Random sequence generation, 
allocation concealment, 
blinding. 
NR NR 
Wood et 
al 2008
107
 
Schulz 1995a, Kjaergard 2001, Egger 2003 Allocation concealment, 
blinding. 
146 1346 
Savović et 
al 2012
108
 
Schulz 1995a, Kjaergard 2001, Balk 2002, 
Egger 2003, Siersma 2007, Contopoulos–
Ioannidis 2005, Pildal 2007 
Random sequence generation, 
allocation concealment, 
blinding 
234 1973 
Table 1.1: (continued) Overview of meta–epidemiological studies investigating the association between 
RCT methodological quality components and treatment effects. 
 NR–Not Reported; MAs–Meta–analyses; RCT–Randomised controlled trial 
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recruiting physicians in order to prevent foreknowledge of which intervention the next 
eligible participant would receive, and thus expose the allocation process to intentional or 
subconscious subversion112–113. Published accounts of the subversion of allocation 
schedules114 attest to clinicians‟ determination to provide what they perceive as being the 
best care to their patients, so adequate methods of concealing which interventions might 
be allocated to the next eligible patient are necessary to enforce clinical equipoise. 
Evidence that inadequate generation of randomisation schedules causes bias was scarce 
until recently, most reviews failing to confirm that this feature is independently associated 
with larger effect sizes97,98,101,103,110. In their now seminal review of 33 meta–analyses 
published by the Pregnancy and Childbirth Group of the Cochrane Collaboration, Schulz 
and co-workers demonstrated that inadequate randomisation was only associated with 
larger treatment effects when limiting the comparison to adequately concealed trials97, 
raising the possibility that adequacy of sequence generation is not sufficient to prevent 
bias if schedules are not subsequently concealed from recruiting care–providers. The 
recent publication of the large meta–meta review that synthesised over 230 meta–
analyses appears, however, to confirm somewhat definitively that inadequate or unclear 
methods are associated with a clear exaggeration in treatment effect of 11% on 
average108. 
Most reviews found that trials using inadequate (including unclear) methods of 
concealment tend to have larger effect sizes of between 17%107 and 30%106, highlighting 
that allocation concealment is critical to the prevention of selection bias. Two meta–
reviews found no such difference101,104, though their results may have been influenced by 
using less rigorous quality appraisal criteria to define „inadequate‟ methods. The criteria 
published by Siersma and colleagues are incomplete104, precluding a firm interpretation of 
the review‟s results, however those published by Balk and colleagues101 have certainly 
been criticised as inconsistent with standardised definitions of methodological 
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adequacy115. Nonetheless, when Balk‟s review was incorporated into a meta–meta–review 
alongside four other reviews97–100, a 25% exaggeration of treatment effects due to 
inadequate methods was still apparent (ROR 0.75, 95%CI: 0.63-0.89)116. This finding was 
confirmed by Savović and colleagues, though the exaggeration was found to be at a much 
smaller 7% (ROR 0.93, 95%CI: 0.89–0.99)108. 
Schulz and colleagues also demonstrated that unclear concealment remained associated 
with larger effect sizes even after accounting for possible biases introduced by inadequate 
methods of randomisation, exclusions after randomisation/missing data, or not blinding 
participants97. What is more, inadequate or unclear allocation concealment has also been 
associated with a greater likelihood of finding statistically significant treatment effects117, as 
well as greater heterogeneity in treatment effects between trials of similar topics97,100,108,111. 
This indicates that selection bias is unpredictable in its impact and can either 
overemphasise or underestimate the true effect of interventions.  
1.2.3 Blinding: performance and ascertainment bias  
„Blinding‟ (or „masking‟) is conducted to satisfy the second chief tenet of experimental 
study designs: to eliminate, as far as is possible, any contamination of the intervention‟s 
effect due to pre-existing beliefs regarding the intervention‟s effectiveness. Much as 
allocation concealment is used to prevent such beliefs from influencing the composition of 
study groups, blinding is conducted to ensure that – other than the treatments under study 
– the provision of care, response to care, and measurement of this response, are all 
conducted equitably across study groups. Thus practical procedures must be established 
to warrant that physicians and other care–providers remain unaware of which interventions 
participants have been assigned to, so that prior expectations of effectiveness do not 
encourage a disparity in other care that is administered. This performance bias is also 
avoided by blinding patients to knowledge of the intervention they are receiving, so as not 
  
26 
26 
Chapter 1: Bias & poor reporting in RCTs 
to unduly influence their response to treatment, while also facilitating the proper blinding of 
treating staff. Those measuring endpoints must be blinded so as not to support systematic 
differences in how outcomes are assessed, so foiling the potential for ascertainment or 
detection bias.  
Despite the clear rationale for the risks imposed by these two types of bias, the available 
empirical evidence is inconsistent in demonstrating that all open (i.e. un–blinded) trials 
produce more biased results than blinded trials. The strongest evidence is derived from 
the three meta–meta–reviews which found that absence of double–blinding was 
associated with treatment effects on average 7%107, 12%106 and 13%108 larger than those 
of trials using double–blinding. These indications of bias appear to be restricted to the 
results of subjective outcomes107–108. Specifically, subjectively measured treatment effects 
were found to be between on average 22%108 and 25%107 larger in open compared to 
blinded trials, whilst no association was found for the similar comparison of objective 
outcomes. Savović and colleagues also found that both between–trial and between–meta-
analysis heterogeneity were considerably higher when the analysis was restricted to trials 
with subjective outcomes108.  
On the other hand, two meta–epidemiological studies, again those by Siersma and Balk, 
failed to show any difference in effect size as a consequence of double–blinding101,104. This 
lack of consensus is likely to reflect a multitude of factors, not least the variation in how 
reviews judged blinding to have occurred. No review examined the adequacy of blinding 
methods but instead all used reporting of „double–blinding‟ as a proxy for methodological 
sufficiency. Trial reports of the methods used to implement blinding remain very poor118–119, 
and so this approach may have underestimated the impact that lack of blinding has on 
effect size if some trials that reported blinding did not in fact implement this safeguard 
adequately. Moreover, use of the term „double–blinding‟ has been shown to denote a 
broad variety of precisely who should be blinded120. This would suggest that trials 
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classified by these reviews as „blind‟ are likely to vary in the degree to which they remain 
at risk of bias, and whether this is performance bias and/or detection bias, both of which 
could have confounded the association between reports of blinding and effect size.  
Other causes of inconsistency in findings may be due to the varying degree to which 
reviews controlled for other aspects of trial quality. At least part of the impact of blinding 
can be explained by the impact of allocation concealment for example, since trials using 
inadequate concealment are also more likely not to implement blinding107. When this 
confounding was controlled for, by limiting the analysis to trials with adequate allocation 
concealment, blinding ceased to cause any overall difference in effect size, though 
maintained an association with overestimated effects once subjective outcomes only were 
analysed, albeit with a very wide confidence interval (ROR=0.80, 95%CI: 0.49–1.31)107. 
Again no differences were observed for objective outcomes. 
This provides two important indications for optimal trial design: first that blinding 
adjudicators for the assessment of objective outcomes may be superfluous to the 
prevention of ascertainment bias since both approaches provide equivalent treatment 
effects. Second that since outcome assessors can substantially influence the evaluation of 
endpoints that accommodate an element of subjectivity, for example symptom frequency, 
blinding these adjudicators may be particularly critical to a trial‟s validity107,121.  
1.2.4 Loss, exclusions and attrition bias  
The fourth threat to the internal validity of RCTs can occur if the groups are no longer 
comparable at the time of analysis. Loss to follow–up as a result of participants becoming 
unavailable during the study period, and the exclusion of randomised participants from a 
trial for a variety of reasons, can theoretically both cause a systematic shift in the 
distribution of prognostic factors that had so carefully been eliminated by proper 
randomisation procedures. Individuals who are lost or excluded from trials are unlikely to 
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constitute a random sample of those initially recruited, and instead may well differ from 
those that remain with regard to their treatment response or other prognostic 
characteristics122. Participants may be in too poor health to continue with the demands of 
study participation, while those that are withdrawn after randomisation are more likely to 
be participants with the poorest response to allocated treatment. The selective elimination 
of randomised individuals from the calculation of treatment effects is thus liable to 
compromise the validity of results by introducing the risk of attrition bias123. Moreover, the 
impact of attrition bias will be heightened if the reasons for losses and exclusions differ 
between study groups as a direct result of the interventions being received, or if study 
groups experience different rates of attrition124. For these reasons, the ideal calculation of 
treatment effects should include all participants in the final analysis as randomised, 
regardless of the interventions they actually receive or whether they complete trial follow–
up123. This approach is referred to as „intention–to–treat‟ analysis.  
Three recent studies attest to the impact that attrition can have on trial results105,125–126. A 
meta–epidemiological analysis that included 14 meta–analyses evaluating treatments for 
osteoarthritis found that trials tended to demonstrate greater benefits of the experimental 
intervention if they suffered attrition than those providing complete analyses105. Similarly, 
two cohort studies that examined within–trial differences in effect size by directly 
comparing intention–to–treat analyses with per–protocol analyses (74 RCTs126 and 133 
RCTs125) both found that calculations excluding participants tended to over exaggerate the 
benefit of experimental treatments than estimates derived from intention–to–treat 
calculations125–126. All three studies found attrition to be associated with both overestimates 
and underestimates of intervention effect, concluding that attrition is unpredictable in its 
impact on effect magnitude. 
Conversely, several studies fail to find that attrition impacts on trial results. A small meta–
regression analysis of a convenience sample of 10 RCTs concluded that both attrition and 
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differential attrition can occur at random, thus not causing attrition bias124. Using individual 
patient data for each included trial, the authors compared the level of baseline imbalance 
in all randomised participants to the degree of imbalance in all patients included in each 
primary analysis124. They found that attrition did not result in baseline imbalances, while 
the level of attrition was not correlated with the observed direction of effect. Similarly, five 
meta–epidemiological analyses failed to find any association between attrition bias and 
effect size97–98,100–101,104. The methods used by each were again highly variable, and all 
relied on different surrogate measures of methodological quality. One review used the 
adequacy of reporting the number and reasons for dropouts and withdrawals, regardless 
of the actual attrition observed100; another used reports of an intention–to–treat analysis 
regardless of whether an ITT was actually conducted104, while two reviews used reports of 
exclusions to indicate poor quality97,101. As with the evidence for blinding, these results are 
highly likely to be confounded by poor reporting quality. In an appraisal of 110 randomly–
selected RCTs conducted within the field of obstetrics and gynaecology, Schulz and 
colleagues found that trials reporting exclusions to the primary analysis exhibited inferior 
study quality to those with no apparent exclusions, thus suggesting that reporting perhaps 
did not reflect true conduct in the latter subgroup127.  
1.2.5 Sample size and type II error 
Recruiting an insufficient number of participants into a trial cannot bias trial results as 
such, though it may distort the interpretation of results by increasing the magnitude of 
random error. In order to conclude whether an observed difference in outcome rates is 
meaningful, investigators must test its statistical significance. Yet deductions reached 
through hypothesis testing can succumb to two errors: false–positive conclusions and 
false–negative conclusions. Type I errors occur when a trial falsely concludes a difference 
between treatments when in reality there is none. Particularly critical to clinical trials are 
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the risk of type II errors, in which real differences between interventions are missed due to 
insufficient sample sizes. The probability of avoiding false conclusions of no effect is 
denoted by the concept of power (1– the probability rate of type II error, or β), which is 
inversely related to sample size; namely the probability of arriving at false–negative 
conclusions decreases as the number of study subjects increases128. Trials with small 
sample sizes are demonstrably at risk of having erroneously concluded an absence of 
treatment effect when in reality the probability of achieving false–negative conclusions was 
high129. At least one–third of published trials may underestimate the sample size required 
to eliminate type II error by more than 10%, and approximately 6% of trials underestimate 
the required sample size by over 50%130, suggesting that the risk of false–negative 
conclusions in published trials is commonplace.  
Nevertheless, it is challenging to quantify the impact that inadequate approaches to 
managing the risk of type II error has on trial findings. Larger trials (>800 participants) have 
been shown to produce more conservative effect estimates with increased precision than 
small trials included within the same meta–analysis103. However this difference may be in 
part explained by publication bias, since smaller trials with non–significant results are less 
likely to be published than large trials110. A similar study also found small trials to have 
exaggerated effect sizes compared to large trials (>1000 participants), though only when 
comparison was limited to trials with inadequate sequence generation (ROR=0.46, 95%CI: 
0.25–0.83), inadequate allocation concealment (ROR=0.49, 95%CI: 0.27–0.86) and a lack 
of double–blinding (ROR= 0.52, 95%CI: 0.28–0.96)100. That no similar difference was 
observed between trials employing rigorous methodological safeguards indicates small 
sample size may be a marker of poor design quality in this cohort.  
Indeed, not all small trials are at risk of type II error, but only those that are underpowered 
to find the desired clinically important treatment effect. Consequently a priori specification 
of a target sample size, in which acceptable α and β error risks and estimated event rates 
  
 
Chapter 1: Bias & poor reporting in RCTs 31 
31Chapter 
1: 
Introductio
n 
 
are defined in advance of trial recruitment, provides a better proxy indicator of trial quality 
than generic sample size. By documenting power calculations trialists demonstrate they 
have considered not only the key issue of type II error risk, but have also reflected on the 
minimum clinically meaningful difference that should be evaluated121. Only two meta–
epidemiological studies have investigated the impact of reporting power calculations on 
effect sizes, and rather unsurprisingly neither found any difference in magnitude101,104. 
Whilst reports of power calculations may indicate that efforts to minimise type II error have 
been made, the risk will only be reduced in trials that recruit their target sample size.  
1.2.6 Reporting quality  
Although randomised controlled trials have the potential to provide the most reliable 
assessments of healthcare effectiveness, they are often complex experiments requiring 
exacting methods to achieve their goal. As summarised above, those failing to achieve 
high methodological standards risk basing their conclusions on biased findings. What is 
more, the considerable proliferation of published trials131–133 requires users and 
commissioners of healthcare to identify the most rigorous evidence in order to select the 
most effective interventions for use in clinical practice. This can only be achieved with full 
and clear reporting of studies121. 
Trial reports are recognised to be necessary though imperfect proxies for actual design 
quality and conduct134. Unambiguous reporting of trial methods allows adequate appraisal 
of methodological quality, which in turn facilitates the synthesis of evidence by enabling 
the most rigorous studies to be identified. Problems ensue with incomplete reporting, since 
readers cannot be definite that absence of description equates with the absence of 
method, or with inadequate method129. This is demonstrated clearly in the above overview 
of bias in RCTs, where several conclusions regarding the relationship between 
methodological quality and treatment effect size were marred by poor reporting.  
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Clear reporting is also indispensable when seeking to translate beneficial interventions into 
clinical practice. Comprehensive accounting of the interventions given to participants in a 
trial is the only approach to guarantee that clinicians can identify and replicate desirable 
treatments safely135. The poor description of interventions has been cited as a major 
barrier to the implementation of research findings into practice136, while inadequate 
description could even cause interventions to be carried out incorrectly, potentially to the 
detriment of resource–use and patient health137. 
Transparent accounting of trial design, conduct and analysis has been a central 
consideration of the evidence–based movement for almost two decades138. Faced with 
empirical evidence that poor reporting of trials was preventing assessments of their 
methodological quality139, a large group of investigators developed the CONsolidated 
Standards Of Reporting Trials (CONSORT) in the early 1990s139–140. The resulting 
checklist was first published in 1996, and itemises which aspects of trial design and 
conduct should be reported in order to ensure that studies are presented in such a way 
that they can be clearly and independently interpreted138. These standards have 
subsequently been revised twice in line with improvements to the evidence–base141–142, 
and are now endorsed by over 50% of the core medical journals143. Since the original 
guidelines targeted parallel treatment RCTs, the most common design, several extensions 
have also been developed to standardise and improve the reporting of different study 
designs (cluster144, non–inferiority/equivalence145 and pragmatic146 RCTs) interventions 
types (non–pharmaceutical147, herbal medicine148 and acupuncture149 interventions), and 
data types (harms150 and abstracts151). Although cross–sectional surveys of published 
trials attest to a poor general level of reporting quality152, the indications are that the 
situation is improving as a result of the CONSORT drive to improve standards of RCT 
research118,153. 
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1.2.7 Summary 
This overview of the methodological basis of RCTs has outlined the threats to a trial‟s 
validity and interpretability that result from using inappropriate approaches to trial design 
and conduct. Nonetheless, many investigators have succeeded in performing rigorous 
trials, that implement the necessary controls to provide reliable and useful evidence for the 
effectiveness of treatments154.  
Using RCT designs to evaluate different types of interventions is not always guaranteed to 
be as successful, however. There is a growing literature that suggests complex 
interventions of various clinical disciplines may be less well suited to evaluation by RCT 
due to the feasibility of implementing the strict methodological controls required to produce 
unbiased evidence. For example, researchers cite the ethical and practical difficulties of 
blinding patients and care–providers to different types of surgery155, or to competing critical 
care services156, or the impossibility of comparing psychiatric treatments in a controlled 
environment when they are so variable and tailored to individual patients157. Although test-
treatment interventions seem not to have been described previously as complex 
interventions, several researchers have expressed similar concerns that the RCT may also 
not be feasible when comparing test-treatment interventions. The following section reviews 
these criticisms.  
1.3 Challenges to the usefulness of test-
treatment RCTs 
 
As discussed earlier, the ideal approach to evaluating diagnostic tests heralds the RCT as 
the theoretical ideal for establishing patient outcome effectiveness. Yet this notion appears 
to have been transposed somewhat automatically from the treatment effectiveness 
paradigm. With the predominant focus of diagnostic research on test accuracy, very few
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studies have been conducted that address the suitability of RCT designs for evaluating the 
effectiveness of diagnostic tests.  
Diagnostic interventions differ considerably from treatment interventions, since in order to 
evaluate tests trials must assess them as components of management strategies that also 
incorporate decision–making and treatment. The resulting complexity of these 
interventions has led some researchers to question the feasibility of conducting high–
quality test-treatment RCTs in view of the unique challenges that these attributes may 
pose. This section summarises four particular challenges that are often cited to limit the 
usefulness of test-treatment RCTs. 
1.3.1 Availability of trial evidence 
The ability to rely on evidence from trials assumes that such evidence exists. Yet 
researchers and guideline developers alike suggest that test-treatment RCTs are rare16,18–
19,21,51,95. Clearly the absence of top-ranking evidence will mean that reviews will have 
difficulty in providing the detailed guidance that is needed on which tests will improve 
downstream patient outcomes.  
Trial findings are notably absent in conferences9, while the explosion of prominent 
research into test accuracy methods, and accompanying increase in primary test accuracy 
studies, has perhaps encouraged patient outcome effectiveness research to focus on 
methods for linking accuracy findings to trial evidence of treatment effectiveness, thus 
bypassing the need to consider the more time–consuming and laborious approach 
required to get direct evidence through RCTs. Indeed many claims that RCTs are rare can 
be traced to works that expound the advantages of decision modelling to overcome the 
practical and methodological difficulties entailed in carrying out comparative effectiveness 
trials of tests6,8,21,84,87–88. While the substantial challenges involved in designing, conducting 
and interpreting these studies lend credence to this assumption of scarcity, there is some 
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evidence that these claims may be justified. An early overview seeking to characterise the 
sorts of evidence available for the performance of MRI failed to find any RCTs of clinical or 
patient outcome impact from a systematically–derived cohort of 285 articles published in 
1981–198748. Taking a random sample of imaging evaluations from two radiology journals 
published in 1988–1989, Taylor and colleagues52 found that only 16% (24/146) assessed 
clinical impact. Though the authors did not report how many of these where randomised 
trials, the implication must be that RCTs formed a small proportion – if any of the 24 
articles retrieved. What is more the authors did not mention patients at any point in their 
analysis, hinting that patient outcome RCTs were probably absent from their cohort of 
studies. 
More recently, the dearth of trials has been reported by reviewers attempting to synthesise 
available evidence. Of the few systematic reviews that address patient outcome 
effectiveness, most have failed to locate relevant test-treatment RCTs24,158–164. Similarly, 
none of the three diagnostic assessment reports published by the NICE DAP so far has 
identified any test-treatment trials165–167. 
Though such findings do indeed support suggestions that RCTs are rare, the evidence is 
limited. It is also somewhat indirect considering that no study has yet sought to verify 
exactly how many test-treatment RCTs exist, while there could be other explanations for 
their absence in systematic reviews. 
It is not clear, for example, to what extent it may be due to difficulties in identifying these 
studies. Efforts to develop reliable search methods for reviews of test accuracy have by 
and large failed to produce high search sensitivities with acceptable levels of precision168 
(see however the recent work of Monica Kastner and colleagues169). Bibliographic indexing 
terms for diagnostic studies have, until very recently170, simply not existed, a factor known 
to have reduced the accuracy of these searches171. These difficulties have been 
compounded by a widespread inconsistency in the application of diagnostic content 
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terminology, as suggested by the variation in performance of search strategies according 
to the clinical question under evaluation172–173. 
By comparison, the synthesis of diagnostic effectiveness research is a relatively new 
endeavour that has yet to receive attention with regard to the development of methods for 
the identification of randomised test-treatment trials. Here, study ascertainment may 
present an even greater challenge. As described above, diagnostic tests are evaluated 
alongside treatment pathways for which a considerable volume of therapeutic evidence 
may well exist that is not per se relevant to the diagnostic question being evaluated. In 
view of the many thousands of trials published every year133, finding test-treatment trials 
that are not indexed as such is likely to prove very difficult. 
1.3.2 Internal validity of test-treatment RCTs 
As described above, threats to the internal validity of RCTs have been well delineated, and 
though the use of inadequate methodological safeguards is shown to cause systematic 
deviations of treatment effects, these can be avoided through judicial planning. Although 
RCTs have therefore maintained their archetypal status as the most reliable 
measurements of treatment effectiveness17, concern has arisen that randomised 
comparisons of test-treatment interventions may commonly fail to provide reliable 
contributions to the effectiveness evidence–base21,51,174–175. This obstacle is hypothesised 
to stem from an underlying incongruity between the complex composition of test-treatment 
interventions on the one hand, and the feasibility of implementing the adequate 
methodological safeguards needed to maintain a trial‟s internal validity on the other.  
S e l e c t i o n  B i a s  
The earlier overview of bias in randomised controlled trials summarised how the distortion 
of treatment effects due to selection bias is mainly driven by unconcealed randomisation 
procedures which allow patient allocation to be influenced by clinicians‟ existing beliefs 
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surrounding the effectiveness of interventions under study. As Wood and colleagues note, 
selection bias should be increased in situations where it is easier for clinicians to assess 
patients‟ prognoses regarding treatment response107. Since randomisation to tests will 
occur earlier in the management process than for treatment RCTs, fewer prognostic 
indications should exist at the time of allocation to test-treatment interventions. Moreover, 
as the methods of concealing allocation schedules are not related to the type of 
intervention under study we can therefore expect no greater impediment to a properly 
randomised and secure allocation procedure in test-treatment evaluations.  
P e r f o r m a n c e  a n d  A s c e r t a i n m e n t  B i a s  
Conversely, some have argued that it may be impossible to control for performance 
bias22,79,176–177. Since tests produce data that must be interpreted in order to select 
between various treatment or other management options, in many circumstances it may 
be impossible to mask the identity of the tests themselves from clinicians22,79. 
Consequently, as patients are often involved in treatment selection, and their care–
providers are aware of group allocations, then effective blinding of participants could also 
be hampered44. Indeed, cursory examination by one author of four published test-
treatment trials found that none reported any form of blinding, suggesting these fears may 
be born out in reality174. These difficulties raise the possibility that the results of trials could 
reflect a measure of current clinician and patient expectations, rather than true differences 
in the effectiveness of test-treatment interventions. On the other hand, methodologists 
argue that it should generally be feasible to blind outcome assessors and thus control for 
ascertainment bias22,44,174. 
A t t r i t i o n  B i a s  
RCT evaluations of complex interventions are vulnerable to increased drop–out rates due 
to the multiple phases of treatment that patients are required to adhere to178, an obstacle 
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also reasoned to affect test-treatment evaluations176. Since the quality and type of 
information patients receive may differ according to the test to which they have been 
randomised, these trials may also be susceptible to differential drop–out and so are at an 
increased risk of serious attrition bias176. As described above the principle of intention–to–
treat, or „intention–to–test‟, helps to limit this bias in any trial design and so remains 
relevant to the test-treatment RCT6. However, Blackmore makes the case that conducting 
these analyses alongside sizeable reductions in patient compliance rates could 
deleteriously affect a trial‟s power to detect the desired clinically important difference and 
so expose findings to the risk of type II error175.  
P o w e r  
Though not a bias, the risk of falsely concluding the absence of an effect due to 
inadequate sample size constitutes an important threat to the validity of any trial, as 
detailed earlier in the chapter. However the hazards of insufficient power may present a 
greater challenge to the design and conduct of test-treatment trials, that are conceived to 
require far larger study populations than is typical for treatment trials176,179–180. It is 
hypothesised that in the majority of comparisons the potential benefits of downstream 
treatment will only be experienced by patients who are reclassified as a result of receiving 
a more accurate test, and so receive a more beneficial treatment176–177. Consequently the 
overall treatment effect will be diluted by what Pletcher and Pignone177 refer to as the 
„unreclassified fraction‟, namely the subgroup of patients who would receive the same 
diagnosis and treatment by both tests under evaluation. Since differences in the diagnostic 
sensitivity of comparative tests are unlikely to be considerable6,51, the „reclassified fraction‟ 
is expected to represent a small subset of the study population; as a result, sample sizes 
will need to be several orders of magnitude larger than is usual for single intervention 
trials, for whom the treatment effect could be experienced by all randomised 
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participants176,179. Trials failing to recognise this methodological peculiarity therefore risk 
being underpowered to detect differences in patient outcomes. 
The results of a small systematic study begin to suggest that this need has yet to be met, 
however. Prompted by the publication of four trials finding no clinical or health benefits 
from the use of fetal fibronectin (FFN) testing in women with threatened preterm labour, 
the authors set out to investigate whether these „negative‟ findings could be explained by 
problems with the design of those trials181. The authors found that only two of the four 
included trials adjusted the power calculation to account for the unreclassified fraction. 
1.3.3 Utility of trial evidence 
Aside from the ability to conduct evaluations that are internally valid, researchers suggest 
that the evidence produced by test-treatment trials may often be difficult to interpret and 
even trickier to use. While the clear reporting of methodological safeguards should be 
equally possible for these studies, the utility of trial evidence may be threatened by the  
increased intricacy required to describe interventions that consist of multiple healthcare 
components176. Moreover, as with other types of complex intervention, test-treatment 
strategies are in fact greater than the sum of their parts182: they not only demand adequate 
description of two healthcare interventions, a test and a treatment, but they should address 
the decision–making processes that occur between the two.  
The recent CONSORT extension for trials of non–pharmaceutical interventions 
emphasises the enhanced requirements needed to document these therapies, which like 
test-treat strategies often include multiple interacting interventions147. The authors 
summarise how such surgical techniques, rehabilitation programmes and behavioural 
interventions have been found to suffer from poor reporting due to their complexity, and 
the resulting possibility for variation in how they are implemented across the healthcare 
services.  
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Similarly, diagnostic decision–making is also likely to be difficult to describe in trial 
protocols, and perhaps more so than non–pharmaceutical therapies since tests create 
different patient subgroups, each of which may receive further testing and multiple 
treatments. Moreover, diagnostic and therapeutic decisions are highly variable. They vary 
between clinicians according to skill, expertise183 and individual attitudes to the balance of 
risks resulting from missing diagnoses or over–treating patients65. Decisions taken on a 
particular test result also vary within individual clinicians; not only is the interpretation of 
diagnostic information likely to evolve as familiarity with a particular test increases6,44, but 
the same test results in the same patients are shown to produce different diagnostic 
interpretations according to the nature of prior information available184. So, even if tests 
and treatments are well–described, it may be considerably challenging to outline the 
approaches used to interpret test results and select subsequent treatments, particularly to 
a degree sufficient to enable these interventions to be reproduced in practice79,174,176. 
Previous examinations of test-treatment trial reports have found it difficult to deduce how 
treatment decisions followed from test results76,181; Vis and colleagues failed to find any 
evidence for how test–treat decisions should be made in all four included RCTs181. Yet 
without a protocol which directs how test information should lead to diagnostic decisions, 
and subsequently to treatment selections, it is impossible to construe the meaning of 
observed effects since we cannot be sure of which processes are actually being 
evaluated22,79. Moreover, if there is no pre–specified instruction on how tests results should 
be used, clinicians taking part in trials may not have sufficient guidance to respond to 
diagnostic information, and to do so consistently. This could lead test-treatment 
interventions to fail in demonstrating an effect due to inadequate implementation of the 
tests involved, rather than through lack of their effectiveness76 .  
Consequently, if the complexity of test-treatment trials means users of evidence cannot 
discern what is being evaluated and how test–treat strategies are being used, it will be 
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impossible to interpret trial findings, compare them across studies or to use beneficial 
interventions in practice. Test-treatment trials therefore run a high risk of not being 
informative. 
1.3.4 Full evaluation of intervention effects 
A final criticism regarding the utility of trials, albeit one that is encountered more rarely in 
the literature, is that they may fail to fully evaluate test-treatment interventions. 
The demonstration of an intervention‟s value is produced by outcomes, hence the choice 
of what is to be measured in a trial is a fundamental aspect of its design and execution185. 
Evaluating outcomes which fail to measure all important effects of an intervention 
adequately are likely to misrepresent its effectiveness, with potentially serious implications 
for the content of future healthcare policy decisions. Outcomes which are too narrowly 
focussed on capturing an intervention‟s benefits, for example, may not be sensitive to an 
intervention‟s harms and could lead a trial to conclude a more beneficial impact than may 
be present in reality. Essentially, a trial may completely miss a potentially beneficial or 
detrimental effect if the selected outcome measures have not been designed to capture it.  
It is well recognised that the selection of which endpoints can offer useful and 
comprehensive measures of treatment effect is a complex task fraught with many 
difficulties185, which must also take into account the validity of outcome measures and 
importance of outcomes to patients186. Current thought alludes to a potential increase in its 
intricacy when we come to consider trials of test–treatment strategies, however. The 
outcome measurements are further removed from the intervention of interest (the 
diagnostic test) by a second interventional stage (the treatment), as well as the diagnostic 
and treatment decision-making processes in between. Thus there is said to be an indirect 
relationship between cause and effect, whereby the end measurement of effect captures 
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not only the impact of testing, but also of the subsequent decision–making and 
treatments59,77,175,187. This creates two complications for trial design.  
First, tests can affect patient outcomes in several ways. Some tests can cause direct harm 
as a consequence of undergoing testing; CT for example exposes patients to radiation, 
which increases an individual‟s lifetime risk of developing cancer188, while endoscopic 
techniques are invasive and can cause more immediate harm due to procedural 
complications189. Other tests may reassure patients as to the absence of serious 
disease48,175,190; in individuals with Chronic Daily Headache, a group of conditions in which 
sufferers experience frequent and long–lasting headaches191, neuroimaging has been 
shown to reassure as to the absence of serious organic disease192. Most tests are 
expected to alter downstream health indirectly through improvements to treatment 
selection afforded by better diagnostic accuracy and more appropriate decision–
making14,193. However, several researchers note that accurate tests do not necessarily 
translate into health improvements because of the intervening requirement for them to 
enhance decision–making14,44–46,193. The results of diagnostic and therapeutic impact 
studies support this theory, finding that more accurate tests can fail to change diagnostic 
decisions, while tests that change diagnoses do not always lead to improvements in 
treatment selection. For example, contrast–enhanced CT was shown to change diagnoses 
in 32% (40/125) of emergency patients with acute abdominal pain, and alter treatment 
plans in 25% (31/125)194. The authors focussed on the seemingly similar percentages of 
change, however when cross–tabulated only 11% (14/125) experienced a change in both 
diagnosis and treatment plan; 65% (26/40) of changed diagnoses failed to be followed by 
alterations to treatment plans, while 55% (17/31) of all changed treatment plans were not 
preceded by a change in diagnosis. The intricacies of how tests affect outcomes are 
therefore likely to increase the number of potential effects in test-treatment trials, and so 
the number of processes that need to be measured.  
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Second, as patients are randomised before testing but the treatments they receive vary 
according to their diagnosis, test–treatment populations will include patients with different 
diagnoses, receiving a variety of treatments. Deeks has highlighted how this increases the 
number of patient outcomes that must be taken into account for a single trial176. Though 
investigators may primarily be concerned with how well a test can detect a particular 
disease, restricting measurements to outcomes that evaluate the response to treatment for 
a single „target condition‟ will provide incomplete evaluations of effectiveness. This is 
because not all randomised patients will be free of disease; some individuals with negative 
diagnostic indications for the target condition will have another disease, as may some of 
those who incorrectly receive a positive diagnosis for the same condition. Since the 
consequences of incorrect diagnosis and/or inappropriate treatment are likely to vary 
between conditions, Deeks contends that these trials need to measure health events 
relevant to all included patients176.  
In summary, because both the number of process effects and of patient outcomes are 
increased in test-treatment comparisons, identifying and measuring them all could prove 
very challenging. In view of the dominance of test accuracy perspectives which stipulate 
the focus on single target conditions, these notions are arguably unlikely to have been 
incorporated in existing RCTs. However, in the absence of research that appraises the 
appropriateness of outcome selection in RCTs, the veracity of this statement remains 
unknown. 
1.3.5 The need for research  
These four areas of potential methodological difficulty threaten the suitability of the RCT to 
questions of diagnostic effectiveness. It is clear that if they are confirmed, it will be 
impossible to produce trial results that are free from bias, and upon which we can rely to 
conclude whether tests have succeeded in changing patient health and clinical decision–
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making for the better. Indeed such a finding would seriously call into question whether the 
RCT can be upheld as the archetypal study design for diagnostic health technology 
appraisals, as is the norm for treatments. Equally, as opinion that test-treatment RCTs are 
often „unattainable‟ begins to spread16, these potentially valuable study designs may be 
avoided unnecessarily if certain issues are discovered to be less challenging than feared. 
Indeed, some authors are more optimistic arguing that though the prospect of producing 
trials is difficult, the existence of completed RCTs suggests the issues entailed are 
surmountable8,57. None of these claims, whether supportive or antithetical to the utility of 
test-treatment RCTs, has so far been defended by an empirical appraisal of the studies 
themselves. Research is needed to verify the extent to which these concerns are 
encountered in test-treatment trials that have been completed. 
1.4 Research questions & thesis overview 
 
1.4.1 Research questions 
Due to the current discord between the RCT‟s traditional standing as the „gold–standard' 
for evaluating the patient outcome effectiveness of diagnostic tests and hypotheses that 
they may not actually be useful, the main aim of this thesis is to investigate how useful 
RCTs are for evaluating the patient health impact of diagnostic tests. This central 
research question will be answered through four secondary aims, each designed to 
evaluate a key methodological challenge that has been posited to impinge on the utility of 
test-treatment RCTs: 
1. Are test-treatment RCTs feasible? 
2. How informative are test-treatment RCTs? 
3. Are test-treatment RCTs internally valid? 
4. Do test-treatment RCTs fully evaluate their interventions? 
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1.4.2 Thesis overview 
The review of methodological challenges to the utility of test-treatment trials highlighted the 
scarcity of evidence to either support or refute the four criticisms. In order to provide this 
evidence, each of the four thesis aims will be addressed by examination of published test-
treatment trials. Chapter 2 presents the methods used to systematically identify a 
representative cohort of published test-treatment RCTs, which will form the basis of all 
further analysis into the methodology. The search strategy and study selection process are 
described, along with the general characteristics of the final group of published test-
treatment RCTs. 
1.4.3 Aim 1: Are test-treatment RCTs feasible?  
Recognising that there may be substantial challenges involved in conducting test-
treatment RCTs, a key question is whether these studies can be completed successfully. 
The availability of published evidence is likely to be one marker of a study design‟s 
feasibility. Though current thought argues that test-treatment trials are rarely conducted, 
there are as yet no studies that explore how many trials are published, nor any that 
investigate what questions these „successful‟ trials have been designed to answer.  
Chapter 3 seeks to ascertain how rare test-treatment trials really are, in order to establish 
whether RCTs are currently useful for providing the evidence that is needed on which tests 
will improve patient outcomes. Acknowledging that these studies may be very difficult to 
find, and thus the search conducted in chapter 2 may have missed some relevant trials, 
chapter 3 presents a different search strategy and compares it to the results of the original 
search. The „capture-recapture‟ technique, developed by ecologists, is used to estimate 
the number of relevant RCTs missed by both strategies. This allows the total number of 
test-treatment trials published during the study timeframe to be estimated. 
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Chapter 4 aims to characterise the diagnostic settings in which RCTs have been executed 
to completion. It describes the cohort of trials identified in chapter 2, provides a descriptive 
overview of the diagnostic questions evaluated by published test-treatment RCTs and 
offers an insight into their methodological approaches. This contextual understanding will 
also serve as a basis for generating hypotheses regarding methodological or practical 
limitations that are discovered in the following chapters. 
1.4.4 Aim 2: How informative are test-treatment RCTs? 
The complexity of test-treatment interventions is also hypothesised to inhibit the 
interpretation of trial findings, the appraisal of their quality, and their translation into 
practice. The extent to which test-treatment trials are not informative is explored in 
chapter 5 by critically appraising the reporting of trial conduct. Perceived barriers to the 
reporting of these studies are discussed by reference to the study characteristics, 
described in chapter 4. 
1.4.5 Aim 3: Are test-treatment RCTs internally valid? 
The second challenge to the utility of trials relates to claims that these interventions may 
be particularly susceptible to several biases due to their complexity. To date, however, 
there are no substantial empirical appraisals of published studies, as have been conducted 
in other areas of healthcare research.  
Chapter 6 aims to substantiate the extent to which these trials are predisposed to the 
biases that are claimed to affect them by appraising the methodological quality of trials 
identified in chapter 2. In the chapter‟s discussion, findings are compared to similar 
reviews of treatment RCTs and complex interventions in order to establish the relative 
susceptibility of test-treatment interventions to selection bias, performance bias, 
ascertainment bias and attrition bias. 
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1.4.6 Aim 4: Do test-treatment RCTs fully evaluate their 
interventions? 
The number of ways in which test-treatment interventions exert their impact on patient 
health is increased, by comparison to single treatment interventions. The final challenge 
therefore speculates that identifying and measuring all important effects may prove very 
challenging. In order to evaluate this contention, the ideal analysis would appraise the 
appropriateness of outcome selection in included trials. In order to be reliable, such a 
judgement would require extensive clinical expertise to be able to identify the most 
important outcomes for the full range of diagnostic settings included. Importantly, the 
appraisal would have to be adjudicated by reference to a solid theoretical understanding of 
how test-treatment interventions cause treatment effects. This theory was found to be 
lacking and in urgent need of development.  
In order to address this important deficit, Chapter 7 develops a theoretical framework that 
conceptualises all the ways in which tests influence health outcomes. It achieves this by 
synthesising existing theoretical notions, and using them to generate a preliminary 
explanatory model. This model is tested, refined and explained by examination of the 
project cohort of published test–treatment RCTs using analytic inductive methods. 
Based on the author‟s experience of using this framework to interpret test-treatment RCTs, 
chapter 8 develops the conceptual framework into a practical tool. The tool is presented 
as a checklist and accompanying graphic schema, and its value to the design, 
interpretation and appraisal of test-treatment RCTs is illustrated by worked examples, 
derived from the project cohort. 
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1.4.7 Central research question: how useful are test-treatment 
RCTs for evaluating the patient health impact of diagnostic 
tests? 
Chapter 9 summarises the main research findings from chapters 2–8, and discusses the 
evidence they provide to address each of the four challenges. This argument is drawn 
together in the final conclusion to answer the overall aim of the thesis. The implications of 
these conclusions for practice and research as well as general limitations of the thesis are 
also discussed.  
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Finding test-treatment 
trials  
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This chapter presents the methods used to identify a cohort of published test-treatment 
RCTs, which are analysed with regard to their clinical context, reporting quality and quality 
of methods in subsequent chapters. The search strategy and study selection process are 
described, along with the general characteristics of the final group of published test-
treatment RCTs.  
In order to examine and develop the methodology that underpins evaluations of test-
treatment interventions, it was first necessary to identify a group of primary studies that 
could highlight the strengths and weaknesses of current research practice. Since the chief 
concern was that these studies should be representative of their study design, a 
systematic method of study ascertainment was selected. 
Systematic search methods hold an eminent position in evidence-based medicine, since 
the reliability with which evidence synthesis is produced depends on the ability to identify 
and incorporate all best evidence123. By incorporating comprehensive searches that are 
objective, and hence reproducible, the systematic review minimises bias in the collection 
of data to the increased validity of resulting effect estimates of healthcare interventions. 
The aims of this search differ slightly from those of systematic reviews designed to inform 
a specific clinical treatment question. So as to characterise the breadth of test-treat 
questions evaluated by these studies (reviewed in Chapter 4), searching was not limited 
by patient group, condition or test technology. Secondly, the search was not intended to be 
exhaustive, i.e. to identify all published test-treatment RCTs ever published, but was aimed 
at generating a group of trials whose analysis of methodological quality could be 
generalised to all test-treatment RCTs.  
Throughout the thesis included trials are listed separately from other references, 
and citations numbers (1–108) are prefixed by the letter ‘T’. 
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2.1.1 Search strategy development 
A search strategy was developed to identify test-treatment RCTs that had been published 
in academic journals. Designed to retrieve as many relevant trials as possible, the initial 
strategy sought to identify studies that evaluated an aspect of a diagnostic test in an RCT 
design, and was developed using Ovid Medline, a database that uses articles indexed by 
the United States National Library of Medicine (US-NLM). Since test-treatment trials are 
not currently indexed as a specific study type, the search concepts were taken from the 
key methodological elements required of included studies, defined simply as: ‘diagnosis’, 
‘randomised controlled trial’ and ‘treatment’. Search terms representing each of these 
concepts were identified, and three similar strategies were tested (Appendix A.1, p. 350), 
each variation focussing on both the different sensitivity and precision of two RCTS 
method filters, and the inclusion of the term ‘control$’ (where $ denotes an unlimited 
truncation). Their combined yields were so considerable as to be considered 
unmanageable (31,896 to 187,895), largely due to their inclusion of a high proportion of 
evidently non-experimental study designs or therapeutic evaluations.  
2.1.2 Final Search Strategy 
In order to obtain more precise results, searching was performed in a bibliographic 
database known to contain a higher proportion of relevant study designs. The Cochrane 
Central Register of Controlled Trials (CENTRAL) includes all reports of RCTs indexed 
through highly sensitive searches of both Medline and Embase, as well as handsearched 
material, and other additional extensive database searches contributed by the Cochrane 
specialised registers195–196. This multisource composition also offered the potential to 
identify articles not included in the US-NLM.  
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The structure of the final strategy was also modified, through an examination of terms 
appearing across all fields in five test-treatment RCTs, found by the author during 
development of the search strategy(T59–T61,T65,T71). Terms denoting a generic phase of 
treatment, as opposed to individual, condition-explicit treatments, were found to be too 
non-specific to discriminate test-treatment from treatment only RCTs, and so were 
discarded (Table 2.1).  
Terminology relating to the concept of ‘diagnosis’ again tended to be specific to test 
technologies (e.g. ‘imaging’ or ‘microbiology’) or test types (e.g. ‘computed tomography’ or 
‘microbial sensitivity test’). However all five articles used a variant of the term ‘diagnosis’ in 
either their title, abstract or keywords, while two also referred to ‘sensitivity’ in the abstract 
or keywords. All other terms commonly included in diagnostic accuracy filters were notably 
absent, including ‘specificity’, ‘accuracy’; ‘prediction’, and ‘detection’172–173,197. ‘Test’ was 
referred to in two articles(T59,T71), however was considered too non-discriminatory to include 
in the strategy. Under advice from an information specialist working for the Cochrane 
Collaboration, and highly experienced in designing searches for diagnostic test accuracy 
reviews (Anne Eisinga, Diagnostic Test Accuracy Working Group, UK Cochrane Centre), 
two strands were added to limit CENTRAL results to randomised trials. A textword 
Search strategy Hits 
#1 sensitiv* or diagnose or diagnosis or diagnostic* in Clinical Trials 70,052 
#2 random* in Clinical Trials 335,175 
#3 "study design" next "rct" in Clinical Trials 150,275 
#4 (#2 OR #3) 449,453 
#5 (#1 AND #4) 50,419 
#6 (#5), from 2004 to 2007 12,892 
Table 2.1: Search strategy for test-treatment RCTs conducted in CENTRAL Issue 2 2009 (Wiley 
InterScience, searched 29 May 2009) – general diagnosis textwords across all fields 
limited to publication years 2004 to 2007 (12,892 records). *denotes truncation of search 
term. 
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component sufficed to pick up Medline RCTs, while Embase and heandsearched RCTs 
were targeted by the specific study type added to these studies by Cochrane indexers198. 
CENTRAL (2007, Issue 2) was searched using this strategy without language restriction, 
succeeded in identifying the five relevant references that had been identified previously, 
and so was adopted. A timeframe of the most recent four years was selected, and in order 
to ensure that all relevant trials had been found by Cochrane indexers and included in 
CENTRAL, the final search was updated in 2009 (29 May, Issue 2). 
2.2 Study Selection 
 
Electronic search returns were imported as text files into Microsoft Access 2007. All entries 
were cross-checked for duplication using a title-matching query function, and removed 
from further review. The selection methodology complied broadly with that of a systematic 
review, the only exception being the absence of a necessity to identify all target studies. 
Titles and potentially relevant abstracts/full papers were screened by the author to 
determine study relevance.  
2.2.1 Study eligibility 
Inclusion criteria dictated the selection of study type, diagnostic setting and outcomes 
measured. Only English-language papers were considered. 
Study Type  
Randomised controlled trial evaluating two or more test-treat strategies. Eligible test-
treatment RCTs randomised patients to two or more testing strategies, subsequently 
provided treatment based on the results of the strategies, and measured at least one 
downstream patient outcome.  
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To be considered an RCT, the study had to contain an explicit statement that study 
patients were randomly assigned to comparative groups, as outlined in the revised 
CONSORT statement121.  
Diagnost i c  se t t ing  
Any clinical test used to classify symptomatic disease for the purposes of treatment 
planning. For the purposes of analysing a single methodological question, selection was 
limited to what could be considered the most common purpose of testing in healthcare: the 
single use of a test in an individual with suspicious signs or symptoms. This encompassed 
tests used to rule suspected disease in or out, to otherwise further a differential diagnosis, 
or to determine the stage or progression of existing disease. Tests used to detect 
preclinical disease in asymptomatic individuals (e.g. population screening), to monitor 
disease using serial testing (e.g. for treatment titration or ongoing observation), or purely to 
establish a prognosis without assisting treatment decisions (e.g. to estimate the likelihood 
of a future health state) were excluded. Tests were not limited by type, and all modalities 
were included. 
Out com es  
Measurement of at least one downstream patient health outcome. These were defined as 
any markers of disease, physiological or psychological status pertaining to an individual, 
that describe an attribute of a subject’s health after the full test-treatment intervention has 
been implemented. Studies that only measured patient outcomes during intervention 
implementation, for example after the test but before treatment, were excluded. 
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2.2.2 Screening Process 
Ti t l e  scr een  
Titles were selected for review of the study abstract if they reported either a generic 
diagnostic term (e.g. ‘assessment’, ‘diagnosis’, ‘examination’) or a particular diagnostic test 
(e.g. ‘ultrasound, ‘radiography’, ‘oximetry’). Titles were excluded if they clearly described a 
study that was: 
 Not an RCT design 
 A treatment RCT  
 An accuracy study of non-RCT design 
Abst ract  and f u l l  paper  scr een  
Abstracts were reviewed by the author using a selection proforma (Appendix A.2, p. 352) 
detailing the full inclusion criteria summarised in table 2.2. Full papers were ordered for all 
potentially relevant entries, as well as those for whom abstracts were unavailable. Final 
selection was conducted on the basis of the full article, and related publications were 
traced for further information. This included searching for associated results of included 
published protocols up to the end of 2009, in order to maximise the project sample size. 
Test-treatment RCTs that only reported downstream patient outcomes in a related 
publication were included.         
1. Randomised trial evaluating a test, i.e. patients randomised to one of two or more 
diagnostic strategies 
2. Incorporation of a treatment phase, contingent on test results 
3. Evaluation of patient outcomes after treatment 
4. Test used for diagnosis or staging 
5. Full paper in English Language 
Table 2.2: Summary of study eligibility criteria 
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2.3 Search Results 
 
 
The search strategy retrieved 12,892 citations (Figure 2.1). After eliminating duplicates, 
the author checked 12,706 unique titles and excluded 88% on the basis that they were 
plainly evaluations of a treatment or a non-RCT study design. Of the remaining 1,569 
abstracts, 1262 were excluded for reasons summarised in table 3.3, and 307 full reports 
Multiple publications 
n=21 
 
Full papers excluded 
n=178 
 
Abstracts excluded 
n=1262 
 
Duplicates excluded 
n=186 
 
Titles retrieved 
n=12,892 
Full papers reviewed  
n=307 
Test-Treatment RCT 
papers selected  
n=129 
Test-Treatment RCT 
studies 
n=108 
Figure 2.1: Study selection process for records retrieved by the final search strategy (CENTRAL 
2009, Issue 2) 
Titles excluded 
n=11,137 
 
Titles reviewed 
n=12,706 
Abstracts reviewed 
n=1569 
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were reviewed for more detailed consideration. In the final stages of selection, most 
exclusions were observational or descriptive evaluations of diagnostic tests (42%), such as 
test development or accuracy studies, while 20% were treatment evaluations that 
generally referred to a diagnostic test in the title (Table 2.3). In total 201 test-treatment 
RCTs were found, of which 64 did not evaluate patient outcomes and 9 did not provide 
treatment on the basis of test results, leaving 129 articles that met the predefined inclusion 
criteria. Common examples of excluded studies are tabulated in Appendix A.3 (p. 353).  
Search precision, defined as the proportion of relevant articles in the total number of 
citations found, was therefore very low (1.0%, 128/12,706) with the author needing to read 
100 titles to identify one relevant test-treatment trial (Table 2.4). Slightly fewer trials were 
published between 2006 and 2007 (n=59) than the preceding two years (n=70), though as 
Reason for exclusion Abstract Full paper Total 
Non RCT evaluation of a test 599 11 610 
Test RCT, no treatment 192 22 214 
Test-Treat RCT, no patient outcomes 37 27 64 
Test-Treat RCT, treatment not contingent on test results  6 3 9 
Evaluating a different test (e.g. monitoring, screening etc) 80 66 146 
Evaluating a treatment (any design) 261 20 281 
Other study (e.g. case-control, cohort, behavioural interventions) 76 12 88 
Foreign Language 8 17 25 
No abstract 3 0 3 
Total 1262 178 1440 
Table 2.3: Reasons for excluding citations from the project cohort 
Year 2004 2005 2006 2007 Total 
Articles published per year 32 38 30 29 129 
Search results 3133 3290 3225 3058 12706 
Search yield 1.0% 1.2% 0.9% 0.9% 1.0% 
Table 2.4: Absolute number of test-treatment RCTs published every year 
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search results were consistent across the four years this creates a marginally lower search 
yield for 2006–2007 (Table 2.4). 
2.3.1 General characteristics of included trials 
When 20 multiple publications were taken into account, the final project cohort consisted of 
108 unique test-treatment RCTs evaluating at least one downstream patient outcome(T1–
T108). Most trials were documented in a single results publication (92, 85%). For the 
remainder, 12 trials (11%) were reported across two articles (e.g. trial design protocols, 
economic analyses or long-term results), three trials (3%) were reported across three 
articles, and one (1%) was reported across five articles.  
Five trials were only published as protocols, with no traceable trial results as of December 
2009.  
The 128 articles were published in 90 different journals, the majority in specialty journals 
(84, 65%). The highest number of reports appeared in Radiology (n=6), Health Technology 
Assessment (n=4), Human Reproduction (n=4), and The New England Journal of Medicine 
(n=4), while approximately two thirds (62, 69%) of journals published a single test-
treatment RCT evaluating health outcomes during the four years.  
2.3.2 Challenges in identifying the relevance of studies 
In certain cases it was difficult to determine an article’s relevance to the project. These 
difficulties arise out of the project’s need to limit the scope of relevance to questions of 
symptomatic diagnosis and staging. In practice however the juncture between the five 
diagnostic settings, that is between screening, diagnosis, staging, monitoring and 
prognosis, can be far from distinct. Similarly, the distinction between diagnostic and 
therapeutic interventions can become blurred, particularly when the two are conducted as 
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part of the same procedure. In order to ensure the reproducibility of the study selection 
process, a few examples of these decisions are described below: 
I s  t he  t es t  under  eva luat ion  used fo r  s cr eening  or  d iagnos i s?  
The most common difficulty was the need to distinguish between tests used for ‘screening’ 
or for ‘diagnosis’. According to the definitions set out in chapter 1 (p. 4–5), in principle 
screening tests differ from diagnostic tests by their intended purpose; namely the former 
are used to detect early disease in asymptomatic individuals. By contrast, diagnostic tests 
are used to establish the cause of a presenting complaint. However, since these functions 
occupy adjacent positions along the wide spectrum of clinical decision–making, there can 
be some uncertainty in discerning between the two when the clinical setting takes place at 
their boundary. Key to these decisions is defining whether the target population is 
‘asymptomatic’, and can therefore be considered ‘preclinical’. The author’s rationale for 
these decisions is clarified by illustrating two test-treatment RCTs, one of which was 
ultimately excluded and the second included. 
The first of the two examples consists of a trial evaluating two imaging regimes to detect 
Down’s syndrome in the unborn foetus199. Pregnant women at ≤13+2 weeks gestation 
were randomised to receive an ultrasound scan (US) at 12 weeks (experimental 
intervention) or at 18 weeks (standard care). The purpose of the US was to measure the 
degree of nuchal translucency, which is strongly associated with Down’s syndrome. 
Women with abnormal results would then receive invasive foetal karyotyping to confirm the 
likely presence of the genetic abnormality; in the experimental arm this was offered to all 
women, while in the controls only those of advanced maternal age (≥35 years) were put 
forward for further testing. Women gestating a foetus with structural anomalies, and hence 
confirmed to be carrying a Down’s syndrome baby, were given counselling by 
obstetricians, after which they could chose to terminate the pregnancy. The primary 
outcome was the live birth rate. 
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This was clearly a ‘test-treatment’ trial, in that individuals were randomised between two 
testing strategies and then received treatment (counselling) on the basis of test results. 
Several patient outcomes were measured after treatment, including the primary outcome, 
thus satisfying the third inclusion criterion. However, the target population could not be 
considered as symptomatic since women did not present with any complaints to raise the 
suspicion of Down’s syndrome. This was therefore deemed to be a screening trial, and 
excluded. 
In the second example, a trial assessed the value of introducing extensive testing to detect 
cancer in patients with a confirmed first–episode of deep vein thrombosis (DVT) or 
pulmonary embolism (PE)(T42). Individuals for whom their DVT/PE diagnosis was idiopathic, 
namely it could not be explained by known concurrent disease or history, were randomised 
to undergo a battery of imaging and laboratory tests (including US, CT, gastroscopy, 
colonoscopy, hemoccult, sputum cytology, mammography, Pap smear, prostate US, 
prostate specific antigen)(experimental intervention) or to receive no further testing, as 
standard. Since cancer is known to affect approximately 10% of individuals with idiopathic 
DVT, the purpose of the new strategy was to detect underlying malignancy. Patients 
received treatment appropriate to their diagnosis, and the primary outcome was cancer-
related mortality. 
As with the first example, this is clearly a test-treatment trial that measured patient 
outcomes after a phase of treatment. However, in this case the study population can be 
considered as ‘symptomatic’; since unexplained DVT may be caused by an underlying 
malignancy the presence of this condition was judged by the present author to act as a 
presenting complaint. Thus, even though the tests were described as ‘screening’ by the 
authors, a more detailed examination of the target population and reasons for testing 
revealed it to be closer to diagnosis, and so was included. 
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I s  t he  t es t  used f or  m oni t or ing  or  d iagnos i s?  
Monitoring situations are most clearly distinguished by the need to repeat tests39, and so 
were generally easier to identify during the study selection process. Difficulties were 
however encountered when considering ‘continuous monitoring’ comparisons since tests 
were often used only once, though for an extended period of time. In these situations, 
decisions of whether to define studies as trials of diagnostic tests rested on how test 
results were used to manage patients.  
To take an example, the bispectral index (BIS) is a form of brain status monitoring used 
whilst a patient is under general anaesthesia. It produces a summary score from various 
electro-encephalographic measures that indicates the patient’s level of consciousness. A 
trial assessing the value of adding BIS to conventional aesthetic management used it to 
optimise the level of anaesthesia received200. Since treatment was modified on multiple 
occasions during one patient’s operative procedure, BIS was judged to constitute 
treatment titration, and so the study was excluded. 
Conversely, the use of cardiotocography and fetal pulse oximetry (FPO) for monitoring 
women in labour were considered as ‘diagnostic’ tests. One trial compared the impact of 
adding FPO to the standard cardiotocographic surveillance on operative delivery rates in 
women with non-reassuring fetal heart rates(T61). Cardiotocography is an 
electrophysiological test that records fetal heart rate and uterine contractions, while FPO 
measures the levels of oxygen in the fetus’s blood. Both are continuous monitoring tests 
designed to detect deteriorations in the baby’s well-being during labour201. During the trial, 
the management of labour was altered in response to any such deterioration, whereby as 
soon as fetal heart rates and oxygen saturation levels decreased beyond a predefined 
level assisted labour was initiated(T61). Since treatment decisions following these tests 
appear to have been made once, the trial was included as a diagnostic example. 
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I s  t he  t es t  used f or  d iagnos i s  or  immedia t e  t r ea tm ent ?  
Although diagnosis and treatment would intuitively appear to be separate entities, several 
instances were encountered where ‘testing’ and treatment were so closely connected that 
it was difficult to determine whether the ‘test’ was being used to make diagnostic 
decisions, or was purely being used as a therapeutic intervention. The use of medical 
devices during surgery serve as a clear example of the latter, for instance a trial comparing 
the efficacy of using ultrasound versus manual palpation to guide femoral puncture for 
cannulation202. Since ultrasound did not result in any diagnosis as such, it was judged to 
constitute part of the treatment process. 
Trials were also excluded when tests were used for diagnostic purposes but the phase of 
treatment included in the trial was not contingent on results from the test. This is illustrated 
in a trial that randomised patients to laparoscopy (experimental intervention) or laparotomy 
(control) for staging and treating a known episode of uterine cancer203. Though the 
examination of resected material did eventually provide further information on cancer 
stage, the immediate aim of the procedures was not to select the subsequent treatment, 
but to remove tumours as part of the treatment process.  
On the other hand, the author included similar comparisons when the test results were 
judged to directly inform the treatment conducted during the trail. Thus one of the selected 
test-treatment trials compared the use of routine axillary lymph node dissection to detect 
metastatic spread in women with a known diagnosis of invasive breast cancer, to a novel 
strategy which first triaged patients using the less–invasive sentinel lymph node biopsy(T24). 
The results of these tests informed the choice between mastectomy or wide local excision; 
since these were also conducted as part of the trial, the study was included.
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2.4 Discussion 
 
The systematic search of CENTRAL led to the identification of 108 test-treatment RCTs 
evaluating a patient outcome after a treatment. These results demonstrate that test-
treatment RCTs are carried out, although they appear to be present in small numbers. 
When examining included numbers by year of publication, the findings suggest that the 
observed trend of steep year-on-year increases in the publication of any RCT131,133 may 
not hold true for test-treatment trials. Although the search was not designed to be 
comprehensive, the method was systematic and consistent for each of the four years so 
any actual increase in numbers published should be apparent. A preliminary inference 
must therefore be that comparative diagnostic effectiveness studies were rare between 
2004 and 2007, and are probably unlikely to increase substantially in numbers in the short-
term. This would favour existing opinion that randomised evaluations of test-treatment 
strategies are in fact rare24.  
Search precision was very low (1.0%), with the author needing to read 99 citations in order 
to identify one relevant study. Since searching was restricted to a database containing only 
clinical trials, the small numbers of relevant studies could also reflect the difficulties in 
identifying primary diagnostic research, largely due to the absence of diagnostic indexing 
terms in bibliographic databases. As a renowned problem in the synthesis of diagnostic 
research173, the low search precision was anticipated and attempts to minimise this 
problem instituted by introducing methodological terms to maximise the search’s 
sensitivity. An unexpected finding was the absence of terminology commonly encountered 
in diagnostic accuracy studies, which may make test-treatment RCTs more difficult to 
identify. Although these were eliminated from the final search strategy, the remaining 
methodological terms may have failed to locate relevant trials that did not include these 
methodological terms in their titles/abstracts or as index terms. If missed articles differ 
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systematically from those ascertained by the project search, this could have resulted in a 
cohort that is unrepresentative of the true range of test-treatment trials.  
A second potential explanation for the small number of included trials is that the author 
failed to identify relevant studies that were retrieved by the search. While missed numbers 
are likely to be low, the range of topics encountered was extensive and it may be the case 
that a screener with clinical expertise could have identified a higher number of test-
treatment RCTs. If so, the search results presented here may have underestimated the 
true number of test-treatment RCTs published during the study timeframe. 
In order to validate the rarity of test-treatment RCTs, the next chapter presents an 
independent verification of search methods which seeks to estimate the total number of 
these studies, and also determine the extent to which the author has overlooked relevant 
trials.  
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Estimating the number 
of test-treatment RCTs:  
A capture-recapture 
analysis & inter–observer 
reliability study 
This chapter has been published:  
Ferrante di Ruffano L, Davenport C, Eisinga A, Hyde C, Deeks J. A capture-recapture analysis demonstrated 
that randomized controlled trials evaluating the impact of diagnostic tests on patient outcomes are rare. J 
Clin Epidemiol 2012;65:282–287. 
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Recognising that the methods used to find published test-treatment RCTs may have 
missed relevant studies, this chapter aims to definitively confirm the total number of trials 
published during the study timeframe. Using the ‘capture-recapture’ technique developed 
by ecologists, a second search of CENTRAL is compared to original search results to 
estimate the number of relevant RCTs missed by both strategies. Search results are also 
screened by a second reviewer to determine the extent to which the author 
underestimated the true number of trials picked up by both strategies.  
RCT evidence of diagnostic clinical effectiveness cannot be considered useful if it is rarely 
available. The last chapter identified 108 test-treatment RCTs measuring patient outcomes 
that were published between 2004 and 2007, suggesting that these studies are very rare. 
However, in order to minimise the considerable number of search hits, whilst maintaining 
adequate search sensitivity, the search strategy may have failed to locate relevant trials 
that did not include these methodological terms in their titles/abstracts or as index terms. 
The search results therefore risk being incomplete, and the number of trials found may be 
an underestimate of the true number of relevant trials published in the study timeframe. 
So as to provide a more definitive indication of the rarity of test-treatment RCTs, a 
‘capture-recapture’ study was designed to estimate the total number of test-treatment 
RCTs published in the study timeframe, achieved by establishing the completeness of the 
original search. To determine whether the author’s retrieval of relevant trials had been 
accurate and could be reproduced, an inter–observer analysis was also conducted. 
3.1 Methods 
 
The capture-mark-recapture method was developed by ecologists to estimate the size of 
animal populations that may be difficult to enumerate directly and completely. In its 
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simplest form, two phases of population census are compared: within a predetermined 
study area, the target species are ‘captured’, counted, ‘marked’, and released. In the 
second phase, this process is repeated allowing the ‘recapture’ of some individuals and 
new capture of others. The number of discrepant captures in each census (i.e. those 
caught by only one survey) are multiplied and divided by the number of recaptures (i.e. 
those caught by both surveys) to provide an estimate of the number missed by both 
searches204.  
The method was first applied in epidemiology as a tool to adjust disease prevalence 
estimates for the likely incompleteness of the multiple registers from which the rates are 
derived205–206. The technique has since been advocated by evidence-based reviewers to 
establish the completeness of literature searches, also notoriously difficult to measure 
directly, where they tend to be referred to as ‘ascertainment intersection’ 171,207–208, as well 
as to develop stopping rules for systematic reviews16 and to assess publication bias210.  
The present study uses the method to estimate the total population size of a specific 
interventional design: the test-treatment RCT. This is achieved by using two alternative 
search strategies, noting the overlap of relevant hits between the searches and then 
estimating the number missed by both. 
3.1.1 Rationale for the second search 
In order to apply the capture–recapture technique, a second search needed to be 
performed within the same bibliographic database. The original search strategy used 
methodological terms to identify test-treatment RCTs, not limited by test type; henceforth it 
is referred to as the ‘all–test–types’ (ATT) search. In order to identify trials indexed in 
CENTRAL that had eluded the ATT search, it was decided that the second search should 
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Imaging Test (IT) search  Hits 
#1 MeSH descriptor Image Interpretation, Computer-Assisted explode all trees  4,967 
#2 MeSH descriptor Magnetic Resonance Imaging explode all trees  3,624 
#3 MeSH descriptor Positron-Emission Tomography explode all trees  520 
#4 MeSH descriptor Endoscopy explode all trees  10,763 
#5 MeSH descriptor Ultrasonography explode all trees  5,860 
#6 (comput* near3 tomogra*):ti,ab,kw 5,730 
#7 (positron emission near3 tomogra*):ti,ab,kw 1,227 
#8 pet:ti,ab  1,320 
#9 CT:ti,ab or CTs:ti,ab  4,315 
#10 CAT:ti,ab near3 (imag* or scan*):ti,ab,kw 16 
#11 SPECT:ti,ab,kw 790 
#12 MRI:ti,ab,kw or fMRI:ti,ab,kw or WBMRI:ti,ab,kw or DWI:ti,ab,kw 2,640 
#13 NMRI:ti,ab,kw 2 
#14 (MR or NMR):ti,ab,kw near3 tomogra*:ti,ab,kw 30 
#15 (MR or NMR):ti,ab,kw near3 imag*:ti,ab,kw 638 
#16 magnetic resonance:ti,ab,kw 5,043 
#17 diffusion weighted:ti,ab,kw 142 
#18 T2-weighted:ti,ab,kw 305 
#19 echoplanar:ti,ab,kw 23 
#20 (ultrasound or ultrasonogra* or ultrasonic*):ti,ab,kw 12,033 
#21 (echocardiogra* or echoencephalogra* or endosonogra*):ti,ab,kw 5,025 
#22 (elastogra* or elastomet* or sonoelastic* or viscoelastic*):ti,ab,kw 288 
#23 (elasticity near3 imag*):ti,ab,kw 29 
#24 acoustic radiation force:ti,ab,kw 1 
#25 (endoscop* or angioscop* or arthoscop* or bronchoscop* or 
cholangiopancreatogra* or colonoscop* or colposcop* or culdoscop* or 
cystoscop*):ti,ab,kw 
11,450 
#26 (duodenoscop* or enteroscop* or esophagogastroduodenoscop* or 
oesophagogastroduodenoscop* or esophagoscop* or oesophagoscop* or 
fetoscop* or foetoscop* or fluoroscop* or gastroscop* or hysteroscop* or 
laparoscop* or laryngoscop* or mediastinoscop* or neuroendoscop* or 
proctoscop*):ti,ab,kw 
9,066 
#27 (sigmoidoscop* or thoracoscop* or ureteroscop* or videolaryngoscop* or 
videoendoscop* or videocapsule* or endocapsule* or pillcam or 
mirocam):ti,ab,kw 
920 
#28 (video-assisted near2 surgery):ti,ab,kw 200 
#29 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 
OR #23 OR #24 OR #25 OR #26 OR #27 OR #28) 
58,895 
#30 (#29), from 2004 to 2007 10,427 
Table 3.1:  The second search: CENTRAL Issue 2 2010 (Wiley InterScience searched 23 February 2010) – 
MeSH and textwords for five imaging modalities limited to publication years 2004 to 2007. 
Asterisk (*) denotes truncation of search term 
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target specific diagnostic tests directly by using content–specific terms. Ideally, this would 
incorporate the names of all diagnostic tests. This should include those evaluated by the 
108 included trials, but also the names of tests not represented in the project cohort. Since 
the number of different tests in existence was huge, the author decided to restrict the types 
of tests searched for in order to make the strategy manageable. So as to be confident that 
the second search would yield enough relevant papers, it was decided to focus on the 
most frequent field of testing as determined by the ATT search. While full details of the 
clinical context of included trials are presented in chapter 4, suffice it to note that 
diagnostic imaging was most often found to be the subject of comparison in test-treatment 
RCTs, of which the most common modalities were: ultrasound, endoscopy, MRI, CT and 
PET. Accordingly, the second search was designed to target these five imaging tests 
directly by using specific test names, and all known permutations thereof, as MeSH terms 
and text words (Table 3.1). The strategy was designed in collaboration with an information 
specialist experienced in the ascertainment of diagnostic studies (Anne Eisinga, UK 
Cochrane Centre, Diagnostic Test Accuracy Working Group). No methodological terms 
were used, and no further restrictions were incorporated other than the publication time–
frame (2004–2007) which remained identical. 
3.1.2 A tale of two search strategies: Imaging Test (IT) & ATT 
searches 
A key prerequisite of the capture–recapture method is that all ‘individuals’ (i.e. test-
treatment RCT articles) in the ‘population’ (i.e. CENTRAL) should have the same 
probability of capture within each search204; this implies that the population of articles in 
CENTRAL should be identical for each search. Since indexing of studies by bibliographic 
databases is known to lag behind true publication dates133, querying the same database 
on later occasions is likely to produce higher hit–rates due to this increasing population.  
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In order to ensure the consistency of the population, both searches were conducted in 
issue 2 of the 2010 CENTRAL database. This involved re–running the ATT search 
(originally run in CENTRAL 2009, issue 2) (Table 3.2), and identifying new records by 
eliminating duplicates using a title-matching query in Microsoft Access 2007.  
Titles and potentially relevant abstracts/full papers were screened by the author, and 
inclusion criteria identical to the 2009 ATT search were applied: randomisation of patients 
to two or more testing strategies, provision of treatment based on the results of the 
strategies, and measurement of at least one downstream patient outcome. Tests used for 
screening asymptomatic individuals, repeated-test monitoring, and estimating the 
probability of future events were again excluded, as were foreign language papers.  
3.1.3 Measuring inter–observer reliability 
In order to measure the reliability of the author’s screening process, a random 10% sample 
of records retrieved by both searches was screened independently by a colleague (Dr. 
Clare Davenport, University of Birmingham), a clinician highly experienced in systematic 
reviews and diagnostic research. The sample was created by: allocating all search hits a 
All Test Types (ATT) Search Hits 
#1 sensitiv* or diagnose or diagnosis or diagnostic* in Clinical Trials 73,262 
#2 random* in Clinical Trials 349,718 
#3 "study design" next "rct" in Clinical Trials 154,113 
#4 (#2 OR #3) 441,388 
#5 (#1 AND #4) 53,074 
#6 (#5), from 2004 to 2007 13,495 
Table 3.2:  ATT search repeated in CENTRAL Issue 2 2010 (Wiley InterScience searched 23 February 2010) – 
general diagnosis text words across all fields limited to publication years 2004 to 2007 (13,495 
records).  
Asterisk (*) denotes truncation of search term 
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number (starting from 1), generating a random series of numbers using STATA (version 11 
SE), and subsequently selecting the hits whose numbers appeared in the random number 
list. The colleague was provided with the resulting database of relevant citations along with 
the study protocol for including trials. Decisions to include studies were based on the 
review of full papers, and any discrepancies were discussed, with final inclusion decisions 
resolved by consensus. Inter-observer agreement was calculated for total agreement 
beyond chance using the kappa statistic (κ), in STATA version 11 SE. 
3.1.4 Estimating the total number of published test-treatment RCTs 
Citations meeting the inclusion criteria were compared between the two searches using 
the capture-recapture technique, allowing an estimate of the number missed by both 
searches to be calculated from the degree of overlap in ascertainment. Relevant articles 
‘captured’ by each search were ‘marked’ for inclusion, and full bibliographic details 
compared to identify those that had been captured by both strategies. Multiple publications 
relating to a single study were individually checked for their capture by either search, but 
treated as one trial for further analysis. If any of the multiple publications were captured by 
a search, the study was considered ‘found’ by that search. 
By summarising the number of relevant studies found by each search in a 2x2 contingency 
table, the number missed by both searches (x) can be estimated, and the number of 
published imaging RCTs (Ni) approximated using the Lincoln-Peterson method (Table 
3.3)204. The formulae for these two estimates rely on 3 key assumptions regarding the 
probability of ‘catching’ an article. First, that the underlying population remains constant 
between searches. Second, that each article therefore has an equal probability of being 
found in any given search. And third that the probability of finding a particular article in one 
search is not influenced by whether or not it is found in the other search; that is to say that 
each article’s probability of ascertainment by both sources is independent. These 
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assumptions imply that the probability of ascertainment by both searches (a/N, table 3.3) 
must be equal to the chances of being found by search 1 ([a+c]/N), multiplied by the 
chances of being found by search 2 ([a+b]/N). 
 
This gives:      
 
Which can be simplified to: 
 
 
Given that: 
The two formulae can be rearranged to find x: 
 
 
 
 
In order to extrapolate this to estimate the number of all published test-treatment RCTs 
(Nt), regardless of test type, Ni was inflated by the proportion of imaging test RCTs found 
in the generic ATT search. 
The calculation of confidence intervals using standard errors has been shown to perform 
poorly with small or moderate-sized capture-recapture samples, producing symmetrical 
intervals that tend to underestimate both the lower limit (i.e. the limit is lower in value than 
the total number of cases actually observed) and higher limit211–212. Consequently a ‘test-
based’ approach was used in favour of the asymptotic standard error, due to the likely 
skewed sampling distribution of N 212.  
N = a+b+c+x 
N =  
(a+c)(a+b) 
a 
a(a+b+c+x) =  (a+c)(a+b) 
x  =   
a+b+c+x =  
(a+c)(a+b) 
a 
cb 
a 
X  = 
N 
a 
N 
a+c 
N 
a+b 
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For the interval surrounding Ni the Fisher’s exact test of association was selected as fewer 
than 80% of cells in the contingency table had values of >4 213. Having populated the 
contingency table with all observed values (cells a, b, c), the value of x was entered as 0, 
thus creating a completed table for which Fisher’s probability of independence was 
calculated. This was repeated for increasing values of x (incrementals of 1) to create a 
series of tables with increasing values of Ni, and for each Fisher’s probability was again 
calculated. Test–based 95% intervals included all values of Ni for which the ensuing 
probability of independence was adequate (>0.05)212. 
 
 Search 2  
Found Missed 
Search 1 
Found a c a + c 
Missed b x b + x 
a + b c + x N 
 
Estimated values Denotation Calculation 
Unobserved cell: x      
Total population: N              
Asymptotic variance*: Var(N) 
                  
           
 
 
Table 3.3:  Contingency table summarising numbers of articles ascertained by two searches, with the 
Lincoln-Peterson estimate for total population size (N) below
204
. 
Where: 
 a is the number of relevant studies found by both searches 
 b is the number of relevant studies found by search 2, but missed by search 1 
c is the number of relevant studies found by search 1, but missed by search 2 
* Note that the asymptotic standard error was not used to calculate confidence 
intervals as the study population has a skewed sampling distribution. 
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As cell sizes were larger for the comparison of all test types, test-based confidence 
intervals for Nt were calculated using the χ
2 test. Values of x were again imputed in 
increasing value until χ2 exceeded 3.84 (α=0.05, 1-tailed at one degree of freedom) and 
was rejected. The confidence interval represents the range of values of x, and hence Nt,for 
which the null hypothesis is not rejected.  
3.2 Results 
 
3.2.1 Search results 
The updated ATT search (2010, issue 2) retrieved 13,495 citations, of which 603 had not 
been identified in the 2009 search of CENTRAL. In addition to the 128 articles ascertained 
by the original search, 12 additional test-treatment RCT articles were identified, of which 
three214–216 were subsidiary publications of trials already included in the project 
cohort(T34,T48,T107). Five new articles reported on five test-treatment RCTs not ascertained by 
the original search217–221. All were published in 2007, and four evaluated a relevant imaging 
test218–221 (Figure 3.1). In addition, the second reviewer identified three trials ascertained 
by the original search that had been missed by the author222–224, two of which evaluated 
imaging modalities222,224 though only one of these evaluated one of the target imaging 
tests222.  
Adding these to the 108 test-treatment RCTs ascertained in chapter 2, a total of 116 test-
treatment RCTs were found by the ATT search. These were reported in 139 articles, giving 
a search yield of 1.0%. Of these, 75 trials (64.7%) evaluated an imaging modality (reported 
in 89 articles), including 68 trials (58.6%) that evaluated one of the five targeted imaging 
tests (reported in 83 articles)(Table 3.4). 
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After removal of 34 duplicates, the IT search retrieved 10,393 unique citations; the study 
selection process is illustrated in Figure 3.2. A total of 97 relevant articles were identified 
(0.9%) reporting on 85 individual test-treatment RCTs (Table 3.4). Three RCTs (reported 
in 4 articles) evaluated non–imaging tests, including biochemical assays(T26,T71) and 
Multiple publications 
n=14 
(1 new article) 
 
Non-imaging RCTs 
n=50 
(4 new articles) 
 
Full papers excluded 
n=179 
(0 new excluded) 
 
Abstracts excluded 
n=1,300 
(38 new excluded) 
 
Titles excluded  
n=11,696 
(559 new excluded) 
 
Titles reviewed  
n=13,309 
(603 new titles) 
Abstracts reviewed 
n=1,613 
(44 new abstracts) 
Full papers reviewed 
n=311 
(6 new papers) 
Test-treatment RCT 
articles  
n=139 
(11 new articles) 
Imaging Test-Treatment 
RCT articles  
n=89 
(7 new articles) 
Imaging Test-Treatment 
RCT studies  
n=75 
(6 new imaging RCTs) 
Figure 3.1: Original search (ATT) study selection process for additional records retrieved (CENTRAL 
2010, Issue 2) 
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biopsy(T24). Four others (4 articles) evaluated imaging tests not targeted by the search (X–
ray224–225, bone scintigraphy(T74), endoscopy(T1)). In sum, therefore, the IT strategy 
ascertained 78 test-treatment RCTs (reported in 89 articles) that evaluated a target 
imaging modality. Overall the two search strategies identified 133 distinct test-treatment 
RCTs evaluating any type of diagnostic test, 92 RCTs evaluating any diagnostic imaging 
modality, and 84 RCTs that assessed one of the five imaging tests specified in the 
methods (Table 3.4). 
Multiple publications 
n=11 
 
Non-imaging RCTs 
n=4 
 
Full papers excluded 
n=122 
 
Abstracts excluded 
n=1,091 
 
Titles excluded 
n=9,083 
 
Titles reviewed 
n=10,393 
Abstracts reviewed 
n=1,310 
Full papers reviewed 
n=219 
Test-Treatment RCT 
articles  
n=97 
Imaging Test-Treatment 
RCT articles  
n=93 
Imaging Test-Treatment 
RCT studies 
n=82 
Figure 3.2: Imaging search (IT) study selection process 
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The author found it more difficult to discern the relevance of titles retrieved by the IT 
search, and this is reflected in the narrow difference in proportion of abstracts retrieved 
from each search (IT 12.0%, ATT 12.6%; relative difference 5%) relative to the similar 
proportion of relevant full paper articles finally included by each strategy (IT 0.9%, ATT 
1.0%; relative difference 11%). Overall search precision was very low in both searches, 
though when considering the identification of topic–specific imaging RCTs the IT strategy 
precision remained constant (0.6%) while that of the ATT strategy decreased (IT 0.9%, 
ATT 0.6%) with the reviewer needing to read 111 and 167 titles respectively to identify one 
relevant imaging test-treatment trial. 
3.2.2 Estimated number of published target imaging trials 
Of the total 84 topic–specific RCTs identified, 62 were captured by both searches and the 
IT strategy ascertained 16 trials not picked up by the general methods–term search. 
 IT Search ATT Search Total 
Titles screened *10,393  13,495  23,688 
Test-Treat RCT:  
 
   
 
articles 97 (0.9%) 139 (1.0%) 158 
studies 85  116  133 
Any imaging test-treat RCT: 
 
   
 
articles 93 (0.9%) 89 (0.7%) 107 
studies 82  75  92 
Target imaging test-treat RCT
†
: 
 
   
 
articles 89 (0.9%) 83 (0.6%) 99 
studies 78  68  84 
Table 3.4: Total number of relevant RCTs found by each strategy. Numbers in parentheses provide search 
precision, given as proportions of full articles of all titles screened. 
* After eliminating 34 duplicates 
† 
A subset
 
of all imaging RCTs, these are the ‘relevant’ imaging trials for the capture–
recapture estimate of Ni : ultrasound, endoscopy, MRI, CT, PET. 
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Although the ATT strategy yielded fewer relevant imaging RCTs (68 vs. 78), it did identify 
6 trials that were undetected by the targeted, content-specific strategy. Table 3.5 
summarises the overlap in ascertainment of included imaging trials. Since trials can only 
be present in whole numbers, the number missed by both searches (x) is calculated to be 
2 (rounded up from 1.6), providing an estimate of 86 (95% CI: 84, 89) for the population of 
these trials published between 2004 and 2007, and indexed in CENTRAL.  
3.2.3 Estimated number of all published test-treatment trials 
Of the 116 trials found by the ATT search, 58.6% (n=68) evaluated a target imaging trial. 
Assuming this proportion is a true reflection of the total frequency of these trials published 
between 2004 and 2007, the total number of all test-treatment RCTs published in the 
same timeframe can be extrapolated by inflating the estimate for Ni by 58.6%. This gives 
85.6/0.586, or 146, which provides an estimate of 37 trials (146/4) published per year. 
 
 
ATT search  
Found Missed 
IT search 
Found 62 16 78 
Missed 6   x 6 + x 
68 16 + x Ni 
 
Number of RCTs:   
 
 
Missing x          = 1.6 
Found in total Ni            = 85.6 
Exact 95% CI  = 84, 89 
Table 3.5: Calculation for estimating the total number of test-treatment trials evaluating an 
imaging test published between 2004 and 2007. 
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Alternatively, Nt can be estimated directly using capture–recapture analysis of all trials 
identified by both searches. Table 3.6 illustrates the resulting contingency table, 
demonstrating that of the total 133 RCTs 68 were ascertained by both searches, 48 were 
found by ATT but not by IT, while 17 ascertained by IT were not picked up in the ATT 
strategy. Accordingly, x is estimated as 12 and Nt as 145 (95% CI: 137, 157), which 
provides an estimate of 36 trials (145/4) published per year. This is a very similar figure to 
that achieved through extrapolation, which would seem to lend support to the estimate. 
3.2.4 Inter–observer agreement 
Overall the author identified 20 test-treatment RCTs in the random 10% sample (n=2591), 
of which 5 were missed by the second reviewer (Table 3.7). The second reviewer 
identified 8 additional potentially relevant studies, of which 3 222–224 were agreed to satisfy 
all inclusion criteria at consensus bringing the total number of RCT articles to 23. All
 
 
ATT Search  
Found Missed 
IT Search 
Found 68 17 85 
Missed 48 x 48 + x 
116 17 + x N 
 
Number of RCTs:   
 
 
Missing x           = 12.0 
Found in total Ni             = 145.0 
Exact 95% CI  = 137, 157 
Table 3.6: Calculation for estimating the total number of test-treatment RCTs, regardless of 
test type, published between 2004 and 2007. 
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studies missed by both reviewers were originally eliminated on the basis of title only. 
Considering the number of citations that were double–screened, observer variability was 
minimal with observed agreement in over 99% across the whole 10% sample, and 
agreement beyond chance calculated to be substantial overall226. 
Agreement differed according to search strategy; with only one disagreement(T29) 
concurrence for content–specific citations was near–perfect. Agreement in identifying ATT 
strategy trials was substantial, however more studies were missed by both reviewers 
possibly due to the need to identify diagnostic RCTs from a very large volume of treatment 
RCTs and diagnostic accuracy evaluations.  
Comparing individual searches and overall ascertainment, observed agreement was 
higher than the resulting κ value. It has been demonstrated that κ is influenced by the 
distribution of observations in a 2 x 2 table, such that if cells of agreement (e.g. include – 
include) or disagreement (e.g. include – exclude) are asymmetrical κ becomes distorted227. 
In this study, very low prevalence (1.1% overall, hence skewed agreement) and skewed 
2nd Screener 
Author 
AObs AExp κ 95% CI 
Include Exclude Total 
5 0 5 
1.00 0.99 0.91 0.77, 1.00 IT Search 
Include 
Exclude 1 1184 1185 
Total 6 1184 1190 
ATT 
Search 
Include 10 3 13 
1.00 0.98 0.74 0.56, 0.93 Exclude 4 1384 1388 
Total 14 1387 1401 
Both 
Searches 
Include 15 3 18 
1.00 0.99 0.68 0.64, 0.93 Exclude 5 2568 2573 
Total 20 2571 2591 
Table 3.7: Agreement between two screeners in the identification of test-treatment RCTs. Selection was 
based on review of full articles. 
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disagreement have constrained κ, which is evidently low for the ATT search despite 
comparably high levels of observed agreement. 
3.3 Discussion 
 
This simple study finds that test-treatment RCTs are rare, with only approximately 36–37 
test-treatment RCTs published per year between 2004 and 2007. This is astoundingly low 
when compared to the approximate rate of 21,949 per year of all RCTs indexed in 
CENTRAL (Table 3.8).  
3.3.1 Validity of the population estimates 
Extrapolation was used to estimate the total number of test-treatment trials, however the 
validity of this method relies on imaging trials being as likely to include methodological 
terms and descriptors as trials of other test technologies. Though this could not be verified 
in the current study, it is nonetheless somewhat reassuring that the capture–recapture 
estimate arrived at an almost identical total population estimate. However, the estimates 
may not be valid if the assumptions inherent in the capture–recapture method do not hold 
for test-treatment RCT publications. As set out in the methods to this chapter, three key 
assumptions should be examined. 
Search for all RCTs indexed in CENTRAL Hits 
#1 RCT in all text 
87,794 
#2 “Randomized Controlled Trial” in Publication Type 
#3 (#1 or #2), from 2004 to 2007 
Table 3.8:  Approximate search for the number of all RCTs indexed in CENTRAL at the time the IT and 
updated ATT searches were conducted (Issue 2 2010, Wiley InterScience searched 10 November 
2010) – RCT text words across all fields and MeSH terms limited to publication years 2004 –
2007.  
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First, the method assumes that the underlying population is ‘closed’, namely that there are 
no new additions or subtractions to it between searches. This requirement was met by 
ensuring that both searches were run concurrently in the same version of CENTRAL. 
Second, all articles should have the same probability of capture in a search. It is possible 
that certain subgroups of test-treatment RCTs have traits that predispose them to 
ascertainment relative to others. Particular clinical specialties, types of diagnostic test or 
even the journal or year of publication may tend to be more accurately indexed, or better 
reported, making them more likely to be detected than other test-treatment RCTs. For 
example, if imaging RCTs were more likely to contain diagnostic methodology descriptors 
than non–imaging RCTs, they would be more ‘catchable’; hence the proportion of imaging 
tests observed in the ATT search would be overestimated. This would mean that the 
method has produced an underestimate of the true total test-treatment RCT population. It 
is difficult to evaluate the impact such ‘variable catchability’204 has had on the final 
population estimate, and further cross-sectional work would be needed to examine the 
nature of associations between indexing quality and clinical specialities, journals and test 
types through time.  
Third, the capture-recapture method assumes that the probability of finding a particular 
article in the IT search should be independent of the chances that it is picked up by the 
ATT search. The approach used in this study aimed to satisfy this requirement by 
employing two separate ascertainment concepts, general diagnostic and methodological 
terms in the ATT strategy and test names in the IT strategy. The possibility remains, 
however, that an RCT appropriately indexed by methodological terms will also be well 
indexed by content-specific terms. If this were true then its chances of retrieval by the IT 
strategy would be positively dependent on the chances of retrieval by the ATT strategy, 
and so the estimate would underestimate the true population. Nonetheless, the searches 
identified articles published during a time period in which the CONSORT guidelines have 
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been routinely applied in many journals; thus to some extent the dangers of dependency 
have been mitigated.  
3.3.2 Reliability of the population estimates 
The most likely source of error in the study data concerns the accuracy with which articles 
were classified as test-treatment RCTs. As argued in chapter 2, the low search precision 
and ensuing high ‘number needed to read’ could have impacted on the accuracy of article 
identification, since with over 23,000 records it is likely that some titles were mistakenly 
excluded due to decreased attentiveness during long periods of screening. Any such 
misclassification would cause an underestimate. 
Indeed, though inter–observer agreement was strong, the second reviewer identified three 
studies within the 10.8% random sample (2,591/23,888) that were missed by the author. 
One could therefore extrapolate that 28 test-treatment RCTs ascertained by the searches 
were missed in total (3/0.108). Extrapolating this underestimate across the whole sample 
would serve to inflate the estimated number of test-treatment trials published per year by 
17.5% to 42–43 RCTs. This would be confirmed more robustly with a second screen of all 
records, which unfortunately was not possible due to time constraints.  
3.3.3 Implications for finding test-treatment RCTs 
Test-treatment RCTs were very difficult to find, a discovery carrying implications for the 
future ascertainment of these studies. Building effective strategies for identifying test-
treatment RCTs presents several challenges that will need attention if future reviews are to 
ascertain the literature on a single diagnostic topic comprehensively.  
Ascertainment is very resource-intensive requiring many thousands of records to be 
checked for yields of 0.9–1%, which risks detrimentally affecting the accuracy of the
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screening process. Of course this study does not fully reflect that of subject-specific 
systematic reviews, where the search concepts and structure would be more developed 
and where the addition of disease–specific terms could help to increase the precision of 
search results. 
Both searches missed relevant imaging trials, however most disturbing are the number 
missed by the IT strategy, approximately 9% (8/86) of relevant imaging trials, suggesting 
that diagnostic content-specific terms are applied inconsistently across Medline, Embase 
and the other sources included in CENTRAL. The ATT search was less effective at 
identifying targeted imaging RCTs missing approximately one–fifth (18/86) of studies, 
though it did capture others missed by the IT strategy emphasising the importance of 
including methodological terms to maximise sensitivity. Nevertheless, these results also 
testify to the inconsistent use of methodological and general diagnostic descriptors. 
These findings imply that future searches will not be able to guarantee the ascertainment 
of all targeted test-treatment RCTs for a systematic review, a failure which could result in 
biased results and loss of precision. These issues are likely to be resolved by 
standardising the application of existing content-specific diagnostic terms and introducing 
methodological terms specific to the evaluation of diagnostic tests. A methodological 
indexing term for test accuracy studies was recently introduced by Embase170; though a 
commendable improvement to the previous situation, efforts to extend such terms will be 
required if the detection of test-treatment RCTs is to improve. As with any study design, 
test-treatment RCTs will stand the greatest chance of being ascertained if they are 
identifiable as such. 
Further research is clearly needed to characterise the precision and sensitivity of test-
treatment RCT search strategies, and to develop methodological and content filters that 
maximise sensitivity for the least losses in precision as has been done for the field of 
diagnostic accuracy. 
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3.4 Conclusions 
 
This study confirms previous claims that RCTs evaluating the impact of diagnostic tests on 
patient outcomes are rare. It is estimated that 36–37 test-treatment RCTs were published 
every year between 2004 and 2007. Even if the methods used have produced a slight 
underestimate, the true figure is likely to be just a tiny fraction of the total number of RCTs 
that are published in medical journals every year. Based on these data, it is therefore 
unlikely that RCT evidence of the patient health impact of diagnostic tests will be available 
to inform guidelines on the use of diagnostic tests in many settings. Guidelines will 
therefore frequently be based on lower grade evidence, which may risk erroneous 
conclusions. 
Despite substantial overall agreement, the independent check of accuracy in identifying 
these studies found that three test-treatment RCTs ascertained in the original search were 
missed by the author. Since only 10% this search were checked, it is possible that up to 28 
relevant trials have therefore not been included in subsequent analyses. If, as seems, 
likely, these were missed due to unclear description, any conclusions on the quality of 
reporting (presented in chapter 5) may therefore be generous estimates of the current 
situation. These implications are considered further in chapter 5 and the general 
discussion and conclusions of the thesis (chapter 9).  
The next chapters outline the clinical context of test-treatment RCTs included by the 
author (chapter 4) and investigate their reporting quality (chapter 5) and methodological 
quality (chapter 6) in order to address whether RCT evidence, when available, is likely to 
be reliable and informative.         
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Trials of Test-Treat 
Strategies:  
Characteristics of included trials 
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This chapter aims to characterise the diagnostic settings in which test-treatment RCTs 
have been executed to completion. It does so by providing a descriptive overview of the 
published trials identified in chapter 2, surveying the diagnostic questions these studies 
have answered and presenting an insight into their methodological approaches.  
Methodological research into assessments of diagnostic accuracy has shown how 
estimates of test performance are affected by many elements of the clinical context, 
including the case–mix of study populations, how tests are carried out and how their 
results are interpreted66, the care setting, role of the new test in the existing pathway, prior 
investigations and practitioner experience60,74. These factors are also likely to influence the 
clinical effectiveness of diagnostic tests. Moreover, the need to compare test-treatment 
strategies in order to achieve this means that the clinical context is potentially much more 
variable and complicated.  
The thesis has so far shown that these trials are rare (chapter 3), however in the absence 
of previous methodological reviews of test-treatment RCTs, very little is known regarding 
the sorts of diagnostic problems these designs have been used to evaluate, and the 
methods employed to answer them. Consequently, this chapter was designed to identify 
the settings, tests and effectiveness questions that RCTs have successfully been used to 
evaluate to completion.  
Accordingly, the following report describes the key clinical and methodological 
characteristics of these studies so as to summarise the spectrum of interventions 
evaluated, their diagnostic contexts and broad methodological approaches. This 
characterisation provides a first indication of the range of clinical questions that have been 
found to underpin diagnostic comparative effectiveness research.  
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4.1 Methods 
 
 
To discern the particulars of the diagnostic questions that published test-treatment trials 
have addressed, information was extracted from each trial in the project cohort to answer 
the following four questions (Table 4.1):  
1. What diagnostic tests have been evaluated? 
2. In which clinical settings are these tests used? 
3. What are the tests being used for?  
4. What types of trial design have been used? 
In view of the ample array of diagnostic technologies used in healthcare, the first question 
was designed to assess the breadth of test-treat topics, and determine the nature of any 
disparities in how frequently the various technologies have been evaluated for patient 
benefit. Questions two and three sought to elucidate the context in which these diagnostic 
effectiveness evaluations were conducted, characterising the clinical pathways involved 
and outlining the diagnostic questions they address. The objective was to establish where 
in the healthcare process these tests were evaluated, and consequently also to examine 
the degree of patient group selection and how narrowly focussed the diagnostic questions 
were. The final question provides a methodological orientation of included studies by 
summarising characteristics of study method and describing variations therein. 
4.1.1 Item generation 
The aim at this stage was to provide a descriptive account of included test-treatment 
RCTs, and not to review quality of reporting or methods. In the absence of existing tools or 
previous studies attempting to characterise test-treat interventions, information determined 
to be important to the description of diagnostic accuracy studies and RCTs was extracted. 
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The STARD72 and CONSORT121 checklists were chosen as each was developed from a 
comprehensive systematic analysis of existing publications on the conduct and reporting of 
diagnostic studies and RCTs respectively, in addition to Delphi consensus by a panel of 
experts138,228. Where this information was insufficient to describe the complex interventions 
and clinical setting fully (noted in table 4.1), additional rubrics were identified. This process 
of identification was iterative; trial reports were examined several times allowing pertinent 
items to be added and modified during extraction.  
4.1.2 Data Extraction  
Data on 12 items were extracted by the author to a relational database (Microsoft Office 
Access 2007), according to the definitions outlined in table 4.2. Due to the widely varying 
Thematic questions: Information extracted: 
1 What diagnostic tests have been evaluated? 
  
  1a Experimental test *†  
  1b Control test *† 
2 In what clinical pathway is the evaluation 
taking place? 
  
  2a Medical speciality  
  2b Country † 
  2c Care service *† 
3 What are the tests being used for?   
  3a Patient group *† 
  3b Target condition * 
  3c Prior tests 
  3d Management decision 
4 What types of trial design have been used?   
  4a RCT design † 
  4b Number of study groups † 
  4c Test comparison *† 
Table 4.1: Items generated to characterise the diagnostic interventions in their clinical setting. 
* denotes item present in STARD checklist
72
 
† denotes item present in CONSORT checklist
121
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Item extracted Description 
Country Countries contributing at least one investigative centre to the trial 
Medical specialty The medical department chiefly responsible for managing patient care 
Care service Healthcare service that testing will take place in, defined as (DH):  
Emergency Care: Urgent healthcare services available to those who need 
medical advice, diagnosis and/or treatment quickly and unexpectedly.  
Primary Care: General healthcare provided by GP practices, dental practices, 
community pharmacies and high street optometrists, that may involve 
onward patient referral to emergency, secondary or tertiary services.  
Secondary Care: Pre-arranged, non-emergency care provided by medical 
specialists in hospitals or clinics. Patients are usually referred from primary 
care professionals, such as a GP. 
Tertiary Care: Highly specialised consultative care, usually on referral from 
primary or secondary care services, provided by centres with personnel and 
facilities for special investigation and treatment.  
Control test The test specifically referred to as the comparator, the current care standard, 
or common clinical practice. In a minority of cases, the control arm was 
identified implicitly by the manner in which study results were discussed. 
Experimental test The test specifically referred to as the new test to be introduced under 
evaluation. 
Comparison type The prospective role of the experimental test in the existing diagnostic 
pathway
11
:  
Replacement: total replacement of the control test by the experimental test 
Triage:  introducing the experimental test to select which patients receive the 
control test 
Add-on: addition of the experimental test alongside the control test 
Patient group The target study group, defined as those eligible for randomisation.  
Target condition The disease or condition to be confirmed through the present episode of 
testing. Related to the purpose of diagnosis, this could also constitute the 
identification of risk factors, stage or grade of known disease or aetiology of 
known condition. 
Prior Tests The tests used to manage the patient’s current condition, prior to enrolment 
in the trial. 
A current condition was defined as a single pathological entity, that may have 
received prior treatment. Disease recurrence was included under this 
definition, comorbid conditions were not. 
Management decision The diagnostic and treatment decisions arrived at through testing 
RCT design Design structure and point of randomisation 
Number of study groups The number of intervention groups patients were initially randomised 
between. 
Table 4.2: Information extracted to characterise test-treatment RCTs. 
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organisation of healthcare structures across the world, a meaningful comparison of care 
settings would be impaired using local definitions. Accordingly, care settings for each trial 
were extracted using the definitions given by the UK Department of Health229, regardless 
of the country of origin. 
4.1.3 Analysis 
Once extraction was complete, data were exported to Microsoft Excel 2007. Data were 
analysed using an inductive method to create an integrative synthesis230. For each item 
descriptions extracted from all trials were examined together and common themes 
identified, from which a series of categories were generated that could characterise the 
range of variation observed across the included studies. This was often performed with 
reference to related items to ensure that the author’s categorisation for each trial was 
consistent with the meaning of the study. 
The analysis presented below is intended to be descriptive, and while it provides 
frequencies with which each characteristic was observed in the cohort, the review aims to 
furnish the reader with a more qualitative description230 of the range of diagnostic 
questions addressed by test-treatment trials included in the project cohort. 
4.2 Results 
 
As reported in chapter 2, the project cohort consists of 108 individual test-treatment RCTs 
that evaluate the patient health impact of diagnostic tests, after a phase of treatment. The 
three additional trials that were missed by the author, and identified by the second 
reviewer in chapter 3, are not included in the project cohort. Citations of trial reports are 
denoted separately from other references, given as numbers preceded by the letter ‘T’. 
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4.2.1 Clinical setting  
Studies were conducted in 30 countries located across the globe (Table 4.3). Most (97, 
90%) took place in a single country, while trials evaluating international test-treat practice 
included centres from between 2 and 11 countries. Trials were more commonly conducted 
Country of Study n (%) 
Western world* 2 (2) 
Worldwide† 4 (4) 
Argentina 1 (1) 
Australia 6 (6) 
Belgium 1 (1) 
Brazil 1 (1) 
Canada‡ 9 (8) 
China 3 (3) 
Czech Republic 1 (1) 
Denmark 3 (3) 
France 4 (4) 
Germany 1 (1) 
India 1 (1) 
Iran 1 (1) 
Israel 1 (1) 
Italy 4 (4) 
Japan 2 (2) 
Indonesia 1 (1) 
Netherlands 16 (15) 
Poland 1 (1) 
Portugal§ 1 (1) 
Spain§** 5 (5) 
Sweden 2 (2) 
Switzerland 4 (4) 
UK** 20 (19) 
USA‡ 18 (17) 
Total 108 
 
Table 4.3: Location of clinical centres under study. 
 * North America and Europe only 
† Western world, Asia (India, Pakistan), Australasia, Africa (Egypt, S. Africa), South America 
(Mexico, Venezuela) 
 ‡ 3 studies carried out in Canada and USA 
 § 1 study carried out in Portugal and Spain 
 ** 1 study carried out in Spain and UK 
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in North America and Europe, the UK being the most common single country of origin. 
Consistent with this distribution and the study selection criteria, the majority of trials were 
conducted in English speaking countries (56, 52%). 
Test-treatment interventions were evaluated across eighteen medical specialties, though 
the distribution was not even (Table 4.4). Cardiovascular settings alone accounted for one 
in three trials. Almost 75% of studies were conducted in one of four departments: 
cardiovascular, obstetrics and gynaecology, gastroenterology or orthopaedics, while fewer 
than one in three trials were conducted in the remaining 14 specialties.  
Clinical Specialty 
 Care Setting 
Emergency Primary Secondary Tertiary Multiple Total (%) 
Cardiovascular Medicine 9 1 17 5 4 36 (33) 
Obstetrics and 
Gynaecology 
0 0 8 10 0 18 (17) 
Gastroenterology 0 5 9 0 0 14 (13) 
Orthopaedics 1 2 6 1 0 10 (9) 
Oncology 0 0 0 6 0 6 (6) 
Multiple* 0 1 1 1 1 4 (4) 
Neurology 1 0 1 0 1 3 (3) 
Respiratory 0 1 1 1 0 3 (3) 
Embryology 0 0 0 2 0 2 (2) 
Ophthalmology 0 0 0 2 0 2 (2) 
Otolaryngology 0 0 0 2 0 2 (2) 
Psychiatry 0 1 1 0 0 2 (2) 
Urology 0 1 0 1 0 2 (2) 
Emergency Medicine 1 0 0 0 0 1 (1) 
General Medicine 0 0 0 0 1 1 (1) 
Geriatrics 0 0 1 0 0 1 (1) 
Infectious diseases 0 0 1 0 0 1 (1) 
Endocrinology 0 0 0 0 0 0 (0) 
Neonatology 0 0 0 0 0 0 (0) 
Total  12 12 46 31 7 108 
 
Table 4.4: Range of clinical departments and care settings the test-treatment trials were conducted in. 
* 1 study covered 7 specialities (including Endocrinology and Neonatology), and the 
remaining three studies covered two specialities 
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Nearly half of all studies managed patients in a secondary care setting, namely in a 
hospital following referral from community or emergency services (Figure 4.1), while a 
considerable proportion of the remainder assessed tests used in specialised tertiary 
clinics. Seven studies took place at the interface of two to three services, either because 
the treatment options varied according to the diagnosis provided by the intervention (n=5), 
or because management in different care settings was integral to the comparison itself 
(n=2). For example one trial set out to assess whether ED patients suspected to have 
suffered a transient ischaemic attack (TIA) would experience a reduction in disease-event 
rates by immediately undergoing a comprehensive testing protocol in the ED, rather than 
being admitted as inpatients to receive a slower and more ad-hoc process of diagnosis(T86). 
In this example, both the types of tests administered and the organisation of testing were 
the subject of evaluation. 
4.2.2 Tests evaluated  
Most trials (97, 90%) compared two testing strategies, though three- (n=6), four- (n=4) and 
five-group (n=1) comparisons were also encountered. Consequently, 224 intervention 
 
 
Figure 4.1: Proportion of trials conducted in each care setting 
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arms were compared, 110 receiving a control test and 124 receiving an experimental test 
(see table 4.2 for definitions). A broad range of tests was evaluated, covering nine types of 
technology. Imaging tests were by far the most common subject of evaluation, with 52 
(42%) experimental interventions assessed in a total of 50 (49%) different test-treatment 
RCTs (Table 4.5a). Endoscopies comprised a fifth of these studies, and were carried out 
for a variety of investigations including the upper or lower gastrointestinal 
tract(T13,T30,T77,T88,T105), joint space(T35), bladder(T1,T90), uterus(T104), stomach(T9,T95) and 
abdominal cavity(T27). The majority however evaluated new radiological techniques 
involving at most minimally-invasive procedures to produce images of anatomical 
structures including X-ray(T6,T14,T20,T28,T40,T73,T99,T108), magnetic resonance imaging (MRI) 
(T4,T5,T10,T19,T47,T70,T92,T103,T107), computed tomography (CT)(T12,T68,T82,T85,T91), positron emission 
tomography (PET)(T52,T84,T96), single positron emission computed tomography (SPECT) 
(T32,T83,T92) or ultrasound (US)(T8,T11,T15,T22,T38,T58,69,T72,T76,T78,T89,T92,T102).  
Four studies evaluated the effectiveness of not giving any test to the patient group (‘No 
test’); three of these assessed the value of eliminating further treatment(T18,T45,T63) (see 
Test Genre Control (%) Experimental (%) 
Biochemical 10 (9) 26 (21) 
Biopsy 2 (2) 3 (2) 
Clinical assessment 15 (14) 13 (10) 
Electrophysiological 7 (6) 11 (9) 
Imaging (radiology) 21 (19) 41 (33) 
Imaging (endoscopy) 15 (14) 11 (9) 
Imaging (total) 36 (33) 52 (42) 
Telemedicine 2 (2) 2 (2) 
Multiple test interventions* 9 (8) 11 (9) 
No Test 18 (16) 5 (4) 
Not reported 11 (10) 1 (1) 
Total †110 
 
†124 
 
Table 4.5a: Test types evaluated in test-treatment RCTs.  
 *detailed in Table 4.5b 
†Note that the denominators refer to the number of interventions not the number 
of trials 
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below) and one the benefits of treating all patients without prior testing(T71). Approximately 
one in five trials evaluated biochemical assays, designed to measure a variety of biological 
substances including blood serum protein levels (n=6), amino acids (n=2), or 
microbiological cultures (n=7). Trials did not solely focus on assessing new or 
technologically advanced tests, and 13 comparisons investigated a new role for clinical 
assessment. Signs and symptoms were for example used in the implementation of ‘watch-
and-wait’ policies, in order to restrict the use of more technologically advanced tests to 
patients who fail to respond to treatment(T27,T33,T36,T65,T71). Tests measuring 
electrophysiological responses accounted for approximately 10% of experimental 
interventions(T2,T39,T41,T54,T56,T61,T67,T78,T80,T101), all but two(T39,T54) of which entailed 
measurement of cardiovascular properties. Eleven trials evaluated protocols containing 
multiple new tests (Table 4.5b), including four that assessed the impact of a new 
diagnostic unit for the provision of specialised diagnosis and management in an earlier 
care setting(T16,T29,T48,T53).  
Non/minimally-invasive imaging modalities were almost twice as likely to be evaluated as 
experimental interventions than control interventions (33% vs. 19%, Figure 4.2), and the 
Multiple test interventions Control (%) Experimental (%) 
Biochemical + Clinical assessment 1 (10) 4 (40) 
Biochemical + Electrophysiology 2 (20) 0 (0) 
Biochemical + Imaging (radiology) 1 (10)  2 (20) 
Biochemical + Imaging (endoscopy + radiology) 0 (0) 1 (10) 
Biopsy + Imaging (radiology) 1 (10) 0 (0) 
Clinical assessment, Electrophysiology, Imaging 
(radiology) 
2 (20) 0 (0) 
No Test + Imaging (radiology) 1 (10) 0 (0) 
Unit of care 1 (10) 4 (40) 
Total *9 
 
*10 
 
Table 4.5b:  Composition of multiple test interventions. 
*Note that the denominators refer to the number of interventions not the number 
of studies 
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same was also true of biochemical assays (21% vs. 9%), which may reflect a general 
increase in the use of these two technologies through time. Conversely, ‘no test’ strategies 
were more commonly used as comparators (16% vs. 4%), signalling a trend towards the 
introduction of new tests into healthcare management.  
Studies were also less likely to report which tests formed the control intervention, 11 trials 
(10%) stating only that ‘standard care’ was used(T10,T16,T32,T43,T45,T56,T69,T72,T86,T97,T100) 
compared to one trial failing to report which tests were used as part of the experimental 
intervention(T86).  
 
 
 
 
Figure 4.2:  Distribution of experimental and comparator intervention test types. 
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4.2.3 Comparisons made 
Control interventions generally constituted current practice (101, 94%), although this was 
unclear in five studies. Two trials did not compare existing practice to new, one evaluating 
two competing variations of a standard care protocol(T88), while another directly compared 
the health impact of two recent technological developments(T19).  
Two thirds of studies evaluated a diagnostic strategy designed to replace the existing 
approach (74, 60%), while 23% (29/124) assessed the impact of adding tests and a further 
17% (21/124) the addition of triage tests (Table 4.6). Seven distinct types of replacement 
comparison were observed, reflecting variations in the number, order and nature of the 
experimental test, relative to the control test, in an existing pathway. Examples of each are 
illustrated in table 4.7. Approximately half (47%) were typical examples of a new test 
replacing the current clinical standard, studies also evaluated the benefit of using existing 
tests in a different order (‘Strategy replacement’, 4%) or administered in different 
healthcare settings (‘Delivery change’, 3%); of evaluating technologically improved existing 
tests (‘Test updated’, 5%); of introducing a test where previously there had been no patient 
selection for subsequent treatment (‘Testing introduced’, 24%), or conversely eliminating 
Experimental Test Genre Triage (%) Replacement (%) Additional (%) 
 
Total (%) 
Biochemical 2 (10) 14 (19) 10 (34)  26 (21) 
Biopsy 1 (5) 2 (3) 0 (0)  3 (2) 
Clinical assessment 5 (24) 7 (9) 1 (3)  13 (10) 
Electrophysiological 0 (0) 6 (8) 5 (17)  11 (9) 
Imaging (radiology) 8 (38) 24 (32) 9 (31)  41 (33) 
Imaging (endoscopy) 0 (0) 8 (11) 3 (10)  11 (9) 
Telemedicine 0 (0) 2 (3) 0 (0)  2 (2) 
Multiple test interventions 5 (24) 5 (7) 1 (3)  11 (9) 
No Test 0 (0) 5 (7) 0 (0)  5 (4) 
Not reported 0 (0) 1 (1) 0 (0)  1 (1) 
Total 21  74  29   124  
Table 4.6: Experimental test types and how they substitute the existing diagnostic pathway. 
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an existing episode of diagnosis from the pathway (‘Testing eliminated’, 7%); or lastly of 
eliminating pre-selection for the use of an existing test (‘Triage eliminated’, 9%). 
In contrast, add-on and triage comparisons were relatively uniform. Experimental tests 
were added to the same part of the existing test-treat pathway in order to evaluate the 
benefit of extra information to diagnostic decision-making. For example focussed 
Replacement comparisons Description Example 
1. Standard replacement 
(n = 35) 
The direct replacement of an 
existing test by a new test 
Is CTA in place of DSA better for 
detecting vascular blockages in 
patients with known PAD
(T12)
  
2. Strategy replacement  
(n = 3) 
Replacement of the order of existing 
tests 
Should MRI be given immediately 
to all patients followed by an 
orthopaedic consultant, or 
should all patients receive an 
orthopaedic consultation 
first?
(T107)
  
3. Testing introduced  
(n = 18) 
New episode of diagnosis introduced 
into pathway 
Should patients with idiopathic 
VTE be screened for malignancies 
using a battery of tests?
(T42)
  
4. Testing eliminated  
(n = 5) 
Existing episode of diagnosis 
eliminated from pathway 
Is it safe to discharge patients 
with suspected VTE on the basis 
of prior tests, rather than 
perform further US?
(T63)
 
5. Triage eliminated  
(n = 7) 
Selective application of old test 
replaced by routine use in all 
Should CA be given to all ACS 
patients immediately, instead of 
on the development of a 
worsening condition during 
admission?
(T99)
 
6. Test updated  
(n = 4) 
Technological development of the 
existing test 
Would patients with a bacterial 
infection benefit if physicians 
received microbiological 
identification and susceptibility 
results more quickly?
(T23)
 
7. Delivery change 
(n = 2) 
Change in how existing test is 
administered 
Will there be any change to 
patient health if upper GI 
endoscopy/FS is nurse-led rather 
than doctor-led?
(T77)
 
Table 4.7: Examples of replacement comparisons. 
CTA – Computed tomographic angiography; DSA - Digital subtraction angiography; PAD – 
Peripheral arterial disease; US – Ultrasonography; CA – Coronary angiography; ACS – Acute 
coronary syndrome; GI – Gastrointestinal; FS – Flexible sigmoidoscopy 
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ultrasound was provided to patients with suspected torso trauma in addition to the 
standard battery of tests in order to reduce complications of delayed treatment(T72), while 
transvaginal US and fetal fibronectin measurements were added to the standard speculum 
examination to assess the presence of preterm labour in high risk patients(T94). 
Triage tests were employed either to restrict the use of an existing invasive test, such as 
using MRI to determine the need for arthroscopy in knee injury patients(T47), or to otherwise 
reduce diagnostic resource use to a subset of patients, for example restricting the use of 
CT in suspected appendicitis patients to those with continuing worsening of symptoms(T60).  
4.2.4 Extent of prior testing 
The degree of patient selection in trial populations was observed to fall into four broad 
categories, reflecting the extent of previous testing (Table 4.8). The most common reason 
for conducting diagnostic clinical effectiveness trials appeared to lay in discerning the 
impact of further testing, either in already highly selected populations (43, 40%), for 
example evaluating blue light cystoscopy to more precisely locate known bladder cancer 
tumours for resection(T1), or in patient groups who had been referred from primary care for 
Extent of prior testing category n (%) 
Unselected: No prior testing – first point of healthcare contact 
for current complaint  
5 (5) 
Limited selection: Limited prior testing – one or two prior tests 
constituting a basic assessment of signs and 
symptoms  
42 (39) 
Narrow selection: Moderate prior testing – several preceding tests 
resulting in a suspected differential diagnosis 
17 (16) 
Considerable selection:  Extensive testing already conducted, generally 
indicating patient has received a diagnosis and 
treatment plan prior to entering the study 
43 (40) 
Table 4.8: Apparent selection of patient populations taking into account the extent of prior testing 
received. 
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further examination (42, 39%), such as elucidating a differential diagnosis in patients with 
dyspepsia(T44). 
Only five studies (5%) were interested in evaluating tests at the beginning of a pathway, 
for example diagnosing urinary tract infections at first presentation of symptoms(T34), while 
the remaining 17 studies (16%) evaluated mixed patient groups with some existing 
diagnostic information, for instance to determine the cause of undifferentiated chest pain in 
ED patients with indeterminate ECG(T48).    
4.2.5 Purpose of test-treat interventions 
Testing was found to serve six diagnostic functions (Table 4.9). Diagnostic interventions 
most often sought to confirm a diagnosis suspected on the basis of prior tests, for example 
to confirm the presence of clinically suspected hip dysplasia in neonates using US(T15). 
Tests were also commonly evaluated earlier in the management pathway, to rule out 
disease for example to exclude the possibility of coronary artery disease in patients 
presenting with acute chest pain(T82), or to contribute to a differential diagnosis in patients 
with more generalised symptoms or indeterminate signs, such as refining the potential 
cause of unexplained syncope(T53).  
Diagnostic purpose of intervention Total (%) 
Various 1 (1) 
Determine risk of disease progression/future event  4 (4) 
Rule out disease 13 (12) 
Narrow the differential diagnosis 16 (15) 
Screen for concomitant disease 21 (19) 
Determine extent of disease/disease characteristics 23 (21) 
Confirm a suspected diagnosis 30 (28) 
Total 108 (100) 
Table 4.9: Purpose of diagnostic investigations in included trials. 
  
 
103 Chapter 4: Results 
Nearly half the trials (48, 44%) evaluated tests in patients with known disease, most often 
to establish the extent or characteristics of disease, for example to stage breast cancer(T24), 
locate the blocked vessel in patients with peripheral artery disease(T70), or identify the 
organism causing infection in pneumonia inpatients(T59), but also occasionally to determine 
a patient’s short-term risk of disease progression, for example the likely progression to a 
full stroke in TIA patients(T86). A less expected though frequent finding was the use of tests 
for ‘opportunistic screening’, that is checking for a possible concomitant condition in 
patients at risk due to underlying disease. For instance imaging patients with idiopathic 
DVT to check for related occult malignancies(T42), or screening embryos for chromosomal 
abnormalities in women of advanced maternal age scheduled for IVF(T98). While the 
purpose of testing in this latter category of trials was observed to be closer to ‘screening’ 
proper, upon closer scrutiny the participants were already patients within the healthcare 
system, could be described as symptomatic and were therefore not ‘preclinical’. Details of 
these inclusion decisions were described in chapter 2 (section 2.3.2, p.58–62). 
Once test results were produced, ensuing diagnoses were used to determine the nature of 
subsequent treatment (55, 51%), the need for further investigation (23, 21%), to aid in the 
implementation of a predetermined treatment (19, 18%), or to identify a subgroup of 
patients in whom a particular treatment may be most suitable (10, 9%). While each of 
these types of management decision was used alongside most diagnostic purposes, there 
was a clear tendency for specific management decisions to follow each diagnostic 
decision. Interventions designed to confirm, rule out or screen for possible diagnoses were 
most often used to select the most appropriate treatment, those allowing a differential 
diagnosis to be reduced were most often used to direct towards appropriate further 
investigation, while tests used to establish the extent of disease were most often used to 
aid in treatment planning (Table 4.10). 
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4.2.6 General characteristics of trial design 
In virtually all trials (101, 94%) the unit of allocation was individuals, while the remainder 
randomised healthcare centres(T64,T66,T71,T97), days on which patients presented(T43,48) or 
families(T51). The latter evaluated the use of a genetic test for familial 
hypercholesterolaemia in both patients with suspected disease, and their relatives. 
In almost all studies groups were evaluated in a simple parallel fashion (105, 97%). Three 
trials employed a 2x2 factorial design to evaluate combinations of test strategies and 
treatment strategies(T18,T62), or of test-treat strategies and an educational intervention(T97). 
In 99 trials (92%) eligible patients were randomised at the time when a clinical decision to 
perform a test would be made in practice. Eleven studies correspond to Lijmer and 
Bossuyt’s22 definition of ‘randomised disclosure’ designs, whereby randomisation is 
essentially delayed to coincide with the point of releasing test results. In the trial evaluating 
the addition of TV-US and fFN mentioned above for example, patients received all tests 
and were randomised to treatment proceeding on the basis of all three tests (the 
experimental intervention) or the control test only(T94) (Figure 4.3a). Figure 4.3b illustrates a 
Diagnostic 
Purpose 
Treatment Purpose 
Rx planning (%) Need 
for Rx 
(%) Further Dx (%) Suitability 
for Rx 
(%) Total (%) 
Risk of disease 0 (0) 1 (2) 2 (9) 1 (1) 4 (4) 
Rule out disease 0 (0) 8 (15) 3 (13) 2 (20) 13 (12) 
Narrow DDx 0 (0) 6 (11) 10 (43) 0 (0) 16 (15) 
Opportunistic 
screening 3 (16) 14 (25) 1 (4) 3 (30) 21 (19) 
Extent disease 13 (68) 4 (7) 3 (13) 3 (30) 23 (21) 
Confirmatory 3 (16) 22 (40) 4 (17) 1 (10) 30 (28) 
Total 19 (100) 55 (100) 23 (100) 10 (100) *108 (100) 
Table 4.10: Cross-tabulation of diagnostic and management decisions. 
 * One study
(T57)
 used a variety of tests covering all test and treatment purposes 
 Dx – Diagnosis; DDx – Differential diagnosis; Rx - Treatment 
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trial evaluating a similar topic using the standard point of randomisation. Though in both 
trials patients are treated according to tests given in one arm only, the randomised 
disclosure comparison allows investigators to establish the prevalence of target disease in 
both randomised groups, and to identify and follow patients with discrepant test results. Of 
course not all test-treat strategies are amenable to this design. The eleven examples 
evaluated biochemical assays(T21,T26,T43,T49,T65,T94,T100) and/or radiological imaging 
+ 
- 
PTL signs/ 
symptoms R 
Clinical 
Exam 
TREAT 
DISCHARGE 
TREAT 
Figure 4.3b: Example of a standard parallel design. Women with suspected signs of preterm 
labour (PTL) receive the standard speculum examination, and are randomised to 
receive a transvaginal ultrasound (TV-US) to guide treatment decisions, or to all 
receive treatment for PTL
(T102)
. 
TV-US 
+ 
- 
PTL signs/ 
symptoms 
R 
Clinical 
Exam 
fFN 
+ 
- 
TREAT 
DISCHARGE 
TREAT 
DISCHARGE 
Figure 4.3a: Example of a randomised disclosure design. Women with suspected signs of 
preterm labour (PTL) receive the standard speculum examination, and two 
experimental tests: fetal fibronectin measurement (fFN) and transvaginal ultrasound 
(TV-US). Randomisation of test results follows, with patient management proceeding 
on the basis of all three tests (the experimental intervention) or the control test 
only
(T94)
 
TV-US 
Disclose 
Clinical Exam 
Disclose all 3 
test results 
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modalities(T4,T8,T69,T94,T103), none of which are invasive or carried out by the treating 
physician. No other variations in the style of randomisation were found. 
4.3 Discussion 
 
RCTs that evaluate the patient health impacts of test-treatment interventions are carried 
out in a wide range of diagnostic settings. Numerous types of tests were conducted to 
inform an extensive spectrum of questions, in diverse patient groups, and across almost all 
medical departments. Though small in number, the participation of 30 different countries 
attests to a widespread recognition of the need to evaluate the clinical effectiveness of 
diagnostic test practice. Although a key objective of the search was to locate test-
treatment RCTs regardless of study topic, the ensuing project cohort contains a very 
heterogeneous collection. No two trials evaluated the same test-treat interventions in 
comparable populations.  
4.3.1 Imaging tests and cardiovascular medicine are the most 
frequent diagnostic settings  
There was a clear predominance for certain study topics, in particular evaluations of 
imaging modalities and evaluations of tests used in cardiovascular medicine, however the 
extent to which this reflects the ‘feasibility’ of performing test-treatment RCTs is unclear. 
This could in part be a manifestation of the well–established research careers that 
characterise these two disciplines, indeed much of the methodological development of 
diagnostic test research originates from the field of radiology62,187,231. This finding may also 
reflect the types of tests being developed and trends in disease; imaging technologies are 
known to be amongst the most proliferous types of test232, whilst the need to diagnose and 
treat cardiovascular disease has been an increasing concern for several decades233. 
Nonetheless, biochemical assays have also proliferated234, though this review suggests 
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they seem not to have reached evaluations of clinical effectiveness as frequently as 
imaging tests, and indeed this supports concerns raised within the clinical chemistry 
community13,235.  
4.3.2 Test-treatment RCTs are highly diverse 
These trials emphasise the complexity of factors taken into consideration when deciding 
on diagnostic practice. Other aspects of test-treat management were evaluated alongside 
test performance; comparing the organisation of test-treatment delivery was a recurring 
theme, seen in trials assessing ‘units’ of care that sought to standardise complex 
diagnostic protocols, or providing specialised diagnostic services earlier in patient care 
pathways. These interventions are likely to pose particular methodological problems due to 
the complexity of test strategies being evaluated, and the opacity of less standardised 
control strategies that have highly variable protocols. 
Moreover, the situation is often more complicated than evaluating the introduction of a test 
to detect a single target condition. Though concerned only with ‘diagnosis’, tests can be 
ordered to address six broad types of diagnostic dilemma, and to aid various management 
decisions. Extracting a ‘target condition’ from each study was not always possible. It 
applied most clearly to confirmatory and opportunistic screening trials, which are typified 
by the targeted search for a specific condition in a more homogenous patient group. 
Conversely, tests were often used to sort patients with limited prior test results into multiple 
management pathways or to guide treatment in patients with known disease. Derived from 
test accuracy research, this terminology simply does not apply to all test-treatment 
situations, exemplifying the dynamic context of diagnostic decision-making that is being 
evaluated in clinical trials compared to the more artificial settings in which diagnostic 
accuracy must be measured.  
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4.3.3 Test-treatment RCTs take place in specialised settings 
RCTs are expensive and resource-intense enterprises, and it is therefore not surprising 
that their application to diagnosis appears focussed on evaluating more technologically 
complicated tests. Since primary care services are usually limited in the availability of 
these tests, the predominance of secondary and tertiary care settings is likely to reflect this 
tendency – and indeed, most primary care test-treatment comparisons (14/18, 78%) 
evaluated clinical assessment and/or biochemical assays, both of which are easily 
accessible technologies. 
This carries implications for the composition of patient groups that tend to be evaluated in 
these RCTs. The further along the referral process a test takes place, the more highly 
selected we can expect patient groups to be. This means that test-treatment RCTs are 
more likely to address highly selected patient groups, and indeed this is born out by the 
finding that almost half the included trials sought to further categorise patients with existing 
disease. A potential consequence could be that there will be very little difference in the 
diagnostic performance of tests in these groups, suggesting sample sizes would need to 
be very large in order to capture true differences in treatment effects. 
4.3.4 RCT study design 
The preponderance of replacement comparisons could be consistent with the principle that 
RCTs should be conducted toward the end of the evaluative trail, following prior 
determination of test accuracy, treatment efficacy or other attributes of the test-treat 
strategy. When tests are first introduced, they may be assessed as add-ons to existing 
tests in order to limit adverse events, whilst as experience of a test’s utility grows 
physicians may start using it on its own. If this is the case, the presence of so many 
replacement comparisons could signify that RCTs are being used appropriately as late 
study designs. Alternatively, it could be that total replacement comparisons are more 
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strongly related to the perceived need to conduct health outcome RCTs, while add-on or 
triage comparisons are considered to be safer and are consequently not evaluated beyond 
test accuracy.  
The diversity found in the composition of test and treatment components draws attention to 
particular combinations that might be best suited to evaluation through the RCT design. To 
this regard, endoscopy interventions are of particular interest. Since testing and treatment 
are often conducted as part of the same procedure, the impact of each component is 
inseparable from the other, and consequently, the only way to evaluate the performance of 
diagnostic endoscopy empirically will be using an RCT study design. The types of trial 
design available will also be limited when evaluating settings in which test and treatment 
components are so closely situated, since it is not feasible for all subjects to receive both 
tests and be randomised to treatment on the basis of test results. This is also true when 
evaluating tests that are highly invasive, such as large-sample biopsy techniques.  
The use of ‘randomised disclosure’ RCT designs, in an albeit limited number of trials, 
demonstrates that trialists do already experiment with the structure of test-treatment trial 
designs. Since none discussed methodological issues or described their RCTs as 
‘randomised disclosure’ designs, their use may represent an intuitive step based on the 
practicalities of organising the trial, rather than being informed by methodological theory.  
Lijmer and Bossuyt22 discuss a second, potentially very powerful trial design that could 
apply to test-treatment comparisons, ‘discordant test result’ RCTs. In these designs, 
eligible patients are given all comparative tests though only patients in whom test results 
do not agree (e.g. test-positive according to the existing test and test-negative according to 
the new test, or vice-versa) are randomised to receive management according to the 
results of each diagnostic strategy being compared. Discordant test result RCTs are not 
included in the project cohort, since they were excluded by the thesis selection criteria 
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(outlined in chapter 2, p. 55), and so a separate review will be needed to ascertain and 
examine them. Several examples have been identified retrospectively amongst excluded 
studies, confirming that these are indeed carried out. In one such study women with 
symptoms of a lower urinary tract infection (dysuria), but with negative urine dipstick test 
results, were randomised to receive three days of antibiotics (i.e. treatment according to 
symptoms) or to placebo (treatment according to the dipstick test result). Women 
responded very favourably to antibiotic treatment in the absence of a positive biomarker, 
experiencing significantly reduced rates of dysuria and increased speed in the resolution of 
symptoms236, and hence the trial demonstrated that although the urine dipstick accurately 
predicts the absence of a detectable infecting organism, it does not predict patients’ 
response to treatment. In eliminating patients from randomisation who would experience 
no change in management as a result of receiving the experimental test, these designs 
enable follow-up to focus solely on the patient group who could show a difference in 
treatment effect, thus increasing the power of the study in comparison to standard pre-test 
randomised designs. As patients are randomised at the point of treatment, discrepant 
design RCTs are even more elusive to the reviewer since they ostensibly resemble 
treatment RCTs, and thus risk being more difficult to ascertain when laying in large 
bibliographic databases that contain many thousands of treatment trials. For future 
methodological studies to investigate them systematically, it will be essential to introduce 
diagnostic indexing terms. 
4.3.5 Study limitations 
During data extraction, difficulties were encountered in trying to discern the composition of 
test-treatment interventions, as well as the aim of diagnosis, in a large proportion of 
studies. Often, these two key pieces of information were not explicitly reported but instead 
concealed within disparate sections of publications, or not reported at all. Consequently, 
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summarising the structure of these test-treatment trials has required careful threading 
together of often implicit information within the trial reports, supplemented by the 
examination of external sources detailing current clinical practice.  
Since the classifications generated to characterise this group of trials is inherently 
dependent on published descriptions, these details may not reflect the breadth of 
questions addressed in all test-treatment RCTs. Chapter 3 concluded that between three 
and 28 trials may have been overlooked by the author during the study selection process, 
thus there may well be other aspects of important variation in study settings that are not 
represented in the project cohort. It is possible, therefore, that the considerable variation 
observed by this analysis has underestimated the true state of affairs. 
The categorisations imposed to enable the synthesis of these studies required the 
simplification of complex clinical settings. Although the author has consulted clinical 
diagnosticians during this process, it is possible that some more complex medical 
comparisons have been incorrectly classified. In addition, due to the time required to 
analyse such studies in depth neither the extractions nor classifications were double–
checked, leading to the possibility that the author’s interpretation may differ from that of 
other non–clinical researchers. In the absence of existing tools to describe test-treatment 
RCTs, efforts to ensure the relevance and consistency of data extraction entailed using 
pre–defined items from existing, validated checklists that are considered important to the 
description of test accuracy studies and general RCTs, as well as ensuring that the 
retrieval of this information was systematic. Nonetheless, analyses using the inductive 
approach will always in part reflect the analyst’s experience and perspective, since 
descriptive categories are generated by the analyst’s interpretation of the literature. As a 
result the classifications illustrated in this chapter present a fusion of the information 
presented in trial reports and the author’s perspective, which has been informed by 
considerable discussion of many included trials with clinicians and methodological experts.
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Since the process has been highly subjective, it would be interesting in future to determine 
whether the resulting classifications are found to be useful to the description of test-
treatment trials. 
4.4 Conclusion 
 
Examination of this systematically–derived cohort of published trials demonstrates that 
test-treatment RCTs have answered a wide variety of diagnostic questions. While there 
was a clear predominance for certain study topics, including cardiovascular department, 
imaging tests, replacement comparisons and confirmatory purpose of testing, overall the 
cohort is very heterogeneous. This is due to the complexity of any given test-treatment 
strategy, which must take into account factors that influence the individual elements of 
these interventions, diagnosis, decision-making and treatment provision, but also the 
delivery of such care. These were all identified as important sources of variation in the 
clinical context. Since variability can limit the applicability of study results, and the extent to 
which different studies may be synthesised for meta-analysis, an important task will be to 
determine what effects these sources of variation can have on the results of test-treatment 
RCTs.  
Several study features, key to understanding how and why interventions are being 
evaluated, appear to be unique to test-treatment RCTs. Examples include the diagnostic 
purpose and therapeutic aims of tests, important additions to the ‘target condition’ which is 
recommended to be reported in diagnostic accuracy studies72. Explicit descriptions of 
which tests and treatments make up the interventions being compared is also essential, as 
poor reporting impedes users of evidence from understanding these trials and from making 
reliable and informative syntheses in future. These traits would indicate that further 
guidance is needed to ensure that these unique studies are reported more 
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comprehensively, and perhaps would benefit from an extension of CONSORT guidelines 
to test-treatment interventions. 
In conclusion, the range of diagnostic questions observed in this cohort of test-treatment 
RCTs suggests that, despite their current rarity, it is feasible to conduct these trials across 
many clinical disciplines. But can test-treatment RCTs be conducted well? This 
fundamental question is addressed in the following two chapters, which appraise the 
reporting quality (chapter 5) and methodological quality (chapter 6) of test-treatment RCTs. 
These reviews also explore whether particular attributes of the study settings highlighted in 
this chapter create obstacles to the production of informative and valid test-treatment 
RCTs. 
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This chapter builds on the findings of chapter 4 to evaluate the second challenge levelled 
at test-treatment RCTs: that these trials risk producing evidence that is difficult to interpret 
and to use. This is achieved by evaluating the reporting quality of trials identified in the 
project cohort, in chapter 2.  
Inadequate documentation of RCTs inhibits the interpretation of results, as well as the 
ability to translate interventions into practice121,136. The complexity of test-treatment 
interventions is hypothesised to create particular difficulties in the ability to produce full and 
informative accounts of their conduct. Since diagnostic decision–making is highly variable, 
trials must pre–specify how test results lead to diagnoses and treatment plans in order to 
be sure of how interventions are creating the observed effects22,76,79. However, researchers 
claim it could be challenging to document multiple interventions entailing decision–making 
to the extent necessary to allow findings to be interpreted, to be compared across studies, 
and to enable beneficial interventions to be translated into practice176. 
The following study has been designed to evaluate the extent to which test-treatment 
RCTs produce informative reports. It aims to achieve this by systematically appraising the 
reporting quality of the published trials ascertained in chapter 2 and characterised in 
chapter 4. 
5.1 Methods 
 
Assessments of reporting quality focussed on three aspects that are fundamental to 
interpreting and using trial findings: the need to understand what happened, to whom, and 
how it was measured. Accordingly, trials were appraised regarding the reader’s ability to 
discern the selection and flow of participants through the trial, how participants should be 
managed according to the allocated test, and how their response to these interventions 
was measured; specifically:  
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1.1 Were test-treatment interventions completely identified and described?  
1.2 Did trials make clear the proportion of eligible patients recruited into the study, 
and document whether some participants did not receive the allocated 
intervention, were lost to follow-up, or were not analysed?  
1.3 Were primary outcomes completely defined, clearly conveying what was being 
measured, how and by whom?  
Reporting of methodological safeguards employed by trialists to maintain a study’s internal 
validity were also appraised, however this was conducted as part of the review of 
methodological quality presented in chapter 6. 
5.1.1 Design of a quality assessment tool 
In the absence of an existing quality assessment tool specific to test-treatment RCTs, 
standardised data collection and appraisal forms were designed. Items were identified 
from two validated, internationally accepted standards for the reporting of RCTs: the 
CONSORT checklist121 and the extension of the CONSORT statement for non-
pharmacologic therapy interventions147. Table 5.1 lists the extracted items. 
This new quality appraisal tool was tested by extraction of five test-treatment trials, 
randomly selected from the project cohort. Minor changes were made to improve the 
standardisation of data collection and quality assessment.  
5.1.2 Data extraction 
Trials identified by the project search with at least one publication of study findings were 
included. All articles reporting on the same trial were examined. Important related 
publications not identified by the restricted timeframe of the project search, such as 
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original trial reports, preliminary design protocols or long-term follow-up papers, were also 
traced through citations and author-title searches of Medline. Data were extracted to a 
purpose built relational database (Microsoft Office Access 2007) and appraised for 
reporting quality using the methods reported below. Extraction and quality assessment 
were performed by the author.  
5.1.3 Appraisal of reporting quality  
Descr i p t ion  o f  i n te r vent i ons  
Trials were assessed for description of the interventions under evaluation. Test-treatment 
interventions were considered in four components: the test method, criteria used to form 
the diagnostic decision, criteria used to select treatments, and the treatment method. Each 
component was judged to have been reported if any relevant information was described or 
referred to by citation to another study (Box 5.1). Specifically, quality judgements were not 
predicated on whether adequate clinical detail was reported for a given component to be 
replicated in clinical practice. Although this would have been desirable, it would have 
Trial Documentation Objectives Item 
1.1    Does the report give a full 
description of all competing test-
treatment interventions? 
Was the test method reported? 
Were treatments reported? 
Were diagnostic decisions reported? 
Were treatment decisions reported? 
Was an algorithm diagram provided for each intervention? 
strategy? 
1.2   For each group, is it clear whether 
some participants did not receive 
the allocated intervention, were 
lost to follow-up, or were not 
analysed?  
The number of eligible participants 
The number of participants randomised to each arm 
The number receiving the allocated intervention 
The number who completed management as allocated 
The number of participants included in the main analysis  
Use of a CONSORT diagram to record participant flow  
1.3   Were primary outcomes 
completely defined, clearly 
conveying what is being 
measured, how and by whom? 
Is a primary outcome clearly defined? 
What was the primary outcome? 
How was it measured? 
Who measured it? 
Table 5.1: Items extracted to evaluate the reporting quality of test-treatment RCTs. 
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Box 5.1: Definition of the four components used to assess the description of test-
treatment interventions, with examples. 
 
Test Method:  Technique used to perform the test. Reporting the name of the test 
only was considered insufficient. 
 e.g. “Radiographs of the knee were obtained in the lateral and anteroposterior 
projection and were supplemented with patellar or tunnel views if pathologic 
abnormalities of the patellofemoral joint or intercondylar notch were 
suspected" 
(T5) 
Diagnostic Decision: Description of the operational criteria used for arriving at a particular 
diagnosis using the test results.  
 e.g. "If the lung scan showed no abnormalities, pulmonary embolism was 
excluded; if there were 1 or more segmental perfusion defects that were 
normally ventilated, the scan was considered diagnostic for pulmonary 
embolism (“high-probability scan”); and if there were perfusion defects that did 
not meet criteria for a “high-probability scan,” the scan was considered 
nondiagnostic." 
(T63) 
Treatment Decision: Description of how treatments were selected as a result of the 
diagnosis.  
 e.g. “Stones detected on EUS [endoscopic ultrasound] were removed 
endoscopically during a separate session; stones detected on ERC [endoscopic 
retrograde cholangiography] were removed immediately, during the same 
session. When the initial ERC or EUS failed, a second procedure was carried 
out." 
(T95) 
Treatment Method: Description of how selected treatments were administered. Reporting 
of the treatment name only was considered insufficient. 
 e.g. “After ultrasound diagnosis of an anal sphincter tear… women were 
brought immediately to the operating room to provide appropriate lighting, 
instruments, and assistants and underwent a surgical exploration of the 
perineum by the obstetrician-in-charge under senior supervision. The anal 
sphincter was exposed and its integrity assessed by inspection and palpation. 
The ends of the sphincter were approximated end-to-end with 2–0 
monofilament polyglyconate sutures (Maxon, Sherwood Davis & Geck, St. Louis, 
MO). Postoperatively, women received dietary advice to avoid constipation, 
with occasional use of stool softeners. For women allocated to the control 
group, the obstetrician sutured the perineum after clinical examination.”  
(T11) 
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required considerable consultation with a wide range of clinical experts, which 
unfortunately was not feasible for the current project.  
Following good practice recommendations by the MRC for the conduct of complex 
interventions83, studies were also appraised for their use of diagrams depicting the 
competing care pathway algorithms. Where present, diagrams were considered complete 
if they reflected all four test-treat components for each trial arm, and partially reported if at 
least one component was not represented. 
Clear  account ing  o f  p a r t i c i pant  f low  
Reports were reviewed to assess whether all participants could be clearly accounted for 
throughout the study, with or without the aid of the flow chart recommended by 
CONSORT. For each study group, the number of participants evaluated for eligibility, 
randomised, receiving the allocated intervention, completing follow–up and included in the 
main analysis were extracted. For cluster-randomised trials the number of clusters 
randomised and analysed were also extracted.  
If the figures reported for one of the five participant flow elements did not agree, for 
example if the number analysed did not tally with the numbers randomised and lost to 
follow up, then that element was considered as inadequately reported. Trials reporting all 
five elements were deemed fully reported. 
Com plet e  descr ip t ion  o f  pr im ar y outcomes  
Trials were appraised for clear reporting of a primary endpoint. Following the approach of 
Chan and Altman152, when studies failed to define their main measure of effect clearly 
outcomes were preferentially extracted according to the variable used in a power 
calculation, followed by a main outcome described explicitly in primary study objectives. If 
none of these was provided, the primary outcome was categorised at ‘not defined’. 
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Endpoints were classified as patient or process outcomes. For the purposes of description, 
outcomes were further categorised according to the response they were designed to 
measure.  
The quality of reporting how outcomes were measured was determined using two criteria: 
documentation of the method of measurement and the timing of measurement. Methods 
were considered as reported if a validated tool was used (for example the Short-Form 36 
to assess general health), if non-validated but fully described tools were used, or if criteria 
to direct a rigorous assessment of outcome were provided (for example the operational 
definition of a target condition and test methods used to arrive at a diagnosis). 
Documentation was considered complete when the time at which the primary assessment 
should be conducted was also made explicit. 
5.1.4 Analysis 
Data were exported from the extraction database to Microsoft Excel 2007 for sorting and 
analysis. The objective of this review was to describe the frequency with which test-
treatment trials were found to have reported their conduct appropriately. Consequently, 
this chapter presents a descriptive summary of these findings using percentages that 
reflect the categorical nature of the data. Comparisons between frequencies were used to 
enhance the description of findings, and aimed to highlight potential associations between 
the variations in reporting quality and aspects of the study settings, as characterised in 
chapter 4. The author did not intend to evaluate specific hypotheses regarding these 
associations, but rather to generate hypotheses for how easily the methods of trial design 
could be employed to conduct informative test-treatment RCTs. As a consequence testing 
for the statistical significance of these comparisons was not appropriate. 
  
Chapter 5: Included studies 122 
 
 
 
 
 
 
 
 
 
5.2 Included studies 
 
 
Of the original cohort, five trials(T22,T25,T43,T80,T84) had no published results and so were not 
appraised for reporting or methodological quality (Figure 5.1)*. This revised cohort (N=103) 
included 103 RCTs that compared 105 control arms with 119 experimental arms. 
Thirty–two trials had multiple publications (range 2-5), including those found by the project 
search and others published outside the project timeframe retrieved by the author through 
targeted searches of Medline. These most commonly reported additional economic 
analyses(T14-15,T38,T48,T49,T55,T57,T61,T68,T71,T90,T107), trial design(T14,T38,T57,T66,T96-97,T101), long-term 
follow-up results(T38,T44,T46,T55-T56,T90,T99), sub-group analyses (T14,T16,T18,T32,T41,T55,T73,T89), 
reproduction of trial results in a full health technology appraisal report(T34,T36,T47) or
                                                 
*
 Citations for included test-treatment RCTs are prefixed with a ‘T’ 
 
RCTs with no published results, 
excluded from quality review 
n=5 
Test-Treatment RCTs included in 
the project cohort 
n=108 
 
Figure 5.1: Test-treatment RCTs appraised for quality of reporting and methods. 
RCTs included in review 
n=103 
Relevant duplicate publications 
used to assess quality 
n=31 
 Found by search n=23 
 Traced manually n=8 
Articles reviewed for quality 
n=134 
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reproduction of an HTA assessment as a short journal article(T57). These additional 
publications are listed as references in Appendix C (p.380). 
5.3 Results 
 
Summaries of reporting quality appraisals are provided in Appendix D (p.386). 
5.3.1 Documentation of test-treatment protocols 
Use of  a  pr otocol  d i agram 
Diagrams illustrating the competing test-treatment strategies were included by 
approximately one-fifth of trials, depicting 24/119 experimental interventions and 22/105 
control interventions. These ‘care pathway’ diagrams were found to be most informative if 
they illustrated how patients might travel through the process according to diagnostic 
findings and their treatment decisions. Fewer than 10% (8 experimental, 7 control) 
provided these full accounts, while the majority of diagrams were considered incomplete 
due to the absence of decision-making protocol elements. 
Figure 5.2a shows a direct copy of a published care pathway for a trial evaluating the 
benefit of adding an ultrasound assessment of the hip to the existing clinical assessment in 
order to confirm the presence of mechanical hip instability in neonates(T15). It was 
considered complete due to its clear delineation of the tests given, the main diagnostic 
decisions taken on the basis of test results, and which treatments these categories should 
lead to. A representative example of a partial diagram is provided in Figure 5.2b, again a 
published care pathway, but this time for a trial assessing the benefits of investigating 
patients in a specialist unit, rather than in the emergency department (ED) as standard, in 
order to establish the cause of syncope for the purpose of directing further investigation 
and treatment(T53). This trial was arguably making a much more complex comparison than 
the previous ultrasound for hip example for several reasons, the most important being that 
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Figure 5.2: Graphic representation of two test-treat algorithms.  
 A: Complete algorithm showing all test-treat decisions. In this example neonates 
with suspected hip instability were randomised to receive standard specialist 
examination (right) versus an additional ultrasound scan (left) to inform whether child 
should be splinted
(T15)
. Reproduced with permission. 
  
 
 B: Partial algorithm showing treatment decisions but omitting diagnostic decisions. 
Patients with syncope of undetermined cause were randomised to a routine ED 
investigation versus more formalised evaluation in a syncope unit
(T53)
. Reproduced with 
permission. 
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the diagnostic strategies involved multiple tests conducted in two different care settings. 
However, as is evident, neither the tests, diagnostic decisions or treatment decisions were 
illustrated in the care pathway. Understanding how patients with unexplained syncope 
were investigated, and the basis upon which they were referred for further management, 
would have to be sought from the written description.  
Repor t i ng  o f  met hods  and dec i s ions  
Written descriptions of the clinical processes involved in test-treatment interventions were 
very poor, characterised by frequent omission of multiple intervention elements and a very 
low level of detail.  
For experimental interventions, all four elements of methods and decision-making were at 
least partially described (or appropriately cited) by 10% (10/103) of trials†, while only 6% 
(6/103) achieved this for the comparator intervention (Table 5.2). Trials were twice as likely 
to omit all description for control interventions, with experimental protocols more likely to 
be at least partially reported than their comparators. Only three test-treatment RCTs(T76, T98, 
T105) outlined four protocol elements for all study arms. 
                                                 
†
 For trials with >2 study groups, the best reported arm was used.  
Number of missing elements  
(in at least one arm*) 
Comparator 
(N=103) 
(%) 
Experimental 
(N=103) 
(%) 
None 6 (6) 10 (10) 
1  16 (16) 20 (19) 
2  23 (22) 35 (34) 
3  19 (18) 26 (25) 
4 40 (39) 19 (18) 
Table 5.2: Contrast in the fullness of reporting control vs. experimental interventions. Table presents 
counts of the total number of included trials (N=103) that omitted reporting between zero 
and all four elements of test-treat protocols. 
 * Some trials evaluated multiple comparator arms and/or multiple experimental arms.  
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As described in chapter 4, not all test-treatment strategies being evaluated by these trials 
included tests and treatments; some evaluated the benefits of not testing and giving 
treatment to all for example. Since description of certain elements was therefore not 
required in these trials, the denominators for frequency calculations were reduced to 
represent only those trials in which description of each given element was necessary. Two 
experimental and 17 control strategies did not involve a diagnostic test (i.e. the 
comparison was to ‘no test’)(T13,T18,T28,T37–39,T42,T45,T49,T52,T58,T63–4,T76,T96,T102–5) and so the 
denominators for reporting of test method and diagnostic decision–making were reduced 
accordingly (Experimental n=101, Comparator n=86). Similarly, one experimental and 8 
control strategies consisted of treating all patients(T13,T38–39,T52,T63,T76,T102,T104–5) and so did not 
involve any treatment decision (Experimental n=102, Comparator n=95), while one 
experimental and three control strategies did not give any treatment to any 
patients(T39,T63,T76,T104) and so did not involve any treatment methods (Experimental n=102, 
Comparator n=100). 
Test methods were the most commonly described element, reported in 58% (59/101) of 
experimental and 29% (25/86) control intervention protocols (Figure 5.3).  
For experimental interventions the criteria by which management decisions were made 
were reported by fewer than half the studies: diagnostic decisions in 43% (43/101) and 
treatment decisions in 46% (47/102). By comparison, only a third of trials reported these 
essential elements for control protocols (diagnostic decisions in 29% [25/86]; treatment 
decisions in 27%, [26/95]). Treatment methods were most poorly reported element, 
outlined for experimental strategies in only 20% (20/102) of trials, and for control strategies 
in only 14% (14/100) of trials. 
Using the number of missing protocol elements as a proxy for quality of reporting, certain 
types of diagnostic tests appeared to be better described. Whether evaluated as the 
experimental or comparator test, biochemical, electrophysiological and clinical examination 
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techniques all tended to have 3 – 4 elements missing, while imaging and endoscopies 
were more likely to be more fully reported (Tables 5.3 and 5.4). Descriptions of new 
radiological imaging modalities were of better quality than existing ones, as were 
interventions introducing multiple new tests. Studies that failed to identify comparator tests 
beyond being ‘standard care’ performed poorly in all elements.  
5.3.2 Participant Flow 
Full accounts of participant flow, encompassing all 5 items recommended by CONSORT, 
were provided by 44 (43%) trials, including 20 (19%) that provided a full flow diagram. 
Other than one study (cluster-randomised) that reported none of these details(T64), the
 
70% 50% 30% 10% 10% 30% 50% 70% 
Test method 
Diagnostic Decision 
Treatment Decision 
Treatment method 
Experimental 
Control 
Figure 5.3:  Proportion of RCTs describing each element of the test-treat protocol according 
to study group. For trials with >2 study groups, elements were considered 
reported if described for at least one experimental intervention. 
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Experimental test 
Number of missing elements % missing  
0 1 2 3 4 Total 
≤2 
elements 
>3 
elements 
Biochemical 1 2 3 12 7 25 24% 76% 
Biopsy 0 1 1 0 0 2 100% 0% 
Clinical 2 1 1 4 5 13 31% 69% 
Electrophysiology 0 1 2 4 3 10 30% 70% 
Endoscopy 3 2 3 1 2 11 73% 27% 
Imaging 2 7 14 10 6 39 59% 41% 
No test 3 0 2 0 0 5 100% 0% 
Telemedicine 0 0 0 0 2 2 0% 100% 
Various 1 3 3 3 2 12 58% 42% 
Total 12 18 31 37 31 119 
  
Table 5.3: Distribution of protocol reporting quality by experimental test type. 
 Denominator is the number of experimental interventions (N=119) 
Comparator test 
Number of missing elements % missing  
0 1 2 3 4 Total 
≤2 
elements 
>3 
elements 
Biochemical 0 1 3 5 1 10 40% 60% 
Biopsy 0 0 0 0 1 1 0% 100% 
Clinical 0 1 1 4 9 15 13% 87% 
Electrophysiology 0 2 0 2 3 7 29% 71% 
Endoscopy 0 3 5 1 5 14 57% 43% 
Imaging 1 2 6 5 7 21 43% 57% 
No test 4 6 7 0 0 17 100% 0% 
Standard Care 0 0 0 0 10 10 0% 100% 
Telemedicine 0 0 0 0 2 2 0% 100% 
Various 0 2 0 2 4 8 25% 75% 
Total 5 18 24 22 46 105 
  
Table 5.4: Distribution of protocol reporting quality by control test type. 
 Denominator is the number of comparator interventions (N=105) 
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remaining 58 (57%) trials published partial information (Table 5.5). Use of a consort 
diagram was more frequently associated with more complete accounting of participant 
flow, with over half such trials considered complete (37/70) compared to just a fifth of 
those not employing flow diagrams (7/33). 
Numbers screened for eligibility and receiving the allocated intervention were the most 
frequent omissions, while the number of patients included in the primary analysis were 
provided in all but two studies(T41,T64) (Table 5.6). Allocation was amongst the most well-
reported of items; only five individually–randomised trials (5%) failed to indicate the 
number of patients randomised to each arm(T7,T49-T50,T82,T86). Two cluster-randomised trials 
  
Cluster–
randomised 
trials 
(n=6) 
Individually-randomised trials 
Total 
(N=103) 
(%) 
2 arms  
(n=87) 
>2 arms 
 (n=10) 
C
o
m
p
le
te
 
Full diagram 3 16 1 20 (19) 
Full text, no 
diagram 
0 6 1 7 (7) 
Partial diagram & 
text 
0 15 2 17 (17) 
Total  3 37 4 44 (43) 
In
co
m
p
le
te
 
Partial diagram, no 
text 
0 10 1 11 (11) 
Partial text, no 
diagram 
0 22 3 25 (24) 
Partial diagram & 
text 
2 18 2 22 (21) 
No diagram or text 1 0 0 1 (1) 
Total 3 50 6 59 (57) 
Table 5.5: Use of the CONSORT participant flow diagram by test-treatment RCTs. 
 Denominator is the number of test-treatment RCTs (N=103) 
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also provided insufficient information in this respect; one did not report the number of 
clusters allocated to each intervention, although the number of participants enrolled in 
each arm was provided(T51), while the second trial provided the number of randomised 
clusters but not participants(T64).  
5.3.3 Definition of primary outcomes 
A total of 150 primary outcomes were reported in 97 test-treatment trials. A quarter of trials 
(27, 26%) failed to clearly identify a principal endpoint, however in 13 trials this was 
deduced using the variable reported in a power calculation(T5,T9-10,T12,T23,T36,T40,T46-
47,T50,T58,T60,T65), while in another seven a variable was deduced from the study 
aim(T7,T28,T33,T76,T87,T105,T108). Six trials(T2,T29,T31,T59,T79,T82) defined none of these. 
The majority of studies focussed on one primary outcome (79/103, 77%), while the 
remaining 18 trials(T4,T7,T11,T16,T18,T24,T26,T28,T30,T32,T39,T51,T53,T55,T66,T93,T100,T107) used between 
two(T11,T16,T26,T30,T32,T53,T55,T100,T107) and 15(T24) separate measurements (median 3, IQR: 2–4).  
Primary outcomes more often measured patient health (54%) than clinical processes 
(39%) (Table 5.7).  
Participant 
flow  
Eligibility (%) Allocation (%) 
*Rec’g 
Itvn 
(%) 
Follow-
up 
(%) Analysis (%) 
           Reported 65 (63) 96 (93) 71 (68) 80 (78) 101 (98)
CONSORT 
diagram 
51 (50) 63 (61) 47 (45) 44 (43) 42 (41) 
text only 14 (14) 33 (32) 24 (23) 36 (35) 59 (57) 
Not reported 38 (37) 7 (7) 34 (32) 23 (22) 2 (2) 
Table 5.6: Publication of participant flow numbers in test-treatment RCTs. 
 Denominator is the number of test-treatment RCTs (N=103) 
 * Rec’g Itvn – Receiving Intervention 
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Pat i ent  hea l th  m easures  
Sixty-eight patient outcomes were measured by 53 trials as primary outcomes. The most 
common measure was symptom frequency, for example the rate of epigastric pain or 
regurgitation in patients managed for dyspepsia(T13,T40,T44,
 T46,T65,T71) (Table 5.7). Adverse 
events (8, 15%) were experienced as a consequence either of diagnostic procedures, 
such as the rate of arm dysfunction suffered as a result of performing biopsy of the axillary 
Outcome Type Number of trials (N=97) (%) 
Patient *53 (54) 
Symptom rate 13 (25) 
Clinical status 9 (17) 
Adverse event rate 8 (15) 
Function 8 (15) 
Residual disease rate 7 (13) 
Recurrent disease rate 6 (11) 
Quality of life 5 (9) 
Mortality 4 (8) 
Health perception 2 (4) 
Psychological morbidity 2 (4) 
Absenteeism 1 (2) 
Satisfaction 1 (2) 
Patient outcome total †66 
 
   Process *38 (39) 
Therapeutic yield 17 (45) 
Timing of care 8 (21) 
Cost 7 (18) 
Appropriateness of treatment decision 5 (13) 
Diagnostic yield 4 (11) 
Process outcome total ‡41 
 
Composite 7 (7) 
Table 5.7: Types of outcomes measured as primary endpoints in test-treatment RCTs 
 * One trial measured both patient and process endpoints
(T93)
 
 † 6 trials measured >1 type of patient outcome: Absenteeism, Function, Health perception, 
Psychological morbidity, Quality of life, Satisfaction, Symptom rate
(T4)
; Mortality, Quality of 
life
(T18)
; Psychological morbidity, Adverse event rate, Function
(T24)
; Symptom rate, Function, 
Quality of life
(T28)
; Disease rate, Symptom rate
(T66)
; Quality of life, Function
(T107)
. 
 ‡ 3 trials each measured two different process outcomes: Diagnostic yield and Therapeutic 
yield
(T53)
; Timing of care and Cost
(T55,T100)
. 
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nodes(T24), or treatment harms and failure, for example fecal incontinence in women 
treated for severe perineal tears(T11). Evaluation of clinical status (9, 17%) generally 
constituted a surrogate for downstream health, for instance the clinical pregnancy rate 
(rather than live, healthy birth rate) in women treated for primary infertility(T104). 
Assessments of function (8, 15%) could be either surrogate outcomes, such as the 
evaluation of maximum exercise endurance in patients with coronary artery disease 
(T20,T41,T92), or true health measures, for example physical mobility experienced by patients 
being treated for chronic lower back pain(T4,T28) or knee derangements(T107). 
Seven trials (13%) were primarily interested in the rate of residual disease, a marker for 
the degree of success in diagnosing and treating disease, for example measuring the 
eradication rate in patients with H.pylori infection(T105), or the rate of venous 
thromboembolism in patients managed for a suspected pulmonary embolism(T63). Another 
six trials measured disease recurrence, defined as new episodes of the presenting 
condition, for example recurring episodes of varicose veins after the removal of primary 
obstructed veins(T58), or of bladder cancer after tumour resection(T1). 
Mortality was the primary measure in only 4 trials, conducted in geriatrics(T18), oncology 
(T42), respiratory medicine(T62) and infectious disease(T23). Similarly, perceptual, emotional 
and behavioural responses to the test-treat process, including quality of life measures, 
were less often the primary focus of test-treatment RCTs, and tended to be measured 
alongside other patient outcomes. 
Process  m easur es  
Thirty–eight trials examined a total of 41 process measures as the primary outcome. The 
quantification of management decisions was the most frequent measure of test-treat 
processes. Approximately half evaluated an aspect of therapeutic yield, defined here as 
the treatment rate, in order to examine the impact of testing on treatment decisions (Table 
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5.7). For example, antibiotic use was quantified in patients with potential pneumonia to 
establish whether point-of-care C-reactive protein tests would lower prescription rates(T97), 
while in two secondary care trials the proportion of women delivering by Caesarean-
section was evaluated to assess the impact of tests used to determine dystocia(T54,T81). The 
appropriateness of treatment decisions was measured in another four studies(T10,T17,T32,T60), 
whereby the working diagnosis was confirmed using additional tests after treatment had 
been given. For example, patients presenting to the ED with chest pain were either 
hospitalised or discharged once acute cardiac ischaemia had been diagnosed or ruled 
out(T32).  
Diagnostic yield, or the rate of diagnoses made, was also used as a primary outcome, 
though by only three (8%) studies(T53,T88,T93). For example, a trial comparing two types of 
endoscopy to investigate obscure gastrointestinal bleeding measured the number of cases 
in whom a definite source of bleeding could be identified(T88).  
Eight studies concentrated on the timing of care, measuring either the total length of 
treatment, such as length of hospital stay(T50,T55,T72,T85–86,T94,T100) or the time taken to reach a 
diagnosis(T56). Cost, either of total management(T5,T55,T70,T100) or diagnostic procedures 
only(T12,T19,T83), was the primary calculation in seven (19%) studies.  
Com posi te  m easur es  
Adverse event and treatment rates were combined into single composite measures in 
seven trials, most commonly in cardiovascular settings(T6,T14,T89,T96,T99,T101) where the 
prevalence of myocardial infarction, death and revascularisation procedures provided a 
summary rate. The combined frequency of procedural morbidity, length of hospitalisation 
and the consequences of missed diagnoses were also used in one gastrointestinal trial, to 
evaluate the effectiveness of two endoscopic techniques for the clearance of bile duct 
stones(T95).
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Descr i b ing  outcome m easurem ent   
Description of how outcomes were measured was considered adequate enough to attempt 
replication in approximately half (53, 51%) of included trials (Table 5.8). Complete reports 
were presented for 49% (74/150) of primary outcomes, while neither the method nor timing 
of measurement were described for 13% (19/150). Incomplete reports most commonly 
omitted the time at which outcomes should be measured (43/57, 75%). Overall, the 
method of measurement was not provided or poorly described for 28% of outcomes 
(42/150) measured in 32% (33/103) of included trials. Box 5.2 illustrates two examples of 
reports that were judged to be completely and incompletely reported. 
5.4 Discussion 
 
The review of reporting quality finds that test-treatment RCTs are currently poorly reported, 
providing often incomplete accounts of precisely what happened, to whom, when, and how 
this was measured. It is clear that this suboptimal detail will impinge on the user’s ability to 
interpret the meaning of trial results, and potentially also to use such findings to improve 
clinical practice. The following discussion considers the main findings with regard to how 
test-treatment trials compare to similar cohorts of treatment RCTs and complex 
Description of outcome measurement 
No. of primary 
outcomes 
(%) 
No. of 
trials 
(%) 
Complete 74 (49) *53 (51) 
Incomplete 57 (38) ‡36 (35) 
Not reported 19 (13) †14 (14) 
Total 150 (100) 103 (100) 
Table 5.8: Completeness of outcome measurement reporting 
 * Trial considered fully reported if all primary outcomes completely described 
 † Trial considered not reported if no primary outcomes were described 
 ‡ Trials with mixed reporting for multiple outcomes considered as incompletely reported. 
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Box 5.2: Examples of adequate and inadequate reports of outcome measurement 
Example of incomplete reporting of outcome measurement:  
A trial sought to determine whether the addition of a SPECT Tc 99m sestamibi scan to the standard 
clinical evaluation strategy (not reported) would more accurately distinguish between ischaemic and 
non–cardiac causes of chest pain, in order to more appropriately identify the patients in need of further 
cardiological investigations and treatment
(T32)
. The study measured two primary outcomes: 1. the rate of 
inappropriate discharge of patients with acute cardiac ischaemia (ACI), and 2. The rate of inappropriate 
admission of patients without ACI. The following extract describes how these outcomes were measured, 
and was judged as incomplete since the criteria for diagnosing ACI using the follow–up tests has not 
been provided or cited:  
“To make the final diagnosis of the presence of ACI, biomarkers and serial ECGs were obtained. Protocol-
specified follow-up stress testing with perfusion or echocardiographic imaging was also performed. For 
patients admitted to the hospital, this was usually accomplished during the period of hospitalization. For 
patients discharged from the ED, a return visit to the study site 24 to 36 hours later was made for follow-
up biomarkers, ECGs, and stress testing. The confirmed final diagnosis was assigned by the principal 
investigator at each site based on cardiac enzyme levels, ECGs, stress test, and when available, cardiac 
catheterization data.” (T32) 
Example of complete reporting of outcome measurement: 
The following excerpt is from a trial evaluating whether patients undergoing explorative investigation for 
clinically suspected bile duct stones might benefit from first receiving a less invasive endoscopic 
ultrasound, proceeding to the more invasive endoscopic retrograde cholangiography only if stones are 
still suspected. The primary outcome evaluated whether the new strategy could reduce the rate of 
negative outcomes in these patients, and the method of arriving at these measurements was judged to 
be comprehensive, consisting of adequate description as well as citations: 
“The primary end point of the study was the proportion of patients with negative outcomes, to related to 
[sic] either endoscopic procedures (complications) or false−negative diagnosis of stones...Complications 
of endoscopic procedures were assessed prospectively by a single investigator who was not blinded to 
group assignment. Severity was graded according to consensus criteria [17,18] as minimal (no need for 
hospitalization), mild (2±3 days of hospitalization), moderate (4±10 days of hospitalization), severe (> 10 
days of hospitalization, or surgery, or intensive care unit admission), or fatal. Because all patients were 
hospitalized, no clear distinction between the first two categories was possible, and they were merged as 
minimal−to−mild. Acute pancreatitis was defined as a new or worsened abdominal pain which lasted for 
more than 24 hours, and was accompanied by a serum amylase level greater than three times the upper 
normal limit *17+. Transient abdominal pain that required medical intervention (face−to−face doctor 
attention and analgesic/antispasmodic drugs), but subsided within 24 hours and did not cause 
prolongation of hospital stay, was recorded as a separate category and graded as a minimal−to−mild 
complication. Bleeding was defined as clinical evidence of hemorrhage, such as melena or hematemesis, 
with an associated decrease of at least 2 g/dL in hemoglobin concentration, or the need for transfusion 
*19+. A negative outcome related to false−negative diagnosis of stones was defined as an occurrence of 
either of the following: (i) detection of bile duct stones during follow−up, or (ii) hospitalization possibly 
related to bile duct stones but without definite stone confirmation (acute pancreatitis, acute cholangitis, 
obstructive jaundice).” 
(T95)
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intervention RCTs, with particular thought given to barriers which may prevent full and 
clear reporting in these trials. 
5.4.1 Trials often fail to provide complete accounts of participant 
flow 
Clear and complete accounting of participant flow as recommended by CONSORT was 
performed in around half the examined trials, with one–fifth of all trials providing a 
complete flow diagram. Of the trials with incomplete reporting, the most worrying 
insufficiencies were the numbers screened for eligibility and the numbers receiving the 
allocated intervention. Without knowledge of the former trialists will be unable to guarantee 
that study populations are representative of the general patient population. This is 
particularly important when evaluating tests, since differences in the case–mix of 
populations are known to impact on test performance67. Importantly, transparency 
regarding the numbers of patients receiving the allocated intervention are key to discerning 
the extent to which observed health effects are due to the interventions being compared121. 
Therefore these findings suggest users will have difficulty in fully interpreting the meaning 
of results in a large proportion of test-treatment RCTs. 
Reporting of participant flow varies considerably in the literature. The prevalence of 
providing flow diagrams ranges from 28%118 to 86%153 in cohorts of recent unselected 
trials, largely comprising single–intervention treatment RCTs, with suggestions that the 
more superior accounts are encountered in articles published by leading journals118. An 
earlier review, of 270 RCTs (mostly pharmacological trials) published in 5 leading journals 
during 1998, found 52% provided a flow diagram of varying degrees of completeness237. 
The most poorly reported aspect was the number of patients receiving the allocated 
intervention (27%, 73), as per the present review though apparently considerably worse 
than found in test-treatment RCTs. A similar review of 63 complex intervention RCTs, 
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evaluating weight loss interventions, found that 25% had provided flow diagrams, though 
the authors based this appraisal on ‘appropriate labelling’ of diagrams and did not state 
whether those encountered were complete. Though only 20% of test-treatment trials 
provided full diagrams, in total 68% (70/103) provided them in some form. Thus, though 
suboptimal, the present cohort would appear to reflect a similar quality of reporting of this 
item when compared to RCTs in general, and possibly better than found in other complex 
intervention trials. 
5.4.2 Trials often provide clear definition of primary measures 
Clear definition of primary endpoints was achieved by three–quarters of included trials, a 
considerably better performance than found by reviews of both single–intervention and 
complex intervention RCTs. For example a review of all trials indexed in PubMed in 
December 2006 (n=616) found primary measures of effect to be clearly defined by 53%118, 
while a previous review by the same researchers of trials indexed in PubMed in December 
2000 (n=519) found a slightly lower rate of 45%152. Similarly 46% of trials evaluating 
complex interventions for the treatment of weight loss (n=63) identified a primary endpoint. 
Moreover, the criteria used to appraise this item follow the approach used by one of these 
reviews152, suggesting the comparison to be an accurate representation of better reporting 
by test-treatment RCTs than other, contemporary trials. Although clearly a positive impact 
on the ability to interpret trial findings, poor description of the measurement of these 
outcomes by half the included studies somewhat hindered the ability to make full use of 
results. Of particular concern was the tendency to omit the timing of primary 
measurements, leaving the reader uninformed regarding when observed effects should 
become manifest in a similar patient group. Nevertheless, the superior reporting quality by 
comparison to treatment and complex intervention trials would suggest that there are no 
particular barriers to the effective reporting of outcome measurement in test-treatment 
RCTs.  
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5.4.3 Trials provide incomplete and insufficient descriptions of test-
treatment interventions 
Documenting the interventions used to test and treat patients proved to be by far the most 
poorly reported aspect of these trials: only three trials provided a full written description of 
all methods and decision-making in all study groups, and only one of these also provided a 
care pathway diagram(T105). This is significantly poorer than found even in reviews of 
complex interventions. Description of back pain interventions were absent in 87% of 
examined RCTs238 and surgical interventions in more than half239. Glasziou and colleagues 
found better reporting of interventions in drug compared to non–pharmaceutical trials136. 
Other researchers report similar findings; in a direct comparison of the methodological 
quality of 60 pharmaceutical and 50 complex non–pharmaceutical treatment RCTs, drug 
interventions were more often described in enough detail to be reproduced than non–
pharmacological interventions, though the latter could still be replicated in 82% of cases240.  
Moreover, by focussing on the frequency of reporting interventions this study is likely to 
have overestimated reporting quality, since components were judged to have been 
described even if only partially outlined. While this approach was necessary, since 
determining the adequacy of descriptions would have required significant input from a wide 
range of clinical experts, it has masked the relative importance of reporting omissions 
whose impact on interpretability are likely to vary according the clinical setting. For 
example, test–treat strategies that seek to investigate presentations for which there are 
multiple potential diagnoses, and consequently more treatment options, may be 
completely un-interpretable if only partial description is given; conversely protocols 
attempting to confirm well-defined disease entities that can be clearly dichotomised into 
two simple treatment options may be more easily reconstructed.  
The importance attached to full and clear accounting of any healthcare intervention was 
highlighted in chapter 1 (p. 31–32). Not only is it required to interpret the meaning of a 
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trial’s results, but it is crucial to clinicians’ ability to identify desirable processes and 
replicate them safely in practice136–137,147. The considerable difficulties encountered in this 
review in trying to decipher how diagnoses were made and how patients were 
subsequently managed emphasises that test–treat strategies may be particularly sensitive 
to poor future implementation. Most important to the utility of results is the delineation of 
how test data should be interpreted and how the resulting diagnostic categories should be 
utilised to guide management, while the subsequent selection of treatments must be made 
explicit22. Yet decision–making processes were amongst the most poorly reported aspects 
of test-treatment trials. 
Although the reproducibility of interventions was not measured directly in this review, 
failure to outline diagnostic procedures, treatment procedures and decision-making criteria 
must mitigate a reader’s ability to reproduce these processes in practice. Based on the 
level of reporting encountered, the current study must conclude that in only three trials is 
this likely to have been possible(T76,T98,T105).  
Bar r ie r s  to  t he  documenta t ion  o f  tes t – t r ea t  i n ter vent ions  
It is certainly true that the complexity of these interventions makes full and accurate 
documentation difficult. The variations in frequency of elements described according to the 
types of tests being evaluated suggests that some diagnostic tests, and their associated 
care pathways, are more difficult to outline. However, there is no specific evidence that this 
difficulty is solely due to the complexity of clinical processes and decision-making. Clinical 
consultations, for example, were largely poorly reported. Although these strategies were 
often simple, consultations are likely to be less amenable to standardisation, and therefore 
more difficult to translate into a prescriptive format. On the other hand, complex 
endoscopic techniques, often part of multistage diagnoses, were often well reported. A 
closer examination of how protocols were reported reveals specific conceptual barriers 
that could be responsible for the observed difficulties. 
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Firstly, a considerable focus was placed on describing experimental techniques to the 
considerable detriment of what they were being compared to. Whether reflecting a widely–
held assumption that ‘conventional investigations’(T56) are standardised and therefore need 
not be made plain or appropriate methods cited, comparator strategies are equally under 
evaluation in any RCT156 and not reporting them poses an irrevocable impediment to the 
interpretability of effect estimates. Without knowing which tests and treatments are being 
administered to one study group, it is impossible to discern how favourable effects have 
benefited patients.  
Secondly, trials focussed on reporting diagnostic procedures, commonly omitting to 
elaborate how test results should be used to arrive at diagnostic decisions, how this should 
inform management, and which treatments should subsequently be prescribed. This 
suggests that trialists may perhaps be following the more familiar reporting practices of 
standard pharmaceutical RCT evaluations, regarding tests as singular interventions rather 
than as part of a broader test–treat strategy. Tellingly, a single trial identified itself as a 
complex intervention RCT(T107). The common failure to recognise that decision–making 
forms part of test-treatment interventions may explain why such elements were so rarely 
described. 
Lastly, trials exhibited difficulties in identifying all diagnostic tests used in an intervention. 
This difficulty varied according to the clinical context and study group. Greater obscurity 
was encountered in descriptions of interventions using batteries of tests, such as the 
‘accelerated diagnostic protocol’ for assessing the likelihood of progression to full stroke in 
transient ischaemic attack patients(T86), or the trial evaluating a specialist unit of care for 
establishing the cause of syncope discussed above(T53). Even though these interventions 
did not appear amongst the most poorly reported (Tables 5.3 & 5.4), this is probably an 
artefact of the appraisal criteria used by the author, where protocol elements were judged 
as ‘reported’ even if some tests and decision–making processes were not provided. There 
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was also a tendency across many studies to disregard the role of clinical examinations in 
diagnostic pathways, with a predilection only to recognise more technological procedures 
as true ‘tests’. This point is illustrated in a trial comparing the standard use of early MRI to 
investigate back pain with a more selective approach providing MRI only on clinical 
indication(T36). The authors do not acknowledge the role of the ‘clinical indication’ as a 
diagnostic process, yet they document clinical indication test–negative patients when 
discussing the reasons for patients not proceeding to MRI. As a consequence, precisely 
which signs and symptoms were used to indicate the need for an MRI were not reported. 
Not only is it difficult then to replicate this strategy, but this non–recognition has led to the 
failure to document important variations in how clinicians use such additional diagnostic 
information, even though it could well have influenced the overall effectiveness of the test-
treatment policy. 
These impediments to full and proper reporting of interventions may therefore reflect 
misplaced perceptions regarding what should be evaluated in a test-treatment trial. It could 
also reflect the common publication of test-treatment RCTs in specialist journals, which 
may presuppose a high degree of assumed knowledge amongst their readership. While 
many test-treatment strategies are highly familiar to specialists, in reality there is likely to 
be wide variation in how techniques are implemented, and how decisions are made.  
These observations suggest that the difficulties in describing test-treatment interventions 
are surmountable. However, the common absence of decision–making criteria may reflect 
the inability to standardise diagnostic and therapeutic decision–making processes. 
Although the suitability of interventions to being standardised was not measured directly, 
this might explain the dearth of decision–making in at least some trial protocols. Trialists 
may have sought to perform pragmatic evaluations to capture important variations in 
practice between study sites. Indeed, several reports describe themselves as ‘pragmatic’ 
studies in which treating clinicians were given discretion regarding how management 
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decisions were made(T5,T12,T19,T34,T36,T57–8,T60,T66,T68,T73,T77,T92,T97,T107). Nonetheless, several of 
these documented at least some of the interventions actually used during the study 
period(T12,T34,T57,T66,T73,T77,T92,T97,T107), suggesting that test–treatment strategies not suited to 
standardisation can also provide informative documentation of patient management.  
5.4.4 Study limitations 
The primary limitation to this review concerns the process of data extraction, which was 
conducted solely by the author. The lack of a second, independent reviewer means it is 
possible that the review’s findings in part reflect certain inaccuracies made in error by the 
author. These effects should have been minimised by taking a systematic approach when 
examining each trial as well as using a standardised extraction tool, developed from 
existing, validated guidelines. 
A second important issue concerns whether the results presented here are generalisable 
to all test-treatment RCTs. Efforts to obtain a representative sample of trials were made by 
ensuring that the search strategy (reported in chapter 2) used only methodological terms, 
and did not target any specific tests, diseases or clinical disciplines. It may be, however, 
that particular disciplines are more or less likely to use these generic methodological terms 
than others, in which case the project cohort will not be entirely representative of all test-
treatment trials published during the search period (2004–2007). Both the capture–
recapture analysis and independent check (reported in chapter 3) concluded that trials 
have been missed; some were missed by the search strategy whilst at least three others 
were overlooked by the author during screening. While it is not possible to compare the 
content of all missed trials to those included in the project cohort, it is unlikely that their 
inclusion would drastically change this review’s conclusions. Both types of omission are 
likely to be associated with a poorer quality of reporting, and so this review may be 
presenting a more favourable conclusion than is realistic.  
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Reporting quality has improved over the last 15 years118,153 so it is possible that trials 
published since 2007 offer superior accounts of their conduct. However, in the absence of 
reporting guidelines specific to test-treatment RCTs quality is unlikely to be substantially 
improved in more recent trials.  
Only primary outcomes were extracted, since the aim was to identify the main 
methodological issues with test-treatment RCTs. Although problems in measurement and 
description of secondary outcomes will be typified by those encountered in primary 
endpoints, the range of outcome types may be different. When looking more broadly at all 
trial outcomes the issues cited here could vary in their relative impact, particularly if 
secondary aims address a greater number of psychosocial, patient health or physician-led 
questions. 
Lastly, this review was limited to examination of three aspects of trial reporting. These 
were selected because they are considered key to interpreting all trials, and could be 
appraised objectively without recourse to detailed clinical expertise. Nonetheless there are 
several other aspects of test-treatment interventions that will probably require a detailed 
appraisal of reporting quality in the future. Chief amongst these is the documentation of 
how interventions were actually administered. Fidelity to the intended intervention is known 
to be poorly reported in all trial types137, and has been found particularly wanting in studies 
of complex therapeutic or surgical interventions239. Likewise, care–provider skill and 
experience are integral to clinical decision–making and, as is recommended for the 
documentation of complex interventions in general83,147, any appraisal of protocol reporting 
quality is arguably incomplete without also considering this issue. Although neither of 
these was investigated in this review, the difficulties encountered in piecing together the 
composition of test–treat interventions from descriptions of intended patient management 
were such that reporting of actual practice is likely to have been even poorer. As the scope 
of this thesis commanded the retrieval of test-treatment RCTs conducted in all medical
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 disciplines, it was also outside the present realms of feasibility to perform an evaluation of 
the replicability of test-treatment interventions since this would have required wide 
consultation with clinical experts from all included disciplines. Consequently, the adequacy 
of protocol reporting has been judged on the basis of a minimal descriptive presence. 
Given that the ability to reproduce test-treatment interventions is likely to require more 
comprehensive reporting than the criteria used here to appraise reporting quality, it would 
be appropriate to conclude, if somewhat tentatively, that the replicability of published test–
treat protocols is likely to be even poorer than is suggested in the present review.  
5.5 Conclusions 
 
To conclude, this review finds a clear need for improvement in the reporting of test-
treatment RCTs. This cohort of 103 trials was characterised by several limitations that may 
hinder the interpretation and application of trial findings.  
1. Incomplete accounting of participant flow is likely to hamper a full interpretation of 
the meaning of observed test-treatment effects; 
2. Incomplete reporting of how primary outcomes are measured is likely to obstruct 
the replication of measurements, and therefore  lead to problems when seeking to 
compare effects between trials; 
3. Insufficient documentation of interventions precludes the interpretation of how test–
treat processes are related to differences in trial outcomes, and is also likely to 
prevent the translation of beneficial interventions into clinical practice. 
These failings are partly explained by the suboptimal quality of reporting generally found in 
all RCTs118,152–153. However, the considerably inferior quality of intervention documentation 
encountered in test-treatment trials, when compared to standard, non–complex 
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intervention trials, does appear to confirm that this issue is more prominent in test-
treatment trials.  
Nonetheless, the review suggests that all three issues are likely to be surmountable by 
improved reporting. Adherence to the CONSORT guidelines will be valuable for improving 
reporting of participant flow and primary outcome measurement, however test-treatment 
interventions are shown to require more detailed attention to several components than 
treatment interventions, or even other types of complex interventions, if they are to provide 
useful information. Since the review findings would indicate that trialists may not always be 
aware of what needs to be reported, more specific guidelines are likely to be necessary to 
achieve the necessary improvement in reporting of these complex interventions. 
The following chapter continues the analysis of test-treatment RCTs by appraising the 
methodological quality of included trials in order to determine how valid and reliable these 
trials are.  
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This chapter presents the third analysis of the project cohort identified in chapter 2 and 
characterised in chapter 4. Its aim is to address the third challenge levelled at test-
treatment RCTs, that they risk producing unreliable evidence due to the feasibility of 
implementing the required methodological controls when evaluating such complex 
interventions. This is achieved by appraising the methodological quality of included trials. 
The chapter ends with a discussion of its findings, with particular regard to whether the 
quality observed is comparable to that found in treatment RCTs and complex intervention 
RCTs. 
Inadequate design and study conduct has been empirically demonstrated to damage the 
reliability and utility of RCTs by exposing their results to bias106–108. 
The complexity of test-treatment interventions is claimed to predispose them to particular 
difficulties in implementing the measures necessary to limit bias. Test results must be 
interpreted by clinicians, and diagnoses recounted to their patients hence it may be 
impossible to eliminate both performance bias and ascertainment bias22,79,176–177. The need 
for patients to progress through multiple interventions (tests and treatments) may increase 
the proportion who drop–out, and since the quality and information patients receive differ 
according to the interventions used, these trials may also be susceptible to differential 
drop–out, which places them at increased risk of attrition bias176. Sample sizes must be 
considerably larger in order to account for the probability that effects are only experienced 
in patients who receive different care as a result of their diagnoses; trials omitting this 
inflation risk being underpowered to detect patient health effects, while it may not be 
feasible to recruit the necessary number of patients in adequately powered trials6,176. Since 
diagnostic decision–making is highly variable, trials must pre–specify how test results lead 
to diagnoses and treatment plans in order to be sure of how interventions are creating the 
observed effects22,76,79. However, it will be challenging to report the multiple interventions 
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used and document decision–making to the extent necessary to allow findings to be 
interpreted, compared across studies, and to inform how beneficial interventions should be 
translated into practice. 
These are serious claims, though there is little existing evidence to support them. The 
following study has been designed to address these challenges by examining the extent to 
which they are encountered in completed trials. It presents a systematic appraisal of the 
methodological quality of test-treatment RCTs ascertained in chapter 2 in order to evaluate 
the extent to which these trials are susceptible to the biases and challenges to utility that 
are claimed to confront them. Since the cause of difficulties in conducting and reporting 
these trials is hypothesised to lay with the complex make–up of test-treatment 
interventions, the analysis ultimately aimed to determine how they perform by contrast to 
standard treatment RCTs.  
6.1 Methods 
 
To evaluate the reliability of test-treatment RCTs, assessments of methodological quality 
focussed on six key indicators of trial internal validity, including control of selection bias at 
recruitment, attrition bias during primary analysis, information biases arising from the 
differential behaviour of participants, care–providers and outcome assessors (performance 
bias and ascertainment bias), and the minimisation of type II error. The review therefore 
sought to answer the following questions:  
1. Did methods of sequence generation adequately protect against selection 
bias? 
2. Did methods of allocation concealment adequately protect against selection 
bias? 
3. Do trials control for performance and ascertainment bias?
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4. Can trials control for performance and ascertainment bias? 
5. Were primary analyses conducted appropriately, to minimise the effects of 
selection bias and attrition bias?  
6. How did studies determine sample size?  
6.1.1 Design of a quality assessment tool 
In the absence of an existing quality assessment tool specific to test-treatment RCTs, 
standardised data collection and appraisal forms were designed. Items required to answer 
the six review questions were identified from three validated, internationally accepted 
standards for the conduct and reporting of RCTs: the CONSORT checklist121, the 
extension of the CONSORT statement for non-pharmacologic therapy interventions147 and 
the Cochrane Collaboration‟s „Risk of Bias‟ tool123. Table 6.1 lists the items extracted. 
This new quality appraisal tool was tested by extraction of five test-treatment trials, 
randomly selected from the project cohort. Minor changes were made to improve the 
standardisation of both data collection and quality assessment.  
6.1.2 Data Extraction 
All included trials with at least one publication of results were appraised, following the 
approach detailed in the review of reporting quality (chapter 5). Data were extracted to a 
purpose built relational database (Microsoft Office Access 2007) and appraised for 
methodological quality using the methods reported below. Extraction and quality 
assessment were performed by the author.  
6.1.3 Interobserver reliability 
In order to ensure consistency in the application of quality criteria, a 65% convenience 
sample was selected prior to any extraction and independently assessed by a second 
reviewer with considerable experience in conducting systematic reviews. Duplicate 
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Trial Methods Objectives Item 
1.  Did methods of sequence 
generation adequately protect 
against selection bias? 
Was the method of sequence generation reported? 
Was it adequate?  
2.  Did methods of allocation 
concealment adequately 
protect against selection bias? 
Was the method of allocation concealment reported? 
Was it adequate? 
3.  How often were participants, 
care–providers and outcome 
assessors blinded to test-
treatment interventions? 
Were clinicians/participants/outcome assessors blinded to the 
test used? 
4   How often was it feasible to 
blind these individuals? 
Was it feasible to blind clinicians/participants/outcome assessors 
to the test used? 
5.  Was the primary analyses 
conducted appropriately, to 
minimise the effects of 
selection bias and attrition 
bias? 
Could the outcome be measured in all randomised participants? 
Was the outcome measured consistently in all arms?  
Was the primary analysis complete? 
Were outcome responses missing? 
How many were missing in each arm? 
Were reasons for missing data reported? 
What methods were used to deal with missing data? 
Did investigators exclude participants from the analysis? 
How many were excluded in each arm? 
Were the reasons for exclusion reported? 
Were patients lost to follow-up? 
How many were lost in each arm? 
Were the reasons for loss to follow-up reported? 
Did trialists report an ‘intention-to-treat’ analysis? 
Were patients analysed according to their randomised allocation, 
regardless of the intervention actually received? 
6.  How did studies determine 
sample size? 
Was a power calculation described? 
What was the estimated target sample size? 
Was the outcome on which the power calculation was based 
reported? 
 
Was this the same as the primary outcome? 
 
If estimated sample size was not achieved, what were the 
reported reasons? 
Table 6.1: Items extracted to evaluate the methodological quality of test-treatment RCTs. 
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assessment was only performed for standardised criteria that are commonly used to 
evaluate methodological quality, namely the quality of sequence generation methods, 
allocation concealment methods, presence of blinding, and documentation of numbers 
analysed for the primary outcome.  
Neither reviewer was blinded to publication details (authors, institutions, journal) or to trial 
results, since the benefits of doing so have not been consistently proven100,241–242. Cohen‟s 
kappa statistic was calculated to convey chance-corrected agreement. The results 
presented below reflect the consensus reached between the author and independent 
reviewer, where applicable. Disagreements in quality assessment were identified by the 
author, and each instance discussed with the independent reviewer to reach consensus.  
6.1.4 Appraisal of Methodological Quality  
Sequence  gener a t ion  and a l locat i on  concea lment  
Randomisation and allocation procedures were extracted for each trial. Methods were 
appraised for their adequacy in preventing selection bias using the rigorous criteria 
recommended for the evaluation of treatment RCTs by the Cochrane Collaboration123 
(Table 6.2). Quality of methods were categorised as „unclear‟ if the information provided 
was insufficient to judge the presence of a random element in the generation of the 
allocation schedule, or the overall predictability of the allocation sequence.  
Bl ind ing  conduct   
Studies were examined for clear reports of whether participants, care–providers (defined 
as those responsible for patient management) and outcome assessors had been masked 
to the identity of tests used for decision-making during the trial. All such attempts were 
extracted to characterise how blinding had been achieved in these studies. Since it is 
theorised that blinding may not always be possible, the reasoning trialists provided to 
explain the absence of blinding was examined.  
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Bl ind ing  feas i b i l i ty  
An attempt was also made to judge the feasibility of blinding in all included studies. This 
subjective assessment was made on a case–by–case basis, since it was recognised that 
the ability to mask individuals is highly dependent on the clinical and comparative context. 
For participants and care–providers the ability to blind was determined by reference to the 
individual clinical setting, including the similarity in characteristics of tests administered 
 Adequate Inadequate Unclear 
   
Se
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 G
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er
at
io
n
 Clear description of a method 
to randomly generating 
numbers, e.g. 
Clear description of a number 
generation method that is partly 
or fully systematic, e.g. 
Missing data or obscure 
description with unclear 
indication of random 
component to sequence 
generation, e.g. 
 computer random number 
generator 
 random number table  
 tossed coin 
 shuffled cards/envelopes 
 throwing dice 
 drawing lots 
 minimisation 
 alternate assignment 
 birth date  
 consultation date 
 hospital number 
 judgement of clinician 
 patient preference 
 test results 
 availability of intervention 
 generic reference to 
'randomisation' 
 use of a randomised list 
 randomisation performed 
by computer 
 random assignment 
 randomisation schedule 
A
ll
o
ca
ti
o
n
 C
o
n
ce
al
m
e
n
t Clear description of an attempt 
to conceal the order of 
allocation from study recruiters 
and patients, e.g. 
Clear description of a 
predictable order of allocation, 
e.g. 
Missing data or obscure 
description that does not allow 
the predictability of schedule to 
be judged, e.g. 
 central remote-site 
randomisation procedure 
(e.g. telephone, independent 
trial office etc)  
 concealment of allocation 
instructions (sequentially 
numbered, sealed and 
opaque envelopes) 
 open random allocation 
schedule (e.g. selection of 
next random number by 
treating staff) 
 unconcealed assignment 
envelopes (e.g. unsealed, 
transparent or not 
sequentially numbered) 
 non-random sequence 
generation which is easily 
predictable (e.g. 
alternate/rotational 
assignment, hospital 
number, birth date etc) 
 generic reference to a 
masked or concealed 
allocation process 
 unclear safeguards for 
assignment envelopes 
 centralised procedure with 
no reference to remote-site, 
or of unclear location 
 Table 6.2: Criteria for appraising methods of sequence generation and allocation  
  concealment. 
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and the nature of their comparison (replacement, add-on or triage). Since the ability to 
blind outcome assessors also depends on the endpoint being measured, feasibility was 
judged separately for each outcome taking into account how the outcome was measured, 
the identity of the outcome assessor and whether the measurement was determined 
objectively or subjectively. The identity of the outcome assessor was extracted directly, or 
surmised from description of measurement methods where possible. Each outcome was 
categorised according to the type of contact between participant and outcome assessor 
required for measurement to take place, using predetermined criteria developed by 
Boutron and colleagues for assessing the quality of non-pharmacological RCTs (Table 
6.3)243. This approach was conducted in order to facilitate subsequent assessments of the 
feasibility of blinding outcome assessors. The degree of interaction between participants, 
care–providers and outcome assessors is particularly convoluted in trials evaluating 
complex interventions, where multiple phases of decision-making may be the subject of 
evaluation. Boutron‟s method was selected since it was designed to categorise outcomes 
and investigate the feasibility of blinding in trials of non-pharmacologic interventions which, 
though not test-treatment RCTs, are nonetheless complex intervention trials and thus 
considered suitable for the present analysis. 
Outcome Type Examples 
  Patient reported Pain, quality of life 
Patient–outcome assessor contact required Walking speed, function 
Patient–outcome assessor contact not required 
Appearance of joint 
structure (X-ray) 
Clinical events and therapeutic outcomes determined by interaction 
between patient and clinician (physician-driven data) 
Length of hospital stay, 
treatment failure 
Clinical events and therapeutic outcomes assessed from data on medical 
forms 
Death, treatment 
prescription 
Table 6.3: Criteria for categorising outcome assessors
243
. 
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Judgements were grouped into three categories, following published methods243: blinding 
was judged as „feasible‟ if the means required to blind were considered common or could 
be applied simply; blinding was judged „difficult‟ if blinding could have been conducted, but 
would have required the implementation of solutions that differ considerably from normal 
clinical practice; and lastly blinding was considered „impossible‟ if the reviewer thought it 
not physically or ethically practicable to mask the identity of the test, even using creative 
solutions. These classifications are illustrated with examples in Box 6.1. 
Appr opr i a teness  o f  t he  mai n  ana l ys is  
Appropriateness was judged according to five criteria: 1. whether outcomes were 
measured in the whole study population (and not a subgroup), 2. whether outcome 
measurement was consistent across trial arms, 3. whether patients were analysed in the 
groups to which they were randomised, 4. whether analyses were complete, and if not why 
5. whether trialists conducted an „intention–to–treat‟ analysis. 
Subgroup analyses 
Published analyses were examined to determine whether the denominators used for 
calculation constituted the whole randomised population. Primary outcomes measured in 
subgroups of the study population were considered inappropriate due to the ensuing risk 
of selection bias when comparing subgroups that may reflect non–random differences in 
composition135. 
Consistency of outcome measurement 
Details of outcome measurement were examined to establish whether the same method of 
ascertainment was used for all arms in each trial. If methods differed, the type of endpoint 
(see chapter 5 p.130–134) was used to judge the comparability of resulting findings. For 
example test performance outcomes (e.g. diagnostic yield or therapeutic yield) by 
definition must be measured using the tests under comparison, and so were judged to 
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Box 6.1: Definition of the blinding feasibility judgement categories used, with examples. 
 
Feasible Clinical setting and nature of comparison easily accommodate blinding, e.g. 
 PARTICIPANTS: Comparison of tests that are very similar or do not carry any risk of 
procedural morbidity, for example d–Dimer blood test vs. ultrasound 
for diagnosis of deep vein thrombosis
(T3)
.  
 CARE–PROVIDERS:  Interpretation of test results are not made by the treating physician 
such that generic reports can be produced, for example in the 
comparison of two laboratory biochemical tests (CK/CK-MB vs. 
Troponin I) to identify chest pain patients at high risk of adverse 
events
(T26)
.  
 OUTCOME  Outcome measurements do not involve contact with patients, 
 ASSESSORS: for example ascertaining the rate of colonic rebleeding during follow–
up from medical notes
(T30)
. 
Difficult Blinding possible, but requires substantial modification of normal clinical 
practice involving ‘creative’ solutions, e.g. 
 PARTICIPANTS: Using simulated test procedures, for example comparing the 
replacement of clinical examination with computed tomography 
(experimental test) for the management of possible intracerebral 
injury, which would involve giving comparator arm patients sham CT 
scans
(T68)
. 
 CARE–PROVIDERS: Providing treating clinicians who are traditionally involved in test 
interpretation with sham test results by a third party, for example 
requiring non–treating physicians to take samples, interpret results 
and produce generic reports when comparing Bronchoalveolar lavage 
and quantitative culture with Endotracheal aspiration and 
nonquantitative culture to identify the organism causing 
pneumonia
(T62)
. 
 OUTCOME Outcome measurements generally conducted by treating 
 ASSESSORS: physicians that need to be rearranged so they are conducted by 
independent physicians, for example measuring the incidence of 
retained products of conception during follow–up using 
gynaecological examination and transvaginal ultrasound
(T76)
. 
Impossible Blinding is not physically possible or ethically acceptable, e.g. 
 PARTICIPANTS: Comparison of invasive tests that render sham procedures unethical, 
for example  endoscopy vs. 13-Carbon urea breath test for detecting 
Helicobacter pylori
(T44)
. 
 CARE–PROVIDERS: Test and treat stages are performed during the same procedure, for 
example comparing white–light cystoscopy with fluorescence 
cystoscopy for the detection and removal of bladder cancer
(T1)
.  
 OUTCOME  Patient–reported outcomes where blinding patients is 
 ASSESSORS: impossible, for example dyspepsia symptom relief measured on 
patient questionnaires to evaluate two complex, partly invasive 
testing strategies where it is not practical or ethical to mask 
patients
(T40)
. 
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have been measured appropriately. Conversely, the measurement of disease rates should 
be made using the same test, and so were judged to have been ascertained 
inappropriately if different tests were used in different arms. 
Incomplete analysis: patient exclusions, missing data and differential attrition 
Participant flow data were examined to reveal whether the main analysis was complete, to 
quantify the amount of data missing from study groups, and to determine the likelihood of 
bias arising from differential attrition between comparative arms.  
For each trial the number of patients randomised was compared with the number analysed 
to determine the magnitude of attrition for all study groups. Analyses were considered 
incomplete if the number analysed was less than the number randomised. Attrition was 
defined as the absence of data (for any reason) for the primary outcome measured at the 
primary time-point, if specified. Otherwise the time-point used in sample size calculations 
was used, and if this also was not available then the most complete analysis was selected. 
When more than one primary outcome was reported, patient outcomes were preferentially 
extracted to reflect their primacy over process outcomes as measures of clinical 
effectiveness. 
Differential attrition was arbitrarily considered at two levels, as ≥5% and as ≥20% 
difference between arms, following the approach advocated by the Centre for Evidence 
Based Medicine when judging the quality of comparative evidence of effectiveness244. 
Reasons for missing data were extracted, and classified as either investigator-determined 
exclusion post-randomisation or loss to follow-up. As recommended by CONSORT121, 
reporting of exclusions was examined to determine whether the apparent absence of 
attrition corresponded with an explicit statement of no exclusions. 
 
 
  
Chapter 6: Methods 158 
Analysis according to randomisation 
Participant flow data for each trial were examined to establish whether deviations from 
protocol had occurred, and if so whether these patients had been analysed according to 
their allocated groups regardless of the test actually received. 
Use of intention–to–treat principle 
Reports clearly stating that primary analysis was by the „intention–to–treat‟ (ITT) principle 
were extracted. These were compared against both components needed in an ideal ITT 
analysis123, namely whether all study patients were analysed as randomised, and whether 
analyses were complete. 
Det erminat ion  o f  sampl e  s i ze  
The assessment of sample size quality was limited to whether sample size calculations 
were reported, extraction of target numbers, appraising whether these calculations used 
primary trial endpoints, and establishing whether target sample sizes were reached. 
Reasons for any deficits were also extracted. Preliminary studies suggest that power 
calculations for test-treatment RCTs are likely to require estimates of test sensitivity and 
prevalence of the target condition176–177. The author initially attempted to trace these data 
for one included trial(T62) in order to replicate the reported power calculation and so 
determine its adequacy, however published information could not be found. In view of the 
wide variety of diagnostic settings encountered in the included studies, and extensive 
bibliographic searching needed to identify the required diagnostic performance parameters 
for each trial, it therefore became necessary to limit this analysis to the presence of power 
calculations and the distribution of attained sample size across included trials. 
6.1.5 Analysis 
The objectives of this review are to describe the frequency with which test-treatment trials 
were found to have used adequate methods to limit bias and enhance the validity of 
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results. Consequently, the analysis presents a descriptive synthesis of these findings using 
percentages that reflect the categorical nature of the data. Comparisons between these 
frequencies were used to enhance the description of findings, and aimed to highlight 
potential associations between particular methodological items and aspects of the study 
settings, as characterised in chapter 4. The author did not intend to evaluate specific 
hypotheses regarding these associations, but rather to generate hypotheses for how easily 
the methods of trial design could be employed to conduct reliable and informative test-
treatment RCTs. As a consequence testing for the statistical significance of these 
comparisons was not appropriate.  
Data were exported from the extraction database to Microsoft Excel 2007 for sorting and 
analysis.  
6.2 Included studies 
 
 
As for the review of reporting quality presented in chapter 5 (p.122–123), methodological 
quality was assessed for the same 103 trials with full results publications*. These 
evaluated 119 experimental and 105 comparator interventions. 
6.2.1 Inter–observer reliability 
For the sample of 66 independently assessed trials, agreement between reviewers was 
substantial for assessing the adequacy of both sequence generation and allocation 
concealment methods (Table 6.4). During the subsequent consensus meeting, it became 
apparent that most disagreements (12/13 for sequence generation and 9/11 for allocation 
concealment methods) concerned differences in opinion as to whether more meagre 
descriptions were sufficient to allow a quality judgement to be made, while the remainder 
were due to errors in data extraction.        
                                                 
*
 Citations for included test-treatment RCTs are prefixed with a ‘T’ 
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2nd Reviewer Author 
*AObs †AExp κ 95% CI 
 
Adeq–
uate 
Inadeq–
uate 
Unclear Total 
Sequence 
Generation 
Adequate 33 0 11 44 
0.809 0.483 0.630 0.5–0.8 
Inadequate 0 1 0 1 
Unclear 1 1 21 23 
Total 34 2 32 68 
Allocation 
Concealment 
Adequate 24 0 10 34 
0.838 0.459 0.701 0.5–0.8 
Inadequate 0 2 1 3 
Unclear 0 0 31 31 
Total 24 2 42 68 
Table 6.4: Inter-reviewer agreement in assessing quality of randomisation and allocation 
concealment methods. 
 *Observed agreement 
 †Expected agreement 
2nd Reviewer Author     
Blind 
Not 
blind 
Total *AObs †AExp κ 95%CI 
 
Patients 
Blind 3 0 3 
1.000 0.913 1.000 x Not blind 0 63 63 
Total 3 63 66 
Care-
providers 
Blind 3 3 6 
0.955 0.872 0.645 0.3–1.0 Not blind 0 60 60 
Total 3 63 66 
Outcome 
assessors 
Blind  16 0 16 
0.970 0.617 0.921 0.8–1.0 Not blind 2 48 50 
 
Total 18 48 66 
Table 6.5: Inter-reviewer agreement in assessing the conduct of blinding. 
 x – not calculable 
 *Observed agreement 
 †Expected agreement 
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Agreement was perfect when judging the presence of patient blinding, near–perfect for 
outcome assessor blinding and substantial for blinding care–providers (Table 6.5). All 
discrepancies were due to inaccuracies in data extraction; the three disagreements 
regarding whether care–providers had been masked owed to the misidentification of 
whether personnel described as blind were treating physicians performing the 
experimental or comparator test.  
6.3 Results: Do trials adequately control for 
selection bias? 
 
 
Evaluation of the methodological quality of included trials began with appraising the 
adequacy of their methods to limit the bias in the creation of study groups (Appendix E.1). 
6.3.1 Adequacy of sequence generation  
Approximately half the trials (59/103) reported robust methods of sequence generation, 
judged as likely to have permitted a truly random order of patient allocation. Two studies 
used non–random and hence inappropriate methods, either allocating systematically by 
the sum of the day and month of birth (even number assigned control)(T23), or employing 
„random sampling‟ to achieve cohorts with similar sizes(T28). The remainder (41%, 42/103) 
failed to report their methods of sequence generation in enough detail to enable an 
independent judgement of methodological quality (Figure 6.1). Of these, 23% (10/43) 
made no reference to sequence generation, 30% (13/43) reported the term „randomisation‟ 
without describing the method used, while 44% referred to either „randomisation by 
computer‟ (7/43), „block randomisation‟ (8/43) or a „centralised system‟ of randomisation 
(4/43) without reference to whether the schedule was generated using a random 
component. 
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6.3.2 Adequacy of allocation concealment 
Approximately one in three trials (38/103) were judged to have adequately concealed the 
randomisation schedule from study recruiters (generally physicians) and patients. Three 
studies (3%) overtly employed inadequate methods; the inadequately randomised trial that 
allocated patients by date of birth(T23) used a clearly predictable schedule, while two cluster 
randomised trials did not conceal established cluster allocations from participant recruiters 
until all patients had been recruited(T48,T97). However the great majority of studies, 60%  
(62/103), did not provide sufficient detail to make an independent judgement of 
methodological quality. Over half of these (34/62) did not refer to allocation concealment. 
The balance provided incomplete descriptions, including unclear safeguards for 
assignment envelopes (19/62), opaque reference to a centralised procedure with no 
reference to a remote-site location (6/62), or statements that concealment was carried out 
without reporting the methods used (3/62).       
 
37%
57%
3%
2%
60%
41%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Allocation concealment
Sequence generation
Adequate % Inadequate % Unclear %
 
Figure 6.1: Adequacy of quality for sequence generation and allocation concealment methods. 
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6.4 Results: Do trials control for performance 
& ascertainment bias? 
 
6.4.1 Conduct of blinding  
Reports of blinding were few in number and of poor quality. Overall authors failed to 
indicate whether blinding had been conducted in approximately two-thirds of studies 
(Table 6.6). Participants, care–providers and primary outcome assessors were masked to 
the identity of the diagnostic strategy used for treatment decisions in 5%, 4% and 21% of 
trials respectively. A summary of judgements is provided in Appendix E.1 (p.410). 
Par t i c ipant s  
Patients were blinded to the test used in four add-on comparisons(T69,T98,T100,T103) and one 
triage comparison(T74) (Table 6.7).  
All four add-on trials evaluated the addition of single, straightforward non-invasive 
strategies. Patient blinding was achieved either by administering experimental and control 
tests to all participants and masking them from test results(T69,T100,T103), or by conducting 
both tests in the same sample of tissue (T98). In the latter case, the tests being compared 
were laboratory-based examinations of preimplantation embryos, hence the test 
Group identified as blind 
Number of trials reported as:  
Blind (%) Not blind (%) Unclear (%) 
Patients 5 (5) 30 (29) 68 (66) 
Care-providers 4 (4) 33 (32) 66 (64) 
Primary outcome assessors* 22 (21) 14 (14) 67 (65) 
Table 6.6: Frequency of blinding in test-treatment RCTs (N=103) 
 * judged as blind if measurement of ≥ 1 primary outcome conducted by a blinded assessor. 
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technologies are ordinarily performed and interpreted in the absence of patients. To 
preserve blinding for the remainder of the study however, trialists prevented patients from 
entering laboratories and did not reveal information on the number or quality of embryos 
transferred during IVF. 
The triage trial blinded patients to a more complex protocol, introducing a non-invasive test 
to select which patients would proceed to the invasive control test. Patients with suspected 
pulmonary embolism (PE), requiring a confirmatory diagnosis to direct further treatment, 
were randomised to management by the standard ventilation-perfusion (V/Q) scan or initial 
triage for ruling out PE(T74). This combined „BIOPED‟ test, comprised two laboratory assays 
(D-dimer and alveolar dead space measurement) and a clinical prediction rule (Well‟s 
seven-variable clinical model), sought to eliminate PE as a possible cause thus sparing 
these test-negative patients the more invasive V/Q scan. While test-negative patients 
could be safely redirected to other treatments, those with a positive „BIOPED‟ score would 
proceed to further V/Q testing for a definitive diagnosis. In order to blind the triage stage, 
the BIOPED was given to all patients. Since receipt of a V/Q scan risked revealing the 
allocation, all patients also underwent a V/Q scan. In order to ensure that rule-out occurred 
only as a result of the triage test results, BIOPED negative patients received a sham V/Q 
procedure, while test positives received a true V/Q scan. 
Car e–pr ovider s  
Attempts to blind treating physicians to the identity of the allocated test strategy were 
reported in four trials (4%)(Table 6.6), three of which also blinded patients(T74,T98,T100).  
Blinding was easily achieved during the evaluation of preimplantation embryo analysis, as 
treating physicians (gynaecologists) were not involved in the conduct or interpretation of 
either test(T98) and, as with patients, they were prevented from entering laboratories and or 
receiving information on the number or quality of embryos transferred during IVF.  
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In a simple replacement comparison for managing patients with suspected PE, physicians 
were provided with generic diagnostic reports in order to conceal test identity(T91). Again, 
this particular clinical setting is conducive to masking an element of the diagnostic process 
since both competing tests, CT pulmonary angiography and V/Q scanning, must be 
performed by nuclear radiologists; hence treating physicians could simply be provided with 
the interpretation (“positive for pulmonary embolism”, “non-diagnostic study” or “no 
evidence of pulmonary embolism”) whilst safely remaining ignorant of the test‟s identity.  
Moving one step further away from diagnostic decision-making, treating physicians in the 
aforementioned BIOPED trial were also masked to the triage stage throughout the duration 
of the study(T74). Interpretation of BIOPED results was passed to third party investigators, 
who used them to decide which patients should go on to receive a V/Q scan. In order to 
maintain blinding, a fake negative nuclear medicine report was subsequently sent to the 
physicians of patients who had received a sham V/Q scan.  
Although reported as „double-blind‟, a trial evaluating whether NT-proBNP gives 
incremental value to managing patients with suspected acute heart failure(T100) cannot 
have blinded its treating physicians, since NT-proBNP results were randomly disclosed in 
order to assess differences in clinical decision-making. The authors were instead referring 
to non-treating cardiologists who produced independent final diagnoses without knowledge 
of the add-on NT-proBNP test results, but did not contribute to management decisions.  
Out com e assessors  
Primary outcome assessors were blinded in one-fifth of trials (22/103, 21%), considerably 
more often than blinding of patients or care–providers (Table 6.6). 
Measurements were blinded by using independent expert panels(T6,T14–
15,T38,T63,T91,T96,T99,T101), clinicians not involved in care provision(T32,T55,T60,T69,T74,T92), or 
research assistants(T18,T33,T42,T57,T66–T67,T72).  
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Ascertaining the identity of the outcome assessor, in order to subsequently determine 
whether or not they had been blinded to diagnostic interventions, was somewhat difficult. 
This was due to the inadequate reporting of primary outcomes, which generally provided 
insufficient details to establish how, and importantly by whom, they had been measured. 
This information was frequently absent from reports as authors focused on listing the 
measurements taken and legitimising their selection of endpoints. Establishing precisely 
who measured the relevant outcomes was therefore often deduced implicitly from the 
outcome type and descriptions of measurement methods. Ultimately, the outcome 
assessor‟s identity could not be discerned in 11 studies (11%), including six that did not 
define a primary outcome and a further five that did not provide enough information on 
how the outcome was measured(T9–10,T56,T94,T108).  
Most trials measured outcomes requiring contact with the patient (57% (59/103), of which 
a third were reported by the patients themselves (20/59, Boutron category #1), almost half 
were driven by patient contact with treating physicians (25/59, 42%; Boutron category #4), 
and relatively few requiring contact with non-treating clinicians (14, 14%; category #2) 
(Table 6.8). The most common method of measurement was the collection of data from 
medical records (43, 29%; category #5). Very few examples of complementary 
Outcome category 
Number of trials 
(N=103) 
(%) 
1. Patient–reported 20 (19) 
2. Patient – Outcome Assessor contact  14 (14) 
3. Outcome Assessor, no contact  2 (2) 
4. Patient – Care-provider contact 25 (24) 
5. Medical form data 39 (38) 
Unclear 5 (5) 
No outcome defined 6 (6) 
Total 103 
 
Table 6.8: Frequency of the five types of outcome measurement in included trials.  
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investigations (3, 2%; category #3) were encountered, namely tests conducted by non-
treating care–providers involving no patient contact. Table 6.9 presents examples for each 
category. 
Outcomes requiring contact with patients were less frequently blinded than other 
categories (Table 6.10). Patient–reported outcomes were never blinded. Almost half the 
outcomes (13/31, 42%) measured by independent assessors but involving contact with 
patients were reportedly blind, however upon closer examination most (12/13) of these 
assessments could not have been blind and so constituted misreporting of trial methods. 
These outcomes were measured in four trials(T18,T66,T69,T92), of which three(T18,T66,T92) had 
blinded the outcome assessor but not the patients, leading one to question how successful 
such attempts at removing ascertainment bias may have been. For example, one trial(T18) 
Boutron outcome 
criteria 
Example Source 
Patient-Reported (1) Dyspeptic symptoms recorded daily in a personal calendar by the 
patient 
T46 
 Coping responses to cancer recorded using the Mental Adjustment to 
Cancer Scale  
T24 
Patient – Outcome 
Assessor contact (2) 
Maximal exercise endurance on the treadmill  T41 
Pregnancy rate, defined as positive urine or serum test in association 
with presence of an intrauterine gestation sac on ultrasound 
T73 
Outcome Assessor, 
no contact (3) 
X-ray appearance of the hip T15 
Diagnostic yield of PCR, defined as the % of embryos with a diagnosis T93 
Patient – Care-
provider contact (4) 
VTE rate, patients with suspicious signs/symptoms on follow-up given 
venography or compression ultrasonography of the proximal deep veins 
for confirmation of diagnosis 
T63 
Time-to-first-recurrence, bladder cancer detected during follow-up with 
cystoscopy and cytology (confirmed histologically) 
T90 
Medical form data 
(5) 
Embryo implantation rate (number of foetal sacs per embryo 
transferred) 
T87 
Futile thoracotomy rate, defines as futile if an intended curative 
thoracotomy ended as explorative surgery without tumour resection, or 
a resected patient died from lung cancer or had recurrent disease 
during follow up 
T17 
Table 6.9: Examples of primary outcomes extracted for each outcome type 
 PCR – polymerase chain reaction 
 VTE – venous thromboembolism 
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measured eight aspects of health–related quality of life, reflecting each of the eight 
domains from the Short–Form 36. These outcome data were obtained through telephone 
interview with unmasked patients, by research assistants who were blind to intervention 
assignments. A single trial(T69) conducted a fully blinded patient–assessor outcome 
measurement, conducting a follow–up ultrasound in masked patients using masked, 
independent assessors.  
A third (9/26, 35%) of outcomes measured by treating clinicians were reported as blind, 
although again one of these trials identified the wrong outcome assessor as being 
masked. Examining the utility of adding a point–of–care ultrasound for investigating trauma 
patients in the ED, time–to–operative–care was recorded by unmasked treating 
physicians, and abstracted from medical notes by blinded researchers(T72). Since the 
outcome value could have also been influenced by the physician, it cannot be claimed to 
be free of bias. 
The remainder (8/9) claimed to have achieved blinding by using masked independent 
experts to adjudicate outcomes initially measured by non–blinded clinicians. For example, 
Assessor category Blind (%) 
Not 
Blind 
(%) Unclear (%) Total (%) 
1.Patient-reported  0 (0) 13 (31) 29 (69) 42 (28) 
2.Patient-3
rd
 party 
assessor contact  13 (42) 0 (0) 18 (58) 31 (21) 
3.Third party 
assessor, no contact 1 (33) 0 (0) 2 (67) 3 (2) 
4.Patient-physician 
contact  9 (35) 2 (8) 15 (58) 26 (17) 
5.Medical form data  11 (26) 7 (16) 25 (58) 43 (29) 
Unclear 0 (0) 1 (20) 4 (80) 5 (3) 
Total 34 (23) 23 (15) 93 (62) 150 (100) 
Table 6.10: Frequency of attempts to blind primary outcome assessments, as reported by trialists. 
Denominator is the number of primary outcomes (n=150). 
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in three trials the frequency of venous thromboembolism in patients managed for 
suspected pulmonary embolism was initially established by treating physicians according 
to the results of various follow–up investigations (compression ultrasound or venography 
or pulmonary angiography or spiral CT or V/Q scan)(T63,T74,T91). These findings were 
subsequently evaluated by an independent committee, blind to initial assignment, in order 
to confirm the occurrence of a true outcome event. The nuclear medics and treating 
clinicians who performed these follow–up tests were not blind, however, and since 
interpretation of the resulting images involve an element of subjectivity it is theoretically 
possible that ascertainment bias may not have been adequately eliminated in these 
studies.  
The majority of trials (60, 58%) used objective outcomes as their primary measure (Table 
6.11), including „hard outcomes‟ like all–cause mortality and healthcare cost but also 
measures of health response assessed using standardised methods of observation, for 
example assessing patients‟ maximal endurance to exercise on the treadmill by calculating 
their mean number of metabolic equivalents using a predefined protocol(T20,T41,T92). 
Although only 27% (16/60) of these trials performed blinded evaluations, the risk of 
introducing ascertainment bias should have been relatively low since these measurements 
are less prone to the influence of opinion. Subjective outcomes are prone to these 
influences, yet were less frequently blinded (7/39, 18%). Moreover, as discussed above, 
Number of trials blinding 
objective vs. subjective 
outcomes 
Blind (%) 
Not Blind/ 
Unclear 
(%) Total 
Objective 16 (27) 44 (73) 60 
Subjective 7 (18) 32 (82) 39 
Unclear 0 (0) 7 (100) 7 
Total *22 (21) †81 (79) 103 
Table 6.11: Frequency of blinding in trials assessing objective versus subjective primary outcomes. 
 * 1 trial measured a mixture of objective and subjective outcomes
(T18)
 
 † 2 trials measured a mixture of objective and subjective outcomes
(T24,T53)
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blinding is unlikely to have been successful in at least 2 of these trials due to the failure to 
mask both patients and interviewers(T18,T66). These findings raise the distinct possibility that 
at least a third of the entire cohort of trials (32/103) are at risk of having produced biased 
primary results.  
6.4.2 Rationale for not blinding 
The reasons trialists provided to explain why blinding was not carried out are now 
reported.  
Pat i ent s  
Of the studies that did not blind, only 23% (7/30) provided specific reasons stating that it 
would not be ethical to do so(T5), that it would not be „pragmatic‟ (T12,T19,T107) or that the 
characteristics of the comparative tests prevented either sham diagnostic procedures or 
the administration of both tests to all patients(T6,T48,T70). Nine trials(T11,T18,T24,T47,T60–61,T66,T83,T92) 
stated simply that it was „not feasible‟ to blind patients, while the remaining 15(T10,T21,T27–
28,T49,T51,T53,T55–56,T68,T71–72,T91,T97,T106) provided no discussion and described the study as an 
open-label or unblinded RCT. 
Car e–pr ovider s  
Similarly, only 27% (9/33) of trials that explicitly did not blind care–providers provided 
specific reasons for doing so, asserting that blinding would prevent an assessment of the 
test‟s impact on clinical decision-making(T92,T107), that is would not be „pragmatic‟ (T12,T19), 
that the nature of the comparative tests prevented clinicians being blinded to their 
results(T6,T24,T54,T70) or that it would have been unethical to blind those planning treatment 
(T58). Six studies alluded to the impossibility of blinding(T11,T18,T47,T57,T60–61), while 18 provided 
no discussion beyond a simple statement of absence(T5,T10,T21,T23,T27–28,T30,T50,T53,T55,T62–
63,T66,T71–T72,T83,T97,T106). 
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Out com e assessors  
Comparatively fewer trials stated explicitly that they did not blind outcome assessors 
(14/103, 14%) than either patients (30/103, 29%) or care–providers (33/103, 32%). Two 
trials appealed to the impossibility of masking, as the measures required to capture health 
impact were of necessity subjective, patient-reported appraisals conducted in a setting 
where it was either „not feasible‟ (T11) or „not pragmatic‟ (T107) to mask patients. The 
remaining 12 trials (86%) failed to provide any reasoning for not blinding assessors, 
although four sought to legitimise their methods by emphasising that open assessment 
would not have influenced outcome results(T10,T21,T26,T53). Yet two of these trials(T10,T53) 
measured subjective endpoints which may have been influenced by the assessor‟s 
knowledge of group allocation. For example, seeking to evaluate whether initial 
investigation in a specialist syncope unit improved the diagnostic yield of patients with 
syncope of undetermined cause, Shen et al compared the number of patients receiving a 
diagnosis in each arm(T53). Outcome assessors in this case are likely to have been treating 
physicians who are inextricably implicated in the success of their respective interventions. 
Consequently, knowledge of the patient‟s allocation (in this case unavoidable due to the 
tests being compared) may have influenced the decision to establish a diagnosis. 
Measurement details were not reported, however a more objective assessment could have 
been made by specifying the full diagnostic criteria required in the trial protocol. 
6.5 Results: Can trials control for 
performance & ascertainment bias? 
 
Since it was theorised that blinding may be impossible to achieve, a subjective 
assessment of whether blinding could have been performed was carried out for all trials, 
regardless of whether they reportedly blinded or not (summarised in Appendix E.1, p.410). 
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6.5.1 Feasibility of blinding 
The subjective feasibility assessment suggests it was not always possible to perform fully 
blinded studies. Taking into account all elements of the clinical setting for each study, the 
author judged that it would rarely have been possible to blind care–providers (11/103, 
11%), while 50% (51/103) of trials could accommodate patient blinding. Masking outcome 
assessment was most often deemed feasible, though even then only 66% (68/103) of trials 
could have achieved this (Figure 6.2). The methods required to blind successfully were 
considered to be difficult to implement when considerable additional resources would be 
required, such as employing additional teams of clinical staff to perform tests for the 
purposes of blinding clinicians(T3,T14,T62), attempting sham procedures to blind patients to 
 
Figure 6.2: The feasibility of blinding patients, care-providers and outcome assessors in test-
treatment RCTs 
 * Trials with multiple primary outcomes were entered once if all outcomes fell into 
the same categories. For four trials outcomes fell into 2 feasibility categories; see 
table 6.14 
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invasive tests(T70,T99,T105) or to multiple phases of testing(T65), or when measuring patient 
outcomes in trials that were considered difficult to also blind patients(T24,T65,T68). Methods 
were judged to be difficult to blind clinicians in a third (4/11, 36%) of these studies and to 
blind patients in 33% (17/52) of trials.  
Masking outcome assessors was judged to be more easily attainable in most comparisons 
(65/68, 96%) however this varied according to the types of outcome measured. Objective 
assessments were easier to blind (90%, 70/78) than subjective ones (25%, 18/72) (Table 
6.12), while patient-reported responses were far more difficult to blind (category #1: 10%, 
4/42) than routine data collections (category #5: 86%, 37/43) (Table 6.13). Though few in 
number, outcomes assessed by independent clinicians or researchers (category #3) were 
more often amenable to blinding, for example assessing the recovery of shoulder mobility 
after invasive surgery for the diagnosis of breast cancer spread(T24) or exercise endurance 
after treatment for coronary stenoses(T20). Assessments made during treatment could be 
masked if independent adjudicators were used, for example to measure the rate of venous 
thrombosis in symptomatic patients previously managed for suspected pulmonary 
embolism presenting during follow-up(T3), which could have been achieved for 73% (19/26) 
of these outcomes. Contrary to expectations, outcomes assessed from data on medical 
forms could not always be made in blinded fashion since the tests received by patients 
could be revealed, for example when collating resource-use for the calculation of 
diagnostic and/or treatment costs(T5,T12,T19,T55,T70,T83). This pitfall was avoided in trials using a 
randomised disclosure design since differences in cost could be calculated for the period 
after randomisation, and hence after testing had taken place(T100). 
Overall, trialists would have found it impossible to blind patients as well as care–providers 
and outcome assessors in at least a fifth of all trials (23, 22%)(T4,T11,T12,T13,T18–19,T24,T27,T30,T34–
37,T39–40,T44,T46,T51,T56,T64,T77,T88,T107). This rate excludes five studies in which blinding appeared 
impossible for patients and care–providers, though the feasibility of blinding outcome 
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assessors could not be determined due to poor reporting of the methods of outcome 
measurement(T108) or primary outcome definition(T2,T29,T79,T82). 
Frequency of  b l i nd i ng  w hen judged f eas i b le  
When these frequencies are examined according to trialists‟ reported attempts to blind  
(Table 6.14), it is apparent that test-treatment trials did not always blind when they could 
have done so. Almost half (47/103, 46%) could have improved their designs by blinding 
patients, including 29% (30/103) that could have done so easily since the nature of the 
test–treat comparison would have enabled all tests to be given ethically to all patients, as 
real or sham procedures. For example, trialists assessing the value of an additional MRI in 
patients with suspected fracture of the scaphoid could have given control patients a sham 
MRI(T10). Another 17 trials could have blinded patients, though with some degree of 
Feasibility of blinding 
outcome assessor 
Objective outcome Subjective outcome Total 
N % N % N % 
Feasible 61 (78) 14 (19) 75 (50) 
Difficult 9 (12) 4 (6) 13 (9) 
Impossible 8 (10) 52 (72) 60 (40) 
Unclear 0 (0) 2 (3) 2 (1) 
Total 78 (100) 72 (100) 150 (100) 
Table 6.12: The feasibility of blinding according to subjectivity of outcome measurement. 
 Individual outcomes used as denominator. 
Blinding 
Feasibility 
Outcome category 
1 (%) 2 (%) 3 (%) 4 (%) 5 (%) Unclear (%) Total (%) 
Feasible 2 (5) 12 (39) 3 (100) 19 (73) 37 (86) 2 (40) 75 (50) 
Difficult 2 (5) 10 (32) 0 (0) 1 (4) 0 (0) 0 (0) 13 (9) 
Impossible 38 (90) 9 (29) 0 (0) 6 (23) 6 (14) 1 (20) 60 (40) 
Unclear 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (40) 2 (1) 
Total 42 
 
22 
 
3 
 
26 
 
43 
 
5 
 
150 
 
Table 6.13: The feasibility of blinding individual outcomes in test-treatment RCTs.  
 Note: since feasibility is contingent on the type of measurement taken, the total number 
of outcomes assessed is used as a denominator. 
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difficulty, for example by giving sham CT or sham plain X–ray in addition to the allocated 
test to patients under investigation of acute abdominal pain within one–hour of 
presentation(T85).  
Similarly, around half the trials examined (46, 45%) could have blinded outcome assessors 
but failed to do so, almost all of which (43/46, 93%) could have achieved this by simple 
methods, such as blinding patients(T41,T68,T71) and/or employing an independent assessor to 
take follow–up measurements(T58,T75,T90).   
Though rarely possible, approximately one in twelve trials (8/103, 8%) could have blinded 
care–providers but failed to do so. This includes five trials that could have done so with 
ease, for example by providing clinicians with standardised diagnostic reports when 
(A) Patients Blind (%) Not Blind (%) Total  (%) 
Feasible 5 (100) 30 (31) 35 (34) 
Difficult 0 (0) 17 (17) 17 (17) 
Impossible 0 (0) 51 (52) 51 (50) 
Total 5 (100) 98 (100) 103 (100) 
(B) Care-providers 
     
 
Feasible 2 (50) 5 (5) 7 (7) 
Difficult 1 (25) 3 (3) 4 (4) 
Impossible 1 (25) 91 (92) 92 (89) 
Total 4 (100) 99 (100) 103 (100) 
(C) Outcome assessors       
Feasible 22 (100) 43 (53) 65 (63) 
Difficult 0 (0) 3 (4) 3 (3) 
Impossible 2 (9) 29 (36) 31 (30) 
Unclear 0 (0) 8 (10) 8 (8) 
Total *22 (100) †81 (100) 103 (100) 
Table 6.14: Feasibility of blinding patients (A), care–providers (B), and outcome assessors (C) 
tabulated against attempts at blinding. 
 Trials with multiple primary outcomes were entered once if all outcomes fell into the same 
categories. For four trials outcomes fell into 2 different categories: 
 * Outcomes in two categories for each of two trials 
(T18,T55)
  
 † Outcomes in two categories for each of two trials
 (T24, T30)
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comparing exercise ECG with stress ECG for the identification of patients with coronary 
artery disease requiring immediate treatment(T89). Another three trials (3%) may have 
achieved blinding through more convoluted means, for example by employing an 
independent team of physicians to take aspirate samples from patients when comparing 
two techniques of aspirate sampling and culture processing for identifying the causative 
organism in patients with ventilator–associated pneumonia(T62). In order to complete the 
masking procedure, care–providers could subsequently be given test results in 
standardised format. 
6.5.2 Mistaken reports of blinding 
Three discrepancies were noted between the subjective assessment of feasibility and 
trialists‟ reports of blinding. In two trials blind outcome assessments could not have been 
successful due to the impossibility of masking the patient in addition to the interviewer 
during assessment of health-related quality of life(T18), or the impossibility of masking 
assessors to the identity of tests used when collating resource use and cost data from the 
medical record(T55). The third trial compared two methods for selecting healthy embryos for 
in–vitro fertility treatment. While the gynaecological care–provider was blind, in this case 
the individual making the treatment decisions (i.e. responsible for selecting the embryos) 
was the laboratory clinician carrying out the tests, who therefore could not have been 
masked(T98).  
6.6 Results: Do trials adequately control for 
attrition bias? 
 
The validity of trial findings is threatened if study groups are no longer similar at the point 
of analysis, and this was posited to be a particular threat in test-treatment RCTs if the 
number of interventions given result in increased drop–out rates. The fourth aim of this 
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review therefore assessed whether main analyses adequately limited the influences of 
attrition bias (summary data provided in Appendix E.2, p.418). 
6.6.1 Appropriateness of the main analysis 
Subgr oup compar isons  
The first criterion for an unbiased primary analysis is that the outcome must be measured 
in all randomised participants. Thirteen studies (13%) used a primary outcome that could 
only be measured in a subgroup of participants. Nine trials (9% of all trials) used the 
subgroup as the denominator for calculating effect differences (Table 6.15), and so are at 
risk of having produced distorted measures of effect by comparing two groups that are not 
analogous in patient characteristics. In order to evaluate the impact of the whole test–
treatment strategy, the proper approach requires observed events to be calculated using 
all randomised participants as the denominator, as performed by the remaining 4 
trials(T17,T61,T78,T102).  
When event rates were recalculated using the full denominator, the results of one trial 
changed enough to require a different interpretation of impact. The trial evaluated whether 
subfertile women attending for intrauterine insemination should all be given diagnostic 
laparoscopy as standard prior to treatment, or instead only be investigated for biological 
causes of infertility (e.g. tubal pathology or endometriosis) after failure of initial intrauterine 
insemination(T27). Hypothesising that laparoscopic abnormalities would be more frequent 
amongst women failing to get pregnant, the authors measured the proportion of 
participants with abnormal laparoscopic findings requiring treatment and/or leading to a 
change in fertility treatment. Using the proportion of participants undergoing investigative 
laparoscopy as the denominator, a non–significant increase was reported (experimental 
13/23, control 31/64; OR=1.4 [95%CI: 0.5–3.6]); however when the full study population is 
used a significant decrease in the proportion of women receiving a change in treatment as 
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Trial Primary outcome Subgroup  
Proportion of patients 
excluded from primary 
outcome* 
Total Expl Comp 
T32† Appropriateness of initial ED 
triage decision (Inappropriate 
discharge home of pts with ACI) 
Patients with a final diagnosis 
of ACI  
(false-negative rate) 
87% 86% 87% 
T26      Rate of in–hospital cardiac 
catheterisation  
Patients who were admitted 
(treatment subgroup) 
86% 82% 90% 
T10      Days unnecessarily immobilised Patients with a final diagnosis 
of no fracture  
(false-positive rate) 
72% 64% 76% 
T72      Mean time from arrival in ED to 
direct transfer to operative care  
Patients receiving operative 
treatment  
(treatment subgroup) 
71% 74% 68% 
T27      Rate of abnormal laparoscopies 
leading to a change in Rx 
Patients receiving laparoscopy  
(treatment subgroup) 
44% 70% 17% 
T60      Negative appendectomy rate Patients who had their 
appendix removed  
(false-positive rate) 
46% 46% 46% 
T7      Proportion prescribed 
antibiotics for non-pneumonic 
acute U/LRTI 
Patients with a diagnosis of 
non-pneumonic U/LRTI 
(treatment subgroup) 
20% 28% 13% 
T91      Frequency of VTE in patients in 
whom PE was excluded 
Patients with a negative test 
result for PE  
(false-negative rate) 
17% 19% 14% 
T74      Recurrence rate of VTE (in pts 
not taking anticoagulants) 
Patients with negative test 
result for VTE  
(false negative rate) 
16% 17% 15% 
T32†     Appropriateness of initial ED 
triage decision (inappropriate 
hospitalisation of pts without 
ACI) 
Patients with a final diagnosis 
of no ACI 
(false-positive rate) 
13% 14% 13% 
Table 6.15: Test-treatment RCTs using subgroup measurements for primary analysis. 
 * calculated as a proportion of the numbers analysed, if different from the numbers 
randomised. This is done in order to differentiate from other reasons for exclusion from 
analysis. 
 † This trial had two subgroup primary outcomes, which if measured together would have 
constituted an appropriate full analysis. 
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a result of undergoing testing after failure of treatment is observed (experimental 13/77, 
control 31/77; OR=0.3 [95%CI: 0.14–0.64]). 
A third trial used two subgroup outcomes to capture differences in the primary study aim: 
the appropriateness of decision–making(T32). Evaluating the addition of single-photon 
emission CT to standard care for the management of suspected acute cardiac ischaemia 
in an emergency setting, patients with a study diagnosis of ischaemia were admitted, 
whilst those in whom ischaemia was ruled out could be discharged. The appropriateness 
of these decisions were measured by independent reassessment of all participants; 
discharged patients were considered incorrectly managed if independently diagnosed as 
having ischaemia, while hospitalised patients were inappropriately managed if found to be 
free of the target condition on independent examination testing. Although these two 
outcomes are complementary and so could have been combined to be analysed as a full–
group outcome, they were kept separate and so open the results to selection bias. 
Whether the results really are biased could be examined by checking for baseline 
imbalances within each subgroup, though unfortunately the authors did not do so. 
Consi s tency o f  out com e measurem ent   
The large majority of trials used appropriate methods (87/103, 84%), either clearly using 
the same method across all study arms (67, 65%) or assessing test performance 
outcomes for which use of different tests was appropriate (20, 19%)(Table 6.16). Nine 
additional trials provided unclear descriptions, however were considered at low risk of bias 
since the nature of the outcome being measured suggests that ascertainment methods are 
likely to be the same(T4,T9,T33,T50,T56,T62,T98,T100,T104,T108). Two, for example, assessed the 
„clinical pregnancy rate‟ in women managed for infertility(T98,T104); though methods of 
assessment were not reported, women were followed–up at the same time point within 
each trial and the tests under comparison (biochemical analysis of embryos(T98) and 
hysteroscopy(T104)) could not have been used. 
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Two trials used inappropriate methods likely to have lead to bias(T10,T32), and two others 
provided unclear descriptions judged to be at high risk of bias if measurements were not 
identical(T16,T91). One trial compared the number of days patients with suspected scaphoid 
fracture were unnecessarily immobilised (also a subgroup comparison, see above) 
following investigation by „standard care‟ or with an additional wrist–MRI(T10). All patients 
were initially immobilised, and those found to have a fracture on the basis of these tests 
subsequently had the plaster removed. Attempting to compare the inappropriate treatment 
rate, defined as fracture–free patients who were initially immobilised, measurement of this 
outcome requires knowledge of the true disease rate (fracture). However the disease rate 
was determined by two different testing strategies, and so the resulting rates are not 
comparable. In order to achieve true comparability, the same test would have to be used 
to determine the true disease rate, as was accomplished in the four other trials that also 
assessed the appropriateness of treatment decisions(T17,T32,T60,T102). A cardiovascular trial 
comparing rates of venous thromboembolism following management for suspected 
pulmonary embolism provides an example of unclear reporting at high risk of bias(T91). 
Patients were randomised to computed tomography pulmonary angiography or V/Q scan 
Consistency  No. of trials (%) 
Consistent 67 (65) 
Inconsistent 2 (2) 
Unclear – low risk of difference 9 (9) 
Unclear – high risk of difference 2 (2) 
Not relevant – test performance measure 20 (19) 
Primary outcome not defined 6 (6) 
Total *103 
 
Table 6.16: Consistency of outcome measurement across trial arms.  
 * 4 trials with multiple outcomes fell into more than one category: Unclear–low risk 
(Health perception) and Yes (Function, Psychological morbidity, Quality of life, 
Satisfaction, Symptom rate)
(T4)
; Yes (Recurrence rate) and No (Recurrence rate)
(T30)
; Yes 
(Clinical status) and Test performance (Diagnostic yield)
(T93)
; Unclear–low risk (length of 
stay) and Yes (Cost)
(T100)
. 
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for confirmation of the suspected diagnosis, but at post–treatment follow–up the authors 
report that venous thromboembolism was ascertained “using either CTPA [computed 
tomography pulmonary angiography] or V/Q scanning”. This statement does not make 
clear whether use of the two tests differed systematically according to study group; if it did 
then the rates of disease can be expected to differ as a consequence of different accuracy, 
which is inappropriate for a downstream outcome.  
6.6.2 Completeness of outcome data 
Two thirds of trials (59/103) analysed fewer patients than were randomised due to the 
exclusion of participants after randomisation and/or missing outcome data (Table 6.17). 
Seventy–six percent of trials (78/103) explicitly reported whether exclusions and missing 
data had occurred, with 35% (27/78) of these claiming their analyses to be complete. 
Trials that did not explicitly report these details were more likely to appear complete 
(14/25, 56%), raising the possibility that real losses may have occurred but were not 
reported. In three trials poor reporting precluded an assessment of whether the analysis 
was complete(T49–50,T86). 
Exclus ion  of  par t i c i pants  a f te r  randomisat i on   
In total, 30 trials (29%) excluded participants after randomisation due to: protocol deviation 
(11)(T33,T37,T39,T46,T51,T58,T70,T85,T88,T104,T108), withdrawal of patient consent 
(10)(T6,T11,T27,T30,T68,T70,T74,T77,T88,T92,T95), subsequent re–evaluation of eligibility (7)(T1,T5,T49–
Primary analysis Reported (%) 
Not 
reported 
(%) Total (%) 
Complete 27 (35) 14 (56) 41 (40) 
Incomplete 51 (65) 8 (32) 59 (57) 
Unclear 0 (0) 3 (12) 3 (3) 
Total 78 (100) 25 (100) 103 (100) 
Table 6.17: Frequency of test-treatment RCTs with complete primary analyses. Incomplete analyses 
defined as those analysing fewer patients than were randomised 
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50,T52,T72,T86,T88), contraindications to receiving the allocated test (3)(T4,T39,T95), patients 
randomised twice (1)(T68), treatment refusal (1)(T90), negative or severe test results (1)(T90), 
the identification of an outlier at analysis (1)(T5) or for no specified reason (2)(T44,T51). 
Overall half the trials (53/103, 51%) documented a deviation from protocol that meant 
some participants did not receive their allocated test and/or treatment intervention, 
although only a minority (11/103) failed to analyse these participants according to their 
randomised groups (Table 6.18). A third of trials (32, 31%) did not report whether protocol 
deviations had occurred, half of which appeared to have no ensuing patient exclusions and 
the other half for whom it was impossible to establish whether either had occurred due to 
very poor reporting. 
Miss ing  outcome data  
Data were missing from primary analyses due to losses during follow–up and/or missing 
responses in 52 studies (51%), 15 (29%) of which also excluded some participants after 
randomisation. Reporting was so poor for two studies that it was impossible to determine – 
even implicitly – whether data were missing or not(T50,T86). Overall one third of trials with 
missing data (16/52) provided specific reasons for all missing responses in each 
comparative arm (Table 6.19), and 21% (11/52) provided no descriptions whatsoever. The 
majority (48%, 25/52) provided partial accounts that were insufficient to determine whether 
Deviations from randomised allocation No. of trials  (%) 
Protocol deviations excluded 11 (11) 
Protocol deviations included 42 (41) 
Stated no protocol deviations  18 (17) 
Implied no protocol deviations 16 (16) 
Unclear 16 (16) 
Total 103 (100) 
Table 6.18: Procedures for handling participants who did not received the allocated intervention.  
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reasons for missing data might be associated with the test–treat strategy, studies for 
example stated simply that patients were „lost to follow–up‟ (T3,T39,T49,T56,T89,T91,T101) or that 
they had suffered „missing data‟ (T11,T32,T96).  
Procedures for handling missing responses were very poorly reported. Most trials failed to 
report any method and excluded all missing responses to perform a complete case 
analysis (69%, 36/52)(Table 6.20). Poor reporting of participant flow by four trials with 
missing data meant that it was unclear what their approach had been(T7,T41,T49,T82). Only 
nine trials (17%) imputed all missing values, while three others imputed partial responses 
but excluded wholly missing records(T4,T57,T99). Imputation methods were reported by 33% 
of these studies (4/12) as the last observation carried forward(T69), use of an earlier or later 
outcome response(T4), allocation of a poor outcome(T57) and censoring(T99). Six trials 
implicitly allocated a poor outcome by including participants with a missing response in the 
denominator but not the numerator. The method could not be discerned in the remaining 
two studies(T10,T76). No trials reported using multiple imputation methods. 
When the quality of reporting was examined against approaches used to deal with missing 
data, over half the trials (29/52, 56%) presented inadequate accounts of methods that 
could potentially create bias if mishandled; namely those that excluded participants, or that 
were unclear regarding whether exclusions had occurred, and failed to fully report the 
causes of data loss for each comparative strategy (Table 6.21). 
Reasons for missing outcome data No. of trials (%) 
Full reasons reported 16 (31) 
Partial reasons reported 25 (48) 
No reasons provided 11 (21) 
Total 52 (100) 
Table 6.19: Quality and frequency of reporting the reasons for missing outcome data 
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6.6.3 Quantification of incomplete analyses & differential loss 
In addition to the three poorly–reported trials where the reviewer was unable to ascertain 
whether analyses were complete, the missing proportion could not be quantified in four 
trials that report exclusions but failed to report the numbers randomised(T7,T82) and/or 
analysed for each arm(T41,T64). In total, therefore, 55 trials (53%) excluded between 
0.1%(T62,T32) and 46%(T60) of randomised participants from primary analyses (median: 7.0%, 
IQR: 1.4%-17.6%), while 24% of all included studies (25/103) excluded more than 10% of 
the original study population (Table 6.22). 
Reasons for 
missing outcome 
data: 
Missing data: 
Total no. 
of trials 
(%) 
Included (%) *Excluded (%) †Unclear (%) 
Fully reported 2 (22) 14 (36) 0 (0) 16 (31) 
Part reported 6 (67) 19 (49) 0 (0) 25 (48) 
Not reported 1 (11) 6 (15) 4 (100) 11 (21) 
Total 9 (100) 39 (100) 4 (100) 52 (100) 
Table 6.21: Reporting quality cross–tabulated with method used to deal with missing data. 
 * studies presenting a mixed approach (including some missing data, but excluding other 
missing data) are considered to have excluded overall. 
 † denotes that the trial’s method to manage missing data (i.e. to include or exclude) was 
unclear. 
 
Missing outcome data No. of trials  (%) 
Stated none missing 33 (32) 
Appeared to have none missing 15 (15) 
Unclear whether data missing 3 (3) 
Excluded all missing 36 (35) 
Imputed some missing 3 (3) 
Imputed all missing 9 (9) 
Unclear whether missing data imputed 4 (4) 
Total 103 (100) 
Table 6.20: Procedures for handling missing outcome data. 
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Participant analysis ITT (%) No ITT (%) 
ITT not 
reported 
(%) Total (%) 
Analysed as randomised 41 (67) 2 (67) 16 (41) 59 (57) 
Not analysed as 
randomised 5 (8) 1 (33) 5 (13) 11 (11) 
Unclear 15 (25) 0 (0) 18 (46) 33 (32) 
Total 61 (100) 3 (100) 39 (100) 103 (100) 
Table 6.24: Trials analysing all participants as randomised compared to their reports of an intention–
to–treat analysis.  
Comparative between-arm 
attrition 
Attrition greatest in: 
No. of 
comparisons 
(%) Experimental 
arm 
Control 
arm 
Equal 
within 5% 24 19 2 45 (68) 
5-9.9% 9 2 0 11 (17) 
10-19.9% 8 1 0 9 (14) 
>20% 1 0 0 1 (2) 
Total 42 22 2 66 (100) 
Table 6.23: Degree of differential attrition in trials with some attrition. Note: the denominator 
used is the number of comparisons. 
Total missing from randomised study population No. of trials % 
<1% 52 (50) 
1–10% 21 (20) 
11–20% 12 (12) 
21–30% 5 (5) 
31–40% 3 (3) 
41–50% 3 (3) 
Unclear 7 (7) 
Total 103 (100) 
Table 6.22: Quantification of the total number of participants excluded from primary analyses for 
each trial. 
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Attrition differed by more than 5% between arms in 21 comparisons made by 16 trials 
(16%)(T4,T20,T27,T34,T37,T39,T40,T46,T51,T65,T66,T88,T90,T92,T92,T94), and in almost all cases experimental 
interventions lost the most participants (Table 6.23). Attrition differed by more than 20% in 
only one trial(T27). This latter study excluded over half the randomised population, including 
70% of experimental group participants, and 17% of comparator arm participants. The trial 
sought to evaluate the clinical utility of performing diagnostic laparoscopy routinely in 
infertile women before intrauterine insemination, compared to standard management that 
performs laparoscopy to detect tubal abnormalities only after a first phase of insemination 
has failed. Acknowledging that in excess of 1000 women would be required to 
demonstrate an impact to the clinically important outcome (pregnancy rate), a process 
measure of diagnostic yield was selected in which the rate of abnormal laparoscopies 
leading to a therapeutic intervention was used as the primary measure of effectiveness. 
However, in the primary analysis trialists excluded all women who failed to receive a 
laparoscopy, a perplexing approach which is at odds with the nature of the comparator 
intervention that did not require testing unless treatment had previously failed. Thus all 
participants who became pregnant during intrauterine insemination treatment were 
excluded from the effectiveness measurement. It is clear that data were not missing at 
random from this study, but being „missing‟ was in fact directly linked to a prognostic 
variable: since excluded individuals might also be expected to have fewer tubal 
abnormalities, the trial‟s results are very likely biased. 
6.6.4 Conduct of an intention–to–treat analysis 
An intention-to-treat analysis was reportedly conducted by 61 trials (59%), 3% (n=3) 
reported that they had not performed one, while the remaining 38% (n=39) did not report 
the type of analysis conducted. Two–thirds of studies (41/61) describing an intention–to–
treat analysis complied with the principle of analysing randomised participants in their 
assigned groups (Table 6.24). Half of these (21/41) also had no missing data or imputed
  
Chapter 6: Results – type II error 188 
missing data, and so comply with the most rigorous definition of intention–to–treat 
analysis123. 
6.7 Results: Do trials adequately control for 
type II error? 
 
Test-treatment trials are likely to require substantially larger study populations, hence they 
risk being underpowered to detect patient health effects, while it may not be feasible to 
recruit the necessary number of patients in adequately powered trials. The final aim 
therefore assessed the size of study populations, whether power calculations were used to 
estimate numbers needed, and how often target sample sizes were reached (summary 
data provided in Appendix E.2, p.418).  
6.7.1 Use of power calculations 
Eighty-one trials (79%) reported an a priori justification of sample size, including all 6 
cluster RCTS. One study offered a post hoc computation of power(T4), while the remaining 
21 trials provided no justification(T1–2,T7,T13,T20,T28–29,T31,T35,T37,T41,T54,T59,T76,T79,T82–83,T87,T90,T104–
105). These trials were also less likely to define primary endpoints (16/22, 27%) than trials 
with adequate reporting of sample size (81/81, 100%), severely compromising the utility of 
their results.  
The outcome parameter used in power calculations was reported by all but two of the 81 
trials (79/81, 98%)(T18,T89). Twelve trials (15%) did not report any primary study endpoints 
other than those used in the power calculation, precluding further appraisal. Fifty-four 
studies (67%) correctly used the primary study outcome as a basis for sample size 
estimates, while six (7%) powered on a single variable when the study evaluated multiple 
primary outcomes(T26,T39,T55,T93,T100,T107). The power variable did not match the primary 
outcome in one trial(T70), although the trialists had consciously done so in order to increase 
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the study‟s power to detect differences in secondary patient outcomes whilst keeping 
resource use (cost) as the main study aim.  
6.7.2 Attainment of target sample size 
Overall, achieved sample sizes ranged from 20(T87) to 5341(T67) participants in individually–
randomised trials (median: 305, IQR: 152–740), and 145(T66) to 972(T48) participants in 
cluster RCTs (median: 577, IQR: 364–760). On average (median) 166 participants were 
recruited to each intervention arm across all trials (n=96, IQR: 72–297)(Table 6.25). Trials 
reporting power calculations had considerably larger study samples (median: 408, 
IQR:157–782) than those omitting such description (median: 212, IQR: 108–304), 
suggesting that reporting may be a good surrogate for rigorous a priori methodological 
planning. Trials using patient primary outcomes had slightly larger median study samples 
(median: 348, IQR: 163–772) compared to those using process outcomes (median 247, 
IQR: 138–500).  
Of the 79 trials in which a comparison between target and achieved sample sizes could be 
made (two did not provide power calculation results(T26,T32)), 41 (52%) achieved 95–105% 
of the estimated target, 25 (32%) achieved >105% and 13 (16%) failed to reach within 5% 
of their target (Figure 6.3). Seven studies exceeded their targets by more than 
20%(T5,T10,T12,T46,T75,T77,T94), and three of these by more than 100%(T5,T10,T77), although in no 
report were the reasons for such over–recruitment documented or rationalised. 
Achieved sample  
size 
2-arm 
trials  
(IQR) 
>2-arm 
trials  
(IQR) Cluster (IQR) 
All 
trials  
(IQR) 
Median per trial 301 148-615 383 219-851 577 364-760 309 153-731 
(n=87) 
 
(n=10) 
 
(n=6) 
 
(n=103) 
 
Median per study 
arm per trial 
152 72-314 124 65-220 227 148-250 166 72-297 
(n=83)  (n=8)  (n=5)  (n=96)  
Table 6.25: median achieved sample sizes of test-treatment RCTs. 25
th
 and 75
th
 quartiles used. 
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Conversely, 11 trials failed to reach 75% of their estimated 
targets(T17,T38,T40,T42,T53,T63,T67,T73,T74,T103,T108), including four that recruited less than 50% of the 
required participants(T38,T42,T63,T73). Of the trials with a ≥5% deficit, four (31%) were stopped 
early as routine practice had evolved during the study period to incorporate the 
experimental strategy(T40,T42), or because interim examination exposed a very low outcome 
rate(T63) or a very high outcome rate(T67). None of these provided details of any stopping 
rules. Another five (38%) reported difficulties in recruiting the desired numbers(T30,T38,T53,T74), 
while three provided no explanation for their failure to recruit the intended 
numbers(T15,T103,T108).  
In total five studies reported modifying their initial power calculations, four revising down 
due to a higher than hypothesised disease prevalence in the study population(T91), a lower 
than expected primary outcome rate(T103), updated observational data(T15), or due to 
difficulties in recruiting(T36), while the fifth produced a higher estimate on the basis that 
disease prevalence was lower than expected(T3).      
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Figure 6.3: Distribution of achieved sample sizes as a proportion of the target sample size in RCTs 
providing power calculations and sample size estimates (n=79) 
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6.8 Discussion 
 
This chapter has assessed the adequacy of methods and reporting quality of a cohort of 
103 test-treatment RCTs. Its overall aim was to establish the extent to which these 
complex intervention trials are susceptible to the particular methodological challenges that 
have been hypothesised to affect them. To answer this charge, the review‟s key findings 
are now discussed by contrasting and comparing them to those observed for the quality of 
standard treatment RCTs and complex interventions trials. 
Tr ia l  conduct  w as  poor l y  r epor ted  
As found in chapters 4 and 5 test-treatment RCTs were generally poorly reported, this time 
with regard to the methods used to ensure internal validity. At times these accounts 
inaccurately represented actual conduct, reflecting the experiences of previous 
researchers reviewing the quality of standard treatment RCTs118,152. Fewer than half of all 
trials provided the methods used to conceal allocation or whether blinding had been 
conducted. A quarter failed to include a power calculation, or to provide the information 
necessary to establish the completeness of the primary analysis, while slightly fewer 
reported methods used to randomise participants or whether an intention–to–treat analysis 
had been carried out.  
It is clear that this level of reporting can neither sustain a proper appraisal of 
methodological quality, nor can it support an independent verification of the effectiveness 
of test–treatment strategies through the interpretation of a trial‟s results. Such sub–optimal 
reporting raises the concern of overestimated treatment effects as well as potentially 
spurious findings, which have been associated with poor reporting97,106–108.   
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6.8.1 Trials often fail to protect against selection bias 
Sequence generation and allocation concealment are not influenced by the clinical setting, 
and so should have been performed adequately in all included RCTs. This was not the 
case; approximately 40% provided inadequate or unclear methods of randomisation, while 
2 in 3 trials presented inadequate or unclear concealment of allocation. This finding, 
particularly the low rate of adequate concealment, raises the concern that many trials have 
failed to protect adequately against selection bias. Since an open allocation process allows 
clinicians the opportunity to select which diagnostic strategy to use in each participant, this 
approach risks falsely underestimating test–treat effects if the experimental technology is 
preferred for more challenging cases who are destined for poorer health outcomes. Of 
course, the direction of bias will vary according to the nature of clinicians‟ preconceptions 
regarding the efficacy of competing tests. 
These rates are generally better than those found in cohorts of general RCTs. In the 
largest study, a meta–analysis of seven meta–epidemiological reviews found 23% of trials 
to have adequate allocation concealment108, while in two more recent populations rates of 
56%117 and 28%104 were reported. Adequate methods of randomising allocation also 
appear less frequently in other populations, ranging between 24%104 and 43%100 in 
individual meta–analyses but reported as only 25% in the large meta–epidemiological 
study108. Test-treatment RCTs also performed better than trials of surgical interventions, 
which randomised adequately in 41% and concealed adequately in 25%239, and non–
pharmaceutical RCTs, performing adequately in 54% and 18% respectively240. Seen within 
the context of common suboptimal performance across clinical disciplines and intervention 
types, these inadequacies in evaluation are not related to test-treatment interventions. 
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6.8.2 Trials very rarely control for performance bias and 
ascertainment bias 
Bl ind ing  is  r are  i n  tes t - t r ea tm ent  RCTs   
Using reporting as a proxy for methods, blinding was conducted by very few test-treatment 
trials. Patients were masked in 5% and care–providers in 4% of included trials. Assuming 
that the lack of blinding exerts the same influence on test–treatment effects as general 
cohorts of trials, these findings indicate that approximately 95% of test-treatment trials risk 
producing results that are distorted by performance bias. Blinded outcome assessments 
were considerably more frequent, though still only implemented by one in five test-
treatment trials. What is more, subjective outcomes were less frequently masked than 
objective outcomes; since existing meta–epidemiological evidence strongly suggests that 
subjective treatment effects are the most strongly distorted in open trials, one can infer that 
at least 30% of the test-treatment trials examined in this review (32/103) are at high risk of 
ascertainment bias. 
This picture is very similar to that produced for other complex intervention RCTs. A review 
of 158 surgical intervention RCTs found masking of patients in 8%, care–providers in 0, 
and outcome assessors in 17% of trials239, highly comparable to the rates observed in the 
current review. Boutron and colleagues directly compared frequencies of blinding in RCTs 
evaluating pharmaceutical interventions and non–pharmaceutical interventions for the 
treatment of hip or knee osteoarthritis243. They also found that blinding was significantly 
less frequent in non–pharmaceutical trials with patients, care–providers and outcome 
assessors blinded in 24%, 6% and 36% of these studies compared to 97%, 82% and 98% 
of drug trials243.  
Comparison to reviews of general cohorts of trials is more difficult. Most reviews appraise 
the frequency of „double–blinding‟, and so rarely provide insights into the frequencies with 
which each of the three separate constituent partakers of trials are masked. Moreover, 
  
Chapter 6: Discussion 194 
definitions of „double–blinding‟ vary widely both with regard to the meaning ascribed by 
reviewers108, and to that originally intended by trialists. Chan and colleagues152 for 
example encountered nine variations in the recipients of blinding by trials describing 
themselves as „double–blind‟. A recent study that combined seven meta–epidemiological 
reviews of methodological quality reported double–blinding to have been conducted by 
56% (590/1057) of their cohort of RCTs, which consisted mostly of pharmacological 
trials108. Taking the most common definition of double–blinding used, that ≥2 of either 
patients, care–providers or outcome assessors should be blind, this frequency is far higher 
than that observed in the current review, where only 5% of test-treatment RCTs (5/103) 
blinded at least two categories of individual. In fact, only 24% (25/103) could be described 
as „single–blind‟, namely blinding either patients or care–providers or outcome assessors. 
Within the context of existing research, this review confirms that blinding is far rarer in test-
treatment RCTs than single intervention treatment trials. 
6.8.3 Blinding is not always feasible in test-treatment trials 
Scarcity of attempts to blind are almost certainly a reflection of the practical and ethical 
difficulties involved in performing sham diagnostic procedures, or indeed in masking real 
test results from patients and their clinicians. This is supported by the results of the 
feasibility analysis, which confirms existing suspicions that blinding is frequently impossible 
in test-treatment RCTs. Only half the trial settings were amenable to blinding participants, 
around one in ten could accommodate care–provider blinding, and two–thirds could have 
masked the primary outcome assessment. These proportions broadly equate with the 
findings of a similar review, which concluded that blinding in RCTs of complex therapies 
for osteoarthritis was possible for patients in 52% of trials, care–providers in 14% and 
outcome assessors in 50%243. This similarity stems from the nature of interventions 
examined by the two reviews: complex therapies for osteoarthritis, as well as test–treat 
strategies, are commonly performed by care–providers, can be invasive, and are typified 
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by active patient participation. As found by Boutron243, these features create difficulties in 
ensuring that the interventions being compared are indistinguishable to both patients and 
their physicians.  
Bar r ie r s  to  b l ind ing  pat ients  and c l in i c ians   
Feasibility was found to hinge on an interplay between four features of the study setting, 
characterised in chapter 4 (p. 92–106): the types of tests being compared, circumstances 
surrounding administration of tests, the type of test comparison and the study question. 
Though it is tempting to categorise feasibility according to these features, the complexity of 
these trials was such that it is not possible to derive simple „rules‟ of feasibility; rather the 
author found that it was more commonly the balance of differences and similarities 
between study settings that determined when blinding might be possible. Table 6.26 
summarises study characteristics that appeared more or less conducive to blinding. 
In order for patients to be masked successfully, they must remain unaware of which test is 
being used to direct their treatment decisions until follow–up is complete. To achieve this 
participants must either receive all testing strategies, or receive a convincing „sham‟ for the 
test that they were not allocated to. As illustrated in table 6.26, similarities in the physical 
characteristics of comparative tests were key to blinding patients, in particular the risks of 
procedural morbidity and mode of administration. 
Patients could most easily be masked when comparative tests were not invasive, thus 
allowing them to be administered safely as real or sham procedures to all patients, as 
occurred in all four trials that did blind. On the other hand, invasive tests could 
accommodate patient blinding in certain settings, for example if the competing techniques 
involved the same method of administration, were conducted in the absence of the patient 
(such as biochemical testing of samples) or under general anaesthetic. The comparison of 
white-light with blue-light cystoscopy for the visualisation of bladder tumours serves as a 
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Patient Clinician 
F
e
a
s
ib
le
 
Comparative tests have no/minor associated 
direct harms and the same physical 
characteristics, or route of administration that 
could easily accommodate shamming or can 
ethically be given to all study participants e.g. 
white light cystoscopy vs. white light + 
fluorescence cystoscopy conducted 
during same procedure for detection of 
bladder cancer (T90) 
Simple comparisons where all tests are 
interpreted by non-treating physicians in a 
manner conducive to production of 
standardised reports, e.g. 
stress test vs. cardiac troponin-I to rule 
out myocardial infarction (T106) 
D
if
fi
c
u
lt
 
Comparative tests differ in physical 
characteristics but are not associated with 
significant harms, e.g. 
 
addition of partogram to clinical notes, 
where both are left at the bedside (T81) 
 
Non-invasive ultrasound for investigation 
of peripheral artery disease vs. contrast-
enhanced MR angiography that requires 
contrast injection (T70) 
Tests that produce similar results amenable to 
standardisation, usually conducted by treating 
clinicians but ethical for non-treating physician 
to conduct, e.g. 
Endotracheal aspiration with non–
quantitative culture vs. Broncho–
alveolar lavage with quantitative 
culture to identify organisms causing 
infection (T62) 
Complex comparisons, such as >2 study arms 
and/or triage trials comparing tests otherwise 
amenable to blinding, e.g. 
 
Prompt endoscopy vs. medical treatment 
± endoscopy vs. carbon urea test ± 
endoscopy for management of 
dyspepsia, where endoscopy is the 
accepted gold standard (T65) 
 
Tests very different but at least one is 
conducted under anaesthesia, e.g. 
 
Empirical therapy vs. gastroendoscopy 
for detection and treatment of H.pylori 
(T105) 
 
Table 6.26: Characterising the feasibility of blinding patients and clinicians to test use (continued 
across page). 
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Patient Clinician 
Im
p
o
ss
ib
le
 
At least one diagnostic strategy carries risks of 
significant harm that are too different from 
comparative strategies to accommodate 
ethical blinding, e.g. 
comparison of non-invasive 13-Carbon 
urea breath test and invasive 
gastroendoscopy for detecting 
Helicobacter pylori infection (T44) 
conservative pharmacological 
treatment compared to invasive 
percutaneous coronary intervention or 
open heart surgery for the management 
of coronary artery disease (T6) 
Comparative tests produce different types of 
results which cannot be standardised, e.g. 
stress test vs. SPECT to detect cardiac 
ischaemia (T32) 
continuous fetal pulse oximetry vs. 
cardiotography to identify fetal 
distress (61) 
Timing of diagnostic decision-making differs 
between interventions, e.g. 
Timing of diagnostic decision-making differs 
between interventions, e.g. 
Early vs. delayed, selective hysteroscopy 
in infertile women (T73) 
Early vs. delayed, selective 
hysteroscopy in infertile women (T73) 
Patient response is an integral part of at least 
one comparative test, e.g. 
Treating clinician must administer the test, 
e.g. 
Clinical examination to detect 
postoperative morbidity (T37) 
Clinical examination to detect 
postoperative morbidity (T37) 
The comparison takes place across different 
care settings, e.g. 
The comparison takes place across different 
care settings, e.g. 
hospital inpatient investigation vs. 
emergency specialist chest pain unit 
investigation (T16) 
hospital inpatient investigation vs. 
emergency specialist chest pain unit 
investigation (T16) 
Knowledge of test results is central to the 
proposed benefit of at least one test, e.g. 
Test and treatment are conducted by the 
clinician in the same procedure, e.g. 
addition of genetic test for familial 
hypercholesterolaemia to standard lipid 
profiles to change patients' perceived 
control over disease (T51) 
two modes of endoscopy for the 
detection and treatment of 
Cholelithiasis (T9) 
 
 At least one test produces visual results used 
in subsequent treatment procedure, e.g. 
 
 duplex ultrasound used to locate 
varicose vein for subsequent removal 
(T58) 
 
 Nature of comparison is too complex to 
produce standard reports, e.g. 
 
 4-arm triage comparison of testing to 
select treatment in known coronary 
artery disease patients (T92) 
Table 6.26 cont.: Characterising the feasibility of blinding patients and clinicians to test use 
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good illustration, both tests being performed under general anaesthetic, in a virtually 
identical manner using similar equipment(T90) with the only difference in method being the 
instillation of a photodynamic dye, which could have been simulated with a placebo in 
white-light arm patients. Though more difficult to achieve, certain minimally-invasive 
imaging modalities could be given as sham procedures to conscious patients; for example 
when comparing duplex ultrasonography with contrast-enhanced MR angiography to 
determine the extent of stenosis in peripheral arterial disease, patients allocated to the 
latter could be administered placebo contrast injections as part of the sham 
angiography(T70). 
Instead, blinding was likely to be impossible due to ethical concerns when the harms 
associated with undergoing diagnostic procedures differed between arms, such as when 
comparing conventional imaging to the implantation of a loop recorder to establish the 
cause of recurrent syncope(T56). 
Certain types of tests were impossible to blind regardless of other aspects of the 
comparison, such as when patient response formed part of the test. This was often found 
to be the case with clinical examinations, for example the comparison of different formats 
for clinical consultation to assess the need for urgent referral in ED patients with 
neurological symptoms. In this trial the experimental consultation entailed video-
conferencing with real-time visualisation of the patient, while the two comparator 
approaches were based on case-conference only, and so neither sham tests nor giving all 
consultations to all patients is possible(T75). Similarly, comparing dissimilar test procedures 
– whether invasive or not – that involved patient participation would not accommodate 
blinding, as was observed in an evaluation of three modes of tilt-table testing for 
diagnosing the cause of syncope(T2). In this example each test aimed to induce syncope by 
administering assorted pharmaceutical stimulants and tilting patients for varying lengths of 
time.   
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The range of comparisons in which care–providers can be blinded appears to be more 
constrained as successful methods rely on the ability to disguise the identity of test results, 
and in order to do so it is necessary to provide them with generic results or sham results. 
Based on the examination of the 103 included trials, this solution does not appear to be 
possible in the greater majority of test-treatment comparisons since all tests across all 
study groups would need to be administered and interpreted by a third party, as 
summarised in table 6.26. Accordingly, care–providers cannot be masked in any 
comparison where at least one test must be administered by them, including clinical 
examinations(T11,T37,T57,T75) or settings where testing and treatment must be conducted in 
the same procedure, for example potentially curative 
endoscopy(T1,T9,T24,T30,T35,T73,T88,T90,T95,T104,T108). This is also true for subjective test results that 
must be interpreted directly by the treating clinician, particularly when they were used to 
guide subsequent treatment, for example using preoperative duplex US to locate and map 
pathological veins for subsequent surgical removal(T58). 
The type of diagnostic information produced by tests was equally important, and it would 
not be possible to create generic reports if the comparative tests described differing 
aspects of the target condition or provided different indicators for subsequent treatment. 
When comparing CT angiography to conventional stress testing for ruling out coronary 
artery disease as the cause of chest pain(T82) for example, stress testing allows the risk of 
stenosis to be determined while angiography would also quantify the degree of stenosis 
present, and so potentially inform the treatment approach in a different way. For similar 
reasons, comparisons of test versus no–test (T18,T34,T45,T49,T63,T71,T76,T102,T105), or comparisons 
evaluating the consequences of expedited decision-making, such as the provision of more 
rapid microbacterial identification in the management of bacterial infection(T23), both also 
preclude blinding.  
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The complexity of diagnostic strategies was a third barrier to blinding care–providers, due 
either to the sheer convolution of doing so for extensive batteries of tests(T34,T40,T42,T46,T92), 
or the impossibility of disowning diagnosticians from the decision-making needed to select 
patients for further testing or treatment in evaluations of multiple phases of decision-
making, such as the introduction of triage tests (T16,T24,T33,T36,T44,T46–47,T60,T65,T73,T82,T92,T108). The 
role of the new test in the existing pathway also appeared to impact on the viability of 
masking patients, though clearly for different reasons. Here, blinding was more often 
possible in add–on (21/28, 75%) than either replacement (27/60, 45%) or triage (5/17, 
29%) comparisons, probably due to the differences in the organisation of care that are at a 
minimum in add-on comparisons since the control intervention must be replicated in both 
arms. In fact, similarity in the organisation of care between interventions was crucial to the 
prospect of blinding both patients and care–providers. Of the four trials assessing the 
impact of new diagnostic units for the provision of specialised diagnosis and 
management(T16,T29,T48,T53), none could have masked patients or care–providers to the 
differing care settings. The use of different treating staff was often a component of these 
new programmes of care. For example, a new chest pain observation unit, situated 
adjacent to routine care in the ED, was staffed by specialist nurses who had received 
additional training in the management of acute undifferentiated chest pain and were not 
available during routine care(T48), thus necessitating a fully open trial.   
Bar r ie r s  to  b l ind ing  outcome assessor s   
The finding that it was impossible to blind outcome assessments in a third of trials is at 
odds with existing hypotheses that such blinding should always be possible22,174. The 
biggest barrier was the impossibility of masking care–providers and patients, who were 
frequently directly involved in the assessment of primary outcomes (table 6.27).  
Though common, patient–reported outcomes were particularly difficult to blind, yet these 
tend to be the most subjective and hence open to the influence of patient (or clinician) 
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expectations. When possible, the use of independent assessors or adjudication panels 
could overcome the inability to mask clinicians, yet whether this approach succeeds in 
removing ascertainment bias is tricky to evaluate. Outcome data given to blind panels may 
have been recorded by unmasked staff; when this information is based on subjective 
interpretation (say an MRI report for example), the possibility of distortion due to 
ascertainment bias theoretically remains. This raises an interesting issue: who should 
trialists be blinding to eliminate ascertainment bias in test-treatment trials? In some 
settings, such as the venous thromboembolism trials discussed earlier (p. 170), blinding 
the individual who performs the follow–up test may be key to ensuring that ascertainment 
bias has been avoided.  
Impl i ca t i ons  fo r  no t  b l ind ing  in  t es t - t r ea tm ent  RCTs  
According to the tenets of standard trial design, these findings present worrying 
implications for the validity of some test-treatment RCTs. If trials cannot blind participants, 
Outcome Type Examples 
Feasibility of blinding the outcome 
assessor 
1 Patient reported Pain, quality of life Same as blinding the patient 
2 Patient –outcome 
assessor contact 
required 
Walking speed, function Feasible if patient is blinded 
 Impossible if patient is not blinded 
3 Patient–outcome 
assessor contact not 
required 
Appearance of joint 
structure (X-ray) 
Always feasible 
4 Clinical events and 
therapeutic outcomes 
determined by 
interaction between 
patient and clinician 
Length of hospital stay, 
treatment failure 
If measured by clinician: same as blinding the 
clinician 
If measured independently: always feasible 
5 Clinical events and 
therapeutic outcomes 
assessed from data on 
medical forms 
Death, treatment 
prescription 
Feasible if relevant records do not contain 
information on diagnostic tests administered 
 Difficult if records include tests administered 
Table 6.27: Characterising the feasibility of blinding outcome assessors to test use 
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clinicians or outcome adjudicators, then little can be done in these cases to protect from 
the threats of performance and ascertainment bias. On the other hand, this review 
suggests there is considerable room for improvement. Approximately half of all trials could 
have introduced measures to blind patients and outcome assessors, and a more modest 
8% could have attempted to blind physicians. Therefore, though the methodological quality 
of existing test-treatment trials is sub–optimal, many more comparisons could control for 
performance and ascertainment bias than is currently attempted.  
This conclusion assumes that the consequences of blinding will always serve to minimise 
performance and ascertainment bias. Yet there are indications that this may not always be 
the case in trials of test-treatment interventions. 
The cohort of trials included some for which blinding patients or care–providers could have 
altered or even eliminated the desired treatment effect. This hypothesis is directly related 
to the proposed benefits of the new test-treatment strategy. For example when the value of 
the new test lays in its ability to alter how patients respond to their management, trials 
would not be able to measure this effect if participants were no longer aware of which tests 
were used to inform their future treatment. This was observed in one of the back pain trials 
where in order to measure whether the addition of MRI to standard orthopaedic 
consultations would reassure patients suffering with acute lower back pain as to the 
absence of serious disease, the investigators gave MRI to all randomised participants (T4). 
Similarly, the methodological benefits of blinding care–providers can also be uncertain, 
particularly when there is no rigid link between test results and management decisions. In 
order to mask treating clinicians we must remove their ability to interpret test results, and 
depending on the types of tests involved also to make the diagnosis, therefore blinding 
could prevent investigators from fully evaluating the test‟s impact on clinical decision–
making.  
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This suggests that blinding may play a very different role in test-treatment trial 
methodology, compared to treatment RCTs. Test-treatment interventions share 
fundamental similarities with therapeutic complex interventions, in that behavioural change 
can be integral to how test-treat strategies are expected to benefit downstream patient 
health interventions, and are not a peripheral, incidental effect245. Since test-treatment 
RCTs commonly evaluate the consequences of patient or clinician behaviour, such as the 
impact of decision-making in the face of new or earlier information, balancing the need to 
evaluate particular effects with the need to minimise performance and ascertainment bias 
is likely to pose considerable difficulties to the design of test-treatment RCTs. 
6.8.4 Trials often exclude patients & fail to protect from attrition 
bias 
The choice of outcomes used raises some concern as to the usefulness of test-treatment 
trials. Although the majority of trials analysed patient outcomes as a primary question, 56% 
of these (30/53) were surrogate measures of health, namely clinical endpoints and disease 
rates. It would seem, therefore, that when test-treatment interventions are evaluated using 
randomised trial designs they do so in the main to answer intermediate questions of 
process and short–term health impact, whose relevance to long–term health may be 
questionable246. This issue is examined further in chapters 7 and 8. 
I nappr opr i a te  compar i sons  
A small proportion of studies (9%) conducted inappropriate analyses by using subgroup 
denominators to analyse their primary measure of effect. Such comparisons are at risk of 
producing misleading results that are not full and true reflections of an intervention‟s 
effectiveness. Firstly, selecting outcomes that are targeted at a particular subgroup ignores 
the consequences of testing and treatment in patients excluded from the subgroup. 
Although one can appreciate the temptation, particularly in test-treatment evaluations 
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where the clinical need to examine the effects of the care process on individuals who have 
been misdiagnosed (false–positive or false–negative patients) is justified, these otherwise 
legitimate comparisons should remain as secondary explanatory additions to a primary 
aim that evaluates a strategy‟s impact to all randomised participants135. By looking 
primarily at the false–negative rate for example, extreme differences in negativity rates 
between the testing strategies would not capture the consequences of overtreatment. As a 
consequence, the 13 studies using such subgroups, albeit a minority of the cohort, must 
be considered to have produced partial and therefore unreliable accounts of downstream 
treatment effects. 
Secondly, subgroup analyses strongly risk providing distorted effect sizes by comparing 
two groups that are not random samples of the original study group, and so may well vary 
in important prognostic factors. Moreover, unlike treatment trials where subgroup analyses 
are generally identified using baseline characteristics247, in test-treatment trials the 
subgroups are created by different tests and so the composition of subgroups will always 
represent unequally selected populations. The impact of this selection bias was illustrated 
in at least two included trials where the author‟s recalculation of endpoints based on all 
randomised participants served to change the trial‟s primary conclusion.  
In a related issue, a small number of trials used differing methods to measure the primary 
outcome across study groups. This approach is virtually guaranteed to cause bias in test-
treatment trials; since different tests will identify different patients in each arm the outcome 
is based on a systematically different ascertainment method which could distort results. 
This issue was only encountered in between 2–4 trials, suggesting that it does not pose a 
frequent threat to the validity of published test-treatment RCTs.  
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I n t en t ion– to– t r ea t ,  m iss ing  data  and a t t r i t i on  b ias  
The majority of trials reported an intention–to–treat analysis (ITT), similar to the 
performance of other cohorts of RCTs, which have found reported rates of 48%248, and 
more recently 54%249 to 62%250. Test-treatment trials appear to perform considerably 
better than surgical trials where only a third (36%) reported an ITT analysis239. Although 
most trials appeared to adhere to the principle of analysing patients in the groups to which 
they had been assigned, most test-treatment analyses proved to be inconsistent with the 
most rigorous definition of ITT123, with only 21% also including all randomised participants. 
Previous studies have discovered similar rates of true ITT analyses in reviews of trials 
(24%248; 28%104) though a more recent analysis shows a higher rate of 39% suggesting 
practice is improving in general250. Boutron and colleagues240 found that pharmaceutical 
RCTs performed better than non–pharmaceutical RCTs in this respect (35% vs. 25%), 
which along with the present findings may indicate that full ITT analyses are more difficult 
to carry out in complex intervention trials. This may be a consequence of the practical 
difficulties involved in maintaining a proper ITT analysis, whereupon the risk of losing 
participants after randomisation is increased due to undergoing numerous interventions. 
This is somewhat substantiated by the high rates of incomplete analyses due to missing 
outcome data. The common inability to blind in these trials is also likely to have driven 
drop–out rates and missing responses, since patients dissatisfied or disillusioned with their 
diagnostic allocations may have been less motivated to comply with the trial follow–up 
protocol. This is demonstrated in at least one trial, where participants with suspected 
fractures randomised to receive an additional MRI scan to the usual X–ray were more 
likely to return their questionnaires than those who knew they had not received the new 
technology(T5). 
Over half the included trials presented incomplete analyses due to exclusions and/or 
missing responses. This is lower than the 75% of trials published in four high impact factor 
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journals during 1997 that reported an ITT analysis248, though akin to more current reviews 
finding 58% in a group of randomly selected RCTs published in 1999251 and 60% in 
general RCTs published in 2002250. A quarter of test-treatment trials excluded at least 10% 
of participants, corroborating early previous research248 though considerably higher than 
the more recent reviews that both report rates of around 10%250–251. This comparably high 
proportion is of concern, particularly since so few studies stated their strategy for handling 
missing data in their analyses.  
The most common approach, deduced implicitly from the numbers reported, was a 
complete case analysis in which protocol deviations or missing responses are excluded. 
This method is inadequate since it damages the distribution of prognostic factors ensured 
through a proper randomisation process, creating a subgroup comparison which will 
produce biased results unless participant data are missing at random252. Trials performing 
such exclusions are shown to produce larger treatment effects with smaller p–values, 
though the direction of bias is variable105. Imputation methods require assumptions of 
missing data that may be difficult to justify, introducing uncertainty around treatment 
effects and potentially themselves introducing bias to results121. Nevertheless some 
approach to include missing data is required since these are likely to be related to 
diagnosis, treatment response and other prognostic characteristics253. Sensitivity analysis 
using multiple imputation is the preferred approach as, though difficult, it allows the impact 
of several imputation strategies on the treatment effect to be quantified254. No included 
study reported that they had done this, although it is worth highlighting that these trials 
largely predate the widespread dissemination of multiple imputation methods. 
Disappointingly, most trials provided insufficient reporting of the reasons for missing data 
for the reader to determine whether the resulting subgroups were likely to differ 
systematically. A single trial openly discussed end composition, stating: “Patients who 
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were lost to follow-up were older and more severely depressed than patients with 
complete follow-up”(T66), with clear implications for the validity of its results. 
The threat to internal validity was particularly high in the 16% of trials that displayed 
attrition differing between arms by more than 5%. Experimental interventions were more 
likely to lose higher proportions of participants and, given that these patients were 
probably the least likely to respond positively to treatment, this finding would indicate that 
attrition bias may have served to favour the new strategies in these studies. Although 
serious threats to internal validity were only found in one trial, with a differential attrition of 
over 20%, the commonplace nature of nonetheless significant attrition in test-treatment 
RCTs attests to a poor general level of methodological quality and hence questionable 
validity of trial results. Unfortunately the author could find no published data on differential 
attrition rates in general cohorts of RCTs with which to compare this interesting finding. 
6.8.5 Trials may be chronically underpowered 
Performing a priori power calculations is a necessary aspect of methodological quality, 
since it demonstrates that the required balance between risk of type II error and sample 
size has been deliberated in advance of a trial121, and ensures that recruitment ceases in 
line with this predetermined target rather than in response to favourable interim 
analyses128. Present in almost 80% of trials, such reporting compared favourably to other 
cohorts of trials in which generally half or fewer provided power calculations118,152,240,249.  
As discussed in chapter 1 (p. 38), attaining a sufficient sample size with enough power to 
detect differences is an important consideration in test-treatment RCTs. Although it was 
outside the scope of this review to assess the adequacy of published sample size 
calculations, the median achieved sample sizes are somewhat smaller than would be 
expected for target populations expected to be so much bigger than standard RCTs. In a 
review of parallel–group RCTs (any intervention type) published during the same 
  
Chapter 6: Discussion 208 
timeframe as the present cohort (2005–6), median sample size was considerably larger at 
425 per arm (IQR: 158–1041)130 than found in the present test-treatment trials (median 
166, IQR: 72–297). Moreover, trials primarily aiming to evaluate the impact of interventions 
on patient health did not recruit significantly greater numbers than those primarily 
interested in process outcomes. Although rather a crude interpretation, these preliminary 
findings may suggest that test-treatment RCTs are chronically underpowered to detect 
clinically important differences in downstream health effects.  
This study also reveals that test-treatment RCTs were found to suffer from practical 
difficulties in achieving target sample sizes, and several trials reported considerable 
problems in recruiting sufficient numbers, or completing recruitment before the 
experimental practice became routine. That over 10% of included RCTs failed to recruit at 
least 95% of the target number of participants provides further indication that these studies 
are likely to suffer from a heightened risk of type II errors. 
6.8.6 Study limitations 
Due to time constraints, several interesting and important aspects of test-treatment trial 
validity unfortunately remain unexplored. For example, the review did not trace protocols in 
order to appraise selective outcome reporting, which is empirically demonstrated to be 
associated with overestimations of treatment effect since unpublished outcomes are less 
likely to be statistically significant findings152. 
Perhaps the most important omission of this study was its failure to directly address 
hypotheses that test-treatment trials are at increased risk of type II errors. Though the 
seemingly small sample sizes suggest included trials were underpowered to detect 
differences in downstream health outcomes, this cannot be confirmed without re–
estimating power calculations using the suggested inflation factor176 to adjust for the 
unreclassified fraction. The difficulties encountered by the author upon initial attempts to 
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find parameter estimates for one study prohibited this more comprehensive approach, and 
so it must be left to future studies to verify this hypothesis rigorously. However, this 
obstacle may also suggest that performing power calculations may be particularly 
challenging for trials of test-treatment interventions, where empirical evidence of diagnostic 
efficacy is less likely to exist than the evidence required to estimate power for trials of 
pharmaceutical treatments. 
As discussed in the limitations to the review of reporting quality (p. 142), although the 
project cohort does not contain all relevant test-treatment RCTs published from 2004–
2007, it is arguably unlikely that their examination would drastically change this review‟s 
conclusions. Even if missed trials were of better quality than encountered in this cohort, 
this would not invalidate the considerable difficulties in achieving the rigorous 
methodological standards that were observed in many included trials. 
The quality of reporting trial methods, and by association methodological quality, have 
improved over the last 15 years118,153 so it is possible that trials published since 2007 are of 
better quality. However if this is the case it is only likely to apply to items found to be 
equivalently achievable in test-treatment and general RCTs, since methods to address 
those that may require different or more exerted efforts for test-treatment evaluations have 
not yet been disseminated.  
Most of the existing studies used for comparative discussion, other than those specifically 
selected to observe the quality of complex interventions, did not select trials for review on 
the basis of the types of intervention evaluated. Consequently complex intervention trials 
did form part of these cohorts, though always constituted a small minority. The comparison 
between such „general‟ cohorts and purely complex intervention cohorts is thus likely to 
remain accurate and valid. 
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Variations in the criteria used by previous reviews to appraise the adequacy of reporting 
and methods mean that not all reviews may be entirely comparable to the current dataset. 
Somewhat paradoxically, these reviews commonly fail to define their appraisal criteria 
explicitly, thus limiting a proper judgement of whether their results are consistent with 
those of others255. In order to limit an unfair comparison, the methods used to appraise 
reporting and quality in the current review were chosen to reflect the highest standard of 
methodological appraisal as recommended by leading groups of methodologists121,123. 
Efforts were also made to compare findings against reviews using these methods, 
however this was not always guaranteed for reviews of complex interventions. 
Consequently, the rigour with which current methods were applied may have reduced the 
apparent performance of test-treatment RCTs if compared to more leniently appraised 
cohorts of trials. Albeit the case, the precise methods used have been detailed to allow 
future researchers the independent verification of this review‟s results. 
Ultimately, the review has relied on the common approach of using trial reports as a proxy 
for actual trial design and conduct, and this has been empirically shown to conceal true 
methodological quality134. Since poorly–designed trials that are reported well will reveal 
their true methodological quality, this is likely to have led to an underestimation of the 
quality of test-treatment RCTs. Nonetheless, this confounding factor affects all such 
reviews of trials, so as a comparative measure of test-treatment RCT performance this 
review‟s findings stand. Moreover, adequate reporting remains key to the „usefulness‟ of 
trials: study findings, and the methods used to produce them, are predominantly accessed 
through journal articles and so the ability to understand trial processes, interpret results 
and consider reproducing them in practice relies on the content transmitted by them.  
Finally, the subjective nature of quality appraisal would caution that the results presented 
here are proposed as tentative results in need of validation through future analyses of test-
treatment trial cohorts. The high levels of interobserver agreement for adequacy of
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randomisation methods and blinding status do suggest the results are reliable. However, 
not all methods were subjected to this analysis. Assessing the feasibility of blinding was a 
particularly subjective exercise, at times impeded by poor reporting of trial conduct, and so 
could have been influenced by the author‟s preliminary hypothesis derived from the 
literature that blinding is difficult to achieve in test-treatment RCTs. It would be interesting 
to explore the degree of agreement in these judgements by comparison to a second 
independent assessor. Moreover, the present author‟s clinical inexperience cannot 
preclude the possibility that certain assessments may have been misjudged. While efforts 
were made to research the clinical practices encountered, the relevance of findings and 
conclusions drawn must be evaluated by the physicians for whom test-treatment RCTs 
have been designed. 
6.9 Conclusions 
 
To conclude, this review finds a clear need for improvement in the methods used to 
conduct test-treatment RCTs. Several weaknesses in design were observed that, by 
reference to the findings of methodological quality meta–reviews, suggest this cohort of 
trials are at risk of several types of bias. The widespread exclusion of noncompliant cases 
and inappropriate use of subgroups may have produced misleading trial results since there 
is no guarantee that a like–for–like comparison is being made. In particular, the rarity of 
blinding – in particular outcome assessors – suggests these trials are more likely to be 
measuring the expectations of trialists and preconceived notions of participants than the 
true effects of test–treatment strategies. Meanwhile other limitations, including inadequate 
randomisation and concealment procedures, may have caused trials to create study 
groups that were systematically different at the outset and thus also produce biased 
results.  
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These failings are partly explained by the suboptimal standards of methodological quality 
generally found in all RCTs97,107. However, the differential performance of particular 
methodological items when compared to standard, non–complex intervention trials does 
appear to confirm that certain methodological problems are more prominent in test-
treatment trials. Specifically: 
1. While the number of RCTs presenting incomplete analyses was equivalent to 
frequencies reported by reviews of treatment RCTs, test-treatment trials tended to 
have higher proportions of missing data. 
2. A seemingly high proportion of trials (16%) presented with attrition that differed 
between arms by more than 5%. 
3. Despite theoretically needing considerably higher sample sizes, test-treatment 
trials had far smaller study populations than trials of treatments, suggesting they 
may be chronically underpowered. 
4. Blinding patients and care–providers was far more rarely conducted, and generally 
impossible to perform. Contrary to expectations, blinding outcome assessors was 
also not always feasible. 
The following chapter completes the analysis of these trials by examining the extent to 
which they fully evaluate test-treatment interventions. 
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Understanding how diagnostic tests influence patient health is a matter of significant 
relevance to trial design and interpretation, yet the relationship between the two is 
fundamentally indirect and complex. This paper develops a theoretical framework that sets 
out the common mechanisms by which tests can change patient outcomes. It builds on 
existing thought by adding new mechanisms identified through an analysis of how test-
treatment interventions have been observed to impact on patients. The framework is 
tested, refined and explained using the project cohort of published test–treatment RCTs, 
identified in Chapter 2.  
7.1 Introduction 
 
The reviews of reporting quality (chapter 5) and methodological quality (Chapter 6) 
concluded that insufficient documentation of test-treatment interventions, including 
decision–making, is a key impediment to the utility of trial reports, since it hinders the 
interpretation of results by concealing what is being evaluated. Another vital requirement 
for useful trials is the selection of endpoint measurements that will capture all the intended 
effects of an intervention; this is hypothesised to be particularly challenging for test-
treatment comparisons where tests are indirectly related to patient health. 
In order to evaluate this contention, the ideal analysis should appraise the appropriateness 
of outcome selection in included trials. Performing a reliable judgement would require 
extensive clinical expertise to be able to identify the most important outcomes for the full 
range of diagnostic settings included. Critically, the appraisal should also be made by 
reference to a solid theoretical model of how test-treatment interventions cause treatment 
effects. Yet examination of existing diagnostic research frameworks suggested such a 
standardised theory was lacking and in urgent need of development. 
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Several authors had attempted to delineate the specific contribution of testing to patient 
health, commonly expecting that changes would be driven by improvements to test 
accuracy14,19,21,49–51,77,176,193,256 or reductions in procedural harms19,45–46,48,77,193, however no 
existing study provided a complete overview of the ways in which changes to patient 
outcomes could occur as a consequence of introducing a new test. 
Upon further investigation the absence of such a conceptual model, or rather the under–
development of the existing theoretical perspective, was found to have been voiced as an 
important barrier to reaching a consensus on which aspects of tests should be measured, 
how they should be measured, and why13,77,187,257–259. Given that the relationship between 
testing and health outcomes is fundamentally indirect, others had described the ensuing 
difficulty in disentangling a test’s contribution to observed changes in patient outcome from 
intermediate elements of the test-treat process6,59,175,260. This principle is recognised in 
complex intervention guidance83, where the importance of developing a good theoretical 
grasp of how the use of a complex intervention may impact on patient health is considered 
essential to constructing a sound scientific rationale for the intended behaviour of the 
intervention. Without a similarly comprehensive understanding for the use of tests, it is 
impossible to evaluate whether outcomes measured in a trial capture the true effects of 
test-treatment interventions, and therefore to determine how thorough the interpretation of 
results has been. 
In order to address this important question, the author sought to develop a framework of 
thought that sets out the relationship between diagnostic tests and patient outcomes. By 
building on existing theoretical notions, its aim is to identify and explain the mechanisms 
by which a diagnostic test can contribute to changes in patient health. The new, 
comprehensive framework is presented as a graphical structure that models the test–
treatment care pathway and illustrates how its components interrelate to change different 
measures of patient health.          
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7.2 Methods 
 
The main aim of this study was to formalise and expand existing knowledge of how 
diagnostic tests can affect downstream patient health. This required an explorative and 
theory–generating approach, in which existing theoretical assumptions could be 
summarised and broadened into a comprehensive explanatory structure which specifies all 
the potential consequences of testing to patient health. In light of the limited current 
theoretical understanding, the cohort of published test-treatment RCTs (identified in 
chapter 2) were considered key to developing the explanatory structure since they might 
shed light on the diagnostic determinants of health in a variety of clinical settings. In this 
way, the theory could be grounded in empirical comparisons of diagnostic strategies in 
order to gain as accurate a representation of reality as possible. 
This approach followed the principles of analytic induction261 whereby theories are 
generated from the observation and analysis of empirical data, in contrast to the deductive 
reasoning more commonly employed in evidence–based health care where data are 
selected and interpreted using existing theory. Key to analytic induction is the role of 
‘disconfirmation’ whereby after tentative explanatory hypotheses are constructed, they are 
developed and refined by finding cases that do not entirely adhere to the new theory262. 
This is an iterative process in which theory is under constant revision whilst all available 
evidence is examined, and where the development of concepts and the relationships 
between them are primarily driven by new insights provided by the analysis of ‘deviant 
cases’263. 
The method was selected for two reasons. First, though existing research frameworks 
address the issue of how tests are linked to patient health obliquely, the notions contained 
therein are nonetheless highly relevant to such a discourse, and so it was considered 
important to use these existing principles as a foundation for developing a generalised, 
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explanatory theory. Second, the availability of 103 published test-treatment RCTs provided 
the opportunity to gain empirically–based insights into how tests have been shown to 
influence health outcomes, and so these primary studies should be used to test the 
strength of existing explanations and elaborate current thinking. 
Following these preliminary deliberations, the explanatory framework is developed in three 
steps: 
7.2.1 Theoretical premise  
The first step was to define a basic theoretical premise of how tests are connected to 
patients. With reference to discussions presented in the existing theoretical literature, the 
key clinical processes that a patient proceeds through from the point of being referred for 
testing to their response to treatment were identified. 
7.2.2 Preliminary explanatory features  
Secondly, existing research frameworks were reviewed for implicit assumptions or explicit 
mention of how these key clinical processes may be of value to downstream patient 
health. These existing notions were added to the initial premise to create a preliminary 
generic model of the diagnostic healthcare process, containing a set of factors which might 
explain differences in how patients respond to treatment.  
7.2.3 Explanatory model revision using ‘deviant cases’ 
The validity of this representation was examined by using it as a structure to interpret how 
differences in observed health outcomes had been created in test-treatment RCTs. For 
each trial competing test–treatment processes were reconstructed and used to populate 
the generic model. Focussing on patient outcomes measured by the trial, the model was 
used as a tool to consider where and how observed differences in patient health might 
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have originated, in a systematic manner. Any trial that appeared to be conceptually 
different, a ‘deviant case’, was analysed in depth. Where existing explanatory concepts 
failed to account for observed findings, the model was supplemented by new hypotheses. 
In this way, the framework was applied to each trial in order to be sure that it could explain 
all available test-treatment comparisons. This allowed the theoretical framework to be 
developed and modified through an iterative process of testing and retesting specific 
hypotheses using the cohort of published test-treatment trials, in order to produce a 
revised and comprehensive framework of thought. 
7.3 Framework development 
 
The current theoretical understanding of how tests create treatment effects is derived from 
three main strands of conceptual research. Foremost in both number and the attention 
they have received are the frameworks outlining a ‘phased evaluation of tests’, in which an 
idealised set of evaluative stages are proposed as necessary to introduce a test into 
practice15,44–54,57. As outlined in Chapter 1 (p. 7–8) these organisational structures contain 
between four and six stages of evaluation, which tend to be arranged hierarchically on the 
premise that tests which are not efficacious at a given evaluative stage will not be capable 
of efficacy at higher and more complex phases of evaluation.  
Closely related to these is a group of more theoretical studies that primarily discuss the 
methodological basis of test evaluation, often within the context of an analytic 
infrastructure of test evaluation6–7,14,19,51,55,59,77,84,175–176,193,257–260,264–265. The now seminal 
work by Fryback and Thornbury14 is one such conceptual framework, which though 
traditionally considered as one of the founding ‘phased evaluation’ frameworks was in fact 
intended as a more general conceptual discourse seeking to draw together the study 
designs available to evaluate aspects of test performance, and the methodological issues 
presented therein57,265. A second important contribution to this group are the proceedings 
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of an international workshop77,175,193,257,259–260,265 convening diagnostic practitioners and 
methodologists in test evaluation to explore the methodological challenges involved in 
assessing the outcomes of diagnostic testing. The resulting set of papers provide a 
particular insight into the conceptual difficulties regarding how to determine which 
endpoints are necessary to demonstrate that a test is efficacious259. 
The remaining theoretical frameworks address the extent to which accuracy studies and 
simplified designs can replace direct evidence gained through RCT designs, and so are 
largely concerned with developing methods to synthesise and appraising existing 
evidence19,21,91,93,256.  
While none of the existing frameworks is specifically directed at explaining how tests 
influence patient health per se, each reveals valuable insights into the conceptual basis for 
this theory, often through assumptions authors make regarding the link between testing 
and health outcomes when discussing appropriate methods to evaluate tests.  
7.3.1 Basic premise: defining how tests are linked to patient 
outcomes 
A central premise of the current theoretical understanding is that the relationship between 
tests and measures of patient health is fundamentally indirect. Acknowledging that 
diagnostic tests are not administered in isolation, but form part of a broader clinical 
process in which a period of testing is followed by decision-making, management planning 
and treatment implementation, existing research frameworks are all inherently founded on 
the principle that tests are linked to patient outcomes by the intervening clinical processes.  
The basic relationship between tests and patients may therefore be conceived as a series 
of intermediate steps occurring between the two. Figure 7.1 depicts this relationship as an 
adaptation of a diagram presented at the 1999 international workshop by Bossuyt and 
Lijmer193, who of all reviewed frameworks most clearly delineated the process. It portrays a 
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simplified patient care pathway, in which a diagnostic test is applied to a patient in order to 
identify a condition [1], the result of the test is considered [2] along with other evidence to 
decide a diagnosis [3], from which a course of treatment is identified [4] and implemented 
[5]. Considered in this way, each step along the test–treat process becomes a component 
that could contribute to improvements in a patient’s health.  
7.3.2 Preliminary explanatory features 
The conceptual papers revealed three theories regarding how aspects of the patient care 
pathway might impact on patient outcomes. There was a general consensus that the key 
prerequisite for a new test to affect downstream patient health is its capacity to change 
diagnostic decision–making, a task achieved by providing superior accuracy6–7,14–15,19,21,44–
51,53–55,77,84,91,93,176,187,193,256–257,260,265. Furthermore, these changes should alter subsequent 
treatment decisions for a difference in health outcomes to be observed. This causal link is 
reflected in the hierarchical structure of the ‘phased test evaluation’ frameworks. Each of
Patient outcome 
Test result produced 
2 
Diagnosis made 
3 
Management decided 
4 
Treatment implemented 
5 
Patient given test 
1 
Figure 7.1: Simplified test-treat pathway showing each step in the pathway as a component of 
the patient’s management which can influence patient health: (1) Patient given test, 
(2) Test result reported, (3) Diagnosis made, (4) Management decided, (5) Treatment 
implemented.   (Adapted from Bossuyt and Lijmer 1999
193
) 
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the five care pathway components in figure 7.1 may be likened to a corresponding phase 
of test evaluation, whereby each phase produces outcomes measuring the utility of a test 
that can be likened to diagnostic attributes. As these attributes share a hierarchical 
relationship, we can posit that one will have an effect on another further up the hierarchical 
chain. 
So, at the bottom of the hierarchy lay evaluations of technical efficacy and diagnostic 
accuracy, attributes of a test that reflect its ability to produce classificatory information 
reliably (precision) and accurately (a test’s ability to identify or exclude disease compared 
to a reference standard)14,44–46. Further up the hierarchy are evaluations of ‘diagnostic 
thinking efficacy’ producing measures of diagnostic yield, defined by Fryback and 
Thornbury14 as the appraisal of how far test results influence the diagnoses patients 
receive. Patient management decisions are conceived as separate decision–making 
events since tests that succeed in changing diagnostic thinking may not always affect 
therapeutic management. Thus a test’s ‘therapeutic efficacy’ must be assessed separately 
by measuring therapeutic yield14,44–46. At the summit of most of these frameworks lays the 
evaluation of patient outcomes, variously referred to as ‘clinical outcome efficacy’ or 
‘patient outcome efficacy’, the patient’s health. Here the impact on patient outcome is 
described as the composite effect of all above elements45–46,49–50,176,193,256. 
A second common assertion was the direct impact that tests can have on patient 
health6,19,21,45–46,48,77,84,93,176,187,193. Conceived in the main as procedural harms, tests were 
noted to influence immediate health outcomes regardless of whether subsequent test 
results correctly identify patients with or without disease.  
Thirdly, several authors drew attention to the potential for test results to reassure or cause 
anxiety to patients, or otherwise affect their perceptions of health and disease19,48,175,193,265. 
These values of testing are seen to lay outside the tiered efficacy model and are defined 
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as ‘non–decisional’ attributes, set apart from the effects of guiding more appropriate 
therapy through better diagnostic accuracy14,175. These concepts are explored 
comprehensively by Bossuyt and McCaffery264 who delineate the cognitive, emotional and 
behavioural changes that can occur both directly, and through a patient’s knowledge of 
test results (Figure 7.2). Their model incorporates the understanding that both the test 
procedure and the information it produces can affect patient outcomes in a way that is 
mediated through a patient’s cognitive facilities, influencing emotional responses, 
treatment compliance and perceptions of self and health state. Guyatt and colleagues 
noted that these effects were not limited to patients, but emphasise that the degree to 
which physicians are reassured by a given test, perhaps even falsely so, could influence 
the adequacy of treatment and consequently patient outcome44. 
 
Figure 7.2: Framework for conceptualising the psychological impacts of testing, designed by 
Bossuyt and McCaffery
264
. Figure reproduced with permission. 
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Pulling these concepts together, the current theoretical position conceives tests to affect 
patient health in three ways: 1) through the provision of improved decision–making, 2) by 
reducing the harmful effects or increasing the beneficial consequences of undergoing 
testing, and 3) through providing different diagnostic information that modifies a patient’s 
perception of their health state. 
7.3.3 Expanding the existing model  
In order to test the preliminary model, the first task for each trial in the cohort was to 
represent its test-treatment processes of a trial diagrammatically. Using the patient care 
pathway, the comparative tests and diagnostic and treatment decisions were mapped onto 
the diagram representing a simplified trial algorithm. The properties of each test and its 
output were positioned at the beginning of the pathway, and patient outcome added at the 
terminus. This representation then allowed the author to conceptualise which elements 
may contribute to an observed change in patient outcome effect, as described above. An 
example of a ‘deviant’ trial is worked through in Box 7.1. During this process certain 
difficulties arose as the number of contributing factors and interrelationships became more 
complex. It became necessary to think very carefully about each specific clinical and study 
setting in order to track the care pathway correctly, paying particular attention to the type 
of diagnostic comparison, the diagnostic and treatment purposes of the test(s) under 
evaluation, the target condition, patient group and care setting. In rare cases where the 
rationale for the intended impact of tests was provided, this tended to be couched in more 
ephemeral descriptions (generally found in introductory statements) regarding the 
proposed benefits of using one diagnostic strategy as opposed to another.  
No cases were found to disconfirm the relevance of any previously identified attributes. 
However this process proved very fruitful for the expansion of the framework, in that it 
identified additional diagnostic attributes that might drive changes or otherwise facilitate 
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Box 7.1: Worked example of a deviant trial: Antibiotic selection patterns in acutely febrile 
new outpatients with or without immediate testing for C–reactive protein and 
leucocyte count (T7) 
Patient Group: Outpatients with acute febrile condition (clinically relevant fever of >37.5˚C) suspected 
of having an infection 
Test Comparison: Clinical consultation with immediate C–Reactive Protein (CRP) response and white 
blood cell count (WBC) results versus clinical consultation only 
Comparison Type: Additional 
Diagnostic question: Does the patient have an infection, and if so is it bacterial or non–bacterial? 
This trial was conducted to evaluate whether the immediate availability of two biochemical tests (CRP and 
WBC) at the time of initial clinical consultation would improve the management of patients presenting with a 
possible infection. Patients randomised to the control arm received a consultation in which clinicians did not 
have recourse to biochemical test results, however clinicians were free to order these tests whereupon 
results would be available at a later consultation. 
The primary outcome was not defined clearly, but was extracted as the proportion receiving antibiotic 
treatment which corresponded with the study aim reported in the article’s introduction. The aim of this 
exercise was to determine how tests impact on health, hence the patient outcome measured by trialists is 
used here: the number of febrile days. The figure below illustrates the reconstructed patient care–pathway 
for the trial. The process of elucidating how the addition of immediate biochemical testing could influence 
the number of febrile days began by considering whether existing factors could be responsible, after which 
the author conceptualised whether previously unidentified factors could also cause any differences. This 
rationale is now explained.  
How could differences in the duration of fever be created? 
Direct test effects are not relevant in this comparison, since neither of the testing strategies is invasive. The 
availability of additional information could possibly alter the dynamic of the initial consultation and thus 
influence the patients’ perception of their health state, although in this setting it is unlikely that this factor 
could change the duration of fever. This outcome is a measure of patient recovery, and so is likely to be 
influenced predominantly by the administration of appropriate treatment. Since the new strategy provides 
the clinician with additional information, which according to the authors has been shown to differentiate 
accurately between bacterial and non–bacterial origins of infection, one could expect it to improve patient 
recovery by allowing more patients to be diagnosed accurately, more of whom would then receive 
appropriate treatment (red arrows). Diagnostic uncertainty is also important here, and as the biochemical 
tests are familiar the new strategy is expected to maximise appropriate decision–making by improving  
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Box 7.1 continued 
 
 Comparative patient care pathways mapped onto the preliminary model. CRP – C–reactive protein 
response; WBC – White blood cell count; Dx – diagnosis; Rx– treatment. 
confidence that the true aetiology of infection has been found.  
Looking at the comparison more closely, it became apparent that improvements to patient health may have a 
second important origin, which could not be explained using existing identified factors. Clinicians using the 
control strategy were free to order additional tests to aid their decision–making, although clearly these 
results would be delayed with respect to the experimental strategy. Thus an important comparison hidden 
within the study design is that of the speed of appropriate decision–making (purple arrows): the new strategy 
allows important information to be available more quickly, which in the context of acute infection could 
certainly influence a patient’s recovery by enabling the right treatment to be given at an earlier stage. This 
factor was tested, developed and refined as a causal concept through examination of subsequent trials. 
 
 
 
 
Signs, symptoms, CRP 
response, white blood 
cell count 
Number febrile 
days 
Bacterial infection or 
viral infection? 
Antibiotics? 
Bacterial 
Yes 
Perception of 
health state 
Viral 
Clinical 
consultation 
Clinical 
consultation with 
CRP and WBC 
results 
No 
Direct test 
effects 
Treatment implemented 
Antibiotics Symptom relief 
 
More 
accurate Dx 
decision 
More appropr 
–iate Rx 
decision 
More 
information 
Improved 
recovery 
Speed of 
information 
More appropr 
–iate Rx 
Earlier 
appropriate Rx 
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improvements to downstream patient health. Importantly the process also allowed a fuller 
conceptualisation of how diagnostic attributes interrelate to create these changes. 
As qualities of a process that interacts with patients, these diagnostic attributes were 
perceived to act as mechanisms through which a test might improve an aspect of patient 
health. Moreover, treatment effects appeared to be triggered by changes to the workings 
of these mechanisms as a result of introducing a new or different test. Indeed, the 
fundamental methodological notion that evidence-based medicine relies on to provide a 
meaningful measure of clinical effectiveness is that of comparison to a second 
experimental intervention. So these mechanisms become comparative changes rather 
than fixed properties, whereby introducing a change in testing or a change in management 
can produce an improvement or decline in the performance of certain mechanisms, and as 
a result alter the effectiveness of a diagnostic strategy.  
Mechanisms were observed to share common interdependencies, forming causal 
networks which would then determine how and to what extent to the experimental strategy 
could lead to differences in patient outcomes. This process was observed to occur along 
four sequences of interactions between mechanisms, which are illustrated below using 
examples from the cohort of test-treatment trials:  
1. Direct route (direct test effects),  
2. Decisional route (altering decisions and actions),  
3. Temporality (changing timeframes)  
4. Perceptions (influencing patient and clinician perceptions).  
Figure 7.3 depicts the final framework schema, illustrating all 14 mechanisms and how 
they relate to their parent components in the care pathway; Table 7.1 defines all confirmed 
and newly–identified diagnostic attributes.        
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Care Pathway 
Component 
Mechanism Definition 
1. Test 
Delivery 
Timing Test The rapidity of performance of a test within the management strategy. 
Feasibility Completion of the test process, where reasons for non-completion are: 
a) Counter-indication (Clinician refusal to administer test) 
b) Patient acceptability (Patient refusal to have test) 
c) Technical failure (Ability of diagnostic equipment to produce data) 
Test Process Patients’ interaction with the test procedure, potentially causing physical or 
psychological harms or benefits. 
2. Test Result Interpretability After successful completion of the test process, the degree to which test 
data can be used to inform a diagnostic classification.  
Accuracy The ability of a test to distinguish between diseased and non-diseased 
patients. 
Timing Result The speed with which test results are available. 
3. Diagnostic  
Decision 
 
Timing 
Diagnosis 
The speed with which a diagnostic decision is made. 
Diagnostic 
Yield 
The degree to which the test contributes to a patient diagnosis in any form, 
including: 
 Provision of definitive diagnosis 
 Confirmation of suspected diagnosis 
 Ruling out a working diagnosis 
 Distinguishing between alternative diagnoses with different treatment  
          implications 
Differentiated from ‘Accuracy’ in that it also incorporates any other 
information used by a clinician to formulate a diagnostic decision (such as 
prior test results). 
Diagnostic 
Confidence 
The degree of confidence clinicians have in the validity or applicability of a 
test result. 
4. Treatment  
Decision 
Therapeutic 
Yield 
The degree to which diagnostic decisions influence therapeutic plans. 
 
Therapeutic 
Confidence 
The certainty with which a clinician pursues a course of treatment. 
5. Treatment 
Implemen–
tation 
Timing 
Treatment 
The speed with which patients receive treatment. 
 
Treatment 
efficacy 
The ability of the treatment intervention to improve patient outcomes 
Adherence The extent to which patients participate in the management plan, as advised 
by their physician, in order to attain the therapeutic goal.  
 
Table 7.1:  Definitions of attributes of each components that may influence the effectiveness 
of a test-treat strategy 
 
  
 
229 Chapter 7: Elaboration & illustration 
7.4 Elaboration and Illustration 
 
Below, each sequence is illustrated by taking each mechanism defined in the schema and 
considering it to produce a difference between how one test operates compared to 
another. 
7.4.1 Direct Route: impact of the test process 
Test  Pr ocess  
As documented in previous research, some test procedures can directly impact on a 
patient’s health independently of subsequent diagnostic or treatment decisions, hence 
those that offer a reduced procedural-related morbidity will be of immediate benefit to 
patients. In the new schema, this effect is defined by the ‘test process’ mechanism and 
was a common observation. For instance, amongst early breast cancer patients being 
investigated for metastatic spread, significantly fewer were demonstrated to suffer from 
postoperative arm swelling, seroma formation, numbness and paresthesia if initially triaged 
with sentinel lymph node biopsy (SLNB) instead of immediate full axillary lymph node 
dissection (ALND). This direct physical benefit was due to the considerable proportion of 
node-negative SLNB patients who were subsequently able to avoid the more invasive 
ALND(T24) (Figure 7.4). 
Tests may also have a direct therapeutic value when the act of experiencing a test can 
confer immediate health benefits. These psychological effects can be understood as 
patient perspectives, and are discussed separately below. 
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7.4.2 Decisional Routes: impacts of diagnostic information and 
decision–making 
Feas ib i l i t y  and I n te rpr e tab i l i t y  
The contribution that a test’s results can make to decision-making is first mediated by its 
ability to produce a diagnostic output (feasibility) that can be interpreted clearly 
(interpretability). These issues were rarely addressed by included trials, yet differences in 
either property could prompt a succession of unfavourable changes to subsequent 
mechanisms. Feasibility in particular was generally not captured by these trials since the 
failure of a test to produce results tended to be listed as a reason for patient exclusion(T67), 
either before(T89) or after randomisation. Nonetheless failed procedures, whether as a 
result of counter-indication to testing (for example claustrophobia in individuals 
randomised to receive an MRI(T4) or peripheral arterial disease preventing catheterisation 
in patients awaiting angiography(T6)) or technical malfunction (for example contaminated 
blood culture samples(T23)), as well as indeterminate results could invite additional 
Figure 7.4:  Direct impact of diagnostic tests. Attributes of the test process can 
influence patient outcomes independently of differences in accuracy or 
diagnostic decision–making.   
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investigations, increase the total diagnostic time or decrease diagnostic and therapeutic 
yields through incorrect decision-making and poor diagnostic confidence. For example, in 
a trial evaluating the diagnosis of coronary artery disease (CAD), patients with acute chest 
pain who were allocated to exercise ECG were significantly more likely to be referred for 
further investigation (coronary angiography) than patients receiving a stress 
echocardiogram. They were also significantly more likely to be diagnosed as having 
intermediate post-test probability of CAD. These findings were caused by the higher 
frequency of failed procedures and inconclusive results produced by the exercise ECG, 
whereby patients with uncertain diagnoses were arbitrarily classified as at intermediate risk 
of CAD(T89). 
Test  Accuracy ,  D iagnost i c  Y i e ld ,  Therapeut ic  Y i e ld  and  Treatment  
E f f i cacy  
The most widely recognised impact on patient health is a composite of the interaction 
between the mechanisms of accuracy, diagnostic yield therapeutic yield and treatment 
efficacy. As posited in the existing literature, diagnostic reclassification afforded by a test 
with greater accuracy could lead to a change in treatment through better-informed 
decision-making. A clear example is provided by a trial evaluating whether photodynamic 
diagnostic cystoscopy (PDD) in addition to standard white light cystoscopy could reduce 
the risk of bladder cancer recurrence. Due to its enhanced accuracy in the detection of 
smaller carcinomas and ability to more clearly define tumour borders PDD identified and 
treated substantially more lesions at initial diagnosis in the experimental group, leading to 
a significant reduction in the frequency of recurrence(T1) (Figure 7.5). Of course, 
improvements to accuracy, diagnostic yield and therapeutic yield will not materialise 
unless the available treatments are efficacious. This may be one reason why a trial 
evaluating three modes of tilt testing to better diagnose the cause of previously 
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unexplained syncope failed to find any difference in the time–to–syncope recurrence(T2). As 
acknowledged by the authors, there are no effective treatments to eliminate syncope and 
so, despite wide differences in the accuracy of the three tests, observing an improvement 
in the primary outcome would have been very unlikely in these patients. 
Diagnost i c  Conf i dence  
While diagnostic yield generally increases with accuracy, it is also independently 
influenced by a physician’s diagnostic confidence. Clinician confidence in test results were 
observed to contribute to the overall effectiveness of test–treatment strategies in more 
ways than anticipated by the preliminary model. Tests that induced greater confidence in 
their results could benefit patients by reducing further investigations (T12), 266 (decreasing 
Figure 7.5:  Decisional impact of tests. The schematic illustrates how information produced 
by a test may influence patient outcomes through how it changes diagnostic 
decisions, treatment decisions and treatment implementation.  
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any associated procedural harms) and expediting the time to treatment, though such 
changes would only benefit patients if the new test is also at least as accurate as the 
existing test.  
A trial evaluating the benefit of adding positron emission topography (PET) to the pre-
operative staging of patients with an established diagnosis of non-small cell lung cancer 
demonstrates how diminished physician confidence in the ability of a test can over-ride the 
benefits of improved accuracy if test results are ignored(T52)(Figure 7.6). As remarked by 
the authors, PET results could have changed downstream management in a quarter of 
participants through the enhanced detection of mediastinal disease, thereby avoiding the 
Figure 7.6:  Decisional mechanisms may fail to cause a change to patient health. Here a more 
accurate test is provided (red arrows), however poor confidence in the discriminatory 
ability of the test may mean the new test is ignored, and consequently the potential 
gains to health from better decision–making are not realised (grey arrows). 
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need to proceed to thoracotomy in incurable patients. Ultimately no difference was 
observed in the proportion of patients avoiding a thoracotomy (the primary outcome) as 
surgeons preferred to confirm PET findings with operative staging, the standard test they 
were accustomed to using. The observed treatment effect does not likely reflect the real 
accuracy of PET, but the physician response to the introduction of a ‘new’ diagnostic 
technology. Clinicians may not have been confident in its accuracy or, more importantly, in 
how its results should be interpreted leading to so-called errors of implementation(T52). Had 
the surgeons trusted the PET results, downstream management could have changed to 
avoid thoracotomy in the quarter of participants where PET had detected incurable 
mediastinal disease. 
Figure 7.7:  Changes in the temporality of the test–treat process impact on health 
outcomes. Hastening the point of testing, the production of results, or the 
time of diagnoses can all indirectly improve patient health through producing 
earlier treatment (red arrows).  
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That increased diagnostic confidence does not automatically confer an increase in 
diagnostic yield is also suggested by the results of some before–after studies, where 
observed increases in diagnostic confidence do not always translate to changes in 
diagnostic decision–making267.  
Therapeut ic  Conf idence  
Physician confidence in the ensuing success of a treatment plan could affect the success 
of treatment by influencing the approach to treatment. Therapeutic confidence is most 
clearly exemplified by tests that directly inform surgery. Digital subtraction angiography 
(DSA) and multi-detector row computed tomographic angiography (MDR–CTA) are used 
to determine the location and degree of vascular narrowing in patients with symptomatic 
hardening of peripheral arteries (atherosclerotic Peripheral Arterial Disease) who have 
been referred for revascularisation. In this setting, a key determinant of improved patient 
health may be the confidence with which a surgeon approaches the revascularisation. An 
RCT evaluating this comparison discovered that physicians using DSA were significantly 
more confident of plans for surgery as a direct consequence of the test’s clearer vascular 
images, while CTA images were found to obscure interpretation and decrease confidence 
in the presence of vessel wall calcifications(T12).  
7.4.3 Temporality: impacts of timing 
Temporality is conceived as a property of each of the five components in the patient care 
pathway. Differences in the speed with which diagnoses are produced and treatment 
administered to patients can provoke changes to patient health regardless of changes in 
decision-making. Strategies that hasten the administration of a test can be of benefit to 
patients, particularly if complemented by earlier treatment (Figure 7.7). The provision of 
coronary angiography (CA) on average 57 hours earlier in a patient’s management was, 
for example, found to decrease the combined risk of death, non-fatal cardiac events and 
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rehospitalisation (the primary outcome) when compared to a delayed strategy* in patients 
with unstable angina and non-ST segment elevated myocardial infarction(T14). As both 
strategies employ the same diagnostic test there can be little impact from more accurate 
decision-making, and the key mechanism improving patient outcome is likely to be the 
more rapid provision of treatment as a consequence of the earlier testing. Reducing the 
turnaround time in the production of test results can also shorten the time-to-treatment. For 
example, patients with ventilator-associated pneumonia who received a rapid antimicrobial 
susceptibility test received definitive reports a mean of 2.8 days earlier than those 
receiving the standard susceptibility test, and suffered significantly fewer days of fever, 
bouts of diarrhoea and days on mechanical ventilation(T59).  
Either of these two mechanisms mainly influences patient outcomes by triggering an 
earlier diagnosis and earlier treatment, although of course this relies on test results and 
ensuing decision-making being deployed equally promptly. Failure to do so can nullify any 
impact of timing, as was demonstrated in an RCT evaluating the addition of Polymerase 
Chain Reaction (PCR) to conventional testing for discerning between viral and bacterial 
aetiologies in lower respiratory tract infection. While PCR results (for the detection of virus) 
were produced earlier than bacterial culture results, the strategy failed to decrease time-to-
treatment (in this case time to the discontinuation or modification of antibiotics) as 
physicians were unwilling to base treatment decisions solely on PCR, preferring to wait for 
slower bacterial results as well(T21). 
 
                                                 
*
 The control strategy entailed initial medical treatment followed by referral for CA if clinically indicated. 
Consequently 97% of immediate testing patients received CA in a median of 22 hours, while 51% of delayed 
strategy patients received CA in a median of 79 hours. 
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7.4.4 Perceptive dimensions: impacts of the patient and clinician 
experience 
Each mechanism has been described from an objective clinical perspective, however this 
understanding may differ from the subjective perceptions of individuals involved. Both the 
patient’s perspective, and more recondite aspects of the clinician’s perspective, are far 
less predictable and hence could mediate the effects of the diagnostic strategy in 
unexpected ways. These unpredictable responses could eliminate potential improvements 
gained from other mechanisms.  
Pat i ent s  
As a key negotiator of treatment decisions, the patient and their perspective of the 
healthcare process represents an all-pervasive dimension in the explanatory framework, 
capable of mitigating the final impact that mechanisms may have on health outcomes. 
Patients’ perceptions of testing, their experience of the testing process and their 
understanding of the test result may all influence patient outcomes. A large number of 
studies show social, emotional, cognitive and behavioural effects of testing across a wide 
range of clinical conditions264.   
Seen from the patient’s perspective the degree to which a test succeeds in producing 
results (its feasibility) relies on their willingness to undergo a procedure. Poor acceptability 
of the procedure is most likely to affect patient outcomes in multiple-testing situations, 
where an unpleasant first test could negatively influence patients’ willingness to attend 
follow-up testing or treatment.  
The experience of undergoing diagnostic procedures can also influence patients’ illness 
cognitions. For example patients with non–Q–wave myocardial infarction who received 
immediate angiography demonstrated significant improvements in angina stability, 
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treatment satisfaction and disease perception than those managed with a non–invasive 
stress test(T20). 
Patient perceptions of testing can also impact on downstream measures of health by 
means of a diagnostic placebo effect, where the impression of a thorough investigation 
encourages improvements in perceptions of health status. This may account for significant 
improvements in health utility (EQ-5D) reported by patients with acute undifferentiated 
chest pain diagnosed in a specialist Chest Pain Unit compared to those diagnosed in 
emergency departments, despite equivalent treatment and rates of adverse cardiac 
events(T48). How patients process test results and react to diagnoses can be unexpected 
and difficult to predict however, and responses are likely to be specific to the tests being 
used as well as the presenting symptomatology and severity of conditions to be detected 
or ruled out. Other studies demonstrate the risk of somatic fixation as a result of 
undergoing testing and receiving a ‘diagnosis’. For example acute lower back pain patients 
receiving an X–ray were found to display worse overall health status 3 weeks later than 
those receiving only standard consultation(T28), suggesting that being labelled with a clinical 
diagnosis, albeit one of minor consequence (e.g. age–related degeneration of the spine), 
may serve to legitimise illness beliefs, rather than reassure as to the absence of severe 
disease as intended.  
Earlier knowledge of one’s diagnosis could also have behavioural and health 
consequences in certain situations. Psychological benefits may occur if serious disease is 
ruled out more promptly, by dispelling anxiety or providing earlier reassurance. These 
effects could also be detrimental; confirming the presence of disease may increase anxiety 
if further investigations are warranted (disease staging), or serve to propel negative 
behaviours. Although not measured in any of the 103 included test–treatment trial, 
examples of the psychosocial impacts of earlier testing are seen in screening 
comparisons268. 
  
 
239 Chapter 7: Elaboration & illustration 
Adher ence  
Experiences and perceptions of the care pathway can also impact on the patient’s 
willingness or motivation to adhere to medical advice269–271. Non-adherence with the 
agreed treatment can mitigate prospective improvements to health gained from advances 
in yield, confidence or other clinical mechanisms. Negative perceptions or experiences of 
testing and diagnosis are responses that could cause patients to lose confidence in the 
diagnosis or management plan, thereby instigating a reluctance to undergo subsequent 
testing or planned treatment. 
Due to its distance from the diagnostic intervention, adherence was seldom measured or 
considered in the interpretation of test-treat trials however it is likely that increasing 
adherence could maximise the potential benefit gained from treatment and preceding 
improvements to the diagnostic strategy. While enhanced adherence has been positively 
correlated with improved clinical outcomes272, there is also an increasing recognition that 
there are multiple influences on adherence and its relationships with health response are 
complex. A recent systematic review found, for example, that interventions succeeding in 
raising adherence did not always improve clinical outcomes269. 
Cl in i c ians  
It is of course important to consider the impact of the clinician’s perspective, emotional, 
cognitive, social or behavioural perspectives which are external to objective medical 
concerns but can nonetheless impact on decision-making. Referring physicians have been 
shown to modify their prescriptions of downstream management according to the nature of 
their relationship with their patient, for example to satisfy their patient’s expectations of 
investigation and treatment273–274, as a response to unstable relationships with their 
patients275, or to prevent a perceived threat of malpractice276–277. The most common 
response to such situations is a request for additional diagnostic information, so-called 
‘defensive medicine’ 277, which can serve to raise the diagnostic threshold needed to 
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trigger a change in management. Limited evidence has begun to indicate that certain 
personality traits may predispose to an overzealous approach to the prescription of 
antibiotics, such as ‘zeal’ and ‘a readiness to serve’ 275, with indications that this may also 
serve to increase investigative referrals278. If these additional tests are less accurate, then 
diagnostic and treatment yield will be adversely affected, potentially cancelling out any 
gains to patient health incurred from preceding mechanisms. If additional tests are more 
harmful to the patient or lead to considerable delays in treatment, then patient health could 
be directly harmed. The effect of extra-clinical concerns on clinical behaviour requires 
more investigation, however at least one study has demonstrated that fear of malpractice 
is an important predictor for the number of tests ordered by clinicians with those so 
affected ordering on average 25% more tests than clinicians not so concerned277. 
Complex public health interventions are known to be sensitive to organisational 
structures83, and the same is likely to apply to test-treat settings with local differences in 
the characteristics and prioritisation of health services as well as variations in resource 
availability and clinical protocols contributing to variations in decision-making and hence 
patient outcome effectiveness. While a discussion of these influences remains beyond this 
discussion, their potential impact on patient health through the channelling of resources 
should be kept in mind. 
7.5 Discussion 
 
 
This study has proposed a framework of thought to explain how diagnostic tests affect 
patients. Building on existing concepts this analysis has defined the key clinical processes 
that link tests to patient health, and revealed it to be composed of a complex network of 
mechanisms through which changing a test might create differences in downstream 
patient outcomes. 
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The framework uses the concept of the ‘patient care pathway’ to make explicit all the ways 
in which health outcome differences might be generated by the introduction of a new 
testing strategy. As the patient moves through the test-treatment process, each 
component can influence the patient’s health trajectory through several mechanisms, as 
well as through the patient’s perception and experience of that component. Each 
mechanism may independently trigger improvements to patient health either directly, or 
indirectly by interacting with other mechanisms as shown in the four sequences above. 
These sequences may be considered as causal pathways of effect, where the potential 
advantages offered by improvement to one mechanism demonstrably fail to improve 
patient health if an interrelating mechanism produces a contrary effect to that desired. 
Founded on a wide body of existing conceptual research, it is no surprise that many of the 
ideas contained in this framework are not new. The founding principle that tests and 
outcomes are indirectly related, and likely to be mediated through intervening treatment 
and other clinical processes, is commonly–held and indeed the ‘patient care pathway’ 
structure was directly informed by the previous work of Patrick Bossuyt and Jeroen 
Lijmer193. Driven by accuracy, the role of diagnostic decision–making as a key factor 
mediating the clinical utility of tests is central to current thought, as is the notion that 
differential adherence to management will mitigate the end success of a testing 
pathway19,77. That tests will have direct effects was similarly widely acknowledged, while 
more recently the psycosocial context of testing and its consequences has been 
characterised264.  
Nonetheless, this schema does differ considerably from previous frameworks in three key 
respects: the number of ways in which tests influence downstream patient health, the 
complexity of how this is achieved, and finally the condition that superior accuracy is a 
necessary precondition for clinical utility.  
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7.5.1 More numerous mechanisms 
The examination of test-treatment RCTs highlighted that diagnostic tests are capable of 
influencing patient health in ways more numerous and complex than currently conceived. 
With a total of 14 individual mechanisms, the framework identifies as least seven 
additional attributes of the test-treat process that are rarely considered to influence clinical 
effectiveness. Not only may health be influenced indirectly by accuracy-driven changes to 
patient management or directly by the test apparatus, but elements of decision-making 
behaviour and other technological properties of tests can modify the extent to which this 
occurs. Tests that are more often feasible, produce results that are more easily 
interpretable or that engender higher therapeutic confidence could each result in more 
effective healthcare. The most enlightening contributions are the four timing mechanisms, 
which although common considerations in the screening literature23 were not considered 
by any of the reviewed frameworks. 
7.5.2 More complex interactions 
Perhaps the most important contribution to existing thought is the elaboration of how these 
mechanisms interact to create (or prevent) differences in treatment effect. Previous 
frameworks conceived the diagnostic determinants of health outcomes to be hierarchically 
ordered, such that improvements in mechanisms earlier in the test–treat process are 
necessary but not sufficient to deliver a favourable downstream outcome. This linear 
approach does not allow for any downstream benefits to occur if earlier diagnostic 
attributes fail to be improved. Conversely, the new framework highlights the importance of 
considering all potential differences in competing test-treatment processes. Within the 
schema each mechanism can trigger improvements to patient health either directly or 
indirectly by acting on other mechanisms with which it is commonly interdependent. In this 
way the new framework is more holistic and less linear than preceding structures. Not only 
  
 
243 Chapter 7: Discussion 
does it encompass a greater number of processes and mechanisms, but it emphasises 
that these processes do not occur in series as is often conceived, but rather as a set of 
interrelated mechanisms governed by the specific clinical setting. Moreover, rather than 
focussing on the singularity of changing decision–making behaviour as a vehicle for 
improving health outcomes effects are created along four causal pathways which can act 
in parallel in any single comparison to influence patient health. 
Of equal importance to explaining how tests might influence health outcomes is the 
exposition of why intended effects might not materialise. Existing theory acknowledges 
that this can occur. Some authors noted that more accurate tests would not always 
produce benefits in decision-making or patient outcome14,44–46, however none extrapolated 
why this might occur, beyond the difficulties of conducting and interpreting test-treatment 
RCTs. By reconceptualising test-treatment cause and effect as causal pathways of 
mechanisms, the new structure has been able to demonstrate how downstream health 
benefits are only realised if the potential advantages of a mechanism are not nullified by 
inadequacies in ensuing mechanisms. Namely, these causal pathways can break down 
and fail to realise intended improvements if at least one mechanism in the causal chain 
produces a contrary effect. That PCR failed to reduce time to treatment(T21) is illustrative of 
the role that successive mechanisms may play in mediating a test’s impact, since potential 
improvements in patient health derived from earlier targeted treatment were cancelled out 
by a decreased confidence in the diagnostic capacity of the new test. 
7.5.3 From accuracy–driven change to complex system interactions  
The review revealed that existing notions regarding the clinical utility of tests have 
traditionally placed accuracy as the central linchpin of clinical effectiveness19,21,44–46,49–
50,77,91,193,256. This stems from the premise that if patients are treated appropriately they will 
have better outcomes59, and so the main value of tests is seen as the mediating role they 
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have in guiding treatment decisions193. A caveat of existing frameworks is that whilst 
superior accuracy is not sufficient for clinical effectiveness, it is nonetheless necessary. 
There can be no doubt that diagnostic accuracy is a key driver of clinical effectiveness, 
however this analysis of test-treatment trials highlights that it can no longer be considered 
the sine qua non of diagnostic performance. Since differences in patient health are not 
solely driven by accuracy but also created through improving the delivery of non-decisional 
aspects of care, superior diagnostic accuracy is not necessary for a test to demonstrate 
superior clinical utility. A diagnostic strategy no different in its ability to influence decision-
making, yet which enables patients to be diagnosed and treated more promptly would be 
unfairly represented in its potential to improve patient health by looking only at its 
accuracy. Nor do improvements to patient health necessarily follow improved accuracy, 
given that several other decisional mechanisms are also accountable for any downstream 
effects. It is only by looking at the whole picture that we can begin to decide which 
outcomes, surrogate or otherwise, will best capture the true impacts on patient health. 
7.5.4 Study limitations 
This study has applied the principle of analytic induction to identify the key mechanisms by 
which test-treatment strategies change patient health, using a cohort of test-treatment 
RCTs to elaborate the model. It is however possible that future studies or missed 
examples may reveal additional mechanisms that are highly specific to diagnostic settings 
not represented in this data set. Therein lies the main drawback of the current method; 
since theory was developed through the use of disconfirmation, technically no theoretical 
construct can ever be considered ‘final’ since the existence of other deviant cases not 
captured by the study cannot be ruled out.  
Equally, the focus on RCTs may have excluded empirical evidence of other ways in which 
tests can impact on patients. As an experimental study design it is less suited to evaluating 
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more subjective aspects of clinical management for example. Nonetheless, RCTs 
encompass the whole test-treatment process and so have presented a useful starting point 
for developing this framework. 
There are also certain diagnostic intricacies that have necessarily been simplified in order 
to produce a generalisable model of the test-treat process. Most relevant is the nature of 
the diagnostic decision, which in practice is generally not the simple dichotomy alluded to 
here but is multiplicitous; a diagnostic test is not only used to rule a condition in or out, but 
to discern between multiple differential diagnoses. By focusing on the target condition the 
framework may fail to identify the impact a new test has on the downstream management 
of test-negative patients, such as receiving an immediate alternative diagnosis or being 
channelled more effectively towards other diagnostic tools to evaluate their condition 
further. Similarly, the framework does not specifically address how the test-treat process 
can react to incidental diagnostic findings, although by their nature these likely affect a 
small proportion of patient management. In an attempt to highlight the importance of the 
patient and clinician perspective, it is also recognised that the current approach is limited 
to that expounded in existing research as well as the author’s individual academic and 
clinical perspective. Consequently there may well remain aspects of the patient 
perspective, and diverse clinical viewpoints, that the author has failed to distinguish as 
important modifiers of downstream health. 
7.6 Conclusions 
 
 
This analysis highlights the multitude and complexity of interactions occurring within test-
treatment interventions. It is presented as a preliminary framework, open to deliberation, 
modification and further development as methodological research into patient outcome 
efficacy progresses.  
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Although theory is crucial to an understanding of how tests change patient health, any 
theory is only truly useful if it can be used to underpin and progress empirical evaluation. 
In this regard an important advantage posed by the new framework is that it addresses a 
fundamental problem of test-treatment trials: that of our ability to disaggregate effects of 
the test from effects of the treatment. The following chapter considers the specifics of how 
the conceptual structure may underpin and progress the design and interpretation of test-
treatment RCTs. 
 
8 
 
Towards a full evaluation 
of test-treatment 
interventions:  
Developing a method to 
select outcomes
This chapter has been published in part:  
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In order to fully evaluate test-treatment interventions it is necessary to identify all the ways 
in which a new strategy might impact on patient health. The theory to underpin this 
rationale was developed in Chapter 7, yet it suggests that elucidating all likely processes 
of change is likely to be a highly complex endeavour for which there is currently no 
guidance. Chapter 8 was designed to address this deficit by developing the framework into 
a practical tool. The tool is presented as a checklist with an accompanying graphic, and its 
value to the design, interpretation and appraisal of test-treatment RCTs is illustrated by 
worked examples, derived from the project cohort. 
The preceding chapter developed a theoretical framework that sets out the common 
mechanisms by which diagnostic tests, and their subsequent actions, can change patient 
health. During the detailed examination of all included trials undertaken to build this 
generalised framework, the author‟s experience was that very few reports provided useful 
accounts of how the experimental strategy was expected to change patient health. This 
severely curtails the ability to appraise whether trialists have selected all important 
outcomes. Critically, if this lack of reporting reflects an incomplete deliberation of how test-
treatment interventions create change, then these trials strongly risk having conducted 
incomplete evaluations of effect. 
The importance of developing a clear scientific rationale is a well established tenet of study 
design121. The principle is given particular emphasis in evaluations of complex 
interventions, where it is recognised that their multiple and interacting components 
engender a wider range of effects than expected from „simple‟ interventions83. Developing 
a „coherent theoretical basis‟ is therefore considered essential to capture and interpret 
these effects, however there is currently little guidance on how to formulate this rationale, 
particularly for test-treatment interventions. Chapter 7 suggests that this is likely to be a 
difficult task to perform for test-treatment interventions; the framework highlights the need 
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to consider multiple causal pathways made up of complex interactions in order to ensure 
that all possible effects have been identified. However, since we now have a generalised 
concept that models the relationship between tests and outcomes, the framework could be 
harnessed to generate a theory of expected change for any given test–treatment strategy 
under evaluation. 
Accordingly, this chapter was developed to address the shortfall in existing guidance by 
designing a standardised tool that researchers can use to discern the scientific rationale of 
how test-treatment strategies cause change. This chapter describes how the framework 
was developed into a tool, presents it as a preliminary version, and discusses its value to 
underpinning reliable evaluations of tests by reference to examples. The chapter 
concludes that its use could benefit four aspects of test-treatment evaluation: designing 
trials, establishing the need for a trial, interpreting trial results and appraising trial quality. 
8.1 Method: developing the tool  
 
 
The author took the central premise that in order to be useful the tool should enable users 
to conceptualise their test-treatment comparison clearly, to think through each framework 
mechanism, and to iterate how all relevant mechanisms might interact to cause change to 
patient health. Furthermore, to be comprehensive and reliable the tool should achieve this 
in a structured way. 
The author‟s experience of appraising test-treatment RCTs and developing the theoretical 
framework highlighted potential approaches that could satisfy these requirements. As part 
of the deviant case analysis each test-treatment trial was examined by mapping out its 
central processes in what was essentially a causal diagram. This lent great clarity to the 
author‟s understanding of test-treatment comparisons, that not only tended to be poorly 
described but were also often highly complicated. Causal diagrams provide a simple
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means of summarising and ordering complicated information, particularly when its 
components are likely to interact both independently and synergistically – as in complex 
interventions279. In epidemiology they have been used for numerous ends, including to 
conceptualise measurement bias280, to model for possible confounding and other forms of 
bias in retrospective observational studies281 and to model links between cause and 
effect282. Within the context of test evaluation research, causal diagrams have also been 
found useful for defining the scope of evidence–synthesis reviews into the effectiveness of 
screening tests78. 
A common approach for achieving a structured consideration of methodological issues in 
evidence–based medicine has been the application of checklists. Used to appraise the 
quality of primary studies71–72,101,283 and evidence–syntheses284, checklists have proven to 
be effective tools for systematising the design and appraisal of epidemiological studies 
since they promote a standardised approach whilst ensuring that important issues or 
features are not missed. These qualities are particularly important to the task in hand due 
to the complexity of interactions expected to occur along the test–treat pathway.  
For these reasons the theoretical framework was developed into two practical elements, a 
diagram and a checklist. 
8.1.1 Graphic schema 
The first suggested task is the completion of a diagram that requires the user to map out 
important features of the diagnostic comparison, specifying what is being done, to whom 
and when (Figure 8.1). The schema depicts two comparative „patient care pathways‟, the 
components and mechanisms of each illustrated in direct opposition to one another. Each 
set of five pathway components must be defined, using the questions provided to guide 
the insertion of key information.  
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Also selected for inclusion in the diagram were two aspects of the healthcare setting that, 
during the process of refining the conceptual model using the cohort of published trials, 
were considered by the author to strongly influence the care–pathway: the type of 
comparison (triage, add–on, replacement) and the patient group.  
By encouraging the user to think about how each sequential component of the new 
pathway could be beneficial (relative to the existing strategy), this process is designed to 
prompt an initial consideration of which mechanisms might be relevant to the comparison.  
8.1.2 Checklist 
The second element is a checklist of questions designed to give more targeted thought as 
to which mechanisms might influence patient health in the comparison (Table 8.1). Each 
item asks the user whether there is likely to be a difference in how one mechanism 
operates between the two strategies. Since patient experience and perspective relates to 
the whole pathway, several additional questions have been introduced to try to capture 
points at which these might also be of influence.  
If the mechanism is not considered relevant, the item is assigned a negative („no‟). 
Questions are given positive answers („yes‟) if primary evidence that the statement is true 
already exists, while queries („?‟) are denoted when the item may be true but no primary 
evidence exists to confirm this supposition. The rationale for how the new strategy can be 
expected to change patient health is guided by selecting all mechanisms whose questions 
have received positive or unknown answers, after which a consideration of the four causal 
pathways (direct, decisional, temporal, perceptual) can be used to refine the process of 
thought. 
Use of this tool is illustrated below by working through a test-treatment comparison 
contained in the project cohort.  
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8.2  Worked example: management of 
suspected acute appendicitis 
 
In order to provide as clear an example as possible, a trial was selected primarily for the 
simplicity of its comparison; namely that it compared two strategies containing a restricted 
number of tests and a narrow array of treatment choices for a target condition with a well–
understood natural history.  
The selected study set out to evaluate the benefits of two diagnostic strategies for 
confirming or ruling out suspected acute appendicitis in adults presenting to the 
emergency department with right lower quadrant abdominal pain(T60). By comparison to the 
routine approach of scanning all such patients with CT, the new strategy aimed to be more 
selective by ordering CT only upon the presence of specific signs and symptoms; hence 
this can be considered as a triage comparison. 
In order to develop the rationale for how the new selective strategy could influence patient 
health, the first step is to map out the alternative diagnostic and management pathways 
that were compared in the trial. The standard diagnostic approach was reported to 
comprise the following elements:  
1) Patients were evaluated by the emergency physician and consulting surgeon,  
2) Routine laboratory tests were ordered for all patients (bloods, urinalysis, pregnancy 
test in women, serum chemistry),  
3) Other consultations or tests were procured at the discretion of the treating clinician,  
4) Abdominal contrast–enhanced CT scan administered and interpreted immediately 
for all patients. 
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The new strategy was designed to allow clinicians to be more selective in which patients 
receive contrast–enhanced CT imaging, thus after following the first three steps clinicians 
could choose whether to order a CT scan, on the basis of all prior diagnostic information.  
In both arms, patients with confirmed appendicitis were treated with either surgical removal 
of the appendix, or in rare instances antibiotics. Patients without worrying indications (such 
as non–specific abdominal pain) were discharged, whilst those with alternative diagnoses 
were treated according to the disease suspected by the diagnostic strategy. Unfortunately, 
as was common for included trials (chapter 5 p. 138–142), the investigators failed to report 
clear details of diagnostic or therapeutic decision–making, and also provided no indication 
of which additional consultations or tests (step 3 above) could be used by clinicians in 
either arm; thus certain assumptions had to be made in order to proceed with the 
comparison. These were discussed with a practising general surgeon to ensure their 
clinical validity: 
 Additional tests were likely to be one or more of: expectant observation, ultrasound, 
X–ray 
 Clinicians following the selective strategy would order CT for patients with atypical 
clinical presentations.  
 Patients with clinical signs and symptoms considered to be typical of appendicitis 
would therefore not receive CT before surgery 
 The „immediate interpretation‟ of CT mandated in the control strategy (step 4 
above) was also implemented for experimental patients receiving a CT scan. 
It is worth noting that this trial was conducted in the United States (US) during the early 
2000s (possibly earlier, the recruitment dates are not reported), so although there are 
notable contrasts to the style of clinical management in the UK (for example CT is not 
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routine for suspected appendicitis in the UK), the rationale below has been developed to 
reflect the setting in which the trial was undertaken.  
8.2.1 Developing a rationale for how selective CT may improve 
patient health 
Figure 8.2 maps out this comparison using a completed care–pathway schema. Guided by 
the checklist, the next step is to note where these components might differ so as to identify 
the mechanisms likely to be driving change to patient health. This process was again 
discussed with the same general surgeon in order to confirm clinical details and ensure 
that causal hypotheses are clinically valid. 
Timing of test (a. Time to test delivery) 
The nature of the comparison could create a differential in the time to test delivery. While 
CT is mandatory in control patients, clinicians managing experimental arm patients must 
evaluate all prior test results and information before deciding whether a CT is necessary. 
Within the context of a busy emergency department this could result in a delay to receiving 
CT for experimental arm patients with atypical clinical signs and symptoms. 
Feasibility (b. Acceptability; c. Clinical contraindication; d. Technical failure rates) 
Although the consumption or injection of contrast can be unpleasant for patients, any 
decreased patient acceptability associated with undergoing CT would be unlikely to result 
in patients refusing this test. 
There are several contraindications to high doses of radiation or the use of contrast 
agents, however in this example all such patients were excluded (pregnancy, renal 
insufficiency ascertained by high serum creatinine level, or history of contrast allergy) and 
so this item no longer needs to be considered for the comparison. 
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Nonetheless, oral contrast is still likely to be tolerated poorly by patients with usual 
symptoms of appendicitis (abdominal pain and vomiting), and as a consequence its use 
may be associated with higher rates of failed procedures where the contrast fails to reach 
the appendix285–286. This could lead to referral for additional tests. Assuming that fewer 
patients undergo CT in the experimental strategy, the technical failure rates might also be 
lower in this group.  
Test Process (e. Procedural harms/benefits; f. Placebo effect) 
Contrast–enhanced CT is more intrusive than any of the alternative imaging tests likely to 
be used in this setting. If prior test results and alternative non–invasive tests can obviate 
the need for CT, fewer patients in the experimental arm will be exposed to the low but 
serious risks of allergic reaction to contrast media287 and radiation exposure288.  
Since the diagnostic setting seeks to detect and treat an acute condition, patients‟ 
perspectives of the thoroughness of their investigations are unlikely to be relevant. 
Interpretability (g. Ease of interpretation) 
The effects of interpretability are relevant, though their direction of influence is unclear. On 
the one hand CT produces high–contrast images of all internal structures and so is more 
likely to produce definitive indications of disease than either the use of physical 
examination alone, or in conjunction with other modalities that tend to produce more 
opaque images (e.g. ultrasound or X–ray). As a consequence more indeterminate test 
results might be expected in the experimental arm, leading to more frequent referral for 
additional diagnostic procedures, but also potentially leading to different treatment 
decisions289. On the other hand these differences could be reduced if problems with 
contrast absorption reduce the clarity of CT images and also result in the production of 
indeterminate scans. 
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Accuracy (h. Accuracy) 
Differences in the accuracy of decision–making between the two strategies are likely to 
drive changes to the health of patients with suspected appendicitis, although the existing 
evidence–base is indirect and contradictory making the magnitude and direction of such 
effects uncertain. Primary evaluations of diagnostic accuracy vary widely in the CT 
technique being evaluated (contrast techniques and scanner technology), the expertise of 
diagnosticians (use of surgeons or general emergency physicians), the target patient 
population (degree of selection on the basis of clinical signs and symptoms) as well as the 
study design used290. Critically, most do not directly compare the performance of contrast–
enhanced CT with clinical judgement alone285,291–295, while one that does has produced 
tentative evidence that clinical judgement may be at least as accurate as treatment 
decisions based also on CT imaged296.  
Certain studies show CT to be more sensitive than other imaging modalities, for example 
ultrasound297. If CT is also more sensitive than clinical judgement alone for typical 
presentations, we would expect fewer true cases of appendicitis to be detected by the 
experimental strategy. CT could be more accurate in the identification of more serious 
differential diagnoses, such as bowel obstruction or diverticulitis298; if these individuals are 
mistaken for typical appendicitis in the experimental arm they would not be referred for CT 
and hence constitute missed true diagnoses, potentially with more severe consequences.  
If CT proves to be more specific than the alternative approach297, we would expect fewer 
false–positive diagnoses in the control arm. In contrast, other studies suggest that CT may 
detect milder and more incipient inflammation of the appendix299 which can overestimate 
the severity of findings298 leading to more false–positive detections in the control arm. 
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Timing of results (i. Time to produce a result) 
Oral contrast requires time to reach the lower bowel285, hence control patients may 
experience a delay in the production of test results when compared to experimental 
patients who are spared a CT. Conversely, experimental patients with atypical indications 
who are delayed in undergoing CT, as it is no longer a routine procedure, may experience 
a delay in the procurement of test results when compared to controls.  
Timing of diagnosis (j. Speed of diagnosis) 
Differences in the timing of test results could translate into delays for the production of 
diagnoses, as iterated for item (i.) above. 
Diagnostic yield (k. Diagnoses made) 
Differences in the accuracy of the two strategies should impact on the diagnoses made for 
patients: if CT is less specific, more experimental patients could receive negative 
diagnoses, of which a higher proportion would be false–negatives (particularly those with 
more serious conditions) and true-negatives; though if CT is more specific then the control 
arm may demonstrate more equivalence in the number of negative diagnoses, of which a 
higher proportion would be true–negatives. 
Potential increases in diagnostic yield afforded by the higher sensitivity of routine CT could 
be reduced if any additional tests ordered as a result of technical failures (d.) or 
indeterminate scans (g.) are less accurate than CT. However this would also depend on 
the frequency with which this occurs in the experimental arm. 
Diagnostic confidence (l. Clinician confidence; m. Patient confidence) 
Diagnostic certainty is key to this comparison. CT has been in use for a long time and is 
the current standard investigation for emergency patients with acute abdomen in the US 
(the study country)(T60); clinicians are therefore likely to find CT useful in reducing clinical 
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uncertainty. Physicians operating within the selective strategy may lack the confidence to 
make treatment decisions solely by clinical indication, fearing the consequences of missed 
diagnoses and unnecessary surgery, which can result in malpractice claims300. If 
confidence is reduced substantially, additional tests may be ordered for patients who – 
according to the protocol – should not receive further testing. If CT is relied upon, all 
potential direct and indirect benefits of selective imaging will effectively be reduced to zero. 
If other less accurate tests are used then diagnostic yield could be reduced. 
Again, patient confidence in the diagnosis is unlikely to be relevant in this comparison due 
to the acute and emergent nature of the clinical setting. 
Therapeutic yield (n. Treatment choices) 
Differences in diagnostic yield should translate into differences in treatment selection, 
though again the direction of effect is uncertain and depends on the true accuracy of CT in 
this population. Fewer experimental patients may be referred for treatment, of which a 
higher proportion would in reality need treatment (false–negatives).If less specific, more 
control patients would receive inappropriate referrals for treatment due to the more 
frequent detection of mild inflammation by CT; though if more specific, treatment referrals 
would be fewer and more often be appropriate. Again these differences would be mitigated 
by the quality of diagnostic information provided by additional tests ordered in either arm, 
as well as the extent to which clinicians base their treatment choices on these findings. 
Additional consideration must be given to the choice between antibiotics and surgery to 
treat appendicitis. Testing strategies could differ in the proportions of patients for whom 
these treatments are indicated; for example  surgeons managing experimental arm 
patients may demonstrate a lower threshold for selecting surgery as a result of reduced 
diagnostic certainty. 
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Therapeutic confidence (o. Clinician confidence; p. Patient confidence) 
Surgeons are traditionally more confident in recognising the signs and symptoms of acute 
appendicitis than general emergency physicians294, however surgeons may find CT 
increases therapeutic confidence since in the US these images are also used as a „road–
map‟ to guide treatment in patients with complicated appendicitis299.  
Patient confidence in the treatment choice is unlikely to be relevant, though could 
conceivably be reduced in disease–free individuals who do not receive an imaging test, 
perhaps leading to an increase in reattendance and resource expenditure in the 
experimental arm. 
Timing of treatment (q. Time to treatment) 
Differences in the speed with which treatment is administered could occur in three ways. 
Firstly, any delays in diagnosis due to the requirement to confirm initial suspicions with a 
CT scan could mean that treatment is delayed in control patients, when compared to 
experimental patients who are spared a CT. However such delays could be longer in the 
subgroup of experimental patients who are referred for CT.  
Second, treatment can be delayed as a consequence of missed diagnoses (false–negative 
appendicitis cases), which are likely to be more numerous in the study arm. Previous 
studies clearly document how a delay in treating acute disease can cause the appendix to 
rupture (or perforate)301, an event associated with a five–fold increased risk of death (from 
1% to >5% case–fatality rate in non–perforated compared to perforated appendices 
respectively), or inflammation to spread to the peritoneum which is associated with other 
severe health complications289,299.  
Third, delays in receiving appropriate treatment could also occur in patients falsely 
diagnosed with appendicitis (false–positive appendicitis cases) who are not disease–free 
but have alternate diagnoses. There is little existing evidence to indicate which diagnostic 
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strategy would more commonly identify such individuals correctly, however CT is thought 
to be valuable when differentiating acute appendix from gynaecological conditions289. If CT 
is superior in all such cases then we might expect the risks of further health deterioration, 
and the development of other morbidities associated with a missed diagnosis, to be more 
common in the experimental arm.  
Treatment efficacy (r. Efficacy of treatment) 
The efficacy of treatment will depend on three factors: whether the treatment is appropriate 
for the patient‟s true condition, whether treatment is delayed, and the quality of treatment. 
All three are argued to differ between the diagnostic strategies under comparison. 
Patients who receive incorrect diagnoses will receive treatments that are unlikely to be 
effective. If therapeutic yield is expected to be lower when using the selective strategy due 
to reduced sensitivity but higher specificity, fewer patients randomised to this arm will 
receive the treatment they need due to a false–negative diagnosis. Although appendicitis 
may resolve spontaneously in some of these302, discharge is unlikely to be effective in all, 
and we might therefore expect higher rates of „recurrence‟, or re–attendance for 
appendicitis symptoms, in the experimental arm.  
In the control arm, higher rates of CT–led over–diagnosis will lead to inappropriate 
treatment in patients without true acute appendicitis; thus the new strategy could be of 
benefit by reducing the risks of unnecessary surgery303. However this is not guaranteed 
since a lower treatment threshold in experimental patients due to decreased confidence, or 
a lower diagnostic specificity compared to CT, could also increase the number over–
treated in this group. 
Any test–related differences in the types of treatment selected (antibiotics or surgical 
removal) could also influence the success of treatment: fewer indications for surgery would 
reduce the rate of associated harms, while higher indications for conservative treatment 
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could increase recurrences due to initial treatment failure (although subsequent 
appendectomy is shown to carry a very low risk of complications)304. Rates of surgery 
could be higher in the control arm if those with indeterminate scans are sent for surgery 
due to fears of reprisals for missed diagnoses. 
On the other hand, if CT might improve treatment success in complicated appendicitis 
cases by avoiding the need for surgery (e.g. percutaneous drainage of abscess) due to the 
increased therapeutic confidence of surgeons. 
Delays in receiving appropriate treatment, whether as a result of missed diagnoses or the 
need to wait for confirmatory imaging, will cause some cases of disease to progress 
risking perforation, abscess and peritonitis in true–appendicitis cases and other morbidities 
in those with differential diagnoses. Following the rationale above, both arms will be 
exposed to these risks, the control arm due to potential delays in receiving a diagnosis and 
the experimental arm due to higher rates of missed disease.   
Adherence (s. Adherence to treatment) 
The concept of adherence is not relevant to surgery, though could influence the health of 
patients prescribed antibiotics. However it is unclear what effects receiving a CT scan 
might have on this mechanism.   
Summ ar y o f  ra t i ona l e  
These considerations can be synthesised to outline the four causal pathways by which the 
selective strategy might be expected to impact on patient health: 
Direct impact: the new strategy is expected to be of clear benefit to patients by reducing 
exposure to the procedural harms of undergoing contrast–enhanced CT. The degree of 
improvement observed will depend on clinicians‟ confidence in proceeding with treatment 
decisions without the aid of CT. 
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Decisional impact: the new strategy is likely to detect fewer true–positives, leading to 
lower rates of treatment success. This disadvantage could be reduced if the selective 
strategy benefits from lower rates of failed procedures (due to oral contrast intolerance) 
and indeterminate results. The new strategy may also detect fewer false–positives, leading 
to lower rates of treatment harm. However this advantage may be mitigated by low 
diagnostic and therapeutic confidence that results in more CTs being ordered than 
necessary, or it may not materialise at all if CT is also more specific causing rates of 
treatment harm to perhaps be higher. 
Temporal impact: the new strategy may be more expedient in treating typical 
presentations, leading to lower morbidity caused by progressing disease. However 
treatment may be less expedient in atypical cases which could mitigate the overall benefits 
observed. 
Perceptive impact: no impact expected. 
8.2.2 Choosing outcomes to evaluate selective CT 
These considerations serve as prompts to select meaningful measures of patient health, 
but also to identify intermediate outcomes that allow us to evaluate whether hypothesised 
mechanisms do affect patient management processes as intended.  
So, direct health impacts are captured by recording the number of patients receiving a CT 
scan, the per–person exposure to radiation and the frequency of contrast–induced 
morbidity (Table 8.2). It is worth noting here that due to their very long–term nature, the 
consequences of radiation will not be quantifiable in an RCT. The above rationale 
concludes that downstream health is likely to be affected by differences in how and when 
diagnostic decisions are made. Thinking through the decisional pathway highlighted three 
groups of patients who could be identified to differing degrees of accuracy: 1) acute 
appendix cases, 2) disease–free cases and 3) diseased individuals with a differential
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Table 8.2 Outcome selection for the putative trial comparing standard routine CT with a more 
selective strategy for patients presenting with suspected appendicitis
(T60)
. 
   
Causal 
Pathway 
Intermediate outcome Patient outcome 
Direct:   
Test Process Number of patients receiving CT Mean per patient exposure to radiation 
% procedural morbidity 
Decisional:   
Feasibility % tests not completed due to 
contraindication, contrast failure or 
other reasons 
 
 
 
 
 
% symptom recurrence 
% resolution of presenting condition 
% complicated disease (of all diagnosed 
conditions, including complicated 
appendicitis [perforated appendix, 
peritonitis, abscess]) 
% therapeutic complications  
% death 
Time–to–recovery 
Interpretab–
ility 
% of indeterminate test results 
Accuracy % diagnosed following initial discharge 
(FN rate) 
% diagnosed with appendicitis during 
follow–up (FN–target condition) 
% diagnosed with non–appendiceal 
disease during follow–up (FN–other 
diagnoses) 
% negative appendectomies (FP rate) 
Diagnostic 
Yield 
Rates of all diagnoses per test 
Rates of final diagnoses 
% diagnosed with acute appendicitis/no 
disease/differential disease 
Therapeutic 
Yield 
Rates of each prescribed treatment 
Treatment 
efficacy 
% readmitted for failed treatment (e.g. 
surgery for failed antibiotics) 
Diagnostic 
confidence 
% cases for whom additional tests 
ordered 
% with a change in diagnosis as a result 
of additional testing  
Reason for ordering additional tests 
% treated against indication of test 
results 
Reason for treating against indication 
Therapeutic 
confidence 
% cases where CT used to guide 
treatment approach 
Temporality:  
Timing test Time–to–CT 
 Timing 
diagnosis 
Time–to–definitive diagnosis 
Timing 
treatment 
Time–to–treatment 
Length of stay 
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diagnosis (appendicitis–free). Consequently the primary useful measure of downstream 
health should evaluate the degree to which their initial complaint has been resolved, 
perhaps by measuring symptom resolution or recurrence at the end of an appropriate 
period of follow–up. To capture mis–diagnosis, rates of perforated appendix, abscess 
formation and wound infection should be measured, as should a more general marker 
such as deterioration in health, in order to capture the effects of misdiagnosis in individuals 
without appendicitis who have differential diagnoses. Of course, these harms may also be 
caused by delays in arriving at a diagnosis. These two causes could be differentiated by 
measuring relevant mechanisms as intermediate outcomes. Accordingly, the impact of 
decision–making could be assessed by recording the number and character of diagnoses 
(diagnostic yield) and treatment decisions (therapeutic yield) made by each strategy. The 
appropriateness (accuracy) of these decisions could be assessed by comparing the 
proportion of patients with recurrent symptoms (total false–negative rate), the proportion 
treated for appendicitis during follow–up (appendicitis–specific false–negative rate), as well 
as the proportion of patients with histologically–normal appendices removed during 
treatment (false–positive rate)*. The impact of other influences on the accuracy and 
appropriateness of decision–making could be assessed by measuring complementary 
aspects of decision–making behaviour, such as referrals for additional tests and the 
resulting changes in diagnosis and treatment selection.  
The extent to which differences in timing might be responsible for downstream patient 
outcomes could subsequently be inferred by looking at time–to–CT completion, time–to–
definitive diagnosis, time–to–treatment and of course time–to–recovery.  
                                                 
*
 It is important to note that while these processes may indicate accuracy, they are not true measures of 
accuracy since a reference diagnosis cannot be administered to all patients. 
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8.3 Applications of the tool
 
This chapter has presented a practical tool to guide researchers in formulating a clear 
scientific rationale for the intended effects of a putative test-treatment intervention, by 
comparison to an existing strategy. The diagram initially focuses the user to give detailed 
consideration to the composition of test-treatment strategies by requiring each of the five 
components to be defined, as well as to other key aspects of comparative diagnostic 
setting. The checklist builds on basic principles by providing a vehicle for elucidating the 
likely processes of change within the comparison, allowing the rationale of the new 
strategy‟s effectiveness to be made explicit through a structures and replicable 
consideration of mechanisms. This thesis argues that in so doing the tool provides a 
strong potential to further the evaluation of a test‟s clinical utility in four key ways.  
8.3.1 Designing test-treatment trials 
Use of the tool can enhance the design of test-treatment RCTs by helping to ensure that 
studies fully evaluate competing strategies. Due to the complexity of interactions that can 
influence health measures, determining which trade–offs are occurring, and estimating 
how they will ultimately exert their effect, is a task beset by convolution and complexity. 
The worked example above illustrates this well; though a seemingly straightforward 
evaluation, the comparison of selective CT vs. routine CT for suspected appendicitis 
contained numerous potential trade–offs which could pull treatment effects to favour either 
strategy. For example, appropriate avoidance of a CT scan in experimental arm patients 
could improve recovery by expediting treatment, yet the new strategy may also delay 
appropriate treatment in others as a result of reduced sensitivity. Establishing the nature of 
these often subtle interactions is difficult without a structured frame of reference, risking 
the incomplete delineation of cause and effect. 
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Based on a generalised theory of how tests impact on patient health, the tool provides the 
necessary frame of reference – a structure for thinking through these issues, allowing 
causal assumptions to be made explicit and clarified, while drawing attention to the 
potential hidden benefits of a competing technology or strategy. This focuses the 
consideration of which endpoints should be measured in order to capture the full range of 
impacts to patient health, while the measurement of relevant mechanisms allows a nested 
evaluation of process outcomes to clarify whether causal pathways are operating as 
hypothesised.  
8.3.2 Establishing the need for an RCT 
Working through the checklist could also assist in ascertaining whether an RCT is 
necessary to demonstrate a test‟s clinical utility. Answering each question demands 
consultation of the existing knowledge base, so a completed checklist provides a summary 
of evidence regarding how mechanisms are already known to differ between tests.  
Comparisons where evidence for all relevant mechanisms has already been documented 
are unlikely to require RCTs that measure long-term outcomes, since the causal pathways 
can be pieced together from existing evidence. This is similar to the approach used by the 
US Preventative Task Force (USPTF), in which causal linkages between a screening 
programme and desired health outcome are conceptualised and used to target the 
evidence needed to produce an effectiveness review78. Lord and colleagues have also 
discussed how existing evidence should be linked in comparisons driven by changes in 
accuracy19,21,93, although the thesis framework suggests these linkages are likely to be 
more numerous and more complicated than previously considered, as discussed in 
Chapter 7.  
In agreement with these authors, however, the framework tool may be useful in 
constructing the case for an RCT when trade–offs occurring between mechanisms cast 
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uncertainty regarding their ultimate impact on patient health. When examining the potential 
effects of the competing diagnostic strategies in suspected appendicitis patients, the 
rationale above highlighted the uncertainty as to whether the selective approach would 
reduce the inappropriate treatment rate through its potentially superior specificity, or 
increase it due to lower diagnostic confidence. The framework highlights the difficulties of 
approximating diagnostic settings with highly complex pathways of causal change to 
patient outcomes. Comparisons that involve multiple causal pathways are unlikely to be 
appropriate for evaluation by decision–modelling, unless sufficient information already 
exists to demonstrate the likely impact to patient health, and in these situations RCTs may 
be the only design that can establish how patients will respond to the entire test-treat 
strategy. 
Yet if adequate evidence of all relevant mechanisms does exist, the wisdom of conducting 
an RCT becomes questionable. An example is found in the project cohort of trials. Liu and 
co-workers set out to evaluate whether triage with endoscopic ultrasound (EUS) in patients 
with suspected biliary pancreatitis reduced morbidity by avoiding endoscopic retrograde 
cholangiopancreatography (ERCP), a more risky and invasive procedure, in test-negative 
patients(T9). Timing here is not at stake since the tests are conducted in series during the 
same anaesthetic. Existing research demonstrates EUS has a lower failure rate than 
ERCP305,306, causes significantly less procedural harm307, is at least equivalent in accuracy 
with higher sensitivity for detecting small stones306,308–311, increases diagnostic 
confidence312 and improves treatment decisions313. Since subsequent mechanisms are all 
positively affected by these attributes no further trade-offs are involved, and since those 
mechanisms that are relevant have already been documented, we can conclude we 
already have enough information without conducting this trial. In such a situation applying 
the framework tool could save significant resources by highlighting that a decision–model 
is the more appropriate choice of study design.  
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This example promotes the framework tool‟s utility to funders: had the trialists submitted 
their trial design with a completed checklist, it would have required them to specify what 
was already known, what they would measure and therefore the nature of additional 
knowledge the trial would provide. Furnished with this information, it is unlikely the above 
trial would have been funded. 
8.3.3 Interpreting and implementing trial results 
Failure to demonstrate effectiveness in an RCT demands cautious interpretation, and 
should be judiciously distinguished from clear evidence of ineffectiveness314. Findings of 
no effect are all too often interpreted as „evidence of absence‟, when in reality studies 
rarely make provision for being able to attribute negative results to a truly ineffective 
diagnostic intervention, a methodologically flawed study design or, importantly, a poorly 
implemented test-treat strategy. The framework tool confronts these problems directly by 
providing guidance as to which processes are relevant and need to be measured. 
All mechanisms in the framework can be measured as process outcomes, and as 
attributes that characterise the workings of a given care pathway their measurement 
provides a critical account of how a test-treat strategy performs. Weak links in the causal 
chain can be identified and strengthened to enhance effectiveness. For example, tests 
which provide earlier information will only yield benefits when information systems exist to 
deliver those results in a timely way to allow clinicians to initiate treatment earlier.  
Assessing relevant mechanisms (e.g. time-to-diagnosis, time-to-treatment) will evaluate 
these processes. Not only would this approach facilitate the identification of which 
components in a new intervention might have failed, thus enabling the adjustment of 
specific mechanisms rather than the entire management strategy, but it also proffers an 
insight into the mechanisms by which an effective intervention has succeeded. This 
information can be harnessed to organise the implementation of successful strategies, 
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since policy makers can more easily identify the causative „ingredients‟ of test-treatment 
interventions and formulate clinical policy guidelines accordingly.  
Identifying and measuring mechanistic outcomes are also of use to monitoring 
discrepancies between the course of management intended with that actually conducted 
during the course of the trial, facilitating a subsequent discourse regarding why such 
differences may have emerged and how they may have affected effectiveness. 
The principle of linking process and patient outcomes has been championed by 
researchers of complex interventions in both healthcare83,315 and social economics316–317, 
both groups of whom have embraced a „theory–based approach‟ which emphasises the 
importance of modelling interventions prior to their evaluation so as to enrich the 
interpretation of subsequent trial results. These discussions have yet to influence 
diagnostic research, however, where the multiplicity of effects a test can exert on the 
treatment effect is generally not well articulated. 
8.3.4 Appraising trial quality 
Lastly, the checklist could assist appraisals of whether test-treatment trials have measured 
all important outcomes. To illustrate let us return briefly to the worked example and 
compare the outcomes highlighted by the framework with those actually measured in the 
trial.  
In their introduction the investigators claim to evaluate the hypothesis that “selective CT 
imaging would reduce the use of CT without increasing the negative appendectomy and 
perforated appendix rates in comparison with mandatory imaging” (T60). To achieve this 
they measured the negative appendectomy rate as the primary endpoint, and also 
compared the frequency of CT scans, diagnoses of acute appendicitis, frequency of 
surgical treatment, mean time to surgical treatment, the rate of perforated appendix and 
mortality. 
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Randomising 152 patients (80 to selective, 72 to control) the authors found no significant 
differences in the negative appendectomy rate (6/43 vs. 1/39, 11.3% absolute difference 
[95%CI: –3.5%, 26.3%]†) or secondary outcomes excepting the number of CT scans which 
were significantly fewer in the selective strategy (70/72 vs. 54/80, 29.7% absolute 
difference [95%CI: 18.2%, 40.8%]). Based on these findings the trialists conclude that 
while a selective strategy will significantly reduce CT use it may also associated with a 
trend to increased rates of negative appendectomy. 
However when this is compared to the framework‟s rationale we can see that this 
conclusion is incomplete and not particularly useful as evidence to indicate the utility of 
either strategy. 
How  appropr ia t e  ar e  pa t ient  outcomes?  
By comparison to the more extensive list of proposed outcomes developed above it is 
immediately clear that trialists measured (or reported) far fewer outcomes than were 
indicated by the framework (Table 8.3). Significantly, the trial does not appear to have fully 
evaluated the impact of the intervention on all relevant patients. Firstly, trialists do not 
measure any downstream health benefits such as symptom recurrence or resolution, thus 
the trial cannot provide a proper indication of whether patients are better off as a result of 
receiving either strategy. Potential harms are also inadequately assessed; the frequency of 
perforated appendix wisely captures an aspect of harm, however its focus on the „target 
condition‟ fails to take into account the health consequences of patients with other 
conditions who may have suffered harms as a result of undergoing inappropriate or 
delayed diagnosis and treatment. We need to know about the total rate of adverse 
outcomes, in all patients who will undergo the strategy, to be sure that the intervention is 
doing more good than harm.  
                                                 
†
 Figures presented as reported; note the wrong denominator is used as discussed in chapter 6 (p.178–180) 
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Table 8.3 Outcomes measured by the selective vs. routine CT for appendicitis trial
(T60)
 (blue) 
compared to those identified by the framework but not measured (grey) and those 
partially measured (red). 
Causal 
Pathway 
Intermediate outcome Patient outcome 
Direct:   
Test Process Number of patients receiving CT Mean per patient exposure to radiation 
% procedural morbidity 
% procedural  complications of CT 
Decisional:   
Feasibility % tests not completed due to 
contraindication, contrast failure or 
other reasons 
 
 
 
 
 
% symptom recurrence 
% resolution of presenting condition 
% complicated disease (of all diagnosed 
conditions, including complicated 
appendicitis [perforated appendix, 
peritonitis, abscess]) 
% therapeutic complications  
% death 
Time–to–recovery 
Interpretab–
ility 
% of indeterminate test results 
Accuracy % diagnosed following initial discharge 
(FN rate) 
% diagnosed with appendicitis during 
follow–up (FN–target condition) 
% diagnosed with non–appendiceal 
disease during follow–up (FN–other 
diagnoses) 
% negative appendectomies (FP rate) 
Diagnostic 
Yield 
Rates of all diagnoses per test 
Rates of final diagnoses 
% diagnosed with acute appendicitis/no 
disease/differential disease 
Therapeutic 
Yield 
Rates of each prescribed treatment 
Treatment 
efficacy 
% readmitted for failed treatment (e.g. 
surgery for failed antibiotics) 
Diagnostic 
confidence 
% cases for whom additional tests 
ordered 
% with a change in diagnosis as a result 
of additional testing  
Reason for ordering additional tests 
% treated against indication of test 
results 
Reason for treating against indication 
Therapeutic 
confidence 
% cases where CT used to guide 
treatment approach 
Temporality:  
Timing test Time–to–CT 
 Timing 
diagnosis 
Time–to–definitive diagnosis 
Timing 
treatment 
Time–to–treatment 
Length of stay 
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How  appropr ia t e  i s  t he  pr im ar y out come?  
The primary outcome (negative appendectomy rate) evaluates the false–positive diagnosis 
rate. The framework perspective highlights that this surrogate outcome only measures 
accuracy and diagnostic yield, without assessing the impact these two mechanisms have 
on patient health. Since we have determined that several other mechanisms may mitigate 
these effects, on its own the false–positive rate is an inadequate surrogate for patient 
health.  
One could argue that a more appropriate study hypothesis would be to assess whether 
selective CT ‘can reduce the overall yield of procedural harms without increasing the risk 
of causing downstream harm to patient health resulting from inappropriate or delayed 
treatment’. In addition to mortality, Table 8.2 listed two adverse health outcomes that 
would capture the effects of the whole care pathway, and hence could constitute an 
appropriate primary outcome. This would of course require a much larger sample size to 
ensure the trial were powered to detect these health effects. 
Sci ent i f i c  ra t i ona le  and in t erm edi a te  out com e s 
There can be little doubt that this incomplete selection of patient outcomes reflects the less 
than comprehensive attention given to the rationalising how the new strategy was 
expected to create differences in both clinical processes and patient health. Authors 
initiated their reasoning appropriately in introductory paragraphs by identifying the potential 
shortcomings of standard care: CT radiation and contrast material may be harmful; as a 
less than perfect test CT may miss or falsely identify disease; inaccurate diagnoses result 
in unnecessary surgery and delay of appropriate treatment, both of which can cause 
morbidity. So far so good. At no point, however, did the investigators frame these 
contributing factors within a comparative context: they failed to make a case for how 
selective CT might differ in these respects to routine use of CT. The only clue is furnished 
in their study hypothesis which expects no difference in decision–making at the benefit of 
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reducing the use of CT. Perhaps as a consequence the investigators have neglected to 
consider other factors that may mediate how a selective approach changes decision–
making and downstream patient health. As a result the actions of several important 
mechanisms, particularly feasibility, diagnostic confidence and therapeutic confidence, 
were not evaluated. What is more, some mechanisms that were identified were not 
measured as comparative indicators of performance; for example the rates of final 
diagnoses were not examined per arm, thus preventing an appraisal of diagnostic yield.  
As a consequence we are unable to fully interpret and therefore use the results of this trial. 
While the selective strategy did significantly reduce the use of CT, no other differences 
were found. Why were there no differences in negative appendectomy or perforated 
appendix rates?‡ Is it because the two strategies produced equivalent diagnostic and 
treatment yields within comparable timeframes? Did clinicians in either arm resort to 
additional diagnostic procedures to achieve this equivalence? Did clinical judgement 
supersede CT results or vice versa? Could important adverse events have occurred after 
the end of study follow–up? Did this equivalence come at the cost of harming patients with 
diagnoses other than appendicitis? None of these questions can be answered on the basis 
of published results. Since we cannot be sure of how these results were achieved, we 
cannot be sure of the impact that implementing a selective CT policy would have on 
patients presenting to emergency departments with acute lower right quadrant abdominal 
pain. In this instance the tool has provided a structure for exploring the scientific rationale 
                                                 
‡
 This trial suffers from several other methodological issues that lead the appraiser to question the validity of 
its conclusions, not least of which is likelihood of type II error; the power calculation did not account for 
negative appendectomies only being detectable in patients undergoing an appendectomy, reported as 
approximately 50% in both arms. To account of this the sample size should have inflated its estimate 
(n=140) by this figure giving 280 (140 x 1/50%). Interestingly, if the same rates of negative appendectomy 
had been observed in this larger population the finding would have been significant (Chi sq =5.638, 
p=0.0176). What is more, the trialists inappropriately used a superiority analysis to evaluate their hypothesis 
that was clearly framed as a question of non–inferiority (that negative appendectomy would be no worse); 
this may also have necessitated a larger sample size
145
. 
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of a trial, unpicking its aims and appraising not only whether it has achieved its aims but 
whether investigators could have evaluated a more useful question. 
8.3.5 Study limitations 
Due to poor reporting, the author had to make certain assumptions regarding how 
diagnostic and therapeutic decision–making might be expected to proceed. These were 
checked with a practicing general surgeon, however since practice is highly variable these 
may well differ from the decisions intended by the trial investigators. The primary aim was 
not to be entirely clinically accurate, but to illustrate how a comparison might be worked 
through to elucidate the workings of comparative test-treatment pathways. It is worth 
noting, however, that use of the framework tool to appraise trials will be hindered if 
reporting of the test-treatment protocol is particularly poor.  
Critically, the future success of the framework will rely on the ability of users to distinguish 
the competing clinical pathways and identify which mechanisms are likely to influence 
patient health trajectories. Whether for appraisal or design clinical expertise in the relevant 
setting is essential to construct valid and reliable care management pathways. The 
framework underlines the importance of incorporating patient and organisational 
perspectives, thus input from all key stakeholders will maximise the reliability of 
subsequent analysis.  
Lastly, the tool is presented as a draft attempt, hence the true extent of the tool‟s utility will 
not be apparent until interested parties have trialled it. It is possible that certain aspects 
may not meet with the demands of those for whom it was intended; two aspects that may 
need to be developed in future are the absence of specific guidance on how to draw 
checklist items together into causal pathways, and the tool‟s restriction to comparing two 
strategies. In order to develop the tool into a valid resource future work will entail piloting it 
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across diagnostic technologies and improving its utility through engagement with 
interested stakeholders.  
8.4 Conclusions 
 
Expectations that a particular test will improve clinical practice inevitably involve some 
assumption regarding how the intervention will produce change. As demonstrated in 
earlier chapters, these assumptions are often poorly articulated and, in all likelihood, 
incompletely grasped due to both the complexity of how tests impact on heath, and the 
absence of a conceptual model that offers a template for the theory of change. 
Accordingly, this thesis has provided a new theoretical framework, and from it developed a 
methodological tool aimed at identifying the assumptions of causality.  
The discussion above argues that the earlier this can be done in the evaluative process, 
the more reliable and efficient our summative assessments of a test‟s clinical utility are 
likely to be. We may avoid unnecessary and expensive trials by recognising we already 
have all the necessary primary data, or alternatively make a strong case for the need to 
conduct an RCT and be in a better position to identify all important outcomes and as a 
consequence provide more reliable trial results that are interpreted comprehensively.  
It is clear from table 8.2 that test-treatment trials will need to measure considerably more 
endpoints than is common in standard treatment trials in order to provide comprehensive 
evaluations that can be interpreted fully. Limiting patient outcomes to the effects 
experienced by patients with the target condition, as is done for trials of treatments, can 
only provide a partial investigation since tests are generally used to differentiate between 
several diseases with contrasting consequences. Moreover, trials will need to incorporate 
the measurement of many process outcomes in order to determine why particular effects 
have been observed. While this presents a considerable addition to the resources needed 
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to undertake a successful test-treatment RCT, measuring these processes could also 
improve the feasibility of conducting these studies. Changes in intermediate outcomes are 
likely to be larger and detected with greater power than patient outcomes, which typically 
only occur in a subgroup of the sample defined by disease status and test results, often a 
small fraction of the total sample. 
Establishing benefit to patient health must remain the priority of diagnostic evaluations, 
however this thesis argues the importance of engaging in the „theory–based approach‟ 
championed by other disciplines83,316–317: it is not sufficient to measure endpoints, but it is 
essential to understand how these outputs are created by conducting tangible analyses of 
their workings. The application of the framework to proposed or completed test-treat 
evaluations facilitates this approach and encourages a comprehensive understanding of 
the intervention, features which will be of use methodologists, trialists, reviewers, guideline 
developers and funders of clinical effectiveness. 
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The introductory paragraphs to this thesis highlighted the ever growing need for a high–
quality evidence–base that can inform clinicians, reviewers and policy–makers on which 
diagnostic tests result in better patient health. Increases in diagnostic test research over 
the last three decades have been dominated by demonstrating the accuracy of these tests. 
Despite agreement that such evidence is insufficient to warrant the uptake of new 
technologies, many diagnostic effectiveness reviews currently fail to find direct evidence of 
the test’s impact on downstream patient health. By analogy with the evidence–based 
evaluation of treatments, RCTs are recommended as the ‘gold–standard’ approach. Yet 
these ‘test-treatment’ RCTs have attracted criticism that lead one to question how useful 
they are likely to be in providing the high–quality evidence that is needed. In the absence 
of substantial systematic exploration of these criticisms, the author set out to begin to 
answer this question by finding and then analysing all identifiable test-treatment RCTs 
published between 2004 and 2007. Four aims were used to address the central research 
question, each reflecting a challenge that these RCTs are hypothesised to face. The 
analyses performed have begun to provide evidence regarding how useful test-treatment 
RCTs are. 
This final chapter first provides a summary and interpretation of main findings from 
chapters 2–8, and discuss the extent to which they answer the four thesis aims set out in 
chapter 1. After considering the limitations to the thesis, implications for practice and 
proposals for future research are presented. The thesis concludes by addressing the 
central research question: how useful are test-treatment RCTs?  
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9.1  Aim 1: Are test-treatment RCTs 
feasible?  
 
In response to concerns that test-treatment RCTs are rarely found when conducting 
effectiveness reviews, the first aim was designed to investigate whether these studies can 
be completed successfully. Two studies were performed to address this question.  
Chapter 3 presented a capture–recapture analysis in which the project search was 
compared to a second, different search of CENTRAL in order to estimate the number of 
relevant RCTs missed by both strategies. By allowing the total number of test-treatment 
trials published (2004–2007) to be estimated, this approach also allowed verification that 
the project search had not inadvertently missed many trials due to the potential difficulties 
in identifying them. Despite using a search strategy that specifically targeted certain tests, 
the analysis confirmed trial ascertainment to be very resource-intensive, requiring many 
thousands of records to be checked for yields of 0.9–1%. Approximately 145–146 test-
treatment trials were indexed in CENTRAL over the search period, suggesting that only 
36–37 test-treatment RCTs were published per year between 2004 and 2007. This is just a 
tiny fraction of the total number of RCTs that are published in medical journals every year. 
These findings confirm existing opinion that test-treatment RCTs are rare. Whilst the very 
low yields of relevant trials found by both searches also attests to the great difficulties in 
locating these studies, the relatively low estimate of missed trials (n=12) suggests the 
rarity is not artefactual.  
That RCTs are not attempted could signal that these designs are often considered too 
difficult to evaluate diagnostic tests. Indeed, this explanation is expounded by individuals 
and research organisations alike, who commonly cite logistical difficulties and resulting 
expense as key barriers to the feasibility of conducting test-treatment RCTs15–16,51,95. 
Hunink and Krestin, researchers with extensive experience of conducting test-treatment
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RCTs, argue that trial results may often not justify the associated ‘price tag’ 6. Discussing 
the conflict between the need to keep up with the rapid development of test technologies 
and the need to perform thorough evaluations of effectiveness, they argue that ‘new’ 
diagnostic tests often either present incremental improvements to existing technologies, or 
are added to existing strategies and thus many trials must recruit unrealistic sample sizes 
in order to capture effects that will generally be very small.   
The detailed characterisation of included trials presented in chapter 4 provides further 
insight into potential reasons for the scarcity of test-treatment trials. Aiming to distinguish 
which diagnostic settings were successfully evaluated to completion, this analysis 
described the cohort of trials identified in chapter 2 and provided an overview of the 
diagnostic questions they evaluated. Despite considerable overall heterogeneity, there 
was a clear predominance of evaluations of imaging and to a lesser extent biochemical 
tests, tests used in cardiovascular medicine, secondary/tertiary care settings, and 
replacement comparisons. The latter finding corroborates the ‘feasibility’ argument, since it 
could indicate that trials are more likely to be attempted or successfully completed when 
effect sizes are largest.  
On the other hand, trials most commonly evaluated questions posed by disciplines that 
also have the strongest traditions of academic research, namely imaging, biochemistry 
and cardiovascular disease. This warrants consideration of an alternative explanation, that 
perhaps trials are not carried out in other disciplines because the need for effectiveness 
research is not as well articulated, and possibly not as well understood. Within the wider 
clinical and research communities, test accuracy studies are commonly misconstrued as 
effectiveness studies – as put eloquently by Patrick Bossuyt, the value of tests are often 
thought to lay in the truth of their results rather than in the consequences of their results318. 
Though the dissemination of rigorous methods for undertaking accuracy studies and 
reviews has had many benefits, not least by highlighting the need for evaluating tests58,
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the focus on such methods may also have unwittingly generated the perception that trials 
of tests are unnecessary when evidence of their accuracy already exists. This is somewhat 
supported by the observation that the complexity of designs per se did not appear to be a 
barrier to performing test-treatment RCTs, with many included studies comparing very 
complicated strategies evaluating multiple phases of testing. Increasing awareness that 
effectiveness evaluations are needed12,44,75,77, as well as providing guidance on how to 
conduct these trials, could therefore increase the number published quite substantially, 
and thus increase the availability of evidence that is needed to discern whether tests do 
more good than harm to patients. 
9.2 Aim 2: How informative are test-
treatment RCTs?  
 
A second key requirement for trials to be useful is that they produce evidence that can be 
interpreted and translated into practice. In response to claims that achieving these two 
requirements could encounter particular difficulties due to the complexities of test-
treatment interventions, the author set out to evaluate the extent to which published trials 
produce evidence that is informative by evaluating the reporting quality of included trials. 
The review examined the extent to which the reader could satisfactorily glean what was 
done, to whom, when and why. This was achieved by appraising the adequacy of 
descriptions of test-treatment interventions, complete reporting of participant flow and 
definition and documentation of primary outcome assessment.  
Observed reporting quality was very poor for each of the three items assessed. Incomplete 
accounting of participant flow was common, hampering a full interpretation of the meaning 
of observed test-treatment effects. Although primary outcomes were defined by almost all 
trials, methods and timing of measurement were beleaguered by incomplete reporting, a 
barrier to the replication of measurements and highly likely to lead to problems when 
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seeking to compare effects between trials. The most important finding was the meagre 
documentation of what interventions were used, how they were used, and why. Only three 
trials provided at least some detail of tests and treatments and decision–making for all 
comparative interventions, and generally several components were missing. Control 
interventions were particularly poorly outlined, as were the decision–making processes of 
all interventions. As a result the nature of what was being compared was frequently 
unclear. This was argued to pose two limitations to using RCT evidence. First, without 
clear and full descriptions of the tests given to patients, the operational criteria for 
diagnoses, and how these should lead to the selection of treatments, it will be almost 
impossible to interpret how observed results were created. 
Second, poor descriptions were likely to inhibit the ability to reproduce apparently 
beneficial interventions in a manner that is not only safe but that will be able to replicate 
the desired effects. On this basis the review of reporting quality concluded that published 
test-treatment trials do not produce sufficient detail for users to interpret trial results, nor to 
translate test-treatment interventions into practice. 
The poor level of reporting was also supported by evidence from other chapters. 
Difficulties were encountered when attempting to characterise the diagnostic questions 
evaluated by included test-treatment trials in chapter 4, particularly in trying to discern 
what these trials had evaluated. The review of methodological quality in chapter 6 also 
revealed that important aspects of trial conduct were very poorly reported, at times 
curtailing the ability to assess the true quality of methods.  
Concerns that the complex nature of these decision–making, multiple–component 
interventions could create increased difficulties in full reporting appeared to be confirmed 
when these findings were compared to similar reviews of treatment RCTs and complex 
intervention RCTs. While failure to report trial methods was partly explained by the 
suboptimal reporting quality found in all RCTs, the considerably inferior quality of
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intervention documentation highlighted an issue of particular concern to the production of 
informative test-treatment trials. 
As has been found with complex interventions156,319, difficulties in standardising diagnostic 
and therapeutic decision–making processes could account for the common absence of 
decision–making criteria. Though certainly more challenging to describe, this issue does 
not in itself prevent adequate documentation.  
Reporting issues were all in essence surmountable, though barriers to informative 
description were also found to be ‘conceptual’; by focusing on the experimental test 
method to the common omission of the three other components, the reporting style evoked 
a sense of being trapped in the mindset of reporting standard treatment trials rather than 
adopting a complex intervention approach which is far closer in nature to test-treatment 
strategies. Indeed, trials did not appear to identify themselves as evaluations of complex 
interventions. 
This would suggest that while test-treatment trials could in future be informative, notions of 
how this is to be achieved must be addressed and disseminated. 
9.3 Aim 3: Are test-treatment RCTs 
internally valid?  
 
If we are to rely on the results of test-treatment RCTs, these studies must offer the 
opportunity to provide internally valid evaluations that are free of bias. Yet researchers 
have claimed that the complex composition of test-treatment interventions makes the 
methods necessary to minimise bias and error difficult, if not impossible, to implement. The 
thesis set out to evaluate whether these claims are justified in chapter 6 by critically 
reviewing the methodological quality of included trials with full results (n=103), and by 
examining whether the issues encountered were likely to constitute particular challenges 
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to test-treatment RCTs by comparing these findings to the internal validity of treatment 
intervention RCTs. 
Due to the lack of an existing tool to appraise test-treatment RCTs, the author reviewed 
the adequacy of the five main threats to the internal validity of RCTs using items contained 
in three validated, internationally accepted standards for the optimal conduct and reporting 
of RCTs: selection bias, performance bias, ascertainment bias, attrition bias and type II 
error. The analysis revealed considerable challenges to the validity of published test-
treatment RCTs due to the suboptimal implementation of all five methodological 
safeguards, raising the distinct possibility that their results reflect artefacts of study design 
and subjective expectations rather than true clinical effectiveness. Comparison to the 
methodological quality of treatment RCTs demonstrated that some of these inadequacies 
could be explained by the suboptimal performances generally found in all RCTs; 
nonetheless test-treatment designs were characterised by higher rates of patient exclusion 
and drop–out, smaller sample sizes and a greatly reduced propensity to blind patients, 
clinicians and to a lesser extent outcome assessors.  
9.3.1 Practical barriers to internal validity: attrition and lack of 
power 
A key finding of the review is the empirical confirmation that test-treatment trials are 
particularly susceptible to attrition and lack of power. Although excluding randomised 
participants is generally inappropriate in any RCT320, the loss of data through patient drop–
out could be amplified by the practical difficulties of maintaining patient compliance during 
trials that involve numerous interventions, and are thus characterised by longer study 
periods and potentially more intensive follow–up regimes.  
These difficulties become particularly acute when trials must recruit much larger study 
populations in order to stand an acceptable chance of detecting a clinically meaningful 
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difference in treatment effect. Failures to attain target sample sizes, accompanied by some 
reports of problems in recruitment, attest to the practical difficulties these trials are likely to 
face in order to address study objectives adequately. Of course, trials that do power 
adequately would need to recruit considerably higher numbers of patients, which as Deeks 
points out could theoretically prove prohibitive if sufficient patient numbers do not exist176. 
Even if they do, attaining large sample sizes will require engagement with more study 
centres, longer recruitment periods, and hence more expense6.  
Nevertheless, as practical issues these difficulties can be overcome: there is no theoretical 
reason why test-treatment RCTs cannot minimise the risks of attrition bias and type II error 
to a similar degree as standard treatment RCTs. 
9.3.2 Methodological barriers to internal validity: performance and 
ascertainment bias 
In contrast, blinding was shown to pose a considerable challenge to the validity of existing 
and future test-treatment RCTs. Very few published trials performed blinding, but critically 
‘double–blinding’ (defined as masking 2 or more of the patient, clinician, outcome 
assessor) is likely to be impossible in virtually all test-treatment RCTs due to the 
considerable practical difficulties involved in performing sham diagnostic procedures, 
masking real test results and producing standardised diagnostic reports. As argued in 
chapter 6, in view of strong meta–epidemiological evidence associating the lack of double–
blinding with bias, these findings can be interpreted to indicate that most test-treatment 
RCTs are at risk of producing distorted treatment effects; and what is more, most future 
trials will not be able to avoid the risk of these biases. 
This inference assumes that test–treat effects are distorted in the same way as effects 
produced by treatment trials, yet how successfully the concept of performance bias is 
transposed to test-treatment designs presents an intriguing dilemma. Blinding was 
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designed to isolate the effects of pharmaceutical treatments from any other influences that 
are extraneous to the subject of evaluation321. These factors constitute any behaviour that 
could influence the causal link between the treatment a patient receives, and its effect on 
health. Clinician behaviour is controlled to avoid knowledge of the allocated treatment 
triggering the provision of additional/differential care. Patient behaviour is controlled to 
avoid knowledge of which treatment has been received influencing adherence, 
consumption of additional medicines or therapies, as well as the treatment response itself. 
Outcome assessor behaviour is controlled to prevent knowledge of the allocated treatment 
from unduly influencing the measurement of study endpoints. When all three controls are 
implemented, this allows us to be more certain that the only factor causing observed 
differences is the treatment322. Thus blinding strengthens our certainty in causality.  
This argument is not quite so straightforward when we consider test-treatment RCTs; 
since these interventions aim to cause effects by changing clinical behaviour it is far more 
difficult to determine which aspects of the intervention are extraneous, and therefore to 
isolate their effects. The finding that blinding patients or care–providers may alter or even 
eliminate desired effects suggests that attempting to control for performance bias is not 
appropriate for all test-treatment RCTs. While further work is urgently required to 
determine how blinding (or the lack of it) influences test-treat effects, this observation 
raises the possibility that the inability to blind clinicians may not always pose a serious 
threat to the internal validity of test-treatment RCTs, and therefore should not automatically 
be considered as an obstacle to achieving reliable results.  
On the other hand, the risk of ascertainment bias is likely to remain when outcomes are 
not assessed in blinded manner. Though blinding outcome assessors was more often 
feasible, it was still judged to be impossible to achieve in a third of trials. This finding 
presents a more pessimistic situation than forecast by previous researchers, who had 
projected that it would generally be possible to blind outcome assessors19,44,174. Most
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worrying was the discovery that it appears virtually impossible to blind assessors 
(generally the patient) when the outcome being measured is subjective. Since distortions 
in treatment effects from lack of blinding are reportedly higher in trials measuring 
subjective outcomes107–108, one can therefore conclude that the risk of ascertainment bias 
is likely to be considerable in test-treatment trials that seek to measure such effects. 
9.4 Aim 4: Do test-treatment RCTs fully 
evaluate their interventions?  
 
The final challenge levelled at test-treatment RCTs speculates that identifying and 
measuring all important effects may prove demanding due to the indirect relationship 
between tests and downstream health outcomes. As an initial step to tackling this issue, 
the thesis undertook to develop a solid theoretical understanding of how test-treatment 
interventions cause effects, which could act as the necessary framework of reference for 
future assessments of whether test-treatment RCTs have fully evaluated their 
interventions. Two studies were conducted to achieve these objectives.  
Chapter 7 was designed to develop the theoretical framework that conceptualises all the 
ways in which tests influence health outcomes. It achieved this by synthesising existing 
theories, and used them to generate a preliminary explanatory model. This model was 
tested, refined and explained by examination of the project cohort of published test–
treatment RCTs using analytic inductive methods. The resulting conceptual framework 
presented 14 mechanisms that interact to influence health outcomes in four ways: by 
direct impact, by altering the decisions made, by altering the timing of the test-treatment 
process, and by altering the patient’s and/or clinician’s perception or experience of the 
test-treatment process. Not only did this framework identify more mechanisms than 
apparent in the existing literature, but it identified a more complex relationship between 
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mechanisms than is commonly accepted. In particular it posits that these relationships are 
not linear, as frequently conceived, but that mechanisms share common 
interdependencies and interact synergistically along multiple causal pathways to alter 
health outcomes. A key implication was that superior accuracy can no longer be 
considered as sufficient or necessary for improvements to patient health, since these 
effects may be achieved through other causal pathways – chiefly by expediting the test-
treatment process. 
Chapter 8 developed these concepts into a practical tool designed to assist users of 
diagnostic evidence to formulate a comprehensive rationale for how a new testing strategy 
is expected to impact on health. The tool was presented as a graphic schema, designed to 
assist researchers to map out the five components of two comparative test-treatment 
strategies, and an accompanying checklist designed to get users to consider all 
mechanisms and conceptualise whether each might influence health outcomes. 
By reference to several examples derived from the project cohort, the tool was argued to 
provide added value to four key evaluative tasks: 
1. By requiring consultation of the evidence–base to address each checklist question, 
the tool can assist in establishing whether an RCT is necessary 
2. By providing a structure for systematically identifying the many trade–offs that are 
likely to be operating in even the more seemingly straightforward comparisons, the 
tool can be used to identify important process and patient outcomes and so could 
assist in trial design 
3. By providing guidance as to which mechanisms are relevant and should be 
measured, the tool could assist investigators to interpret how interventions have 
caused important health effects 
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4. By providing a comprehensive frame of reference for all the ways in which test-
treatment strategies may differ, the tool could assist to appraise whether existing 
trials have measured all appropriate outcomes  
9.4.1 Have published test-treatment RCTs fully evaluated their 
interventions? 
Although the question of whether trials fully evaluated test-treatment interventions was not 
assessed directly, the updated theory provided by the new framework, alongside other 
observations regarding the characteristics and reviews of published trials, begin to provide 
a tentative insight into this matter.  
Firstly, although 50% of trials used health outcomes as their primary measure, half of 
these were surrogate measures which are not guaranteed to capture all the intended 
effects of multiple, synergistic causal pathways. Second, during examination of how test-
treatment comparisons may be causing their effects for the purposes of developing the 
theoretical framework, the author found that most trials presented at best partial rationales 
for how the experimental strategy was expected to benefit patients. Along with the poor 
documentation of interventions, this may indicate that comprehensive thought was not 
given as to which aspects of comparative strategies differed and thus were likely to cause 
an effect. Third, the test-treatment framework revealed more numerous and complex 
causal pathways than commonly recognised by existing research frameworks. Since the 
previous perspective did not encompass the increased breadth and complexity of 
mechanisms at the time these trials were designed, it is a reasonable assumption that 
many failed to identify all the ways in which new interventions may be causing their effects. 
If this is the case, then one can deduce that many published trials are unlikely to have fully 
evaluated their test-treatment interventions.  
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This of course suggests that existing trials may suffer from not having measured the 
impact of test-treatment strategies on all individuals who undergo them. An equally 
important adverse consequence is that by not measuring all important intermediate 
processes, their results are unlikely to furnish readers with sufficient information regarding 
why health effects were, or were not, created.  
This has also been a major critique of complex interventions. Early RCT evaluations were 
criticised for selecting a desired health benefit of an intervention and concentrating on 
whether this effect was statistically significant, to the detriment of how understanding how 
it was created317. Although this ‘black box’ approach is adequate for pharmaceutical RCTs, 
which evaluate a short and direct causal chain, it is considered insufficient for complex 
interventions which are characterised by multiple, interacting components that influence 
health outcomes in a compound, and often unexpected, way323–324. Recent guidance for 
evaluating83 and reporting147 these evaluations emphasise the depth of attention that must 
be paid to the internal workings of these black boxes in order to perform comprehensive 
evaluations that can also reveal why particular effects were achieved. Process 
evaluations, in which the causal mechanisms of interventions are identified and measured, 
are now promoted as a gold–standard adjunct to complex intervention RCTs83,315 in order 
to isolate the ‘active ingredient’ of the intervention. While this point lays at the centre of the 
MRC’s framework that guides the development and evaluation of complex interventions83, 
the framework does not provide guidance as to which processes to measure. 
The test-treatment framework sits comfortably within the complex intervention structure, 
and as illustrated in chapter 8 it can be applied to each of the recommended five stages of 
evaluation: it enables researchers to construct a coherent theoretical argument for how 
desired improvements will occur; it draws attention to areas of uncertain causality which 
can be piloted during pre–trial planning; it informs the choice of which outcomes to 
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measure during the trial; it can aid documentation by making the composition of test-
treatment interventions clear and the differences between them explicit; and finally it can 
be used to demonstrate which active ingredients have caused change to facilitate the 
implementation of successful strategies. The MRC framework enriches the test-treatment 
framework by iterating how one stage of evaluation should proceed to the next (the MRC’s 
‘development–evaluation–implementation’ process)83, whilst its focus on the impact of 
organisational differences serves to ‘ground’ the test-treatment framework which is more 
conceptual and systems–driven.  
Arguably, however, the framework presented by this thesis goes further than the complex 
intervention guidance. By setting out a comprehensive list of all possible causal 
mechanisms, it provides explicit guidance on which processes should be identified and 
measured in order to perform a full process evaluation within a test-treatment RCT. Hence 
a key conclusion is that trials will be able to conduct full evaluations if they follow a similar 
process as that advocated by the framework tool. An important caveat is that such efforts 
are likely to highlight the need to measure many patient and process outcomes, which 
could prove both costly and challenging. 
9.5 Limitations  
 
Limitations to the methods used for individual analyses were discussed in each of the 
relevant chapters, however it is also appropriate to consider whether the general approach 
taken may have failed to answer the main thesis question comprehensively. 
9.5.1 Indirect methods for evaluating feasibility 
The first shortcoming concerns the indirect approach used for investigating how feasible it 
is to perform test-treatment RCTs. By limiting the analysis to completed and published 
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trials, this research may have missed or underemphasised key practical obstacles to the 
ability to perform these trials. This potential form of ‘publication bias’ would have required 
extensive searching of trial registration databases to quantify, and possibly interviews with 
trialists to try to capture practical issues more directly. While this was not possible to 
perform due to time constraints, the author knows of at least two trials originally funded by 
the NETSCC HTA that were discontinued, and a further 3 that were not accepted for the 
publication in the associated journal (of which one was published in another journal within 
the searching timeframe(T31)). Establishing the reasons for discontinuation could provide 
very interesting insights into the interplay between the practical needs of these difficult 
studies (particularly recruitment) and the expectations of funders.  
9.5.2 Confounding of true methodological quality 
An issue already raised in chapters 5 and 6, the thesis established the relative 
performance of test-treatment designs by comparing frequencies of observed quality items 
to those found by previous reviews of treatment RCTs and complex intervention RCTs. 
This is a somewhat crude measure, since it assumes that methodological quality was 
assessed in the same way by all investigators, and also that reporting reflects 
methodological quality to an equal extent across all types of RCT. If this were not the case 
then the interpretation deduced here may not be entirely valid. However the author could 
find no overt suggestions that reporting of adequate methods was worse, since several 
methods of trial conduct were found to have been reported with similar frequencies, and in 
some cases more frequently, than standard RCTs. Additionally, measures were taken to 
ensure that quality appraisal was conducted to the most rigorous standards, and while 
some judgements were independently verified to a high degree of inter–rater agreement 
by an experienced reviewer for a sample of included trials, the findings would benefit from 
a complete independent appraisal.  
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9.5.3 Generalisability of test-treatment trials 
This thesis did not explore the extent to which published test-treatment RCTs were 
generalisable, largely because the review’s inclusion criteria necessitated the selection of 
a wide range of clinical settings. Since generalisability is a highly contextualised 
judgement325, its assessment in this study would have presented a complex and time–
consuming task involving consultation with a wide range of clinical specialists. 
However this issue has proven to be a key difficulty for complex interventions, for reasons 
that are also likely to apply to test-treatment interventions. Due to their many interacting 
components, complex interventions tend to be characterised by poor fidelity if over–
standardised. Therefore there is a tension between designing methodologically rigorous 
RCTs, which requires standardisation in order to be reproducible, and achieving 
generalisable results. As discussed above, the properties of test-treatment interventions 
are likely to be very similar in this regard, thus the threat to the generalisability of test-
treatment results could prove to be a crucial determinant of whether these studies are 
ultimately considered to be useful.  
This view is not accepted by within the complex intervention community, however, and 
recent discussions place the ‘exploratory versus pragmatic’ argument as a relic of the 
traditions established within the pharmaceutical RCT paradigm182,326. Rather, carrying out 
embedded process evaluations that measure how interventions are actually administered 
has become a critical part of the evaluation itself 317. Some have put forward the need to 
reconceptualise the notion of ‘fidelity to complex interventions’, whereby rather than 
seeking to standardise how the physical intervention is administered, the intended function 
is standardised instead182. Following this reasoning, the intervention is designed to achieve 
common, pre–defined goals though can be modified at a local level to suit organisational 
differences. Although diagnostic tests differ from the public health interventions for which
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this approach was conceived, it may turn out to be an interesting proposition when seeking 
to evaluate ‘unstandardisable’ tests, in particular clinical examinations. 
9.5.4 Indirect appraisal of appropriate outcome measures 
The thesis did not directly evaluate the extent to which each included trial had measured 
all the outcomes necessary to have fully evaluated its interventions. The possibility 
therefore remains that trials performed better in this respect than has been deduced. 
Performing a reliable appraisal would have required extensive consultation with clinical 
experts so as to identify the most important outcomes for the full range of diagnostic 
settings included. Nonetheless, included trials were afforded a highly detailed examination, 
through appraisal of their methods but also to scrutinise how health effects were created 
whilst developing the theoretical framework. The author’s experience of this thorough 
process strongly intimates that the greater majority of trials failed to identify and measure 
all potential benefits, however these suspicions must be investigated further. 
9.6  A comment on the need for trials 
 
This thesis has examined whether the RCT is fit for purpose for evaluating the clinical 
effectiveness of diagnostic tests. To the author’s knowledge there is no existing research 
that has sought to tackle this issue directly. However there is a larger body of research that 
has examined the closely related question of when RCTs might be needed to evaluate 
diagnostic tests. Though the present work did not intend to address this directly, it is the 
author’s belief that some findings may contribute to this discourse and thus merit brief 
discussion. 
Working under the premise that test-treatment RCTs are unlikely to be feasible, and are 
therefore unavailable to provide direct evidence of health impact, several researchers have 
examined what evidence should be sought to estimate health effects without needing to 
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resort to an RCT. Most of these works focus on the ability to use existing evidence of test 
performance and treatment efficacy to establish the nature of trade–offs between the 
health consequences of comparative sensitivity, specificity and the procedural harms of 
undergoing testing and treatment21,91,256. Attention is drawn in particular to the meticulous 
and thought–provoking research published by Sally Lord and colleagues19,21,93. The 
authors argue that assumptions linking changes in accuracy to health outcomes can be 
confirmed by existing evidence of therapeutic benefit in individuals who would receive 
discrepant diagnoses as a result of receiving the new test. The authors present a 
framework19 for setting out these assumptions, and identifying the discrepant groups so 
that all possible health consequences of reclassification can subsequently be iterated. For 
example, they deduce that if the new test has a higher sensitivity but lower specificity than 
its comparator, then the health consequences of more patients receiving appropriate 
treatment must be balanced against those of the higher proportion of patients being over–
treated (or receiving inappropriate treatment). They argue that discrepancy can also be 
created when new tests diagnose cases that represent a different spectrum of disease, 
even though the number of true– and false–positives are equivalent. Key to establishing 
the need for an RCT is identifying the expected benefits of a new test, which they propose 
doing by examining the trade–offs occurring within the decisional causal pathway to 
identify how the potential value to patient health is generated. The authors conclude that 
comparisons will only require test-treatment RCTs when the treatment response is 
uncertain in newly identified individuals. Thus when assumptions linking accuracy to health 
outcomes are not in doubt, lower levels of diagnostic evidence linked with evidence of 
treatment efficacy will be sufficient. 
More recently, Lord et al produced a second framework to assist users in determining what 
evidence is needed to compare the health impact of tests19. This builds on the 2006 
framework by presenting the idea of using a hypothetical RCT to identify where differences 
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might arise between two entire test-treatment pathways. While working through the RCT 
comparison, what the authors refer to as the ‘test evaluation flow diagram’, the authors 
advocate that the evidence needed to replace an RCT is determined by where differences 
between arms are likely to occur, and whether their health consequences have been 
demonstrated. The authors conclude that RCTs are not necessary when all potential 
consequences of the new test have already been evaluated using studies located earlier in 
the evaluative hierarchy, which can then be linked together.  
As with their earlier framework, the authors concentrate on two potential differences: those 
defined in this thesis as the ‘direct’ and the ‘decisional’ causal pathways; that is, they 
conceive that differences in the performance of test-treatment strategies can occur due to 
the direct impact of tests, and mainly due to the impact of differences in accuracy 
characteristics.  
Although their primary intention was to discusses to what extent accuracy studies and 
simplified designs could replace RCT designs, the work of Lord and colleagues19 shares 
some similarities to the framework presented in chapters 7 and 8. Both share the same 
premise, that determining the effectiveness of new tests requires the evaluator to map out 
the competing test-treatment pathways and conceptualise where differences in important 
processes may occur. Both frameworks also posit that identifying key intermediate 
processes should drive the rationale for how tests are to be evaluated, since the potential 
benefits of a new strategy are expressed through these intermediate outcomes. 
Discussion of the thesis framework tool (chapter 8) considered how the identification of 
mechanisms (and conceptualisation of how they interact within causal pathways) could be 
used to target the evidence needed to demonstrate effectiveness, and as a consequence 
determine whether an RCT is needed; this was of course also the key aim of the Lord 
framework19. Finally, the two works also concur that benefits and harms can be created 
along multiple causal pathways.        
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Although these notions are the same, the thesis framework adds to the practical value of 
Lord’s framework by setting out a complete list of possible mechanisms and causal 
pathways; this allows the associated tool to offer more specific guidance on how to work 
through all possible differences between strategies.  
However the thesis also augments the conceptual basis of the Lord framework. Finding 
that the relationship between tests and patient outcomes is far more complex than 
previously conceived, this thesis reveals a slightly different position to that expounded by 
Lord and colleagues. The existence of more mechanisms means that in order to avoid an 
RCT, reviewers will need to find more evidence so as to ensure that potential effects 
caused by all relevant causal pathways can be quantified. Since mechanisms are far more 
complex in the ways they interact to cause change, the process of linking this evidence 
together will therefore require many more assumptions about how interactions between 
mechanisms will impact on health outcomes. This in turn could portend that uncertain 
linkages will be more numerous, for example because mechanisms cannot be guaranteed 
to perform as desired. Not only does this imply that the process of linking evidence 
together could be more challenging than previously thought, but a logical deduction 
following the approach advocated by Lord and colleagues would be that RCTs may be 
needed more often than is currently thought necessary in order to confirm that complicated 
mechanistic synergies are functioning as hypothesised, or to capture unintended effects 
which may remain obscure during the development of the scientific rationale. 
9.7 Implications for practice 
 
Aside from questions of whether RCTs are useful, the thesis findings suggest several 
recommendations for how these evaluations should be improved when they are attempted. 
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9.7.1 Moving towards a full documentation of test-treatment 
interventions  
The reporting of test-treatment trials was very poor and urgently needs improvement if 
results are to be used to improve diagnostic practice. The framework in chapter 7 suggests 
that five key components of care must be described for each intervention in order for 
reports to be useful. Thus even when test-treatment comparisons are relatively simple, 
adequate reporting is likely to require far more detailed documentation of the study setting 
than is currently expected for standard treatment trials. Particular attention will need to be 
paid to interventions that are less amenable to standardisation, since this study suggests 
they were more poorly reported. Attempts to provide fuller descriptions for these 
intrinsically more variable strategies are likely to necessitate more lengthy reports.  
At the same time, it is important to acknowledge that the space premium is a major issue 
for journals and although complex multiple interventions require more detailed attention to 
reporting of interventions and their implementation, they are unlikely to receive preferential 
increases in word counts. In addition to making use of more recent opportunities to append 
supplementary documents to journal publication, one approach to accommodate both 
space restrictions and adequate reporting of interventions may be to present some 
information graphically. It has been suggested that graphical representation of complex 
interventions aids reporting, and hence dons clarity to the interpretation of trial results83,136. 
This was certainly confirmed in the current study, where the complexity of test-treat 
strategies and extensive variation in clinical settings compounded the disadvantages of 
opaque reporting. Perera and colleagues327 have proposed a standardised schema to 
accompany written descriptions of non–pharmaceutical interventions, developed to 
elucidate all components of a complex intervention, their timing, and how they contrast 
with the composition of their comparators. Since test-treatment interventions differ in terms 
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of the key components that influence change, the graphic tool presented in chapter 8 could 
present a suitable alternative.  
Further guidance may be needed to ensure that test-treatment trials are reported 
consistently and comprehensively. Much of the CONSORT statement, particularly the 
extension for non–pharmacologic interventions147 remains relevant to test-treat RCTs and 
should be followed as is recommended for all trials. However, the conceptual barriers 
identified would indicate that in order to improve, specific guidance will be needed to 
disseminate the notion that test-treatment RCTs must evaluate whole management 
pathways. The present analysis therefore suggests that the requirements for full reporting 
of test-treatment RCTs are sufficiently different from those of other designs to warrant their 
own CONSORT extension. 
9.7.2 Defining all intended benefits of a new intervention 
A key output from this thesis concerns the attention drawn to the multiple and complex 
ways in which tests exert their effects on patient health. In order to evaluate test-treatment 
interventions fully, trials are likely to need to measure many more outcomes than is 
common in standard trials. More patient outcomes need to be measured to ensure that the 
impact of the strategy on all randomised individuals is assessed, while more process 
outcomes need to be measured to ensure that the resulting health effects can be 
interpreted and translated into clinical practice.  
As argued in chapter 8, new trials are likely to benefit greatly by carefully developing a 
comprehensive rationale for how test-treatment interventions are expected to impact on 
patient health prior to evaluation. This will require extensive consultation between clinical 
experts, researchers and at times also patient representatives. Although not yet fully 
validated, this thesis would recommend that the theoretical framework and its associated 
tool are used as an aid to think through these processes.      
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9.7.3 Improving methodological quality 
The methodological quality of published trials was found to be poor and in urgent need of 
improvement. While advances to validity can be made by promoting standard trial 
methods, the thesis highlights that certain methods differ to those needed for treatment 
trials. Chief amongst these are the requirements to inflate sample sizes by the reclassified 
fraction in order to properly power for health effects, and the need to consider whether 
blinding may actually eliminate the desired effects. These points should be disseminated 
to the research community by the production of methodological guidelines designed 
specifically for test-treatment trials. 
9.7.4 Offsetting the challenges of blinding with process evaluation 
Blinding is unlikely to be feasible or appropriate in many instances, however trialists may 
be able to offset the practical and methodological challenges of blinding by implementing 
other methodological safeguards. One key solution will involve the close accounting of 
actual clinical behaviour, including test use, decision–making and treatment use, in order 
to monitor how actual patient management differs from the intended test-treatment 
protocol. In this way, investigators may be able to discern between–arm differences due to 
genuine divergence in diagnostic impact, from those that reflect artefacts of study design. 
To limit ascertainment bias, the solution will entail ensuring that measurements are 
standardised so as to minimise systematic differences occurring between arms. 
Characterising any differences that do occur will also allow the possibility and extent of 
ascertainment bias to be incorporated into the interpretation of trial findings. 
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9.8 Future research 
 
Through an analysis of the thesis findings, as well as its limitations, this research reveals 
several methodological issues that should be researched further. 
9.8.1 Methodological research into the role of blinding is urgently 
needed 
The considerable challenges to implementing blinding demand that researchers explore 
methods to achieve it. Perhaps more urgent, however, is the need to improve our current 
understanding of the situations in which the absence of blinding truly threatens trial 
validity. The in–depth examination of trials for the purposes of the feasibility analysis begin 
to suggest that the consequences of blinding and not blinding are likely to pose a particular 
dilemma for test-treatment trials. For example, in order to mask treating clinicians we must 
remove their ability to interpret test results and, depending on the types of tests involved, 
also remove their ability to make the diagnosis. However, as demonstrated by the 
framework in chapter 7, differences in clinical behaviour often form part of the causal 
pathway for test–treatment effects, and so in these situations blinding could serve to 
remove or alter the treatment effect. These observations begin to suggest that deciding 
whether or not to blind will require a very careful deliberation by trialists in order to ensure 
that the correct balance is achieved between minimising the risks to performance and 
ascertainment bias and ensuring that important intended effects are measured. Research 
is urgently needed to determine how the lack of blinding impacts on treatment effects, and 
to establish explicit recommendations for the situations in which blinding is inappropriate.  
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9.8.2 Methodological development of sample size calculations is 
needed  
The delineation of four separate causal pathways of test-treatment effect may suggest that 
power calculations might not always require inflation, however this needs to be explored. 
The inflation factors proposed by previous authors176–177,179 assume that health benefits 
occurring as a result of the test will only occur in the subgroup of patients who will have 
been managed differently as a result of receiving the new diagnostic intervention. When 
intended effects are driven by decisional mechanisms, the framework supports this 
assumption since differences in accuracy and diagnostic/therapeutic yield can only be 
observed in a small proportion of the study population. The same assumption is 
contradicted when we consider the remaining 3 causal pathways, in particular temporal or 
perceptual effects since direct test effects are likely to be compared as trade–offs against 
the other causal pathways. Most importantly, changes to the timing of test-treatment 
strategies are likely to be experienced by all randomised participants, therefore it is 
possible that no correction need be applied. Similarly effects hypothetically driven by 
changing patient perceptions and experience may only need to be adjusted if the principle 
cause of effect is perception of the diagnostic category assigned to the patient. These 
hypotheses need to be evaluated and developed further by statistical analysis of test-
treatment RCTs.  
9.8.3 Developing the framework tool for trial design and appraisal  
As posited in chapter 8, the framework tool could be of use to several aspects of 
diagnostic test evaluation. However, the version presented in this thesis is a preliminary 
attempt that must be piloted, discussed more extensively with clinicians, and refined so 
that it can be useful to those who need to commission, design and appraise test-treatment 
RCTs.  
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9.8.4 Tool for appraising the methodological quality of test-
treatment RCTs is needed  
Since the methods needed to conduct valid trials differ from standard requirements, future 
appraisals of methodological quality will need to modify the current approach in order to 
ensure that studies are not inappropriately excluded from syntheses, but also that they are 
critiqued comprehensively. For example, while the absence of blinding may be considered 
an exclusion criterion when synthesising treatment trials, this approach is unlikely to be 
appropriate or sufficient for test-treatment syntheses. These issues require further 
exploration, perhaps by further empirical analysis of the correlations between treatment 
effect sizes and failure to implement methodological safeguards, and dissemination to the 
wider evidence–synthesis community. 
9.8.5 Further research must urgently address when RCT evidence is 
needed and the role of decision models 
Due to the current scarcity of RCT evidence, decision–modelling is likely to remain the 
most common source of diagnostic practice guidelines in the near future. Yet the more 
complex relationship between tests and health outcomes revealed by the theoretical 
framework may suggest that our current appreciation of what evidence to link together in 
decision models is incomplete. The notions of what evidence is required for decision–
analysis therefore needs to be revisited in light of the framework. At the same time, it will 
also be critical to evaluate the validity and reliability of the estimated health effects 
produced by decision–models.  
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9.9  Conclusions: How useful are test-
treatment RCTs? 
 
This thesis has presented the first empirically–based review of RCT methods for 
evaluating test-treatment interventions. The examination of this fascinating cohort of 
published trials provides empirical credence to assertions that test-treatment RCTs are 
highly complex studies that will be challenging to perform to a reliable standard. The 
interventions are difficult to capture and translate into protocols; several methodological 
safeguards traditionally used to eliminate bias are more difficult to implement, and in the 
case of blinding could be impossible to implement in the majority of comparisons; and the 
way in which test-treatment strategies impact on patient health are both numerous and 
highly complicated. Taking all these factors into account, the quality of published trials is 
certainly very poor and there can be little doubt that they present scarce, uninformative, 
unreliable and incomplete evidence for the effectiveness of the tests they sought to 
evaluate. But does this mean that RCTs are not useful to answer such questions? At this 
stage the answer is not straightforward. 
Although most trials generally committed a litany of methodological offenses, many of 
these threats to their validity and utility are theoretically surmountable given the adequate 
dissemination of methodological guidance. Interventions can be described with more care; 
selection and attrition bias can be minimised by improving standard RCT methods; type II 
errors can be avoided by performing power calculations that correctly adjust for the 
reclassified fraction, allowing the appropriate number of patients to be recruited; and 
interventions could be evaluated comprehensive by carefully composing a scientific 
rationale for how they are expected to impact on patients. The latter point highlights what 
the author believes is the greatest contribution of this thesis to existing knowledge. Though 
the conceptual framework and associated tool must now be validated through piloting and 
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discussion amongst the academic and clinical communities, it presents a potential solution 
to an issue that had been posited as an inherent failure of the test-treatment design: that 
one cannot disentangle the contribution of the test from that of treatment in observed test–
treat effects59,77,175,187. Instead, we can now posit that these contributions can be 
distinguished by measuring the workings of the test–treatment strategy – the processes 
contained within the ‘black box’. 
Several of the issues highlighted in this thesis could also be rectified by following the 
MRC’s guidance for developing and piloting complex interventions83, before proceeding to 
a full trial. More conscientious development of new test-treatment interventions, and more 
careful mapping out of control interventions, would significantly improve the ability to 
convey the nature of what is to be evaluated in trial protocols. Piloting these interventions 
could serve to check that patient numbers are recruitable, provide insight into how much 
attrition might be expected, whilst also checking whether predicted effect sizes are 
realistic. 
On the other hand, significant obstacles remain that would indicate long–term RCTs will 
not be the most appropriate method in some diagnostic settings. Chief amongst these is 
frequent inability to blind outcome assessors to subjective outcomes, a proven source of 
bias in treatment trials. While further research is needed to establish whether test-
treatment interventions risk similar bias, it could be that trials are unlikely to provide 
reliable answers when patients can’t be blinded and subjective outcomes must be 
measured. Arguably the biggest threat to the utility of the RCT probably lays in the 
practical ability to recruit the number of patients necessary to avoid type II errors, the 
willingness of funders to pay for these costs and the enthusiasm of policy–makers to 
accept that trial evidence will take far longer to produce than is common for treatment 
RCTs. When the sample sizes required to measure downstream health outcomes are 
considered impractical, one solution could be to use RCTs as tools to ensure that the 
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workings of test-treatment strategies operate as intended, since by evaluating intermediate 
outcomes trials will have greater power to detect effects, and use the resulting data to 
model the impacts to downstream patient health. Then again, models may not be able to 
incorporate all relevant mechanisms in particularly complex comparisons, nor will they be 
able to account for unexpected or unpredictable effects. A key advantage of the RCT is 
that it can reflect the test-treatment process accurately. In reality patient management 
decisions occur as part of an iterative process between test results and available treatment 
options, and if trials are designed and conducted well they provide unique tools to capture 
this process in its entirety and relate it directly to observed changes in health outcomes.  
Trials have the potential to be very useful instruments for evaluating whether tests do more 
good than harm to patients. Though highly challenging, these designs can prove to be 
both reliable and informative. However, it must be acknowledged that these complex 
designs will not be suited to all comparisons, thus placing the RCT at the summit of a rigid 
hierarchy of evidence is also unlikely to be the best way forward.  
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Appendix A:  
Search strategy & study selection 
This appendix provides additional details of the project search for published test-treatment 
RCTs and the study selection process. 
A.1 Development of search strategy 
 
 
Three initial strategies were tested in Ovid MEDLINE in May 2006. General diagnosis terms 
across all fields, for publication years 1966 – 2006. Truncations are denoted by $. 
A.1.1 Haynes sensitive RCT methods filter  
Methods filters are predefined search strategies designed to maximise search precision by 
filtering content in bibliographic databases according to methodologic characteristics. Haynes 
and colleagues developed a series of methods filters by handsearching key journals, and 
identifying the optimal search strings using index and text terms from all relevant studies. 
These were tested and validated specifically for use in the MEDLINE database. The Haynes 
RCT filters limit search results to the RCT study design, and was chosen to maximise the 
project search’s precision as it has demonstrated the highest sensitivity and amongst the 
highest specificities of 19 similar filters, when carried out in MEDLINEA1. 
The first strategy uses the sensitive Haynes RCT filter, which uses a broad range of terms to 
identify articles associated with an RCT study. These could hence also include secondary 
evidence in addition to the primary RCTs sought by the project. 
 
 
 
 
Yield = 187,895 
Diagnosis: sensitive$.mp.; diagnosis$.mp.; di.fs ; “sensitivity and specificity”/ (combined OR) 
RCT: sensitive RCT methods filter (Haynes et al) 
Treatment: intervention.mp.; experimental.mp.; study group$.mp.; treatment.mp.; treatment 
outcome/ (combined OR) 
 
  
 
351 Appendix A: Selection Proforma 
A.1.2  Haynes specific RCT methods filter and control$.mp search 
term 
The second strategy uses the specific RCT methods filter, which uses a more closely defined 
set of terms to limit findings to primary RCT reports (e.g. rather than systematic reviews).  
 
 
 
 
Yield = 51,699 
A.1.3 RCT.pt and control$.mp search terms 
The third strategy refers solely to the RCT as a publication type, which targets only articles 
indexed as primary RCT reports.  
 
 
 
  
 
Yield = 31,896 
Diagnosis: sensitive$.mp.;  diagnosis$.mp.;  di.fs ; “sensitivity and specificity”/ (combined OR) 
RCT: RCT.pt. 
Treatment: intervention.mp.; experimental.mp.; study group$.mp.; treatment.mp.; treatment 
outcome/; control$.mp. (combined OR) 
Diagnosis: sensitive$.mp.;  diagnosis$.mp.;  di.fs ; “sensitivity and specificity”/ (combined OR) 
RCT: specific RCT methods filter (Haynes et al) 
Treatment: intervention.mp.; experimental.mp.; study group$.mp.; treatment.mp.; treatment 
outcome/; control$.mp. (combined OR) 
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A.2 Abstract/Full Paper Inclusion Proforma 
 
 
Title: 
Authors: 
Publication details: Ref ID: 
 
 
 
Screen: 
S
tu
d
y
 T
y
p
e
 
Is this a randomised controlled trial? Y / N 
Do participants have a clinical complaint? (i.e. not healthy or asymptomatic) Y / N 
Are patients randomised to different diagnostic strategies? Y / N 
Is the test used to classify suspected or existing disease for the purposes of treatment 
planning? 
Y / N 
Is the test used repeatedly to monitor disease progression or titrate treatment? Y / N 
Is treatment given as a result of dianostic information? (either explicitly mentioned or 
implicit from type of outcomes evaluated) Y / N 
Are patient outcomes assessed after treatment? Y / N 
INCLUDE / EXCLUDE 
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A.3 Common examples of excluded trials 
 
The table below lists some common examples of exclusions: 
Title Reason for exclusion Source 
Acute barrier disruption by adhesive tapes is influenced by 
pressure, time and anatomical location: integrity and cohesion 
assessed by sequential tape stripping. A randomized, controlled 
study 
Test RCT, development of use 
of healthy volunteers 
[A2] 
The Ekman 60 Faces Test as a diagnostic instrument in 
frontotemporal dementia 
Non-randomised evaluation of 
a test  
[A3] 
Measurement of the intraocular pressure with the 'transpalpebral 
tonometer' TGDc-01 in comparison with applanation tonometry 
Non RCT, Test accuracy study [A4] 
Brain Imaging and Mental Disorders of Aging Intervention Treatment RCT [A5] 
A prospective randomized comparative study on the safety and 
tolerability of transnasal esophagogastroduodenoscopy 
Test RCT with no treatment 
phase 
[A6] 
Autofluorescence bronchoscopy with white light bronchoscopy 
compared with white light bronchoscopy alone for the detection 
of precancerous lesions: a European randomised controlled 
multicentre trial 
Test RCT, Accuracy [A7] 
Application of contrast-enhanced ultrasound to increase the 
diagnostic rate of liver tumor by biopsy 
Test-treatment RCT with no 
downstream patient outcomes 
[A8] 
A comparison of an evidence based regime with the standard 
protocol for monitoring postoperative observation: a randomised 
controlled trial 
Test RCT evaluating monitoring 
test 
[A9] 
Acceptability, benefit and costs of early screening for hearing 
disability: a study of potential screening tests and models 
Test RCT evaluating 
asymptomatic screening 
[A10] 
 
A.4 References 
 
[A1] Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR for the Hedges 
Team. Optimal search strategies for retrieving scientifically strong studies of treatment 
from Medline: analytical survey. BMJ 2005;330(7501):1179–85. 
[A2] Breternitz M, Flach M, Prässler J, Elsner P, Fluhr JW. Acute barrier disruption by 
adhesive tapes is influenced by pressure, time and anatomical location: integrity and 
cohesion assessed by sequential tape stripping. A randomized, controlled study. Br J 
Dermatol 2007; 156: 231–240. 
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[A3] Diehl-Schmid J, Pohl C, Ruprecht C, Wagenpfeil S, Foerstl H, Kurz A. The Ekman 60 
Faces Test as a diagnostic instrument in frontotemporal dementia. Arch Clin 
Neuropsychol 2007; 22:459–464.  
[A4] Sandner D, Böhm A, Kostov S, Pillunat L. Measurement of the intraocular pressure 
with the "transpalpebral tonometer" TGDc-01 in comparison with applanation 
tonometry. Graefes Arch Clin Exp Ophthalmol. 2005; 243:563–569.  
[A5] Small GW. Brain Imaging and Mental Disorders of Aging Intervention. 
ClinicalTrials.gov NCT00267163 [internet]. Available from: 
http://www.clinicaltrials.gov/ct2/show/NCT00267163?term=NCT00267163&rank=1  
[A6] Yagi J, Adachi K, Arima N, Tanaka S, Ose T, Azumi T, et al. A prospective 
randomized comparative study on the safety and tolerability of transnasal 
esophagogastroduodenoscopy. Endoscopy 2005; 37:1226–1231. 
[A7] Häussinger K, Becker H, Stanzel F, Kreuzer A, Schmidt B, Strausz J, et al. 
Autofluorescence bronchoscopy with white light bronchoscopy compared with white 
light bronchoscopy alone for the detection of precancerous lesions: a European 
randomised controlled multicentre trial. Thorax 2005; 60:496–503. 
[A8] Wu W, Chen MH, Yan K, Yin SS, Dai Y, Fan ZH, et al. Application of contrast-
enhanced ultrasound to increase the diagnostic rate of liver tumor by biopsy. 
Zhonghua Yi Xue Za Zhi 2006; 86:116–120. 
[A9] Fernandez R, Griffiths R. A comparison of an evidence based regime with the 
standard protocol for monitoring postoperative observation: a randomised controlled 
trial. Aust J Adv Nurs 2005; 23:15–21. 
[A10] Davis A, Smith P, Ferguson M, Stephens D, Gianopoulos I. Acceptability, benefit and 
costs of early screening for hearing disability: a study of potential screening tests and 
models. Health Technol Assess 2007; 11:1-294. 
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Appendix B:  
Diagnostic characteristics  
 
This appendix lists all 108 included test-treatment RCTs, and provides basic details of trial 
design, patient population, the diagnostic interventions and the purpose of testing. 
The following abbreviations are used throughout: 
CCU Coronary care unit 
CK Creatine kinase 
CKMB Creatine kinase MB 
CPU Chest pain unit 
CT Computed tomography 
CTG Cardiotocography 
ECG Electrocardiography 
EUS Endoscopic ultrasound 
ERCP Endoscopic retrograde cholangiopancreatography 
FDG-PET Fludeoxyglucose (18F) enhanced Positron emission 
tomography 
FISH Fluorescence in situ hybridization 
FFN Fetal fibronectin 
FNA Fine needle aspiration 
FPO Fetal pulse oximetry 
MRI Magnetic resonance imaging 
NT–proBNP N-terminal prohormone of brain natriuretic peptide 
PCR Polymerase chain reaction 
PSA Prostate antigen biomarker 
PSG Polysomnography 
SPECT Single-photon emission computed tomography 
SPECT MPI SPECT Myocardial perfusion imaging 
US Ultrasound 
V/Q Ventilation–perfusion scan 
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Appendix C:  
Additional publications 
 
This appendix lists the additional publications, associated with included test-treatment trials, that were 
used to supplement the analysis of reporting quality (chapter 5) and methodological quality (chapter 6). 
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Below are listed summaries of the data abstraction for appraising the reporting quality of 
included trials, which was presented in chapter 5.  
The following abbreviations are used throughout: 
CCU Coronary care unit 
ECG Electrocardiogram 
ED Emergency department 
FISH Fluorescence in situ hybridization 
PCR Polymerase chain reaction 
QoL Quality of Life 
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Appendix E:  
Methodological quality summary data 
 
This appendix lists summary data for all methodological quality items appraised during the 
review presented in chapter 6. It is arranged in two tables; the first presents quality 
judgements for reported methods of sequence generation and allocation concealment, as 
well as reports of blinding conduct and judgements of blinding feasibility. The second is a 
catalogue of sample sizes and methods of analysis. 
The following abbreviations are used throughout: 
NR Not reported 
n/a Not applicable 
Prot devs Protocol deviations 
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E.1 Sequence generation, allocation 
concealment & blinding 
 
  
 
Appendix E.1: Sequence Generation, allocation concealment, blinding 411 
O
b
je
ct
iv
it
y 
o
f 
o
u
tc
o
m
e 
O
b
je
ct
iv
e
 
n
/a
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
B
lin
d
in
g 
Fe
as
ib
ili
ty
 
A
ss
e
ss
o
rs
 
Fe
as
ib
le
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
U
n
cl
ea
r 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
C
lin
ic
ia
n
s 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
P
at
ie
n
ts
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
B
lin
d
in
g 
C
o
n
d
u
ct
 
A
ss
e
ss
o
rs
 
N
R
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
N
R
 
N
R
 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
P
re
se
n
t 
P
re
se
n
t 
N
R
 
C
lin
ic
ia
n
s 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
P
at
ie
n
ts
 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
A
llo
ca
ti
o
n
 
C
o
n
ce
al
m
e
n
t 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
Se
q
u
e
n
ce
 
G
e
n
e
ra
ti
o
n
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
Tr
ia
l 
R
e
f 
T1
 
T2
 
T3
 
T4
 
T5
 
T6
 
T7
 
T8
 
T9
 
T1
0
 
T1
1
 
T1
2
 
T1
3
 
T1
4
 
T1
5
 
T1
6
 
 
  
Appendix E.1: Sequence Generation, allocation concealment, blinding 412 
O
b
je
ct
iv
it
y 
o
f 
o
u
tc
o
m
e 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e;
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e;
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
n
/a
 
O
b
je
ct
iv
e
 
n
/a
 
B
lin
d
in
g 
Fe
as
ib
ili
ty
 
A
ss
e
ss
o
rs
 
Fe
as
ib
le
 
Fe
as
ib
le
; 
Im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
D
if
fi
cu
lt
; 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
Fe
as
ib
le
; 
Im
p
o
ss
ib
le
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
C
lin
ic
ia
n
s 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
P
at
ie
n
ts
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
B
lin
d
in
g 
C
o
n
d
u
ct
 
A
ss
e
ss
o
rs
 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
A
b
se
n
t 
N
R
 
N
R
 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
N
R
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
C
lin
ic
ia
n
s 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
N
R
 
P
at
ie
n
ts
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
A
llo
ca
ti
o
n
 
C
o
n
ce
al
m
e
n
t 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
In
ad
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
Se
q
u
e
n
ce
 
G
e
n
e
ra
ti
o
n
 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
In
ad
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
In
ad
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
Tr
ia
l 
R
e
f 
T1
7
 
T1
8
 
T1
9
 
T2
0
 
T2
1
 
T2
3
 
T2
4
 
T2
6
 
T2
7
 
T2
8
 
T2
9
 
T3
0
 
T3
1
 
 
  
 
Appendix E.1: Sequence Generation, allocation concealment, blinding 413 
O
b
je
ct
iv
it
y 
o
f 
o
u
tc
o
m
e 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
B
lin
d
in
g 
Fe
as
ib
ili
ty
 
A
ss
e
ss
o
rs
 
Fe
as
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
C
lin
ic
ia
n
s 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
P
at
ie
n
ts
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
B
lin
d
in
g 
C
o
n
d
u
ct
 
A
ss
e
ss
o
rs
 
P
re
se
n
t 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
C
lin
ic
ia
n
s 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
N
R
 
N
R
 
P
at
ie
n
ts
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
llo
ca
ti
o
n
 
C
o
n
ce
al
m
e
n
t 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
In
ad
eq
u
at
e
 
A
d
eq
u
at
e
 
Se
q
u
e
n
ce
 
G
e
n
e
ra
ti
o
n
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
Tr
ia
l 
R
e
f 
T3
2
 
T3
3
 
T3
4
 
T3
5
 
T3
6
 
T3
7
 
T3
8
 
T3
9
 
T4
0
 
T4
1
 
T4
2
 
T4
4
 
T4
5
 
T4
6
 
T4
7
 
T4
8
 
T4
9
 
 
  
Appendix E.1: Sequence Generation, allocation concealment, blinding 414 
O
b
je
ct
iv
it
y 
o
f 
o
u
tc
o
m
e 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e;
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
n
/a
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
B
lin
d
in
g 
Fe
as
ib
ili
ty
 
A
ss
e
ss
o
rs
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
; 
Im
p
o
ss
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
C
lin
ic
ia
n
s 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
P
at
ie
n
ts
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
B
lin
d
in
g 
C
o
n
d
u
ct
 
A
ss
e
ss
o
rs
 
N
R
 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
P
re
se
n
t 
N
R
 
A
b
se
n
t 
P
re
se
n
t 
N
R
 
C
lin
ic
ia
n
s 
A
b
se
n
t 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
P
at
ie
n
ts
 
N
R
 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
A
llo
ca
ti
o
n
 
C
o
n
ce
al
m
e
n
t 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
Se
q
u
e
n
ce
 
G
e
n
e
ra
ti
o
n
 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
Tr
ia
l 
R
e
f 
T5
0
 
T5
1
 
T5
2
 
T5
3
 
T5
4
 
T5
5
 
T5
6
 
T5
7
 
T5
8
 
T5
9
 
T6
0
 
T6
1
 
T6
2
 
T6
3
 
T6
4
 
 
  
 
Appendix E.1: Sequence Generation, allocation concealment, blinding 415 
O
b
je
ct
iv
it
y 
o
f 
o
u
tc
o
m
e 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
n
/a
 
O
b
je
ct
iv
e
 
B
lin
d
in
g 
Fe
as
ib
ili
ty
 
A
ss
e
ss
o
rs
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
Fe
as
ib
le
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
fe
as
ib
le
 
D
if
fi
cu
lt
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
Fe
as
ib
le
 
C
lin
ic
ia
n
s 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
P
at
ie
n
ts
 
D
if
fi
cu
lt
 
D
if
fi
cu
lt
 
D
if
fi
cu
lt
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
B
lin
d
in
g 
C
o
n
d
u
ct
 
A
ss
e
ss
o
rs
 
N
R
 
P
re
se
n
t 
P
re
se
n
t 
A
b
se
n
t 
P
re
se
n
t 
N
R
 
A
b
se
n
t 
P
re
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
N
R
 
C
lin
ic
ia
n
s 
N
R
 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
P
at
ie
n
ts
 
N
R
 
A
b
se
n
t 
N
R
 
A
b
se
n
t 
P
re
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
A
llo
ca
ti
o
n
 
C
o
n
ce
al
m
e
n
t 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
Se
q
u
e
n
ce
 
G
e
n
e
ra
ti
o
n
 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
Tr
ia
l 
R
e
f 
T6
5
 
T6
6
 
T6
7
 
T6
8
 
T6
9
 
T7
0
 
T7
1
 
T7
2
 
T7
3
 
T7
4
 
T7
5
 
T7
6
 
T7
7
 
T7
8
 
T7
9
 
T8
1
 
 
  
Appendix E.1: Sequence Generation, allocation concealment, blinding 416 
O
b
je
ct
iv
it
y 
o
f 
o
u
tc
o
m
e 
n
/a
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
B
lin
d
in
g 
Fe
as
ib
ili
ty
 
A
ss
e
ss
o
rs
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
C
lin
ic
ia
n
s 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
P
at
ie
n
ts
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
D
if
fi
cu
lt
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
B
lin
d
in
g 
C
o
n
d
u
ct
 
A
ss
e
ss
o
rs
 
N
o
 p
ri
m
ar
y 
o
u
tc
o
m
e
 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
P
re
se
n
t 
P
re
se
n
t 
N
R
 
N
R
 
A
b
se
n
t 
P
re
se
n
t 
A
b
se
n
t 
C
lin
ic
ia
n
s 
N
R
 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
P
re
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
P
at
ie
n
ts
 
N
R
 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
llo
ca
ti
o
n
 
C
o
n
ce
al
m
e
n
t 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
In
ad
eq
u
at
e
 
Se
q
u
e
n
ce
 
G
e
n
e
ra
ti
o
n
 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
Tr
ia
l 
R
e
f 
T8
2
 
T8
3
 
T8
5
 
T8
6
 
T8
7
 
T8
8
 
T8
9
 
T9
0
 
T9
1
 
T9
2
 
T9
3
 
T9
4
 
T9
5
 
T9
6
 
T9
7
 
 
  
 
Appendix E.1: Sequence Generation, allocation concealment, blinding 417 
O
b
je
ct
iv
it
y 
o
f 
o
u
tc
o
m
e 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
O
b
je
ct
iv
e
 
Su
b
je
ct
iv
e
 
U
n
cl
ea
r 
B
lin
d
in
g 
Fe
as
ib
ili
ty
 
A
ss
e
ss
o
rs
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Fe
as
ib
le
 
im
p
o
ss
ib
le
 
U
n
cl
ea
r 
C
lin
ic
ia
n
s 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
P
at
ie
n
ts
 
Fe
as
ib
le
 
D
if
fi
cu
lt
 
Fe
as
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
Fe
as
ib
le
 
Im
p
o
ss
ib
le
 
D
if
fi
cu
lt
 
D
if
fi
cu
lt
 
Im
p
o
ss
ib
le
 
Im
p
o
ss
ib
le
 
B
lin
d
in
g 
C
o
n
d
u
ct
 
A
ss
e
ss
o
rs
 
N
R
 
P
re
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
N
R
 
C
lin
ic
ia
n
s 
P
re
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
P
at
ie
n
ts
 
P
re
se
n
t 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
P
re
se
n
t 
N
R
 
N
R
 
A
b
se
n
t 
A
b
se
n
t 
N
R
 
A
llo
ca
ti
o
n
 
C
o
n
ce
al
m
e
n
t 
A
d
eq
u
at
e
 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e
 
U
n
cl
ea
r 
Se
q
u
e
n
ce
 
G
e
n
e
ra
ti
o
n
 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
A
d
eq
u
at
e 
U
n
cl
ea
r 
U
n
cl
ea
r 
A
d
eq
u
at
e 
Tr
ia
l 
R
e
f 
T9
8
 
T9
9
 
T1
0
0
 
T1
0
1
 
T1
0
2
 
T1
0
3
 
T1
0
4
 
T1
0
5
 
T1
0
6
 
T1
0
7
 
T1
0
8
 
  
Appendix E.2: Sample sizes, attrition & intention–to–treat 418 
 
 
 
 
 
 
 
 
E.2 Sample sizes, attrition & intention–to–
treat 
 
The second table lists target sample sizes, actual sample size, presence of missing data and 
exclusions, analysis of patients according to randomised allocation and trial reports of 
intention–to–treat analysis 
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